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Fibroblast growth factor 10 (FGF10) is a paracrine molecule, serving crucial 
mesenchymal-to-epithelial signalling roles during development and postnatally. FGF10 
binds specifically to FGF-receptor 2 IIIb (FGFR2-IIIb) and their interaction results in 
signal transduction pathways, which promote epithelial proliferation, motility and 
survival. Human heterozygous mutations in the Fgf10 gene result in LADD (lacrimo-
auriculo-dento-digital) and ALSG (aplasia of lacrimal and salivary glands) syndromes, 
which to date have been solely attributed to perturbed FGF10 paracrine function. 
However, the molecular dynamics undelaying LADD-causing G138E FGF10 mutation, 
which falls outside its receptor interaction interface, has remained enigmatic. Moreover, 
Fgf10 is expressed within mouse hypothalamus, which is not accompanied by 
expression of its cognate receptor, signifying FGF10 may have additional intracrine 
function. In this study, FGF10 was investigated in a context of nuclear translocation 
and putative endogenous function within mesenchymal and hypothalamic cells. 
Through interrogation of FGF10’s sequence and subcellular distribution, the protein 
was found to possess two putative nuclear localization sequences, termed NLS1 and 
NLS2, which were shown implicated in nuclear translocation of FGF10. Furthermore, 
the protein was found localising to the cell nucleolus. Subsequent examination of the 
LADD-causing G138E, through site-directed mutagenesis, revealed its curious 
positioning within NLS1 and its role in abrogation of both, nuclear and secretory 
function of the FGF10. Additionally, specific combinatorial mutations within NLS2 
abolished the protein’s nuclear translocation, yet did not diminish the protein’s 
progression through the secretory pathway, showing importance of this motif in the 
nuclear transport of FGF10. Interestingly, endogenous FGF10 was shown to disrupt 
differentiation of mesenchymal chondrogenitors, whereas externally applied protein 
caused the opposite effect, promoting cell differentiation, suggesting contrary function 
of paracrine and nuclear FGF10. Moreover, novel culture of hypothalamic Fgf10 
expressing tanycytes derived from transgenic mice was generated and characterised, 
showing that intracrine FGF10 may be potentially implicated in control of cell cycle of 
neural stem cells.   
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Cell activities and functions are governed by a complex system of 
communication and signals received from environment or generated intrinsically. Each 
cell possesses the ability to perceive and respond to their microenvironment, which is 
the sole basis of development and adult tissue homeostasis, and malfunctions result in 
syndromes, diseases and cancer. Biochemical signals (i.e. proteins, lipids, ions as well 
as gases) can be categorised basing on the distance between signalling and responder 
cells. Cells can communicate with each other via direct contact or over short distances, 
where signals are secreted into the extracellular matrix (ECM) and subsequently 
binding to a receptor present on a surface of an adjacent cell. Normally, thus activated 
receptor generates transduction signals, which often result in alteration of gene 
expression affecting cell survival, proliferation or motility. This is known as paracrine 
signalling, as the signals target cells in the vicinity of the emitting cell (Fig. 1.1A). In 
similar fashion cells can receive signals arising in distal parts of the body and travelling 
with the blood stream, which is referred to as endocrine signalling, typically associated 
with hormones. Additionally, cells can signal in an autocrine fashion (which is also 
known as self-signalling), through secretion of ligands that bind to the cell’s own 
receptors (Fig. 1.1B). 
Moreover, during autocrine signalling the ligands can also be endocytosed into the cell 
cytoplasm, either with or without its corresponding receptor, resulting in cytoplasmic 
signalling. Additionally, the secretory ligands can be translocated directly from the 
cytoplasm into the cell nucleus, acting in the intracrine fashion (Fig. 1.1C). 
There is a broad range of signalling molecules and their target cells can be 
diverse. Malfunction and disruption to signalling pathways result in a variety of 
syndromes and disorders as well as cancer and aging. Therefore, detailed knowledge 
of the cell signalling mechanisms could result in identification of novel drug targets, 
treatment and prevention of diseases and cancer.  
One of the major groups of signalling molecules are Fibroblast Growth Factors, 
known as FGFs.  
 
 
Part 1.1 Introduction to the family of Fibroblast Growth Factors (FGFs) 
 
1.1.1 Overview of FGFs 
 
 Fibroblast Growth Factors (FGFs) are known for their regulatory functions 
during development, tissue homeostasis and repair as well as maintenance of cell 
metabolism. They were first identified in early 70s, from pituitary extracts and shown to 
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stimulate proliferation in the 3T3 mouse fibroblast cell culture (Armelin, 1973, 
Gospodarowicz, 1974). FGFs are now known to belong to a large family of signalling 
molecules, comprised of 22 members (Fig. 1.2). They range in molecular mass from 17 
to 34kDa and can be characterised by 13-74% amino acid conservation (Ornitz and 
Itoh, 2001). The protein sequence of the FGFs has a homologous core region that 
consists of 120–130 amino acids, ordered into 12 antiparallel β-strands (β1–β12) and 
flanked by divergent amino and carboxyl termini. 
 
 










Importantly these flanking N- and C-terminal tails show the greatest sequence variation 
between FGFs, and therefore are responsible for the differences in biological 
properties of the ligands (Beenken and Mohammadi, 2009).   
Figure 1.1 Schematic representations of cell signalling variations of secreted 
molecules. (A) Paracrine and endocrine signalling signifies secretion of a ligand by 
one cell targeting a receptor present on a surface of a different cell, triggering 
downstream signal transduction events. (B) During autocrine signalling a cell’s 
receptors are activated by ligands they have secreted themselves. (C) Intracrine 
signalling takes place, when signals are produced within the cell itself, either within 
the cytoplasm or nucleus.  














Based on their biochemical, structural and functional properties, as well as 
sequence homology and phylogeny, FGF proteins are grouped into six subfamilies: 
Fgf1, Fgf4, Fgf7, Fgf9, Fgf8, Fgf15/19 (species specific) and Fgf11 (Fig. 1.2). 
Subfamilies of FGFs tend to have similar patterns of expression however each FGF 
has also some unique sites of expression. Moreover FGFs 3, 4, 8, 15, 17 and 19 are 
present mainly during embryonic development whilst others also function in the adult 
tissue (Ornitz and Itoh, 2001).  
 
Figure 1.2 Schematic of phylogenetic tree of the Fgf family. The 22 members can be 
arranged into seven subfamilies. The members of Fgf1, Fgf4, Fgf7, Fgf8, and Fgf9 
subfamily genes encode secreted paracrine ligands, which bind to and activate FGF 
receptors (FGFRs) with heparin as a cofactor, whereas members of the Fgf15/19 
subfamily encode endocrine proteins, which bind to and activate FGFRs with the 
Klotho family protein as a cofactor. Members of the Fgf11 subfamily encode 
intracellular FGFs; contrary to others, these are non-signalling proteins, and majorly 
serve as cofactors for voltage gated sodium channels. Figure adapted from (Ornitz 
and Itoh, 2015). 
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Most of the FGFs mediate biological responses by binding to and activating cell 
surface tyrosine kinase receptors, known as the FGFRs. The specific binding of a 
ligand to the receptor triggers particular downstream signalling pathways leading to 
expression of different genes (Fig. 1.4). Only the intracrine FGFs (FGF11, FGF12, 
FGF13 and FGF14), also known as FGF homologous factors 1-4 (FHF1-FHF4), act in 
the FGFR-independent manner. They are not secreted (Smallwood et al., 1996), 
therefore function intracellularly and are predominately expressed within the nervous 
system where they regulate diverse functions, such as the control of the voltage gated 
sodium channels (Goldfarb et al., 2007, Zhang et al., 2012).  
 
 
1.1.2 Evolution of FGFs  
 
FGFs are found in species of invertebrates and vertebrates but not in the single 
cell organisms like bacteria or yeast. While vertebrates are characterised by a large 
number of Fgf genes, only one Fgf-like gene (branchless) have been identified in 
Drosophila melanogaster (Sutherland et al., 1996) and two (egl-17 and let-756) in 
Caenorhabditis elegants (Burdine et al., 1997, Roubin et al., 1999).  
Fgf genes tend to be scattered around the genome and distributed variably 
across multiple chromosomes, which are often not conserved among species. Several 
Fgfs however, have been found clustered on the same chromosomes, for example, 
Fgf3, Fgf4 and Fgf19 in humans are located on the 11q13 chromosome (Kim and 
Crow, 1998, Yoshida et al., 1988, Xie et al., 1999) and in mice on chromosome 7F 
(Peters et al., 1989); and are separated by no more than 40 to 80 kb. Similarly, Fgf6 
and Fgf23 are both positioned on chromosome 12p13 in humans (Marics et al., 1989, 
Yamashita et al., 2000), separated by only 55 kb; and in mice on the chromosome 6F3-
G1 (de Lapeyriere et al., 1990, Yamashita et al., 2000). Moreover human Fgf17 and 
Fgf20 are both present on chromosome 8p12-p22 (Xu et al., 1999, Kirikoshi et al., 
2000). It has been suggested that such a gene clustering is a result of a historical gene 
duplication and translocation (Ornitz and Itoh, 2001).  
Interestingly Fgf7, located in humans on chromosome 15, has been found 
amplified to approximately 16 highly related copies, which are dispersed around human 
genome. Moreover, they are transcriptionally active and undergo a tissue dependent 
regulation (Kelley et al., 1992). Similar number of copies Fgf7 were also found in 
several species of apes and monkeys suggesting implications of Fgfs during human 
evolution (Kelley et al., 1992).  
The large gene number, their curious clustering on the chromosomes and 
variations in copy numbers has led to hypothesis that many Fgf genes arose due to 
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global gene duplications that took place during evolution of vertebrates (Ornitz and 
Itoh, 2001). Moreover, it is postulated that, FGFs did not arise from local duplication 
events, because FGFs which belong to same subfamilies and share most similarities 
are not clustered on the same chromosomes (Ornitz and Itoh, 2001). 
 
1.1.3 Gene and protein organisation of FGFs 
 
Most FGFs are encoded by three exons, where exon1 contains the AUG 
initiation start site. However there are several variations from this general pattern. Fgf2 
and Fgf3 genes are transcribed from additional CUG codon, located in the 5’ upstream 
region, generating proteins of various molecular weight, with different intracellular 
distribution and sometimes serving opposite function (Florkiewicz and Sommer, 1989, 
Arnaud et al., 1999, Kiefer et al., 1994a). In addition to the UTR, the exon1 itself can be 
a subject of multiple splicing variations as observed in Fgf8. In human and mice, the 
exon1 of Fgf8 is further subdivided into four sub-exons that undergo alternative splicing 
producing eight possible FGF8 isoforms (named “a-h”), that differ at their N-terminus. 
The FGF8 isoforms show diverse biological activity, are often expressed in different 
tissues and range in binding affinities to the receptors (Sunmonu et al., 2011). Similarly 
the intracellular Fgf11-14 (the FHFs) have two or more transcription initiation sites 
within their exon1, that give rise to proteins with different amino-terminal sequences 
(Goldfarb, 2005).  
Conservation of Fgfs is reflected in proteins’ structure and they share an 
internal core region characterised by 28 highly conserved residues of which at least six 
are invariant (Ornitz, 2000). Therefore, most FGFs adopt a β trefoil structure where 
approximately 12 β-sheets are arranged into four-stranded triangular manner (Ornitz, 
2000). Most FGF molecules usually contain N-terminally located signal peptide (SP) 
sequence that targets the molecule to the secretory pathway. FGFs 1, 2, 9, 16 and 20 
lack obvious secretory signals but are nevertheless secreted in a nonconventional 
manner (Miyamoto et al., 1993, Miyake et al., 1998, Barak et al., 2012, Kirov et al., 
2015, Zacherl et al., 2015). Furthermore, the paracrine FGFs possess a receptor 
binding site and an additional region that is responsible for heparin binding.   
Recent studies revealed that most secreted FGF proteins, at physiological 
conditions, exist mainly as unstable protein variants. FGF1 has been shown to have a 
limited half-life in vivo and about 50% of the protein exists in its unfolded state, prone to 
proteolytic degradation (Copeland et al., 1991), although introduction of specific 
mutations, was shown to increase the stability of the protein structure (Culajay et al., 
2000, Zakrzewska et al., 2004). Limited ligand stability is thought to be linked to 
protein’s biological activity, by restricting it to the neighbouring tissue and therefore 
                                                                                                                                            
21 
 
regulating the signalling potential through constraining the time of signal production. 
Additionally heparin sulphate was shown to influence FGF’s turnover and in a pre-
conditioned tissue culture medium at physiological temperature, binding of heparin 
stabilises the protein structure in majority of paracrine FGFs (FGF1–4/6–9/16–
18/20/22), in the exception of FGF10, which rapid degradation is independent of the 
presence of heparin (Buchtova et al., 2015). However heparin and other polyanions, 
such as sucrose octasulfate (SOS), and inositol hexaphosphate (IHP), as well as 
negatively charged liposomes, increase thermo-unfolding of FGF10 by 9-15ºC, which 
was proposed to play a role in a protein transport events (Derrick et al., 2007). 
The importance of appropriate regulation of FGF stability is further shown by 
the pathological signalling of FGF23. Mutations within FGF23 that generate protein 
resistant to degradation, result in human hypophosphatemic rickets (ADHR) (White et 
al., 2001) and familial tumoral calcinosis (FTC) (Kato et al., 2006).  
 
1.1.4 The FGF Receptors 
 
Secreted FGF ligands bind to and activate FGF Receptors (FGFRs). There are 
4 known FGFRs, that belong to the family of tyrosine kinase (TK) transmembrane 
receptors, which are composed of ∼800 amino acids and located within cell 
membrane. The extracellular, ligand binding part of the FGFRs is composed of three 
immunoglobulin (Ig)–like domains (D1-D3) and a heparin binding region. FGFRs are 
anchored within the cell membrane by a single transmembrane helix and extend into 
the cell cytoplasm with a split TK domain (Fig. 1.3 & 1.5). 
The Ig-like domains play a crucial role in FGF signalling. The D2 and D3 form 
the ligand-binding pocket and determine the affinity and specificity for the FGF and 
heparan sulphate proteoglycans (HSPGs) (Chellaiah et al., 1999). On the other hand, 
D1 is considered a negative regulator of the FGF signalling. It was shown that mutant 
receptors, lacking the D1 module, show higher affinity for the ligand and heparin 
binding than the full 3 domain receptors (Olsen et al., 2004). Moreover, D1 domain is 
an auto-inhibitor of FGFR-FGF signalling, as it binds the D2 in the ligand/heparin 
pocket thus competing with the FGF molecules for the D2 interaction. This auto-
inhibition serves two roles: primarily it further regulates FGF signalling and secondary, 
it prevents receptor self-activation through spontaneous FGFR dimerization through 
D2-D2 interaction (Kiselyov et al., 2006).  
Moreover, FGFRs contain an acidic amino acid motif, called an ’acid box’, 
which is a serine rich sequence in the linker region between the D1 and D2 domain 
(Fig. 1.3). Presence of the receptor’s acidic box aids the ligand binding regulation 
function of the D1 domain. Its importance is highlighted in neural cells, where it is 
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involved in the stabilisation of a cell surface receptor, providing interaction with N-
cadherin and neural cell adhesion molecules (NCAMs) (Sanchez-Heras et al., 2006), 













The D3 domain is encoded by three exons named the IIIa, IIIb and IIIc. The 
exon IIIa is invariant, but exons IIIb and IIIc undergo alternative splicing, resulting in 
two different isoforms of the receptor (Fig. 1.4A). The isoforms differ significantly in 
their ligand binding specificity and are transcribed in a tissue-specific manner. In 
general the IIIb isoform is expressed on a surface of epithelial cells, whilst the IIIc 
isoforms is present on the mesenchymal cells (Miki et al., 1992, Orr-Urtreger et al., 
1993, Ornitz and Itoh, 2015). Each FGF binds to either, epithelial or mesenchymal 
FGFR, with the exception of FGF1 that interacts with both receptor splice isoforms 
(Zhang et al., 2006) (Fig. 1.4B). There are four FgfR genes but only FGFR1-3 are 
alternatively spliced (Partanen et al., 1991).  
Other identified splice variants of FGFRs include Fgfr1 encoding only D2 and 
D3, generating a secreted protein which was shown to act as FGF signalling inhibitor  
(Duan et al., 1992). Moreover, an isoform of Fgfr3, lacking the transmembrane domain 
encoding exons 8 to 10, also generates a secreted protein variant, that inhibits the 
signalling pathways through binding the FGF ligands (Terada et al., 2001, Tomlinson et 
al., 2005). Furthermore, a novel membrane bound FGFR was identified, called the 
FGFR5 or FGFRL1 (Fig. 1.5), that contains either three (FGFR5β) or two (FGFR5γ) 
extracellular Ig domains, but lacks the TK domain. It is able to bind with low affinity the 
Figure 1.3 Representation of the basic structure of FGFR, showing the three 
extracellular immunoglobulin-like domains (D1, D2 and D3), indicating the position of 
the acid box (red) and heparin binding site (green). FGFR possesses a cleavable 
signal peptide (SP) targeting the protein to the membrane, anchored there via 
transmembrane domain (TM) and leaving two intracellular tyrosine kinase domains 
(TK1 and TK2) located within cell cytoplasm. 
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FGF2 ligand (but not members of the FGF7 subfamily) (Sleeman et al., 2001). 
Moreover, FGFRL1 has been found expressed in the adult pancreatic tissue, where it 




Figure 1.4 Specificity of the ligands to the receptors. (A) The immunoglobulin-like 
domain 3 (D3) of the receptors Fgfr1–Fgfr3 is encoded by three exons (a,b and c), 
where the first (a) is invariant, but second and third are alternatively spliced, 
generating either IIIb or IIIc isoforms. These are major determinants of ligand-binding 
specificity and expressed in a tissue specific manner. (B) Table showing the ligand to 
receptor specificity, which use either heparin/Heparin Sulphate or Klotho molecules as 
cofactors for the binding. The FGF7 subfamily (red) shows exclusiveness to the 
FGFR2IIIb binding (and with a lesser degree binds to the FGFR1IIIb). Figure modified 
from (Ornitz and Itoh, 2015).  
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The FGF-FGFR form a 1:1 complex (Schlessinger et al., 2000) through a strong 
network of H-bonds. However, activation of the receptor takes place only when two 
units of FGF-FGFR form a dimer. These are juxtaposed in a symmetrical complex 
fortified by binding of heparan sulphate glycosaminoglycans (HSGAG), together 
generating a ratio of 2:2:1 of FGF-FGFR-HSGAG (Harmer et al., 2004). In the complex, 
the two receptors form direct bonds between each other; moreover, each FGF ligand 
interacts with both receptors – in addition to the main interaction with the primary 
receptor, each FGF was found to bind within D2 of the second receptor through the 
‘receptor secondary binding site’. The HSGAG facilitates formation of the complex by 
simultaneously binding the ligand and the receptor, through a canyon of basic residues 
shaped by the complex itself, therefore stabilizing the multivalent protein binding 
interactions (Ibrahimi et al., 2005). The dimerization of FGFRs enables their 
cytoplasmic TK domains to transphosphorylate (therefore activate) and interact with 
phospholipase C (PLC) γ1 (or FRS1) and FGFR substrate 2 (FRS2), triggering further 
downstream pathways, resulting in the modification in cells’ gene expression (Fig. 1.5).  
 
1.1.5 Major regulators of FGF signalling 
 
The FGF signalling plays key regulatory roles during development and in the 
adult, therefore it requires a tight control itself, executed by a plethora of molecules. 
These can be promoting or inhibiting and can be either ligand or receptor specific as 
well as of a more general function.  
One of the major regulators of the FGF signalling is protein expressed by the 
Kal1 gene, called anosmin-1 (An1). An1 binds to heparan sulphate (HS) present on cell 
surface within ECM. It has a dual effect on modulation of FGF signalling. In the 
presence of HS, An1 can act as an amplifier of the endogenous and exogenous FGF 
signals. However free An1 (not-bound to HS) directly interacts with FGFRs, which 
prevents formation of active FGF-FGFR complex (Hu et al., 2009, Korsensky and Ron, 
2016).  
Another important modulator of FGF signalling is FGF-binding protein (FGF-
BP), known as a carrier and bio-activator of FGFs. It functions by releasing the ligands 
from the HSGAG binding, trapped within the ECM, therefore making them more 
accessible to the receptor. Its expression is closely regulated in a tissue specific 
manner and it plays main role during embryogenesis and wound healing. The 
importance of FGF-BP is highlighted by its high expression in most squamous cell 
carcinoma and  upregulation in breast, colon and prostate cancer (Abuharbeid et al., 
2006). FGF-BP binds to FGF2 in a specific dose-dependent manner that can be 
inhibited by FGF1, heparansulphate and heparinoids (Tassi et al., 2001).  
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Fibronectin leucine-rich transmembrane protein 3 (FLRT3), is also a protein 
known as a major activator of FGF signalling (Fig. 1.5). FLRT3 is co-expressed with the 
FGFs, meaning that its expression is induced during the FGF signalling and down-
regulated when the FGF signalling is inhibited. FLRT3 interacts with the FGFRs and 
acts as the transmembrane facilitator of the FGF induced MAP kinase pathway 
(Bottcher et al., 2004).  
An important inhibitor of the FGF signalling is protein similar expression to fgf 
genes (SEF) (Fig. 1.5). Although the expression of Sef gene itself is induced by the 
FGF signalling, it attenuates the FGF-induced Ras/MAPK pathway, in a species 
specific manner. SEF possesses two splice forms, both capable of inhibiting the ERK 
phosphorylation: one, membrane-bound, directly interacts with the FGFRs and acts 
independently of the ligand binding (Tsang et al., 2002) and second, which is confined 
to the cytoplasm and can inhibit FGF-mitogenic activity via an ERK-independent 
mechanism (Kovalenko et al., 2003, Tsang and Dawid, 2004). SEF-regulation of FGF 
signals plays key roles, for example during embryogenesis SEF is involved in 
establishment of the body axis, and postnatally SEF regulates FGF-mediated cell 
proliferation (e.g. of osteoprogenitors) (Korsensky and Ron, 2016).  
Another key inhibitor of FGF induced MAPK signalling, is the sprouty family of 
proteins (SPRY), which act through generation of a negative feedback loop (Fig. 1.5). 
FGFs activate SPRYs, which indirectly prevent ERK phosphorylation through 
interaction with growth factor receptor-bound protein 2 (GRB2), son of sevenless 
(SOS1) and RAF1 (Ozaki et al., 2005, Mason et al., 2004). Moreover, the MAP kinase 
phosphatase 3 (MKP3), through dephosphorylation of ERK also antagonises the FGF 
signalling (Fig. 1.5). It is important regulator of the FGF and retinoic acid (RA) signalling 
during organogenesis (Le Bouffant et al., 2012, Li et al., 2007).  
 
  





Figure 1.5 Schematic of intracellular signalling transduction pathways induced by FGF-
FGFR. Ligand binding to the receptor promotes complex dimerization, resulting in the 
receptors’ kinase domains mutual transphosphorylation. This activates RAS/MAPK and 
P13K-AKT signalling pathways (resulting in expression of target genes), as well as 
induction of signal transducer and activator of transcription (STAT) and phospholipase 
Cγ (PLCγ) (orange boxes). Negative regulation of the signalling is achieved through 
binding of SEF, SPRY, MAPK phosphatase 1 (MKP1) and MKP3 (red boxes). Other 
components of the pathways include: FRS2, GRB2, SOS, protein kinase C (PKC), 
inositol trisphosphate (IP3), phosphatidylinositol-4,5-bisphosphate (PIP2), 
diacylglycerol (DAG) (purple boxes). Figure adapted from (Turner and Grose, 2010). 
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Part 1.2 Introduction to Fibroblast Growth Factor 10 (FGF10) 
 
1.2.1 Overview of FGF10’s subfamily – the FGF7 subfamily  
 
FGF10, together with FGF3, FGF7 and FGF22 forms the FGF7 subfamily of 
paracrine ligands (Fig. 1.2). FGF3 is considered a member of this subfamily, based on 
its phylogenetic and functional properties, however, interestingly its chromosome 
localisation indicates association with FGF4 and FGF6 (Itoh and Ornitz, 2004). FGF7 
and FGF10 play a major role during wound healing, in the epidermal cells called 
Keratinocytes, and therefore they are also known as Keratinocyte Growth Factors 
(KGFs) (Marchese et al., 2001, Komi-Kuramochi et al., 2005). Importantly, unlike other 
FGFs, members of the FGF7 subfamily are expressed and secreted by mesenchymal 
cells and bind on the adjacent epithelial cells, generating (a unique to this subfamily) 
mesenchymal-to-epithelial (MTE) signalling (Nakao et al., 2013). Other paracrine FGFs 
act in an opposite fashion, creating an epithelial-to-mesenchymal (ETM) signals (Ornitz 
and Itoh, 2015). Moreover the characteristic of the FGF7 subfamily is an exclusive 
specificity of its ligands for the FGFR2IIIb and none of the other FGFs activate this 
receptor spliceform (Zhang et al., 2006) (Fig. 1.4). As most paracrine ligands, FGF7 
subfamily members have high affinity for HSGAG, (hence act in a localized manner, 
near the source of their expression), but they differ between each other in the strength 
of that affinity, which is linked to their differential biological function (Beenken and 
Mohammadi, 2009, Makarenkova et al., 2009). 
Despite high conservation and structure similarities, members of FGF7 
subfamily possess individual biological functions and properties. FGF7 is implicated in 
wound healing, because in skin injury the Fgf7 expression becomes significantly 
upregulated (Werner et al., 1992) and it is thought to stimulate keratinocyte proliferation 
(Dlugosz et al., 1994) and migration (Karvinen et al., 2003) resulting in wound 
reepithelialization. Moreover, FGF7 is involved in growth, development and 
differentiation of hair follicle (Danilenko et al., 1995). Interestingly, FGF7 knockout mice 
are viable and fertile with minor abnormalities, i.e. matted hair (Guo et al., 1996) and 
reduction in nephron branching in kidney (Qiao et al., 1999).  
FGF3 is a major player in inner ear development and homozygous deletions of 
FGF3 in humans lead to hereditary deafness and total inner ear agenesis (Tekin et al., 
2007). Moreover knockout mice often do not survive till adulthood and also show 
severe defects in inner ear development as well as display tail abnormalities (Mansour 
et al., 1993).  
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Unlike other members of the family, the FGF22 knockout mice are viable and 
fertile, without any obvious abnormalities (Jarosz et al., 2012). In the adult mouse 
FGF22 is expressed in skin, tongue, as well as brain tissue (Beyer et al., 2003). 
Although FGF22 is dispensable within normal and “an unchallenged” tissue (Jarosz et 
al., 2012), it has a key regulatory role in synaptogenesis (Terauchi et al., 2010, 
Terauchi et al., 2015) and in circuit remodelling in the injured spinal cord (Jacobi et al., 
2015).   
Although each member of the FGF7 subfamily has a unique role, they display 
high level of redundancy and often compensate for the lack of one another; therefore 
FGF7 and FGF22 knock out mice do not display obvious defects. Moreover their 
function is often interlinked, e.g. FGF3 and FGF10 act collectively to induce the otic 
placode (Wright and Mansour, 2003).   
 
1.2.2 Genomic localisation and control of Fgf10 expression 
 
FGF10 was first identified in 1996 from a rat brain (Yamasaki et al., 1996), 
displaying high homology to FGF3 and FGF7 proteins. Soon after Fgf10 clones were 
also derived from human (Emoto et al., 1997) and mouse (Beer et al., 1997) genomes. 
The genomic localisation of Fgf10 is not conserved among vertebrate species – in 
humans it is found on a chromosome 5 (Emoto et al., 1997, Bagai et al., 2002), in mice 
on chromosome 13 (Crackower et al., 1998) and in rats on a chromosome 2. In all 
species however structure of the Fgf10 gene consists of three exons separated by one 











There is a discrepancy within the scientific literature regarding the exact 
positioning of the Fgf10’s promoter. The genomic sequence upstream of the ATG 
transcription start site does not contain a canonical promoter TATA box. An insertion of 
Figure 1.6 Representation of genomic structure of human Fgf10 locus positioned on a 
chromosome 5. The promoter region upstream of the ATG transcription site is still under 
scientific scrutiny however, it is known to comprise multiple regulatory enhancer 
elements (see text below). FGF10 is encoded by three exons, separated by two introns, 
which layout is conserved among vertebrate species.  
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lacZ gene 114kb upstream of the Fgf10 translational start site generates an expression 
of the reporter within domains that correspond to the Fgf10 expression patterns. 
Therefore majority of the regulatory elements driving the Fgf10 expression were not 
disturbed and therefore are likely to be placed within this 114kb region (Kelly et al., 
2001, Hajihosseini et al., 2008). There is a possibility that there is no unique promoter 
region and expression of Fgf10 is driven by a magnitude of specific enhancers acting in 
a spatio-temporal manner.  
The 5’ region, 6.6kb upstream of Fgf10 transcription start site is well conserved 
(up to 75%) between human, mouse and chicken genomes (Ohuchi et al., 2005). 
Moreover, bioinformatics tools predict that within this region lay multiple binding sites 
for at least 37 transcription factors, including MSX, SOX5, LHX3, NKX25, LEF1, AP1, 
PAX6, ISL1, FAST1, GATA2 and GATA3 (Ohuchi et al., 2005). Several other binding 
sites were recognised in human, mouse and chick Fgf10 promoter located 2kb 
upstream of the translational start site. These include NFAT, MYT1, COUP, CMYB, 
VMYB, ETSF, GFI1, PIT1, AP1F, MZF1, EGRF, AREB, AP4R, PAX5, OCT1, COMP, 
and FKHD. Moreover within the 0.7-0.2kb upstream region lays an enhancer specific 
for the limb cartilage expression (Sasak et al., 2002). The bioinformatics provides a 
strong research base; however the Fgf10 expression is mediated in a time and tissue 
specific manner, with a degree of tissue-related enhancer’s sites redundancy, which 
requires experimental investigation.  
The 5’ RLM-RACE experiments investigating mouse embryonic RNA extracted 
from a lung tissue revealed, that a start site for the Fgf10 transcription is located 
1001bp (~1kb) upstream of the protein translation start site, in a GC-rich region. This 
promoter region contains binding sites for polyoma enhancer activator 3 (PEA3), that 
was shown to negatively regulate expression of Fgf10. Authors of this work however, 
have not claimed this to be an exclusive regulatory region of the Fgf10 expression 
(Chioni and Grose, 2009) suggesting a possibility of additional regulatory sites for 
Fgf10’s expression.  
Moreover, within 6.5kb of genomic DNA upstream of the Fgf10 there are three 
T-box transcription factor 5 (TBX5) binding sites (GTGTGA), homologous between 
mouse and rat species. Moreover, TBX5 has been shown to directly activate the Fgf10 
gene in order to drive the induction of an outgrowth of a limb bud (Agarwal et al., 2003). 
Interestingly, these TBX5 binding sites are utilised by the TBX1 to drive the Fgf10 
expression during heart development, specifically during differentiation of myocardial 
precursors (Xu et al., 2004). Furthermore, a single consensus (β catenin activated) T-
cell factor/lymphoid enhancer factor TCF1/LEF1 binding site (TTCAAAG) was 
discovered in mouse and human Fgf10, within the same 6.5kb promoter region, 
implicating Wnt signalling in a control of Fgf10 expression (Agarwal et al., 2003).  
                                                                                                                                            
30 
 
 Interestingly, there have been identified numerous binding sites for a nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB), within region of 5.9kb 
upstream of the Fgf10, but the NF-κB does not interact with any of them (Benjamin et 
al., 2010). Furthermore, this Fgf10 genomic region also contains multiple guanosine-
cytosine boxes (GC boxes), promoting binding of specificity protein 1 (Sp1) family 
transcription factors, and driving Fgf10 expression in the foetal lung mesenchyme, that 
is then in turn inhibited by NF-κB binding to Sp1 (Benjamin et al., 2010). Another 
protein that controls expression of Fgf10 within developing lung mesenchyme is Pre-B-
cell leukaemia transcription factor 1 (Pbx1). The ChIP assay revealed five Pbx1 binding 
sites within 4kb upstream of Fgf10 and the gene activation is further enhanced by Pbx1 
interactions with Meis and Hox proteins (Li et al., 2014b).  
Furthermore, three binding sites of trans-acting T-cell-specific transcription 
factor GATA3 (GATA3) were found present within 1.4kb upstream of the Fgf10 
(Economou et al., 2013), corresponding to the bioinformatics predictions (Ohuchi et al., 
2005). Curiously, reporter assays analysis revealed that only one of these sites is 
crucial to control Fgf10 expression throughout the development of an inner ear 
(Economou et al., 2013), but the other two might be stimulated in different tissues. 
During limb development the transcription of Fgf10 was shown to be controlled through 
an evolutionarily conserved cis-regulatory ‘AGAAAR’ element. This cluster serves as 
binding site for the ETS translocation variant1 (Etv1) trans-acting factor, which in 
cooperation with EWS RNA-Binding Protein1 (Ewsr1), regulates Fgf10 promoter 
activity generating mesenchyme-specific expression of Fgf10 in the limb buds 
(Yamamoto-Shiraishi et al., 2014).  
 Expression of Fgf10 is differentially controlled in a spatio-temporal manner. For 
example artificially increased Wnt signalling from epithelium (through overexpression of 
β-catenin) was shown to reduce Fgf10 expression in in pancreatic mesenchyme 
(Heiser et al., 2006). However, in the lung tissue overexpression of Wnt5a within the 
epithelium increases the Fgf10 expression in the mesenchyme (Li et al., 2005). 
Furthermore, it was shown that in the developing prostate, treatment with TGFβ1 
downregulated the expression of Fgf10 in the ventral mesenchymal pad, but not in the 
urethra. This regulation was achieved through TGFβ1-specific promoter element 
located between nucleotides -182 and -172, which additionally contained a consensus 
Sp1 binding site (Tomlinson et al., 2004).  
Importantly, the regulatory elements driving the Fgf10 expression are also 
located downstream of the transcription start site, within the exonic and intronic 
regions. Several binding sites are located within the first intron, that allow interactions 
of Smad4, Nkx2.5, Tbx5 and Isl1 transcription factors. Disruption of these sites by 
insertion of Cre-ERT2 cassette reduces transcript levels of the Fgf10 (El Agha et al., 
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2012). Furthermore, during development of human heart, the insulin gene enhancer 
protein 1 (Isl1) does not associate with the bioinformatics’ predicted Isl1-binding sites 
within the Fgf10 promoter region (Ohuchi et al., 2005), but it does interact, in a tissue-
specific manner, with a region within the first intron (327bp) (Golzio et al., 2012, El 
Agha et al., 2012). Treatment with retinoic acid (RA) was shown to increase expression 
of Fgf10 in mouse lung-specific mesenchymal cell line and decrease in non-lung-
derived NIH3T3 cells, through selective activation of enhancer located within 1kb 




1.2.3 FGF10 protein structure  
 
FGF10 displays high protein sequence homology between species of 
vertebrates, with 91-96% amino acid conservation between human, mouse and rat 
(Yamasaki et al., 1996, Beer et al., 1997, Igarashi, 1998). Full size of FGF10 protein 
ranges from 23-26kDa; human FGF10 corresponds to 208 amino acids (Igarashi, 
1998), mouse FGF10 is 209 amino acids (Beer et al., 1997) and rat FGF10 protein is 
composed of 215 amino acids with an intriguing long serine-repeat positioned at the N-
terminus (Emoto et al., 1997). The serine-repeat is a unique feature, not found in any 
other species however also noticed in FGF5 (Goldfarb et al., 1991); its function might 
be linked to regulation of O-type glycosylation status, but it requires further 
investigation (Yamasaki et al., 1996).  Interestingly, it has been predicted that mRNA of 
FGF10 might possess a second translational site at Met position 42 (of rat sequence) 
generating a protein of 19.2kDa however, the potential function of this isoform has not 
been described yet (Lu et al., 1999).  
FGF10’s crystal structure was determined in 2003 from which it was established 
that the protein adopts a β-trefoil fold structure consisting of 12 β-strands (Yeh et al., 
2003, Derrick et al., 2007). The first 35-40 amino acids of the FGF10 N-terminus are 
hydrophobic and correspond to a secretory signal peptide (SP) (Yamasaki et al., 1996, 
Emoto et al., 1997, Lu, 1999). FGF10 is unstable at physiological temperature (37.5ºC) 
and it undergoes thermal unfolding as well as shows presence of secondary and 
tertiary structures that change concurrently (Derrick et al., 2007). However, the protein 
structure is stabilised by binding to polyanions, such as heparin (Derrick et al., 2007, 
Buchtova et al., 2015). Low stability of all FGFs and limited half-life is thought to be a 
regulatory system, allowing time-restricted and therefore controlled signalling 
(Buchtova et al., 2015). Recombinant FGF10, stabilised by binding to heparan 
sulphate, can form dimers which show low stability at physiological temperature. The 
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stability of these dimers as well as other bigger aggregates (that have a potential of 
forming) increases with temperature below or above 37.5ºC however, it is unknown 
whether these have any functional properties (Derrick et al., 2007).    
From comparison of protein structures it was shown that the β1 strand of 
FGF10 is longer than in FGF1 and FGF2. This extension provides a unique to FGF10 
(as well as other members of its subfamily) conformation of the β1-β2 and β9-β10 
loops, that is not found in other FGFs. Moreover the β10/β11 strand pair of FGF10 is 
defined by a single hydrogen bond between the two strands. The N-terminus of 
receptor-bound FGF10 is substantially more ordered than receptor bound N-terminus 
of FGF1 or FGF2, and the first five ordered residues in FGF10 form a short helix which 
connects to β1 via a short loop. These unique structural characteristics of the FGF7 
subfamily members determine their specificity for the FGFR2IIIb splice isoform (Yeh et 
al., 2003).  
Further analysis of human protein FGF10-FGFR2IIIb complex crystal structure 
revealed that FGF10 forms specific and extensive contacts with the cleft of the D3 
domain of the FGFR2IIIb, of which most are direct or water mediated H-bonds. Sites of 
FGF10 that are known to interact with its cognate receptor are: the short helix at the N-
terminus of the protein, the β1, β4 and β8 strands and the β7-β8 loop (Yeh et al., 
2003). Furthermore, two highly specific bonds form between FGF10 Aspartate at 
position 76 (D76) and FGFR2IIIb Serine residue at position 315 (S315). The D76 is 
unique to FGF7 subfamily (being present also in FGF7 and FGF22) and the S315 is 
specific to the “b” isoform of the FGFR2, therefore bonds between these residues 
underscore the high specificity of the ligands to the receptor. Mutations of the D76 or 
S315 introduced to the ligand or receptor result in loss of the specificity and significant 
reduction or loss of the binding (Yeh et al., 2003). In addition, binding of FGF10 
generates three H-bonds with the D2 domain of the receptor, simultaneously  
introducing a 40º rotation of the D2 domain, which further confers the ligand to receptor 
specificity (Yeh et al., 2003). Within a controlled system FGF10 and FGF7 exhibit 
similar affinity towards the receptor and compete with each other for the binding 
(Igarashi, 1998, Lu, 1999). Recombinant FGF10 and FGF7 ligands, applied at high 
concentration can also bind the FGFR1IIIb isoform, but with much lower affinity than 
other FGFs (Lu, 1999, Zhang et al., 2006). This interaction with FGFR1IIIb has not 
been confirmed to take place under the normal physiological conditions, yet.  
The paracrine functioning of FGF10 is also linked to its affinity to herapan 
sulphate. This ubiquitously present component of proteoglycans is found on cell 
surfaces, in extracellular matrix as well as at basement membranes. It has divergent 
sulphation patterns (including 2-O-sulphation and 6-O-sulphation), which determine its 
binding properties with other molecules and can be directly translated onto a diverse 
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functions it serves (Ashikari-Hada et al., 2004). FGF10 is specific to the 6-O-sulphation 
of heparan but not the 2-O-sulphation, whereas FGF7 requires both (Ashikari-Hada et 
al., 2004). This might result in a fact that FGF10 has a higher affinity for immobilized 
heparin comparing to FGF7. Moreover the pericellular matrix of epithelial cells exhibits 
4 times more heparan binding sites for FGF10 than for FGF7  (Lu et al., 1999). The 
difference in the affinity for heparan sulphate reflects the differential function these 
ligands serve. Mutations of Hs6st  (a 6-O-sulfotransferase that adds sulfate groups to 
the C-6 carbon of the glucosamine residues of heparan) results in the lack of formation 
of lacrimal glands, a phenotype observed also in the FGF10 but not in FGF7 knockout 
mice, further suggesting that FGF10 and Hs6st operate in the same signalling pathway 
(Qu et al., 2011). During branching morphogenesis of the developing lacrimal and 
salivary gland epithelium buds, the variation of the binding affinity between FGF10 and 
FGF7 dictates their function. FGF10 is restricted to a domain adjacent to the tips of 
epithelial buds and is responsible for the bud elongation, whilst FGF7 is more diffuse 
and introduces branching (see section below) (Fig. 1.9). The distribution pattern and 
function of the proteins is controlled by the binding to heparan sulphate. FGF10 mutant 
in the heparan sulphate binding site, can mimic the expression pattern and function of 
FGF7 within the growing epithelial bud (Makarenkova et al., 2009).  
 
 
Part 1.3 Tissue specific function of FGF10 during development and in an adult  
 
Formation of a fully functioning organism from a single cell requires a tight 
spatio-temporal regulation of all the components involved. FGF10 is a well-known 
inducer of tissue morphogenesis during embryonic development. Particularly, FGF10 
stimulates the limb outgrowth as well as branching morphogenesis of lungs, limbs, 
lacrimal and salivary glands, teeth as well as formation of inner ear, eye structures and 
many more. Importantly Fgf10 expression has been found in mouse hypothalamus, 
which is not accompanied by expression of its cognate receptor (Hajihosseini et al., 
2008), and function of the protein in this tissue is still under investigation (see Chapter 
6).  
Fgf10 knockout mice do not survive beyond birth due to impaired lung 
development and additionally suffer from an absence of salivary, thyroid and pituitary 
glands, with minor defects in the formation of teeth, kidneys, hair follicles and digestive 
organs and are characterised by a lack of limbs (Min et al., 1998, Ohuchi et al., 2000, 
Sekine et al., 1999, Steinberg et al., 2005). Furthermore, insufficiency of FGF10 
signalling affects lacrimal and salivary glands and ducts, ears, teeth, distal limb 
segments, which was shown both, in mice and humans. Heterozygous mutations within 
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the human FGF10 gene can result in an autosomal dominant aplasia of lacrimal and 
salivary glands (ALSG) and autosomal dominant lacrimo-auriculo-dento-digital (LADD) 
syndromes (Entesarian et al., 2007, Milunsky et al., 2006), which was explored further 
in Chapter 4 (see part 4.2).  
Interestingly, elevated levels of FGF10 were also shown to cause several tissue 
defects. Higher than usual FGF10 transcript levels in adult eye sclera were found 
associated with extreme myopia (short-sightedness) in Chinese and Japanese 
populations (Yoshida et al., 2013, Hsi et al., 2013). The mechanisms underlying 
FGF10’s overproduction, as well as molecular consequences that follow, are yet to be 
described, but they might be linked to alterations in extra-cellular matrix.  
 In order to understand the molecular reasons underlying the observed 
phenotypes generated through malfunction of FGF10, key roles of this protein in 
different tissues are still under scientific scrutiny. The most prominent function of 
FGF10 in limb and lung formation, has already been well summarised in several 
reviews (Volckaert and De Langhe, 2014, Itoh and Ohta, 2014, Yamamoto-Shiraishi et 
al., 2014), although it is still under constant further investigation. However, in order to 
understand the underlying causes of symptoms resulting from FGF10’s malfunction, 
visible in LADD and ALSG, it is important to inspect the protein’s role in the teeth, ear, 
eye as well as lacrimal and salivary glands during development and in the adult tissue.  
 
1.3.1 Function of FGF10 in dental tissue and tooth formation 
 
FGF10 knockout mouse embryos show dysgenesis of teeth and absence of 
epithelial stem cell loop, which maintains and regenerates mouse incisors (Ohuchi et 
al., 2000). Human individuals with haploinsufficiency of FGF10 suffer from hypoplastic 
teeth (Entesarian et al., 2005, Milunsky et al., 2006, Entesarian et al., 2007, McKenna 
et al., 2009). FGF10 therefore is crucial for the normal development and maintenance 
of teeth. 
Odontogenesis (tooth development) is a complex process taking place during 
development as well as postnatally. The vertebrate teeth develop through inductive 
interactions between ectoderm of the first pharyngeal arch and the underlying 
ectomesenchyme derived from the neural crest (Fig. 1.7). This cross-talk between the 
two tissues results in formation of odontoblasts (derived from the mesenchyme), which 
further produces dentine, and ameloblasts (derived from the epithelium), that later 
generate enamel. 
Briefly, the tooth development begins with the initiation stage, called the 
placode, with the distinction between the vestibular and the dental lamina. Then a 
group of epithelial cells, at the periphery of the dental lamina, proliferate into a bud 
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within the ectomesenchyme of the jaw. Each tooth bud is separated from the 
ectomesenchyme by a basement membrane. Later arises the dental papilla, which is 
created by ectomesenchymal aggregation, allowing the tooth bud to grow into a “cap” 
structure. This is succeeded by the early formation of enamel and dental sac. During 
the subsequent stage, called the “bell” several complex processes take place, involving 
proliferation of progenitor cells, their differentiation, matrix deposition, and subsequent 
mineralization, overall called the histo-differentiation and morpho-differentiation. These 
lead to final mature tooth shaping and its eruption (Fig. 1.7).  
In mice, absence of FGF10 causes formation of hypoplastic teeth (Ohuchi et al., 
2000) signifying that FGF10 is not required for the induction of a tooth formation. 
Furthermore, analysis of Fgf10-deficient mice revealed that FGF10 is not involved in 
the early signalling networks, at early morphogenesis of tooth initiation (Harada et al., 
2002b).  
In postnatal mice incisor (closely resembling the developmental stages) Fgf10 
as well as Fgf3, are expressed within a restricted area of the dental mesenchyme of 
the apical end of the tooth. Fgf10 specifically is expressed in the mesenchyme under 
the inner enamel epithelium and extends into the mesenchyme surrounding the 
cervical loop, a zone underlying inner enamel epithelium (Harada et al., 1999, 
Tummers and Thesleff, 2003), which is known to expresses the cognate receptor 
FGFR2-IIIb (Fig. 1.7). Expression of Fgf3 closely resembles that of Fgf10 (Harada et 
al., 1999), and therefore it is not certain whether these two co-operate to regulate tooth 
formation, or are mutually redundant. However, expression of both Fgf10 and Fgf3 
disappears when the tooth begins to form its root (Tummers and Thesleff, 2003) (Fig. 
1.7). Another Fgf expressed during teeth formation and acting as  a major player is 
FGF9, which unlike Fgf10 and Fgf3, is detected in both dental epithelium and 
mesenchyme, however the epithelial expression is more prominent (Zhao et al., 2011) 
(Fig. 1.7).  
During the early tooth development FGF10 signalling is thought to activate cell 
proliferation in the inner dental epithelial cells (Kawano et al., 2004) via stimulation of 
the MAPK and pERK pathway, which subsequently leads to regulation of the PI3K 
activity (Cho et al., 2009). Interestingly, the pERK pathway was also activated in the 
mesenchymal cells expressing Fgf10 and inhibition of the FGF receptor does not 
reduce the levels of activated ERK in mesenchymal cells, however it does in the 
epithelium (Cho et al., 2009). Therefore potentially endogenous FGF10 could be 
responsible for the pERK stimulation in developing tooth mesenchymal cells. 
 





















Figure 1.7 Schematic representation of molar development. (A) The primary 
(initiation) stage of tooth formation is ‘the placode’ where FGF10 is expressed 
predominantly within mesenchyme, however low levels can also be detected within 
the epithelium, together with Fgf9; the Fgfr2IIIb is also present within the epithelium. 
(B) When the dental lamina forms, expression of Fgf9 and Fgfr2IIIb is localized in 
epithelium and Fgf10, at this stage, is only found within mesenchyme, together with 
the Fgfr1IIIc. (C) At bud stage, expression of Fgf3 is detectable within the epithelium, 
as well as Fgf9 and Fgfr2IIIb, however the major expression of Fgf3 now closely 
resembles that of Fgf10 in underlying and surrounding mesenchyme, where the 
Fgfr1IIIc and Fgfr2IIIc are also present. (D) When cap stage is reached, the dental 
epithelium expresses mainly the receptors Fgfr1IIIb, Fgfr1IIIc and Fgfr2IIIb; the 
mesenchyme (expressing Fgf10, Fgf3 as well as Fgfr1IIIc, Fgfr2IIIc), forms the dental 
papilla underlying the enamel knot, where Fgf3 is also expressed. (E)  During the bell 
stage, the dental epithelium still mainly expresses the Fgfr1IIIb and Fgfr1IIIc, whereas 
the expression of Fgf10 and Fgf3 is now restricted to the mesenchyme of the dental 
papilla, which also expresses the Fgfr1IIIb, Fgfr1IIIc and Fgfr2IIIc. (F) At the final, 
maturation stage, ameloblasts form from the epithelium and express Fgf9, Fgfr1IIIb 
and Fgfr1IIIc; whereas the mesenchymal cells give rise to odontoblasts that express 
Fgfr1IIIb and Fgfr1IIIc; Fgf10 and Fgf3 are no longer expressed. Figure based (Li et 
al., 2014a).  
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Furthermore, an externally applied FGF10 was shown to stimulate in vitro 
growth of a cervical loop epithelium of apical ends of the postnatal mouse incisors. 
Moreover FGF10 signalling regulates the expression of the lunatic fringe (Lfng) gene 
within the cervical loop epithelium and inner enamel epithelium (Harada et al., 1999). 
Lunatic fringe is a secretory molecule involved in the modulation of Notch signalling 
(Shifley and Cole, 2008). During tooth development, Notch signalling has been 
associated with the differentiation of dental epithelial and mesenchymal cells (Cai et al., 
2011). Therefore, FGF10 secreted by the mesenchymal cells, acts on epithelium to 
stimulate LFNG protein production, that in turn, through inhibiting Notch, promotes cell 
proliferation (Harada et al., 1999).  
Fgf10 is constantly expressed during development and postnatally (adult teeth 
that show constant growth, such as mouse incisors and vole molars) and in a dose-
dependent manner FGF10 signalling is involved in maintaining proliferation of tooth 
epithelial cells (Kawano et al., 2004), as well as establishment and maintenance of the 
stem cell compartment (Harada et al., 2002b, Harada et al., 2002a, Yokohama-Tamaki 
et al., 2006). Direct evidence shows that within the mice incisors FGF10 prevents stem 
cell apoptosis, and mesenchymal FGF10 signals maintains them within their 
undifferentiated state (Harada et al., 2002b). Expression of Fgf10 disappears after the 
initiation of root development (Yokohama-Tamaki et al., 2006), where the cells begin to 
differentiate, which demonstrates that lack of FGF10 signal results in a lack of the stem 
cell niche.  
Furthermore, FGF10 signalling controls the generation of the crown epithelium 
and FGF10 is required for the production of the stratum intermedium, which in turn 
produces enamel structures (Kawano et al., 2004). Lack of Fgf10 expression, during 
molar development leads to termination of formation of the crown and ablation of a 
stem cell compartment. Moreover, overexpression of Fgf10 causes formation of 
epithelial bulges resembling apical buds and the expansion of the crown epithelium of 
the tooth during molar development (Yokohama-Tamaki et al., 2006).  
In conclusion, FGF10 signalling promotes crown formation and ablation of 
FGF10 allows formation of a root. The termination of cell division and differentiation of 
enamel epithelial cells is one of the most important events in the transition from crown 
to root development. Control of FGF10 signal is therefore crucial for this transition to 
take place. In addition the expression of Fgf10 can occur in a variety of patterns, which 
might be linked to the diversification of teeth, i.e. the size of the tooth, a number of 
cusps and whether the teeth are of continuous or limited growth (Yokohama-Tamaki et 
al., 2006). 
Furthermore, within dental tissue the FGF10 signalling is negatively regulated 
by Sprouty proteins. Loss of sprouty genes (from both epithelium and mesenchyme) 
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causes hypersensitivity to FGF10 in the mouse dental epithelium, resulting in 
duplication and incisors oversize associated with abnormal subdivision of the 
epithelium. Reduction of FGF10 levels in the sprouty mutants partially rescues the 
normal phenotype. Moreover sprouty mutant mice show upregulation of Fgf10 
expression, but expression of other Fgfs, such as Fgf9 was unaltered (Charles et al., 
2011).  
Another factor known to affect expression of Fgf10 as well as Fgf3 and Fgf9, is 
TGFβ type I receptor (Alk5). Loss of Alk5 results in significant reduction in expression 
of Fgfs in dental tissue, which is followed by reduced number of proliferating cells in 
developing tooth. However, expression of Fgf10 (but not Fgf3 or Fgf9) can be re-
established by addition of external TGFβ2, which shows the direct control of TGFβ 
pathway over Fgf10 signalling. Moreover, FGF10 is able to rescue the dental epithelial 
stem cell defects in the Alk5 null mutant. On the contrary, FGF3 only partially and 
temporarily supports the teeth growth in the Alk5 null mice, stimulating only the transit-
amplifying cell population but (unlike FGF10) fails to rescue the true stem cells 
proliferation. Concluding therefore, FGF10 is located downstream of TGFβ signalling, 
and interactions of these two pathways forms a signalling transduction cascade that 
mediates tissue-tissue interaction during teeth formation (Zhao et al., 2011). 
Interestingly, similar TGFβ-FGF pathways were shown crucial for development of a 
tongue and other craniofacial structures (Hosokawa et al., 2010, Sasaki et al., 2006).  
 
1.3.2 Role of FGF10 in the inner ear  
 
 FGF10 is implicated in formation of the inner ear, where it acts, similarly to the 
tooth formation, in concert with the member of its subfamily FGF3. The mammalian 
inner ear arises from a simple epithelium, specifically the ectodermal placode, adjacent 
to the developing hindbrain. The otic placode is specified through multistep process of 
inductive interactions of endoderm, mesoderm and neural ectoderm. The endoderm 
and mesoderm generate the initial signals for placode induction, which subsequently 
invaginates and forms a closed vesicle in a process that is strictly controlled by the 
signals from neural ectoderm (i.e. the adjacent hindbrain). The otic vesicle initiates 
cellular differentiation and morphogenesis, resulting in mature and very complex inner 
ear containing sensory epithelia innervated by the cochlea-vestibular ganglion (Wright 
and Mansour, 2003, Alvarez et al., 2003). 
Both Fgf10 and Fgf3 are expressed during the inner ear development and are 
thought to act in combination with each other as neural signals for otic vesicle 
formation. Both Fgf10 and Fgf3 are required for induction of the otic placode, because 
the knockout of both genes results in complete absence of otic vesicle. On the 
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contrary, defects caused by single knockouts of Fgf10 or Fgf3 have incomplete 
penetrance and variable expressivity, suggestive of gene redundancy (Wright and 
Mansour, 2003). Moreover, in the Fgf10 and Fgf3 double knockout mouse embryos, 
ectopically expressed Fgf10 in hindbrain, in the place where Fgf3 is usually expressed, 
rescues the formation of the otic vesicles (Alvarez et al., 2003). This further supports 
the idea that FGF10 and FGF3 display partial redundancy.  
 
 
    
Figure 1.8 Schematic model illustrating the cochlear’s developmental defects caused 
by knockout of FGF10. At the early stages of E12.5-E13.5 in the absence of FGF10, 
induction of Reissner's membrane is abolished and does not form. At the following 
stages of E15.5, in the FGF10’s absence the outer sulcus fails to develop normally, 
which is clearly visible at the stage E18.5. Therefore, FGF10 plays a significant role in 
induction and development of non-sensory cochlear domains. Figure adapted from 
(Urness et al., 2015).  
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Importantly, each ligand is known to play individual roles, and FGF3 was shown 
to affect later stages of ear development, i.e. after formation of an otic vesicle and the 
later stages of vesicle morphogenesis. Fgf3 null mice form the otocyst as normal which 
subsequently fails to form an endolymphatic duct (Mansour et al., 1993). Similarly, the 
Fgf10 knockout mice display only a mild abnormality in the inner ear development and 
the ear appears morphologically normal during the early developmental stages, up to 
formation of the otic vesicle  (Ohuchi et al., 2000). However, at the later developmental 
stages, lack of FGF10 leads to morphogenetic and innervation abnormalities of the 
inner ear (Fig. 1.8) (Pauley et al., 2003).  
During development Fgf10 is expressed in the ventral part of the otic epithelium 
whereas its cognate receptor, the Fgfr2IIIb is activated within the dorsal side (Fig. 1.8). 
The expression of Fgf10 during the inner ear development is directly controlled by a 
GATA3 transcription factor (Economou et al., 2013). As the development progresses 
the FGF10 becomes confined to the presumptive cochlear and vestibular sensory 
epithelia and to the neuronal precursors and neuron. The receptor on the other hand, is 
found expressed in the non-sensory epithelium of the otocyst, which gives rise to 
structures such as the endolymphatic and semi-circular ducts. Therefore, FGF10-
FGFR2IIIb signalling mediates inductive processes, from sensory to non-sensory 
epithelium, during semi-circular canal formation (Fig. 1.8) (Pirvola et al., 2000).  
At the subsequent stages, Fgf10 is expressed within the mesenchyme 
underlying the prospective otic placode and signals to the receptor expressing 
epithelial cells (Wright and Mansour, 2003). Moreover, FGF10 is required for the 
removal of the fused cells after semi-circular plate formation, especially prominent at 
the posterior canal. Fgf10 null mice fail to develop the posterior crista and the posterior 
semi-circular canal and show deformations of the anterior and horizontal cristae as well 
as reduced formation of the anterior and horizontal canals (Ohuchi et al., 2005). In 
addition, the correct formation of this region is FGF10 dose-dependent, as mice 
heterozygous for Fgf10 also generate vestibular defects (i.e. a small or absent 
posterior semi-circular canal) (Urness et al., 2015). Moreover, ablation of Fgf10 
expression affects the posterior canal sensory neurons, which form initially and project 
rather normally, but they quickly disappear (within 2 days) (Pauley et al., 2003).  
In addition, recent studies show that removal of the Fgf10’s expression in the 
inner ear results in complete absence of all of the vestibular membrane (membrane 
inside the cochlea) as well as a substantial portion of the outer sulcus. These two are 
non-sensory domains, not adjacent to each other, making the FGF10 a bi-directional 
signal that promotes sequential specification of the cochlear epithelium. Failure to 
generate these two non-sensory tissues in Fgf10 null mice is not linked to 
compromised cell proliferation or increased cell death and results from lack of 
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specification of the progenitor cells through compromised signalling (Fig. 1.8) (Urness 
et al., 2015). Unlike the typical mesenchymal-to- epithelial FGF10 signalling seen in 
other tissues, it was postulated that the non-sensory development of the inner ear 
could depend on intra-epithelial signalling of FGF10.   
Furthermore, in a developing ear FGF10 induces expression of Fgf8. 
Misexpression of Fgf10, but not Fgf3, was shown to induce ectopic expression of Fgf8 
in the hindbrain (Zelarayan et al., 2007). Similar processes occur during limb formation 
(Ohuchi et al., 1999) 
 
1.3.3 FGF10 function in the development of an eyelid and an eye 
 
Mammalian eyelids develop in a similar fashion among different species. During 
gestation human and mouse eyelids close and fuse temporarily. In human they reopen 
prior to birth, whilst mouse eyelids reopen shortly after birth. The eyelid forms in few 
stages, beginning with the initiation step, marked by an ectoderm morphogenesis and 
groove formation at E11.5. Then a mesenchymal protrusion of the eyelid extends 
(E13.5), which leads to formation of projecting epithelial ridge at the tip of the eyelid 
margin at E15. Subsequently at E15/16 epithelium of upper and lower eyelid extends 
and fuses together and this fusion process is followed by extension of the 
mesenchymal cells at E16.5/17.5.  
One of the many characteristics of Fgf10 null mice is the open-eyelid phenotype 
exhibited at birth (Sekine et al., 1999, Tao et al., 2005). Moreover, a heterozygous 
mutation in Fgf10 that causes truncation of the protein and most likely leads to protein 
degradation, results in dominant slit-eye phenotype. It is characterised by abnormal 
eye-lids and atrophy of Harderian glands, but the eye displays normal size and 
morphology (Puk et al., 2009). Therefore, FGF10 is involved in normal formation of 
eye-lids in a dose sensitive manner.  
Another aberration associated with abnormal eyelid development is the ‘eyes-
open at birth’ phenotype, found in mice lacking: Activin βB (Vassalli et al., 1994), 
transforming growth factor α (TGFα) (Mann et al., 1993), epidermal growth factor 
receptor (EGFR) (Miettinen et al., 1999), aristaless-like homeobox protein (Alx4) 
(Curtain et al., 2015) and fibroblast growth factor receptor 2b (FGFR2b) (Li et al., 
2001). Therefore, together with FGF10, these molecules are required for normal eyelid 
formation.  
FGF10 is present during all of the stages of the eyelid development (Tao et al., 
2005) and its expression is partially regulated by Alx4, putatively through binding to cis 
elements within Fgf10’s promoter region (Curtain et al., 2015). During the eyelid 
initiation Fgf10 is expressed in the mesenchyme residing underneath the epithelium of 
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the emerging eyelid groove, which expresses the FgfR2IIIb. At the later stages, the 
expression of Fgf10 becomes restricted to mesenchymal cells lying just beneath the 
epithelial tip and in the developing corneal stroma. At the final stages of eyelid 
formation, Fgf10 is expressed in the eyelid mesenchyme, around the whole eye (Tao et 
al., 2005).  
FGF10 null mice show formation of the eyelid protrusion, therefore the protein 
expression is not essential for the initial stage of eyelid induction, similarly to the inner 
ear formation (see above). However, expression of Fgf10 is essential for the 
subsequent stages of morphogenic changes and maintenance of the epithelial grove. 
FGF10 signalling regulates the normal formation of mice eyelids by two means: 
maintenance of epithelial cell proliferation (at the early stages) and then stimulation of 
coordinated cell migration (at the later stages). Signalling of FGF10 regulates formation 
of actin stress fibres (F-actin) within epithelial leading edge cells of the developing 
eyelid, through activation of TGFα and Activin βB (Tao et al., 2005, Tao et al., 2006). 
Through regulation of these molecular pathways, FGF10 indirectly affects maintenance 
of epithelial cell polarisation and controls the reorganisation of the epithelial 
cytoskeleton. Moreover, when the primitive periderm cells start streaming onto the 
ocular surface, FGF10 opposes the SHH signals (arising at the leading tip) further 
promoting cell migration (Tao et al., 2005, Tao et al., 2006). 
Furthermore, FGF10 might be implicated in the development on other eye 
compartments, such as the lens and retina, where it is expressed at an embryonic 
stage E12.5 in mice. Curiously, varying from its usual mesenchymal association, at the 
late embryonic stages (E15.5 - E17.5) expression of Fgf10 is restricted to the lens 
epithelial cells. Within retina FGF10 is found within the posterior parts of the inner and 
outer nuclear layers and then within the prospective photoreceptor cells. However, 
eyes of Fgf10 heterozygous and null embryos show only minor misshaping of the 
central lens area (Puk et al., 2009), suggesting that FGF10 function might be mostly 
redundant during lens and retina formation.  
On the other hand overproduction of FGF10 causes implications in the 
formation of sclera, most likely through mediating TFGβ signalling and remodelling the 
extra-cellular matrix. In young adult mice with form deprivation myopia (FDM), i.e. a 
short sightedness, Fgf10 transcript levels are increased within the scleral cells, but not 
within retina, as compared to healthy individuals (Hsi et al., 2013). In addition, 
individuals within Chinese and Japanese population that suffer from extreme myopia, 
show overexpression of Fgf10 in eye sclera (Hsi et al., 2013, Yoshida et al., 2013). 
Moreover, abnormally expressed Fgf10 within the epithelium of cornea promotes cell 
proliferation and induces formation of ectopic ocular glands-like structures 
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(Govindarajan et al., 2000). Hence, main function of FGF10 within the ocular system is 
the formation of the lacrimal and Harderian glands (see below).  
 
1.3.4 Role of FGF10 in lacrimal and salivary glands  
 
Patients suffering from LADD and ALSG syndromes, caused by heterozygous 
mutations in FGF10, are characterised mainly by their defects affecting lacrimal and 
salivary glands and ducts (Milunsky et al., 2006, Entesarian et al., 2007). Moreover, the 
Fgf10 knockout mice do not form lacrimal and salivary glands (Min et al., 1998, Ohuchi 
et al., 2000), signifying that FGF10 is a key player in development and maintenance of 
these tissues.  
The lacrimal glands are a pair of almond-shaped structures localised at each 
side of a head, by eyes, and are responsible for a production of tears. The lacrimal 
glands secrete a layer of tear film which then flows through tear canals into the lacrimal 
sacs that drain through the lacrimal duct into the nose. Formation of the lacrimal glands 
at the embryonic stages occurs via epithelial-to-mesenchymal interaction, in a very 
similar fashion to formation of limbs, lungs and teeth. At first a small bud-like epithelial 
structure arises which is surrounded by periocular mesenchymal cells of neural crest 
origin. A tubular invagination is then shaped and subsequently extends and branches 
to generate the lobular structure of the mature gland.  
During embryogenesis Fgf10 is present in the mesenchyme adjacent to the 
budding lacrimal epithelium, where FGFR2IIIb is expressed. Analysis of the knockout 
mice revealed that, in the absence of FGF10 the mesenchyme forms as normal, 
however the epithelial component of the gland fails to develop. Similar results are 
obtained by inhibiting the FGFR2IIIb receptor, meaning that FGF10 induces the 
epithelium formation via its cognate receptor (Makarenkova et al., 2000, Govindarajan 
et al., 2000). The FGF10-FGFR2IIIb signalling within the lacrimal glands is controlled 
by the bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1 (NDST1) 
enzyme as mutations within the Ndst1 gene disrupt the Fgf10 dependent lacrimal gland 
induction. Ndst1 generates specific N-sulphation on the heparan sulphate, which in turn 
selectively potentiates the FGF10-FGFR2IIIb interaction at lacrimal gland bud. 
Activation of the receptor results in phosphorylation of ERK via Shp2 protein. Phospho-
ERK signalling pathway stimulates the Pea3/Erm transcription and cell proliferation 
(Pan et al., 2008).  
Interestingly, within the lacrimal bud region expression of Fgf7 is less distinctive 
than Fgf10, however both proteins FGF10 and FGF7, can stimulate ectopic lacrimal 
bud formation (Makarenkova et al., 2000), suggesting a degree of functional 
redundancy.  
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Salivary glands can be divided into few categories: submandibular, sublingual 
and parotid. These develop from neural crest derived mesenchyme and ectoderm 
derived epithelium. Salivary glands form in a series of stages: thickening of an oral 
epithelium, then forming a pre-bud that leads to initial bud and then pseudo-glandular, 
at the end generating a canalicular gland.  
Fgf10 is expressed within the mesenchyme surrounding the salivary gland. 
Absence of FGF10 or its receptor results in aplasia of salivary glands, however a small 
invagination forms, suggesting that initiation of the bud formation is not dependent on 
FGF10-FGFR2IIIb signalling (Jaskoll et al., 2005). Moreover, heterozygosity of FGF10 
and FGFR2IIIb leads to branching hypoplasia of the submandibular gland in mice 
(Jaskoll et al., 2005) and in humans (Entesarian et al., 2005, Entesarian et al., 2007). 
Similarly, excess of FGF10 signalling induces branching morphogenesis of the 
submandibular gland in vivo which is caused by increase in epithelial proliferation 
(Jaskoll et al., 2005). Furthermore, FGF10 induced branching of the salivary gland is 
potentially aided by the FGF8 signalling, but despite stimulation of similar intracellular 
cascades, the FGF10 and FGF8 act through different receptors and therefore cannot 
compensate in vivo for each other’s loss (Jaskoll et al., 2005).   
Similarly to the processes within lacrimal glands (Makarenkova et al., 2009), 
FGF10 promotes elongation of the salivary duct, without enlargement of the epithelial 
buds, whereas FGF7 causes budding of the epithelial rudiment, in a dose dependent 
manner (Steinberg et al., 2005). Moreover, FGF10 increases the length of the 
branches through activating the MEK1/2-dependent pathway and promoting cell 
proliferation at the tips of the growing ducts (Steinberg et al., 2005). On the other hand, 
the FGF7 promotes epithelial budding via PI3K- and MEK1/2-dependent signalling.  
Regardless of activating the same receptor isoform, FGF10 and FGF7 differ in 
the effects they cause during formation and morphogenesis of lacrimal and salivary 
glands (Fig. 1.9). FGF10 and FGF7 generate varying morphogen patterns through the 
extra-cellular matrix (ECM) determined by the affinity towards the heparin sulphate 
(HS). FGF10 with higher than FGF7 binding affinity towards HS, diffuses locally, close 
to the source of its expression, i.e. mesenchymal cells domain adjacent to the tips of 
epithelial buds. The morphogenic gradient of FGF10 is defined as ‘steep’, in which the 
concentration of ligand falls off sharply, and results in promoting cell proliferation 
mainly at the tip of the bud, causing its elongation. FGF7 on the contrary, is 
characterised by lower HS affinity than FGF10, and therefore is able to diffuse more 
freely across the ECM, forming a shallow gradient in which the concentration of ligand 
falls off gradually, in a result triggering branching of the buds (Fig. 1.9). Interestingly, 
these morphogenic patterns are not receptor or dose mediated, as reducing the 
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strength of the FGFR2IIIb binding or varying the dose of the ligands regulates the 








Figure 1.9 FGF10 and FGF7 regulate lacrimal gland bud morphogenesis. Branching 
morphogenesis is a multistep process that involves specification of the epithelium by 
the signals provided by surrounding mesenchyme. It begins by induction and shaping 
of a primary bud, which is followed by a repetitive bud elongation and cleft formation 
resulting in development of the mature and complex organ. A proposed model of 
FGF10 and FGF7 functioning in lacrimal gland bud demonstrates that FGF10, with 
high affinity to heparan sulfate, shows restricted diffusion through extra-cellular matrix, 
limited to the tip of the epithelial bud, resulting in bud elongation towards the FGF10 
source. On the contrary, FGF7 with low affinity for heparan sulfate shows a wider and 
broader diffusion range, resulting in affecting cells residing in more distal parts of the 
epithelial bud, leading to bud branching. Figure adapted from (Makarenkova et al., 
2009). This may serve as an example of branching morphogenesis taking place in 
other organs, such as lungs, pancreas, kidneys and salivary glands.  
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Interaction with HS is generated via four residues within FGF10, which in 
human protein sequence correspond to Arg187, Arg193, Lys195 and Thr197. Of these, 
the Arg187 and Arg193 were shown to be crucial for the HS binding. The R187V 
mutation abolished the interaction with HS groups, resulting in significant reduction of 
FGF10-to-HS binding in relation to wild type FGF10, whereas R193K substitution 
showed an immediate loss of heparin binding. Moreover, in lacrimal and salivary 
glands, the FGF10 R187V mutant mimics the function of FGF7 by inducing bud 
branching. Moreover, unlike wild type FGF10 but similarly to FGF7, the R187V mutant 
promotes cell proliferation in domains distal from the tip of the developing gland and 
triggers the same gene expression as FGF7 (Makarenkova et al., 2009). Furthermore, 
the FGF10 signalling during the formation of lacrimal glands is affected by modification 
of HS or other glycosaminoglycans (GAGs). Ablation of a UDP-glucose dehydrogenase 
(Ugdh) (which is an essential biosynthetic enzyme for GAGs), although does not affect 
the expression of Fgf10 in the periocular mesenchyme, leads to excessive dispersion 
of the FGF10 protein, which subsequently fails to stimulate the budding morphogenesis 
in the presumptive lacrimal gland epithelium (Qu et al., 2012).  
Another molecule known to accompany the FGF signalling during the formation 
of lacrimal and salivary glands is paired box protein 6 (Pax6), which is a transcription 
factor that signals from the conjunctival epithelium to induce the outgrowth of the 
lacrimal bud. Expression of Pax6 is a primary signal of lacrimal gland development and 
even heterozygous mutations in Pax6 cause formation of vestigial lacrimal glands and 
lead to small eye phenotype (Sey) in mice. However, Pax6 does not affect the 
expression of FGF10 within mesenchymal cells, and FGF10 does not rescue the 
defects caused by Pax6 ablation. Therefore these two proteins indirectly co-regulate 
the normal development of lacrimal glands (Makarenkova et al., 2000).   
Another molecule implicated in formation of ocular glands, alongside of FGF10, 
is Sry-related HMG box 9 (Sox9) transcription factor, and deletion of Sox9 within the 
ocular surface results in lack of formation of lacrimal gland. The FGF10 signalling was 
shown to regulate the expression of Sox9 gene, that in turn controls the initial budding 
and the elongation of the lacrimal bud, through regulation of production of the extra-
cellular matrix. Subsequently, Sox9 activates Sox10 that further controls the elongation 
and branching of the lacrimal bud as well as the formation of secretory acini. 
Interestingly, in a Sox9 knockout mice, overexpression of FGF10 in a tissue specific 
manner, only partly rescues the formation of lacrimal gland. Furthermore, Sox9 
indirectly regulates the FGF10 signalling through affecting the expression of heparan 
sulfate-synthesizing enzymes (HSSE), which are required for the synthesis and 
function of heparan sulfate (HS). Therefore, FGF10 and Sox9 generate a feedback 
loop mechanism during development of the ocular glands (Chen et al., 2014).  
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Furthermore, a homeobox protein Barx2, is expressed in the epithelium of 
lacrimal and salivary glands, and Barx2 null mice display a significant reduction and 
malformation of lacrimal glands, but not affecting the salivary glands formation. Barx2 
is required for elongation of the FGF10 induced lacrimal bud. Expressed by 
surrounding mesenchyme FGF10 generates a transducing signal that guides the 
elongation of the Barx2 expressing epithelial bug, and stimulates its outgrowth. The 
exact relationship of Barx2 and FGF10 is still under scrutiny however, Barx2 null cells 
are unresponsive to FGF10 treatment, signifying Barx2 is downstream of FGF10. At 
the succeeding stages, Barx2 and FGF10 cooperatively regulate the expression of 
matrix metalloproteinases (MMPs), which are necessary for the epithelial bud 
outgrowth and cell proliferation. It has been proposed that MMPs control the signalling 
gradient of FGFs, through degradation of the extra-cellular matrix and release of these 
signalling ligands from binding to heparan sulphate and other proteoglycans, 
generating a regulatory feedback mechanism. Barx2, controlled by FGF10 signalling, 
binds directly to the promoter region of mouse MMP2, promoting gene expression. 
Surprisingly, this regulatory mechanism is unique to lacrimal glands, as despite the 
high levels of expression of Barx2 in the salivary glands, in the knockout mice salivary 
glands develop as normal, suggesting a redundant role of the protein in this tissue and 
highlights the tissue specificity of the FGF10 functioning (Tsau et al., 2011). 
 
1.3.5 Overview of role and function of FGF10 in other tissues 
 
 Beyond those described above FGF10 is implicated in development and 
maintenance of multiple tissues and organs. For example, FGF10 is abundantly 
expressed within adult vascular-stromal fraction of a white adipose tissue, majorly 
composed of adipocyte precursors, raising interesting possibility of FGF10’s 
involvement in adipogenesis (Sakaue et al., 2002). Moreover, FGF10 was shown to 
promote differentiation of the precursors into mature adipocytes (Zhang et al., 2010b). 
Importantly, in the FGF10 null mice embryos, development of the white adipose tissue 
is greatly impaired, displaying decreased proliferative activity of preadipocytes and 
greatly reduced expression of C/EBPβ and PPARγ transcription factors (Asaki et al., 
2004).  
 FGF10 signalling plays also a crucial part in formation of heart’s right ventricle 
and its outflow tract from myocardial progenitors (Urness et al., 2011). Fgf10 knockout 
mice show reduced proliferation of cardiomyocyte in heart’s right ventricle. FGF10 
signalling was shown to promote phosphorylation of forkhead box O 3 (FOXO3) 
transcription factor, which leads to decrease in expression of the cyclin-dependent 
kinase inhibitor p27kip1 and promotes proliferation. Interestingly, in the adult tissue, 
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overexpression of Fgf10 generates rapid induction of cardiomyocyte cell cycle re-entry 
(Rochais et al., 2014). 
 Fgf10 knockout affects liver, through impairing the proliferation of hepatoblasts. 
The FGF10 signalling was shown to stimulate the embryonic stellate/myofibroblastic 
cells to promote β-catenin activation and survival of hepatoblasts (Berg et al., 2007). 
Furthermore, FGF10 is implicated in bladder formation and was shown to stimulate the 
differentiation of human stem cell into urothelial cells (Chung and Koh, 2013). 
Interestingly, FGF10 was found present in the nuclei of human urothelial cells (Kosman 
et al., 2007). Several other paracrine FGFs were shown to act from the cell nucleus, 
which is described in more detail below.   
 
 
Part 1.4 Role and function of nuclear FGFs 
 
1.4.1 General overview of nuclear proteins 
 
In addition to an extracellular receptor-mediated signalling, several paracrine 
FGFs were shown to function in an intracellular fashion through direct interaction with 
cytosolic and/or nuclear proteins. For example,  FGF1 and FGF2 both can bind to 
casein kinase 2 (CK2) protein, which is involved in control of a cell-cycle progression 
(Skjerpen et al., 2002). Furthermore, FGF1 binds to acidic FGF intracellular binding 
protein (FIBP) (Kolpakova et al., 1998) and mortalin (Mizukoshi et al., 1999), although 
the functional result of this interaction is yet not clear. FGF2 has been postulated to 
modulate a ribosomal activity via direct interaction with ribosomal proteins 
L6/TAXREB107 (Shen et al., 1998) and RPS19 (Soulet et al., 2001), postulating a role 
of FGF2 in preribosomal assembly and translational control of cell growth during viral 
infection. 
Interestingly, FGF1, FGF2, FGF8 and FGF22 as well as FGFR1, FGFR2 and 
FGFR3 have been found translocating to and functioning from a cell nucleus, either 
individually or as a ligand-receptor complex. 
 
1.4.2 Mediators of protein nuclear import  
 
Cell nucleus encloses the genetic material and the transcriptional apparatus, 
separating it from the cytoplasmic translational and metabolic machinery via a double 
phospholipid membrane, that prevents larger molecules to freely shuttle across. 
Therefore, movement of proteins and other molecules across the nuclear envelope is 
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strictly controlled and takes place via nuclear pore complexes (NPCs). These are large 
macromolecular structures (~124MDa) (Reichelt et al., 1990), composed of at least 456 
individual protein molecules and with a total diameter of ~120nm (Winey et al., 1997), 
spanning both nuclear membranes. NPCs are typically built from multiple copies of a 
protein termed nucleoporin (Nups). These nuclear channels are large enough to allow 
passive diffusion of proteins smaller than 40μm in diameter (or ~40kDa). However, it 
has been demonstrated that, even some of the smallest proteins in a cell, such as 
PTHrP (Cingolani et al., 2002) and histone H1 (Jakel et al., 1999), use specific carrier-
mediated transport, demonstrating that, for the nuclear import, the rate at which cargos 
enter cell nucleus is more important factor than the protein’s size. Therefore, it is 
thought that all proteins serving particular nuclear functions are selectively and actively 
uptaken into the nucleus, regardless of their size (Christie et al., 2015).   
Carriers that mediate this nuclear protein transport belong to the β-karyopherin 
(β-Kap) superfamily of solenoid proteins, which is composed of importins and 
exportins. Structure of all β-Kap family members includes two tandem HEAT repeats 
(antiparallel α-helices of ~40–45 amino acids), named A and B and linked by a loop. 
Furthermore, the nuclear transport is dependent on a small GTPase named Ran (Fig. 
1.10), which cycles between GDP/GTP-bound states, as determined by Ran regulatory 
proteins, such as nuclear located Ran guanine nucleotide exchange factor (RanGEF) 
and cytoplasmic Ran GTPase-activating protein (RanGAP) (Lui and Huang, 2009). Ran 
protein contains a small G-domain and two surface loops (switch-I and switch-II), which 
change conformation depending on the nucleotide-bound state of the protein. 
Importantly, the gradient of RanGDP/GTP generated by the regulatory proteins 
(RanGEF and RanGAP), establishes directionality in nucleocytoplasmic transport 
pathways (Gorlich et al., 1996).  
There are few known pathways that provide protein’s nuclear transport. Majority 
of proteins contain specific motifs on their surface called a Nuclear Localisation (NLS) 
or Nuclear Export Sequence (NES), and nuclear import and export are usually 
mediated via different pathways. NLSs are short peptide motifs, classified into classical 
(if consensus) and non-classical (if of unique pattern). Moreover, NLS can also be 
monopartite, consisting of a cluster of basic (Arginines/R and Lysines/K) amino acid 
residues and bipartite, where two smaller clusters of basic residues are separated by a 
stretch of about 10 amino acids, which typically fold into close proximity in the 3D 
structure of a protein.  
Typically, the classical NLS is recognized by one of the isomers of importin-α 
(Imp-α) protein family, that serves as an adaptor linking the cargo to a carrier protein, 
i.e. one of the isoforms of the importin-β (Imp-β1) protein family, which transports the 
complex through the NPC (Fig. 1.10) (Christie et al., 2015). Alternatively, several 
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members of the importin-β family were shown to directly bind to cargo proteins, or use 
a different adaptor protein, called snurportin1 (SNP1) (Mitrousis et al., 2008, Marfori et 
al., 2011).  
 Importantly, the Imp-α possesses two functional and structurally distinctive 
domains. These are the N-terminal Impβ1-binding domain (αIBB), and a C-terminal 
armadillo (Arm) domain, which consists of 10 tandem Arm repeats, each generated by 
three α-helices (H1, H2 and H3) (Herold et al., 1998, Marfori et al., 2011).  Structural 
studies revealed that cargo’s classical NLS typically binds in a highly conserved 
concave groove on a surface of Imp-α. This groove typically contains an array of 
Tryptophan/W and Asparagine/N residues at the third and fourth turns of the H3 
helices. Furthermore, the groove is divided into the high-affinity “major” (residues from 
Arm repeats 2–4) and the “minor” sites (Arm repeats 6–8). Monopartite NLSs can bind 
in either of the two sites, whereas the bipartite NLSs bind in an extended conformation 
to both major and minor binding sites, with the N-terminal basic cluster in the minor 
site, and the C-terminal basic cluster in the major site (Marfori et al., 2011).  
 Interaction of cargo protein’s NLS with the Imp-α subsequently leads to further 
complex formation with the Imp-β1 (Fig. 1.10). Imp-β1 binds with high affinity the Imp-
α, wrapping tightly around the Imp-α’s αIBB domain and covering over 40% of its 
surface area (Cingolani et al., 1999). After complex formation, in order to pass through 
the nuclear pore the Impβ1 interacts directly with Nups, through the HEAT motif located 
on the importin and ‘Phenylalanine-Glycine’ (‘FG’) tandem repeats of nucleoporins 
(Marfori et al., 2011, Christie et al., 2015).  
The family of the β-Kap proteins shows a large repertoire of proteins with low 
sequence conservation but high degree of structure similarity. In humans there have 
been identified around 20 β-Kaps, of which 10 are known to mediate transport of 
proteins into the nucleus, another 7 mediate the reverse, nucleus to the cytoplasm 
transport, other 2 were shown to mediate translocation in both directions and the 
remaining one is still not fully characterized. Different β-Kaps are known to be 
expressed in a tissue-specific manner and typically recognize different classes of cargo 
proteins. However, there is also a degree of redundancy present as several β-Kap 
receptors able to recognize the same cargoes (Chook and Suel, 2011, Christie et al., 
2015).  








  Figure 1.10 Model representing different nuclear import pathways. In the classical 
pathway, the nuclear localisation sequence (NLS) present on the cargo’s surface 
binds to Importin-α (Imp-α) adaptor that subsequently interacts with the Importin-β 
(Imp-β1), resulting in the whole complex translocation through the nuclear pore (blue). 
Alternatively, Importin-β binds directly to the cargo protein allowing its nuclear import. 
The complexes dissociate in the nucleus in the presence of RanGTP (solid gray). 
Proteins may also be chaperoned into the nucleus through alternative pathways, not 
involving the classical imporin-mediated pathways, although these are not well 
described so far. Figure based on (Christie et al., 2015). 
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Many proteins shuttle in as well as out of the nucleus, and the nuclear export 
pathway is typically mediated via interaction between NES and exportins. There are 
seven identified exportins so far, among which the chromosomal maintenance 1 
(CRM1) protein is the major nuclear export receptor for protein cargos (Xu et al., 2012). 
CRM1 transports not only proteins, but also mRNAs and rRNSs however, functions 
only in the form of a ternary complex, which also includes the RanGTP (Ishizawa et al., 
2015).  
 
1.4.3 Import and function of nuclear FGF1 
 
Externally applied to eukaryotic cells FGF1 (also known as acidic FGF), was 
found to translocate into the cell nucleus (Wiedłocha et al., 1994, Klingenberg et al., 
1998) where it was thought to stimulate DNA synthesis (Wesche et al., 2005a). The 
nuclear uptake of this paracrine molecule is preceded by an endocytosis of the protein 
through a cell membrane. FGF1 is able to interact with all of the FGFRs (Fig. 1.4B), 
located on a cell surface, but the endocytosis of the protein is stimulated only by 
binding to the FGFR1 or FGFR4 (Sorensen et al., 2006). This process was shown to 
be dependent on the receptor’s C-terminal tail, although interestingly it is independent 
of the receptor’s tyrosine kinase domain activity (also located within the receptor’s C-
terminus) (Sorensen et al., 2006). Endocytosis of the complex is further induced by a 
vesicular membrane potential (Malecki et al., 2002).  
The internalised FGF1 translocates into the cell nucleus via the classical 
nuclear import pathway mediated by importins Kpnα1 & Kpnβ1, Ran GTPase as well 
as a leucine rich repeat containing 59 (LRRC59) protein (Sorensen et al., 2006, Nilsen 
et al., 2007). Interestingly, FGF1 contains two NLS sequences. One, a monopartite 
NLS is located within the N-terminal domain of the protein (Imamura et al., 1990), 
whereas the second, bipartite NLS resides within the C-terminus of the protein 
(Wesche et al., 2005a). Both NLSs are required for efficient nuclear transport of 
endocytosed FGF1. Interestingly, simultaneous mutation of both NLSs significantly 
reduces the FGF1 ability to stimulate DNA synthesis, while single mutations do not 
seem to have any considerable effect  (Wesche et al., 2005a).  
The comparison of the FGF1 primary sequences revealed that both of the NLSs 
are highly conserved across various vertebrate species (Wesche et al., 2005a), which 
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1.4.4 Overview of nuclear FGF2 
 
FGF2 belongs to the same subfamily of FGF proteins as FGF1 (Fig. 1.2) 
however, the process of nuclear FGF2 translocation differs from the one associated 
with FGF1 (Bouche et al., 1987). Unlike other FGFs, the FGF2 does not contain the 
classical signal peptide motif and therefore is secreted out of the cell through 
unconventional pathway, which does not involve the Endoplasmic Reticulum and Golgi 
(Mignatti et al., 1992). Furthermore, there are 5 distinct forms of human FGF2 protein 
arising from differential translation of the mRNA. These so called “protein isoforms” are 
synthesised through an alternative translation initiation process rather than gene 
alternative splicing. Four of FGF2 isoforms are CUG-initiated, called high molecular 
weight (HMW) (22-34kDa) and found exclusively in the cell nucleus. The smaller AUG-
initiated protein is called  low molecular weight (LMW) (18kDa) and found in both the 
cytoplasm and nucleus (Renko et al., 1990).  
The HMW protein isoforms contain an N-terminal NLS which confer their 
exclusive nuclear localisation (Quarto et al., 1991). Moreover, the nuclear accumulation 
of the HMW isoforms (but not the LMW) is further controlled by the post-translational 
modifications. It appears that methylation of specific arginine residues is essential for 
the nuclear localisation of the HMW isoforms. Treatment of fibroblast cells with 
Methyltransferase inhibitors prevents methylation of these arginine residues and results 
in significant reduction of the HMW FGF2 nuclear accumulation (Pintucci et al., 1996). 
The secreted LMW FGF2 binds and activates several isoforms of FGFRs (Fig. 1.4B) 
and interestingly, the ligand-receptor complex can be internalised into the cytoplasm, in 
a similar fashion to FGF1 (Malecki et al., 2004), and chaperoned by heat shock protein 
90 (Hsp90) protein (Wesche et al., 2006). From the cytoplasm the endocytosed LMW 
FGF2, despite the lack of the N-terminal NLS, can translocate into the cell nucleus 
(Clarke et al., 2001), where it possibly functions to up-regulate the ribosomal RNA 
synthesis (Bouche et al., 1987). Interestingly, an endogenous LMW FGF2 is also 
uptaken into the cell nucleus. Inhibition of FGFR within epithelial cells, preventing the 
internalisation of the secreted molecule, did not abolish the nuclear localisation of the 
LMW protein (Dell'Era et al., 1991). The critical factor of the nuclear-cellular shuttling of 
LMW FGF2 is translokin/CEP57 protein (Bossard et al., 2003, Meunier et al., 2009) 
because decline in translokin levels leads to reduced translocation of FGF2 and affects 
its mitogenic function decreasing cell proliferation (Bossard et al., 2003).  
FGF2 is thought to contain a second N-terminal NLS based on its sequence 
similarity to the NLS found within the FGF1 protein. Importantly, this sequence is 
present also within the LMW FGF2 (Presta et al., 1993). However, mutations of this 
NLS did not prevent the FGF2 from entering the cell nucleus, indicating that this is not 
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a unique motif that determines the intracellular localisation of the protein (Presta et al., 
1993) but potentially aids the protein translocation. All forms of the FGF2 protein 
contain also a non-classical bipartite NLS within the C-terminus (Sheng et al., 2004). 
Mutating both NLS motifs (at the N and C terminus) fully prevents the nuclear 
localisation of the protein (Foletti et al., 2003). Moreover, the C-terminal NLS plays a 
significant role in the nucleolar targeting and localisation of FGF2 (Sheng et al., 2004). 
Overall, these studies show therefore that HMW FGF2 contains two NLSs at the N-
terminus (of which one is a weak one) and one bipartite NLS at the C-terminus. The 
LMW FGF2 contains a weak NLS at the N-terminus and a bipartite NLS at the C-
terminus, which is sufficient for their nuclear localisation.  
The intracellular differences in distribution of FGF2 variants, HMW within the 
nucleus and LMW directed to the secretory pathway, is the major determinant of their 
functional diversity. The LMW FGF2 serves a paracrine function through activation of 
the transmembrane receptor, whereas the HMW FGF2 plays FGFR-independent 
intracellular role. This leads to differential routes of nuclear translocation, i.e. LMW 
FGF2 nuclear import is translokin and/or FGFR dependent, whereas the HMW FGF2 
does not relay on the receptor complex formation and possesses the N-terminal NLS, 
absent in the LMW FGF2. These differences then reflect on the differential nuclear 
distribution of the FGF2 variants and lead to differential functions they serve within the 
nucleus.  
The nuclear LMW FGF2 in Schwann cells (Claus et al., 2003) or the NIH3T3 
cell line (Dini et al., 2002) is localised in nucleoli and Cajal bodies, which are a sub-
organelles found in the nucleus of proliferative cells (Claus et al., 2004). This is 
reflected in the protein function, as LMW FGF2 has been found to stimulate rRNA 
synthesis, and induces cell proliferation and chemotactic movement (Dini et al., 2002).  
The HMW FGF2 shows a punctuate pattern in the nucleoplasm and periphery of 
nucleoli, and co-localises with DNA and mitotic chromosomes (Claus et al., 2003). 
HMW FGF2 was detected in a variety of cultured cells, including osteoblasts (Sobue et 
al., 2001), cartilage (Krejci et al., 2007), epithelial (Galy et al., 1999), aortic endothelial 
(Couderc et al., 1991) cell lines as well as primary astrocytes (Li et al., 2006). The 
HMW FGF2 increases the proliferative potential of NIH3T3 and A31 cells, whilst the 
LMW FGF2 effect on cell proliferation of these cells is much lower. On the other hand, 
cells expressing the LMW FGF2 show higher migratory potential than cells expressing 
the HMW variants (Dini et al., 2002). Another difference is that the HMW FGF2 but not 
LMW variant is necessary for promoting estradiol dependent angiogenesis as well as 
endothelial cell migration and proliferation (Garmy-Susini et al., 2004). 
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1.4.5 Nuclear FGF3 
 
FGF3 protein belongs to FGF7 subfamily of FGFs (Fig. 1.2). It was first 
identified as a secretory molecule acting as an oncogene in mouse mammary tumours 
(Muller et al., 1990), suggesting its role in cell proliferation. Nuclear FGF3 is thought to 
serve a quite opposite function, inhibiting DNA synthesis and reducing cell growth 
(Kiefer and Dickson, 1995b). 
The unusual feature of FGF3 biosynthesis (similarly to FGF2) is the use of 
alternative initiation codon CUG. This generates different protein isoforms extended at 
the amino terminus (Dickson et al., 1989). Alike FGF2, the high molecular weight 
isoforms (HMW) of FGF3, with extended N-terminal, seem to accumulate directly in the 
cell nucleus (Acland et al., 1990).  
FGF3 appears to be targeted in a similar proportion to the nucleus and to the 
secretory pathway. The signals responsible of directing the protein either for the 
nuclear import or endoplasmic reticulum (ER) entry are placed at the amino terminus 
within the protein sequence itself. Newly synthesised protein contains a hydrophobic 
signal peptide (SP) at its N-terminus that targets FGF3 for the vectorial transport 
across the ER (Dickson et al., 1991, Kiefer et al., 1994a). Next to the SP resides a 
classical, but relatively weak, bipartite NLS that allows protein entry to the cell nucleus 
(Kiefer et al., 1994a). This bipartite NLS is not crucial for the nuclear accumulation and 
nucleolar association of the protein. In the absence of the signal peptide mutations of 
this bipartite NLS did not prevent FGF3 from entering the nucleus (Kiefer and Dickson, 
1995b). However this sequence is sufficient for the recognition and binding of an 
importin protein (karyopherin α/NPI-1) (Antoine et al., 1997) which is essential for the 
active transport of the complex through nuclear pores.  
The weak signals at the N-terminus are thought to allow competition between 
the intracellular distributions of the protein. Weak NLS however, is not sufficient to 
cause nuclear transport of the protein, therefore FGF3 contains several additional weak 
NLS-like motifs which act to enhance nuclear uptake without affecting the balance 
between the two opposing trafficking pathways. These additional motifs are rich in 
basic residues and reside within the C-terminus of the FGF3 sequence. They act as 
fine tuning factors supporting the N-terminal NLS for the nuclear targeting of the protein 
when required but individually are not able to define the protein to the nucleus (Kiefer 
and Dickson, 1995b). Moreover, these factors also aid retaining the protein in the 
nucleus by facilitating binding to nucleolar proteins through (functionally conserved 
between mouse and human) nucleolar binding motifs (NBM) (Antoine et al., 1997). 
Interestingly, the nucleolar retention of FGF3 results in inhibition of cell growth and 
proliferation (Kiefer and Dickson, 1995b). Moreover, nucleolar FGF3 directly interacts 
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with nucleolar binding protein (NoBP), which might function to regulate division stage of 
cell cycle (Reimers et al., 2001).    
 
1.4.6 Nuclear localisation of FGF8 and FGF22 
 
FGF8 is known for its conventional mitogenic function during development and 
patterning of vertebrate embryo. FGF8 gene is alternatively spliced, in humans 
generating four protein isoforms (a-d), each serving different functions, for example 
during brain patterning (Olsen et al., 2006). Importantly, exogenously applied mouse 
FGF8b was observed to translocate into the nucleus of mouse fibroblast cells (Suzuki 
et al., 2012). The molecule is secreted out of the cell, then internalised by the 
surrounding cells (possibly through interaction with FGFRs) and incorporated into their 
nucleus, as demonstrated on the chick embryonic neural tube studies.  
Sequence analysis revealed that FGF8 might potentially contain a NLS, 
although this point requires further investigation. Nonetheless FGF8b, that lacks signal 
peptide mostly localises to the cell nucleus of mouse fibroblast cells. Moreover 
endogenous FGF8 was detected in vivo, in the nuclei of the embryonic mouse isthmus 
(Suzuki et al., 2012). It was postulated that nuclear FGF8 directly induces expression 
of Sprouty2 gene (Suzuki et al., 2012).  
FGF22 is a member of the FGF7 subfamily, to which FGF3 and FGF10 also 
belong (see Fig. 1.2). Transiently transfected FGF22 (fused to a small hemagglutinin A 
(HA) tag) into human breast adenocarcinoma MCF-7 cells was found localised to large 
nuclear bodies. Interestingly, transfection into monkey kidney, fibroblast-like COS-1 
cells FGF22-HA was localising to the reticular and perinuclear cell compartments, 
indicating its association with ER and secretory pathway network (Beyer et al., 2003). 
The molecular mechanisms driving the nuclear import of FGF22 and its nuclear 
function are currently not described.  
 
1.4.7 Nuclear FGF10 
 
Interestingly recombinant FGF10 has been found in the nuclei of cultured 
urothelial cells (Bagai et al., 2002) and was postulated to contain a NLS, in human 
corresponding to residues 132MNKKGKL141 of a full protein sequence (Kosman et al., 
2007). This NLS sequence was identified basing on its similarity to the NLS present in 
the FGF1 protein (21NYKKPKL27). Interestingly, mutation of this FGF10’s NLS region, 
did not prevent the protein from localising within the nucleus however, it has shown that 
it might play a role in retaining FGF10 within the nucleus (Kosman et al., 2007). 
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Part 1.5 Introduction to hypothalamic stem cells and neurogenesis 
 
Expression of Fgf10 was found in several brain regions, one of which is 
hypothalamus, where the protein is expressed mainly by cells named tanycytes 
(Hajihosseini et al., 2008, Haan and Hajihosseini, 2009). Although tanycytes that 
FGF10 demarcates were shown to possess neurogenic potential, the function of the 
protein itself within this these cells is currently unclear. Importantly, expression of 
FGF10’s cognate receptor FGFR2IIIb was not detected in the adult mouse brain 
(Hajihosseini et al., 2008), suggesting an alternative mode of function of FGF10 
protein. Therefore, studies of FGF10’s mode of action within hypothalamus might 
generate interesting insight into intracellular/nuclear function of the protein.  
 
1.5.1 Overview of hypothalamus 
 
The hypothalamus is situated around the brain’s third ventricle (3V), below 
thalamus and above pituitary gland (Fig. 1.11A). The hypothalamus is known as the 
centre of neuroendocrine and autonomic regulations that control the homeostatic body 
functions, which include: maintenance of body temperature, regulation of metabolic 
processes as well we coordination of hormonal and circadian cycles. Moreover, 
regions within hypothalamus were shown triggered during various emotional and 
instinctive activities, such as reproduction as well as aspects of parenting and 
attachment behaviours (Narita et al., 2012, Savic et al., 2005, Berglund et al., 2006). 
Importantly, hypothalamus is also the core regulator of appetite as well as energy 
uptake and expenditure (Sousa-Ferreira et al., 2011, Graham et al., 2003a).  
Grossly, the hypothalamus is composed of three main structures referred to as 
the ependyma, the median eminence (ME) and the parenchyma (Fig. 1.11B). The 
parenchyma flanks the 3V and contains distinct ‘neuronal nuclei’ sharing neuronal 
interconnections. These are: the arcuate nucleus (ARC), the ventromedial (VMN), 
lateral (LHN), dorsomedial (DMN) and the paraventricular (PVN) nucleus (Fig. 1.11C). 
The median eminence (ME) is positioned on the ventral side of the hypothalamus (Fig. 
1.11B), providing connection between hypothalamus and the pituitary gland and 
generating the hypophyseal portal system. One of the key functions of the median 
eminence is the transmission and secretion of hormones, such as corticotropin-
releasing factor (CRF) (Romanov et al., 2015), gonadotropin-releasing hormone 
(GnRH) (Kenealy et al., 2015), thyrotropin-releasing hormone (TRH) (McKelvy et al., 
1975), growth hormone-releasing hormone (GHRH) (Anderson et al., 2010) and 
dopamine (DA) (Arita and Kimura, 1986).   
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The ependyma corresponds to a single cell layer of epithelial-like cells that 
forms a boundary between the hypothalamus and the third ventricle (Fig. 1.11B). It is 
therefore also referred to as the ependymal wall of the third ventricle. Ciliated cells 
occupy the more dorsal parts of the ependymal whilst, non-ciliated cells with radial 
glial-like characteristics, such as tanycytes, reside in the floor and ventral lateral parts. 
 
  
Figure 1.11 Localisation and structure of mouse hypothalamus. (A) Schematic 
drawing showing hypothalamus (red) located on a ventral side of mouse brain. (B) 
Schematic of hypothalamic coronal section showing the three main structures 
composing hypothalamus (C) Hypothalamic micrograph with superimposed schematic 
adapted from (Goodman and Hajihosseini, 2015), showing the organisation of 
tanycytes residing around the third ventricle (3V) and extending to the specific 
hypothalamic nuclei – α tanycytes reside medio-dorsally and extend mainly to the 
ventromedial (VMN) nucleus, while β tanycytes are located ventro-medially, within the 
median eminence (ME) and the arcuate nucleus (Arc). 
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1.5.2 Hypothalamic tanycytes – overview of the origin and organisation 
 
The term “tanycytes” was first proposed by Horstmann in 1954 – it originates 
from the Greek word tanus, meaning “elongated”. Tanycytes are bipolar cells, known to 
be crucial connectors between hypothalamus and pituitary gland (Rodriguez et al., 
2005). Tanycytes have a very distinctive elongated shape and can be distinguished 
from other ependymal cells by the lack of beating cilia. However, they possess a single, 
long basal process that projects to the VMN and ARC nuclei and to the median 
eminence (Fig. 1.11C). They emerge from a subpopulation of radial glial cells during 
the perinatal embryonic stages - E19 in rats and E17 in mice. In developing brain, 
these pre-tanycyte radial glial cells are regarded as neural stem/progenitor cells. In 
developing brain, radial glial cells are widely regarded as neural stem/progenitor cells. 
Tanycytes display several intriguing characteristics, such as ability to proliferate, short 
term signalling via changes in intracellular Ca2+ (Dale, 2011) and expression of specific 
markers (e.g. Nestin, Vimentin, Sox2 and Musashi) (Wei et al., 2002), which indicate 
that they have retained the properties of radial glial cells. The process of specification 
of tanycytes from the ciliated ependymal cells is regulated in part by transcription factor 
Lhx2 acting upstream of the gene Rax. It was shown that in the absence of Lhx2, the 
development of tanycytes is severely disrupted. Loss of Lhx2 resulted in lack of 
expression of tanycyte-specific genes and instead activation of ependymal-specific 
markers (Salvatierra et al., 2014).  
Tanycytes are divided into two main groups (α and β), based on their 
positioning, morphology and function – cells located near to the dorso-ventral and 
ventro-medial hypothalamic nuclei are referred to as α1 and α2 tanycytes; and cells 
positioned more ventrally, close to the ARC and median eminence are known as β1 
and β2 tanycytes (Fig. 1.11C). However, there is no clear boundary between the α and 
β tanycytes as cells of the different subtypes interdigitate forming a transition zone 
(Fig. 1.11C). For that reason reliable isolations of specific subtypes through 
microdissection of fresh brain extracts is particularly difficult (Goodman and 
Hajihosseini, 2015). In general, α tanycytes bridge the lumen of the third ventricle and 
terminate in close proximity of neurons within parenchyma, while β tanycytes establish 
a link between the ventricular cerebrospinal fluid (CSF) and the portal blood. Cell 
processes of the β1-tanycytes contact the parenchymal capillaries and segregate the 
ARC from the median eminence and the β2-tanycytes arch back medially and ventrally 
to contact the pial surface (Fig. 1.11C).   
Anatomical tanycyte subdivisions have been additionally characterised by 
molecular markers, further highlighting differences between the subgroups. Although 
the α and β tanycytes share expression of Sox2 (Haan et al., 2013), Vimentin 
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(Brauksiepe et al., 2014) and Glucose transporter 1 (GLUT1) (Peruzzo et al., 2000), 
they also express cell-type specific genes/markers. For example, α tanycytes, express 
GFAP (Haan et al., 2013), GLAST (Robins et al., 2013), S-100β (Goodman and 
Hajihosseini, 2015) and Connexin43 (Rodriguez et al., 2010) which are also found 
within the dorsal ependymal cells, but not found in β tanycytes. On the other hand β 
tanycytes express BLBP (Haan et al., 2013), CNTFR (Kokoeva et al., 2005) and 
FGF10 (Hajihosseini et al., 2008) that are absent from the α tanycytes and the dorsal 
ependymal cells.  
Moreover, there are further marker expression differences defining the specific 
tanycyte subtypes, for example the GLUT1 expression can be detected in the α and in 
the β1 tanycytes but it is absent from the β2 tanycytes (Peruzzo et al., 2000, Robins et 
al., 2013), and the adenosine triphosphate (ATP) is abundant in the α1 tanycytes 
(which are facing the VMN) and absent from all the other subtypes (Rodriguez et al., 
2005).   
The functions of the specific subtypes of tanycytes is still under investigation, 
however their strategic positioning at particular places around the 3V suggests their 
involvement in regulation of homeostasis (Fekete and Lechan, 2014) and control of 
appetite and energy expenditure (Frayling et al., 2011, Bolborea and Dale, 2013). 
Moreover tanycytes express several genes that have been linked to control of body 
weight and energy levels, including G protein-coupled receptor 50 (GPR50 receptor) 
(Sidibe et al., 2010), several genes involved in thyroid hormone signalling (Bolborea 
and Dale, 2013), Neuromedin U receptor (Graham et al., 2003a) and genes involved in 
the retinoic acid signalling pathway (Bolborea and Dale, 2013). Importantly, tanycytes 
have been shown implicated in generation of new neuronal cells, in a process of 
neurogenesis (Hajihosseini et al., 2008, Haan et al., 2013, Robins et al., 2013).  
 
1.5.3 Overview of adult neurogenesis  
 
The vast majority of neurons in the adult mammalian brain are terminally 
differentiated, post-mitotic cells, unable to renew themselves. This makes the brain 
particularly susceptible to effects of damage, cell death, neurodegenerative disease 
and ischemic stroke. However, the adult brain is not a static structure as it was once 
believed. In 1960, Altman and Das showed that generation of new neurons occurs in 
discrete areas of the postnatal and adult brain (Altman and Das, 1965). Subsequent 
studies confirmed this in a wide range of mammalian species, including humans (Zhao 
et al., 2008).  
Neurogenesis is a multistep process production of new neurons from neural 
stem cells (NSCs). NSCs are undifferentiated cells with the ability to proliferate, self-
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renew, and differentiate into not only neurons but also glial cells - astrocytes and 
oligodendrocytes. Although NSCs persist and can be found in the adult brain, they 
arise during embryonic development. In the adult brain, most NSCs are in a quiescent 
stage, except for few specific niches, where they have a very slow dividing turnover, 
which on average is approximately a few weeks. However, in an adult brain, beside 
the true stem cells, there is a population of neural progenitors, which are highly mitotic 
cells with the ability to give rise to terminally differentiated cells, but unlike NSCs, they 
are not capable of indefinite self-renewal, and their multipotency might be restricted 
(Abrous et al., 2005).  
Adult neurogenesis closely resembles neurogenesis during embryonic 
development, which includes processes such as cell proliferation and cell fate 
specification of neural cell progenitors, followed by their differentiation, migration and 
functional incorporation into the existing neuronal circuitry (Ming and Song, 2005). The 
two main niches of adult neurogenesis are the subventricular zone (SVZ) of the lateral 
ventricles and the subgranular zone (SGZ) of the dentate gyrus in the hippocampus 
(Fig. 1.11A).  
In the SVZ a niche of the NSC resides in a close proximity to the ventricular 
wall and similarly to hypothalamus, the ventricle is lined with ciliated ependymal cells. 
Although these ependymal cells themselves are not the NSC, the stem cells are 
closely associated with the ependyma (Zhao et al., 2003). The ependymal cells play 
important role in maintaining the stem cell niche by preventing their premature 
differentiation, for example through secretion of noggin (BMP antagonist) and FGF2 
growth factor (Peretto et al., 2004). The proliferating stem cells possess radial glia-like 
characteristics and give rise to transient amplifying cells, which in turn generate 
neuroblasts (Fig. 1.12). The newly generated neuroblasts form a chain and migrate 
through the rostral migratory stream (RMS) to the olfactory bulb, where they migrate 
radially toward glomeruli and differentiate into different subtypes of interneurons (Ming 


















In contrast to SVZ, the stem cell niche of SGZ does not reside in the vicinity of 
brain ventricles (Fig. 1.11A). Proliferating stem cells/precursors within the SGZ 
generate intermediate progenitors, which then give rise to neuroblasts (Fig. 1.13). 
These immature neurons then migrate into the granule cell layer of the dentate gyrus 
where they differentiate into neurons (Fig. 1.13), which follow processes for synaptic 
integration into the existing circuitry. In comparison to mature cells, these new neurons 
exhibit hyperexcitability and enhanced synaptic plasticity (Ming and Song, 2011). 
Figure 1.12 Schematic of the neurogenic processes taking place in the subventricular 
zone (SVZ). (A) Proliferative cells (red) reside around the ventricles of the SVZ, newly 
generated neuroblasts migrate along the rostral migratory stream (RMS) to reach the 
olfactory bulb (OB), where they migrate radially and undergo maturation. (B) 
Neurogenesis is a multistep process, during which, different types of cells express 
particular markers (shown in panels below) allowing their specification. Figure 
adapted from (Abrous et al., 2005).  
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Although the exact function of these new neurons is still under investigation, they 







Figure 1.13 Schematic representation of neurogenesis within the subranular zone 
(SGZ). (A) Proliferative cells (red) reside within the sub-granular layer and the newly 
generated cells migrate to the granular layer, where they differentiate into mature 
neurons. (B) During neurogenesis the different cell types express specific lineage 
markers (shown in panels below) allowing their identification. Figure adapted from 
(Abrous et al., 2005).  
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Moreover, production of new neurons in the adult brain was also reported to 
take place in in the neocortex, the olfactory bulbs, the piriform cortex, the amygdala, 
the striatum, the substantia nigra, the dorsal vagal complex and the hypothalamus. 
However, neurogenic processes within these areas are under scientific debate due to 
discrepancy of results, and the fact that production of new cells is detectable only post 
injury or pharmacological treatments and manipulations (Migaud et al., 2010, Gould, 
2007).  
In the hypothalamus, the basis for the origin of the putative stem cell niche is 
established early during mammalian development, around the embryonic stage 10 
(Shimada and Nakamura, 1973). The mouse hypothalamus has been found to contain 
a relatively quiescent resident stem cell population but cell proliferation can be 
stimulated by a number of factors and molecules, for example CNTF (Kokoeva et al., 
2005), BDNF (Pencea et al., 2001) and IGF-I (Perez-Martin et al., 2010). There are 
still few discrepancies in terms of the exact location of the stem/progenitors cell niche: 
whether these reside within the hypothalamic parenchyma, its ependymal layer or 
within both. The hypothalamic parenchyma was shown to contain multipotent 
progenitor cells, expressing Sox2 and NG2 markers of proliferative cells and neuroglia 
respectively (Li et al., 2012a, Robins et al., 2013).  However, their high mitotic activity 
and their punctate dispersal throughout the parenchyma suggest these are trans-
amplifying progenitors rather than stem cells. The true stem cells are thought to reside 
within or in close proximity to the wall of the 3V (Haan et al., 2013, Robins et al., 
2013).  
In the postnatal hypothalamus, tanycytes are thought to act as bona fide stem 
cells, due to their strong resemblance to radial glial cells, their distinct arrangement 
within the third ventricle and their expression of neural stem/progenitor cell markers. 
The cells within the ependymo-tanycyte layer were shown to incorporate BrdU, a 
marker of proliferating cells (Kokoeva et al., 2005, Perez-Martin et al., 2010, Haan et 
al., 2013). Through lineage-tracing of GLAST-expressing α tanycytes it was shown 
that these cells are capable of expansion, even entering the domain of β tanycytes, 
contributing mostly however to  the astroglial lineage within the parenchyma (Robins et 
al., 2013). By contrast, β tanycytes, marked by expression of Fgf10, were shown to 
proliferate, self-propagate within the ependyma and contribute to new neurons within 
the ARC nucleus as well as the VMN, DMN, and LHN. Furthermore the generated 
progeny continued to proliferate further within the parenchyma itself (Haan and 
Hajihosseini, 2009, Haan et al., 2013). However, the exact mechanisms controlling the 
hypothalamic stem cells are still under scrutiny, and involvement of FGF10 in 
hypothalamic tanycytes in general as well as within neurogenesis is still unclear.  
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1.5.4 Overview of FGFs in the central nervous system and neurogenesis 
 
 FGFs in general are implicated in development, patterning and maintenance of 
the nervous system. During early development at the stage of neural induction FGFs 
are essential for neural fate specification and act through antagonizing BMP signalling 
(Marchal et al., 2009). Then, throughout the whole embryonic development FGFs are 
involved in patterning of the neural plate, induction and patterning of the peripheral 
nervous system (PNS), as well as induction of the otic, epibranchial and olfactory 
placodes. Moreover FGF signalling contributes to shaping and forming of the brain and 
CNS, for example FGFs produced by the isthmic organizer, including FGF8, FGF17 
and FGF18, collectively orchestrate the development of the midbrain anteriorly and the 
cerebellum posteriorly (Guillemot and Zimmer, 2011). Moreover, studies using Fgf8 
hypomorphic mice have shown that this protein plays a prominent role during shaping 
and specification of developing neuroendocrine hypothalamus. Reduced levels of Fgf8 
during hypothalamic development result in reduced number of PVN neurons as well as 
within hypothalamic region called the supraoptic nucleus (SON). However overall, the 
reduction of Fgf8 levels was shown to have a greater impact on the ventral 
hypothalamic structures, such as SON than the more dorsal nuclei, residing in a 
proximity to PVN (Tsai et al., 2011).  
Importantly, FGFs play important roles in maintenance of survival, expansion 
and progression of neurogenic lineages from cortical neural stem/precursor cells, 
through immature trans-amplifying progenitors to mature neurons in the developing 
and adult brain. For example, FGF2 and FGF8 maintain the proliferative properties of 
neuroepithelial cells and onset of neurogenesis (Raballo et al., 2000, Storm et al., 
2003). In the adult SVZ neurogenesis, FGF2 might promote stem/progenitor cell 
proliferation and maintain a slow-dividing stem cell pool postnatally (Zheng et al., 
2004). FGF2 is thought to be a key factor regulating cortical neuro- and gliogenesis, as 
mice lacking Fgf2 expression contain even 50% less neurons than WT and show 
partially impaired neuronal migration (Vaccarino et al., 1999). Moreover FGF2 was 
shown to promote cell division, survival and neuronal differentiation of cell precursors 
(Tropepe et al., 1999, Hajihosseini and Dickson, 1999). Interestingly, FGF4 and FGF8 
were shown to mimic the survival and mitogenic effect of FGF2 in a culture of neuronal 
precursors (Hajihosseini and Dickson, 1999), potentially suggesting a degree of 
redundancy between the signalling proteins. Furthermore, FGF8 was found to promote 
differentiation of a subpopulation of cortical neuronal precursors predominantly into the 
astrocyte lineage (Hajihosseini and Dickson, 1999). In hypothalamus FGF2 was also 
shown to promote proliferation of the α tanycytes in vivo (Robins et al., 2013).  
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 FGF10 and other members of the FGF7 subfamily have a significant role 
within the nervous system, but most prominently are studied during embryogenesis. 
FGF7, FGF10 and FGF22 have been shown to promote neurite outgrowth (Umemori 
et al., 2004). FGF7 and FGF22 are expressed in the adult hippocampus where they 
function in formation of inhibitory and excitatory synapses (Terauchi et al., 2010). 
During corticogenesis, Fgf10 is transiently expressed by cell progenitors and was 
shown to determine the onset of cortical neurogenesis by promoting maturation of 
symmetrically dividing neuroepithelial cells into asymmetrically dividing radial glia cells. 
Although FGF10 regulates the radial glia differentiation, it does not affect proliferative 
capacity of the progenitors, nor their cell cycle or cell death (Sahara and O'Leary, 
2009). Furthermore, FGF10 and FGF3 might have a role in innervation and 
vascularisation of the developing hypothalamus (Liu et al., 2013). Interestingly and 
importantly FGF10’s cognate receptor, the FGFR2IIIb, is absent from the postnatal 
hypothalamus (Hajihosseini et al., 2008), which means that FGF10 may not be acting 
in a paracrine fashion in this brain region.  
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Part 1.6 General Aims 
 
FGF10 is a paracrine molecule, serving crucial roles during embryonic 
development and within adult tissue. However, there are still unexplored areas of 
FGF10’s function, which require further insight. Interestingly, several paracrine 
members of FGF family have been found to possess additional intracrine function, from 
a cell nucleus. FGF10 has been found present in a nucleus of urothelial cells (Kosman 
et al., 2007), but the molecular mechanisms underlying this process as well as its 
nuclear function are still unclear. In the light of the knowledge that paracrine FGF10 
has been found translocating into cell nucleus, the main objective of this project was to 
determine whether there are additional factors, beyond the NLS proposed by Kosman 
et al. (Kosman et al., 2007), driving the nuclear translocation of the protein, as well as 
explore potential nuclear function of FGF10. These main aims were then subdivided 
further, as follows: 
 
1. Using bioinformatics predictions determine whether FGF10 may possess any 
additional motifs providing its nuclear import. Furthermore, analyse FGF10’s 
genomic and protein structure to gather knowledge of its putative mode of 
function alternative to the secretory pathway.  
2. Through generation and use of a recombinant FGF10 detectable with 
antibodies, investigate whether FGF10 nuclear translocation is a cell type 
specific event and whether it is affected by reported protein mutations of human 
LADD and ALSG syndromes 
3. Since FGF10 is typically produced by mesenchymal cells, determine, whether 
FGF10 serves an intracrine/nuclear role within mesenchymal cell line, affecting 
cell proliferation or differentiation 
4. Fgf10 is expressed in hypothalamus, but expression of its cognate receptor is 
lacking (Hajihosseini et al., 2008), suggesting its intracrine/nuclear role may be 
of the most significance within this tissue. Therefore, the aim is to characterise 
the Fgf10-expressing hypothalamic cells in vitro and analyse putative function 
of FGF10 in the hypothalamus.  
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Chapter 2  
Material and Methods 
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Part 2.1 Tools and software used for bioinformatics analysis 
 
Human, mouse and rat genomic, cDNA and protein primary sequences were 
obtained from the NCBI website (http://www.ncbi.nlm.nih.gov/). Protein primary 
sequences in a ‘FASTA’ format were obtained from UniProt server 
(http://www.uniprot.org/). Unless specified otherwise, the primary sequence of mouse, 
rat and human FGF10 protein was analysed using the following, freely-available 
mathematical algorithms:  
 
2.1.1 Prediction of Nuclear Localisation Sequence (NLS)  
 
Programs such as WoLF PSORT: Advanced Protein Subcellular Localization 
Prediction Tool (http://wolfpsort.org) and PSORT II (http://psort.hgc.jp/cgi-
bin/runpsort.pl) are commonly used to predict the putative localisation of a protein 
within a cell, including nuclear, cytoplasmic or membrane-bound position. These tools 
often can predict the classical type of NLSs. The programs are based on rules derived 
from experimental observations searching for the consensus motifs within a sequence. 
Briefly they operate by converting a protein's amino acid sequences into numerical 
localization features (based on sorting signals, amino acid composition and functional 
motifs).   
In-depth analysis of non-classical NLSs was performed using NLStradamus 
(http://www.moseslab.csb) that is based on a simple Hidden Markov Model for nuclear 
localization signal prediction (Nguyen Ba et al., 2009) and NucPred 
(http://www.sbc.su.se) (Brameier et al., 2007). These programs analyse the 
composition of the basic residues within the protein sequence and able to predicts if 
the protein is likely to translocate to the nucleus.  
 
2.1.2 Prediction of Nuclear Export Sequence (NES) 
 
To determine if FGF10 is exported form the nucleus in the classical way the 
LocNes (http://omictools.com/locnes-s7902.html) tool was used. It is a Support Vector 
Machine (SVM) predictor, i.e. mathematical model that functions by locating classical 
nuclear export signals (NESs) in proteins that are cargoes of the Karyopherin β, called 
the chromosomal region maintenance 1 (CRM1). The CRM1 recognizes and exports 
from the nucleus hundreds of broadly functioning proteins (Ishizawa et al., 2015). Most 
CRM1 cargoes contain the classical leucine-rich NESs – a peptide of regularly spaced 
8-15 conserved hydrophobic residues. 
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The obtained results were validated further using the ValidNESs 
(http://validness.ym.edu.tw/PREDICTION.php), a mathematical algorithm using regions 
of protein intrinsic disorder and other features such as the frequency of specific amino 
acids within particular regions, to predict leucine-rich NESs within protein sequence (Fu 
et al., 2011, Fu et al., 2013). 
 
2.1.3 Predictions of putative post-translational modifications regarding FGF10 
 
Analysis of protein SUMOylation was performed by a prediction algorithm GPS 
SUMO (http://sumosp.biocuckoo.org) that is based on experimental data, and able to 
determine the canonical consensus motifs as well as novel SUMO-interaction Motifs 
(SIMs) (Zhao et al., 2014). The PCI-SUMO (http://bioinf.sce.carleton.ca/SUMO) 
program on the other hand uses parallel cascade identification (PCI), a mathematical 
nonlinear system, that predicts the SUMO sites without any prior experimental 
knowledge regarding protein’s subcellular localization.  
Prediction of cut-off point of signal peptide (SP) of FGF10, was performed using 
SignalP 4.1 (http://www.cbs.dtu.dk), a program based on a combination of several 
artificial neural networks that incorporates a prediction of SP cleavage sites. Moreover 
the program can distinguish between the actual SP and protein transmembrane motifs 
(Petersen et al., 2011).  
To prediction sites of glycosylation within FGF10 the NetNGlyc 1.0 Server 
(http://genome.cbs.dtu.dk) was applied. It predicts N-glycosylation sites in human 
proteins using artificial neural networks that examine the sequence in context of 
consensus motifs. Similarly the NetOGlyc 4.0 Server (http://www.cbs.dtu.dk) is based 
on same principles and generates neural network predictions of O-glycosylation sites in 
mammalian proteins. To further confirm the results, the GlycoEP 
(http://www.imtech.res.in) bioinformatics tool was used, that is a Support Vector 
Machine (SVM) predictor, trained and optimised using eukaryotic glycosites’ datasets, 
performing stringent predictions of all types of glycosylation.   
 
2.1.4 Searches of putative regulatory promoter sites of Fgf10 
 
To determine any putative regulatory promoter sites, from human genomic 
sequence located on chromosome 13, a region was selected spanning from -77087 to -
9000bp upstream of the Fgf10 translational start site. This region was then analysed 
using Promoter 2.0 Prediction (http://www.cbs.dtu.dk), program based on variation of 
neural networks and genetic algorithms; developed as an evolution of simulated 
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transcription factors that interact with sequences in promoter regions. It predicts 
specifically transcription start sites of vertebrate Polymerase II promoters in DNA 
sequences.  
To enhance further the searches, the region between -1000 to +100 
downstream of the ATG start site was analysed using Neural Network Promoter 
Prediction (http://www.fruitfly.org), and EPD - Eukaryotic Promoter Database 
(http://epd.vital-it.ch), two independent software tools that are based on collection of 
already discovered eukaryotic POL II promoters and comparing the existing knowledge 
to the sequence provided.  
 
2.1.5 Other bioinformatics tools 
 
Protein sequences were aligned using the CLUSTAL 2.1 multiple sequence 
alignment tool - Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). Sequencing 
data received from Source Bioscience was processed in SerialCloner1-3 and 
visualised in a form of peaks using ChromasLite program. Protein 3D structures were 
analysed and imagined using Chimera 1.9 (using protein structure data from Protein 
Data Bank - RCSB PDB). ImageJ and Photoshop programs were used to process 
images and generate cell counts. To calculate co-localisation of fluorescent markers on 
microscope images Volocity 6.3 software was used.  
 
2.1.6 In silico Predictions of FGF10 binding to Importin using haptics-assisted 
molecular docking system 
 
To determine if FGF10 is potentially able to interact with Importin molecules, the 
two proteins were fitted together in silico using a molecular docking system innovated 
with haptic system. Briefly, molecular docking systems generate predictions of the most 
plausible binding orientations of one protein to another. They aim to model and 
simulate in silico the intermolecular biochemical interactions, providing visual aid to the 
experimental studies. The haptics-assisted docking, in regards to rigid mathematical 
algorithms, enables the user to interact with the simulation via their sense of touch (Fig. 
2.1). The repulsion forces arising between the two interacting proteins are calculated 
by the software, basing on the atoms coming into a close contact, and they determine 
the preferred orientation of the binding molecules. The closer the repulsion forces to 
zero, the more likely the interaction to occur in nature. Incorrect binding generate 
repulsing forces that can be sensed through the haptic device, avoiding misleading 
predictions and allowing quick adjustments of the molecules (Iakovou et al., 2015, 
Iakovou et al., 2014). 
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Within the tertiary structure of FGF10 (PDB 1NUN file), the NLS2 motif was 
selected, highlighted and fitted to isoforms of Importin-α (PDB 3WPT file) and Importin-
β (PDB 1M5N file). Files showing the potential interactions were visualised, presented 
and imaged using Chimera 1.9 software (see Chapter 3). The molecular docking 
software with the haptic device was generated by Georgios Iakovou, who also kindly 
created the fittings of FGF10 to the Importins.  Only cases that match specific repulse 










Part 2.2 Generation of Hemagglutinin A (HA) tagged rat FGF10 (rFGF10-HA) 
construct 
 
2.2.1 PCR amplification of rFGF10-HA sequence  
 
Rat FGF10 cDNA sequence was amplified from a rFgf10-pGEM-T vector (kind 
gift of Prof Saverio Bellusci) using forward primer with implemented EcoRI restriction 
enzyme site and reverse primer with implemented HA-tag DNA sequence and NotI 
restriction enzyme site (Fig. 2.2). The amplified PCR product was precipitated using 
Sodium Acetate (pH 5.2) and 100% EtOH, then treated with endonuclease restriction 
enzymes, EcoRI and NotI (NEBiolabs), at 37ºC overnight, to generate 'sticky ends’ for 
following ligation into a vector. The digested DNA samples were then purified using 
GeneClean kit (MP bio).  
 
Figure 2.1 The haptics-assisted molecular docking system generates in silico 
predictions of protein-protein interactions (A) An example of the haptic device used for 
molecular docking (http://souvrsophie.blog.com) (B) Vibrations generated by the 
repulsion forces of the interacting proteins allow manual adjustment of the so called 
“molecular fittings” (Iakovou et al., 2014).  






Figure 2.2 Generation and amplification of HA tagged rat Fgf10 construct. (A) 
Sequence of rat Fgf10 (rFgf10) cDNA, incorporated within the pGEM-T vector 
between SphI and NdeI restriction sites, was provided as a kind gift of Prof S Bellusci. 
(B,C) Schematic diagram with a corresponding table of generation of HA-tagged 
rFgf10 through PCR amplification of the rFgf10 sequence using forward primer (FP) 
with incorporated EcoRI restriction enzyme binding site (purple) and reverse primer 
(RP) with incorporated HA tag DNA coding sequence (red) and NotI restriction 
enzyme (blue) binding site. (D) Schematic showing excision of mCherry sequence 
from the pmCherry-N1 vector (herein called “pmN1”) and substituting it with rFgf10-
HA flanked by EcoRI and NotI restriction enzyme sites. 
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2.2.2 Preparation of the cloning vector 
 
As a backbone vector, a pmCherry-N1 (Clontech Laboratories, Inc.) mammalian 
expression plasmid was used, from which the cDNA sequence of mCherry was 
removed between the EcoRI and NotI sites (Fig. 2.2D), by digestion with the restriction 
enzymes (NEBiolabs), at 37ºC overnight. Moreover treatment with enzymes generated 
‘sticky ends’ allowing ligation of the PCR product of the rFGF10-HA sequence. The 
linearised vector sequence was separated from the residual mCherry DNA fragment by 
gel extraction from TAE 0.8% agarose gel (from now on called pmN1), where the band 
size was determined by comparing to 1kb Plus DNA Ladder (Thermo Scientific 
SM1331). To prevent re-circularization of linearized vector DNA, it was then treated 
with Calf-intestinal alkaline phosphatase (CIP) (Invitrogen 18009-027) for 1h and 
purified using GeneClean kit (MPbio).  
 
2.2.3 Ligation and cloning of the rFGF10HA and vector sequence 
 
The purified PCR product and vector sequences were ligated at ~18ºC 
overnight using T4 ligase (Sigma Aldrich) in a ratio 1:5 of ‘pmN1’ vector (20ng) to 
rFgf10-HA PCR insert (15ng), taking into account the length of both DNA strands, 




Where: “kb” – kilo bases, “Vng” – nano-grams of vector, “Ing” – nano-grams of insert
     
    
Ligated product was transformed into DH5α competent cells, before culturing on 
Kanamycin antibiotic containing selection medium. 16 hours later, DNA was extracted 
from several selected colonies using mini and maxi-prep kits (Qiagen) according to the 
manufacturer’s instructions. Concentration of the DNA was determined by conventional 
spectrophotometer or Nanodrop spectrophotometer.   
 
2.2.4 Verification of the generated rFGF10HA construct 
 
The presence of the rFgf10-HA insert within the pmN1 vector was verified by 
two means: (i) by digest with restriction nuclease enzymes (~200ng of DNA treated 
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with ScaI only or EcoRI and NotI for 1h 37ºC) and (ii) PCR reaction (see Chapter 4). 
For the diagnostic PCR (Table 2.1), the forward (5’ 
CTACCGGACTCAGATCTCGAGCTC 3’) and reverse (5’ 
GCCTTAAGATACATTGATGAGTTTGG 3’) primers bind to the vector sequence s 
flanking the insert. In the presence of an insert an expected band of 941bp would be 
observed, whilst in its absence, a 369bp band would be visible (see Chapter 4). 
 





Samples carrying the correct, insert were then subjected to Sanger sequencing 
(Source Bioscience) to check for any PCR-introduced undesired mutations. 
 
 
Part 2.3 Site-directed mutagenesis  
 
All point mutation-bearing FGF10 products were generated by PCR (Fig. 2.3) 
using a QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) 
according to manufacturer’s instructions with the relevant custom designed mutation-
bearing primers (Table 2.2).  
  
Table 2.1 Cycles used for the diagnostic PCR of successful incorporation of rFgf10-
HA insert into pm-N1 vector.  












2.3.1 Primer design  
 
In order to generate a double-stranded vector in PCR reaction, it was essential 
to design each pair of primers individually, ensuring that both (forward and backward) 
mutagenic primers contained the desired mutation and annealed to the same sequence 
on opposite strands of the plasmid (Fig. 2.3). Primers were designed for optimal PCR 
performance, by minimising primer dimer formation, ensuring balanced GC content and 
melting temperature (Tm) according to the 4+2 rule. Typically, a primer would consist 
of 25 base pairs, with a Tm of ~73 to 78°C. The desired point mutation was 
incorporated close to the middle of the primer with ~10–15 bases of template sequence 
flanking it. Typical GC content was 40% and primers terminated in one or more C or G 
bases at their 3’ ends (Table 2.2). To generate a quadruple mutation within the NLS2 
region, the R194T&R195T forward and reverse primers were used in conjunction with 
the R200T&K202T plasmid template. The technical limitations of the kit prevented 
generation of a triple mutation of R194T&R195T&K198T – such modification within 
primers disabled the PCR reaction.   
Figure 2.3 Schematic of site-directed mutagenesis procedure. The technique involves 
PCR reaction utilising a derivative of PfuUltra high-fidelity DNA polymerase, a pair of 
custom designed mutation-bearing primers and a dsDNA vector template (isolated 
from competent E.coli cells that caused its methylation). The obtained PCR product is 
subsequently treated with DpnI endonuclease enzyme, which recognises and digests 
methylated DNA, therefore removes the template. Green pentagon – DNA 
methylation; in orange – DpnI enzyme. 









2.3.2 PCR reactions of mutated constructs 
 
 The PCR reactions of the mutation-bearing constructs using the QuikChange 
Lightning were performed according to manufactures suggestions, as a 50µl reaction, 
using 50ng of the rFgf10-HA template, 5µl of 10x reaction buffer, 125ng of each of the 
primers, 1µl of QuickSolution reagent and 1µl of QuickChange Lightning Enzyme. The 





Table 2.2 Primer sequences with specific mutation incorporated shown in bold used 
to generate nucleotide substitution of rFGF10-HA.  









2.3.3 PCR mutation-bearing construct processing and validation  
 
Following the PCR reaction the obtained product was purified from the template 
(non-mutated) DNA, by treatment with DpnI endonuclease enzyme at 37ºC for 10min 
(Fig. 2.3). The template plasmid has been previously isolated from competent E.coli 
cells, where it became methylated by a ‘dam’ methylase. The DpnI enzyme is specific 
to methylated DNA (targets the 5’Gm6ATC3’ sequence), and digests it, leaving purified 
mutation-bearing DNA product (Fig. 2.3), which was subsequently transformed into XL-
10 Gold competent cells, through 30sec heat-shock at 42ºC. Several bacterial colonies, 
cultured on a Kanamycin selective medium, have been isolated, DNA extracted and the 














Table 2.3 PCR cycles used for site-directed mutagenesis. Note the annealing 
temperature range (*), which was adjusted accordingly to the primers’ melting 
temperature.  
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Part 2.4 Transgenic Animals 
 
All animals used in this study were maintained, bred, treated and culled in strict 
compliance with terms of a Home Office licence granted to Dr Mohammad 
Hajihosseini. In vivo drug administrations, such as tamoxifen, were performed by Dr 
Timothy Goodman. For genotyping, DNA was extracted from tail biopsies and digested 
at 55ºC overnight, in a digest buffer (1M Tris, 0.5M EDTA, 5M NaCl, 2mg/mL SDS in 
ddH20) containing 7µg/mL Proteinase K. Genomic DNA was then precipitated using 
isopropanol and subjected to Expand Long Template PCR (Roche) using gene-specific 





Table 2.4 Primer sequences used for genotyping transgenic mice, with corresponding 
expected PCR product sizes shown in kilo-bases (kb) 
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Table 2.5 PCR cycles used for genotyping transgenic mice using corresponding 
primers from Table 2.3 
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2.4.1 Fgf10+/CreERT2 ::ROSA26Rtomato-DsRed reporter mice 
 
The Fgf10+/CreERT2 ::ROSA26Rtomato-DsRed mouse (Fgf10-tomato) is a conditional 
reporter allele, so that the system becomes activated only upon treatment with 
Tamoxifen drug. The mouse was generated by incorporating a Cre-ERT2-IRES-YFP 
into the end sequence of the first exon and beginning of the first intronic sequence of 
the Fgf10 gene (Fig. 2.4B). This insertion leaves the first exon dysfunctional and 
disrupts some regulatory cis sequences of the first Fgf10 intron leaving the allele non-
functional and therefore mice were bread as heterozygotes – homozygous Fgf10CreERT2 
mice are not viable (El Agha et al., 2012). The inserted construct encodes a Cre 
recombinase fused to the ERT2, becoming expressed in Fgf10-expressing cells only. 
This protein complex is retained in the cytoplasm in its inactive form. Treatment with 
the tamoxifen activates the Cre-ERT2 complex and allows its entry into the nucleus, 
where Cre binds to and excises loxP sites flanking a STOP cassette positioned ahead 
of transcription start site of red fluorescent protein, named tomato, (Fig. 2.4D), that is 
driven by a ROSA26 promoter.  
In summary, upon treatment of the tamoxifen, all the Fgf10 expressing cells and 
their descendants, express also a tomato fluorescent reporter protein.  
To activate tomato-DsRed (tomato) tamoxifen was administered via 
intraperitoneal injections of 20mg/mL solution (in 10%EtOH/corn oil mixed several 
hours at 55ºC) at 80-100mg/Kg mouse bodyweight. Depending on the experiment, 
mice were induced with tamoxifen at varying ages ranging from postnatal day 4 (P4) to 
postnatal day 40 (P40). Tamoxifen inductions were performed over a period of two 
days, and induced mice were culled, by cervical dislocation, 7 days later to allow for 
sufficient gene recombination. 
 
2.4.2 Fgf10nLacZ/+ (Fgf10-LacZ reporter) mice 
 
Fgf10-lacZ mice had previously been generated by Kelly and colleagues though 
incorporation of nuclear targeted lacZ-transgene 114kb upstream of Fgf10 translational 
start site (Kelly et al., 2001) (Fig. 2.4C). Although this insertion does not disrupt the 
Fgf10’s translation, it appears to impair some regulatory cis sequences generating a 
slight hypomorph of FGF10 (Mailleux et al., 2005). Hence, the mice were maintained 
as heterozygotes (Fgf10lacZ/+). The insertion of nLacZ is not a protein fusion and 
produces two separate transcripts.  In tissues derived from this mouse, the product of 
the nLacZ gene, the β-galactosidase (β-gal) will appear mostly in the nucleus of Fgf10-
expressing cells. 
                                                                                                                                            
83 
 
The generated β-galactosidase enzyme cleaves lactose into glucose and 
galactose. Upon treatment with X-gal solution (analogue of lactose, consists of 
galactose linked to a substituted indole) an intensely blue product is produced which is 
insoluble and can be easily visualised. The presence of β-galactosidase can also be 














2.4.3 Dissection and preparation of hypothalamic cell suspension 
 
Mice were sacrificed by cervical dislocation (in accordance to Schedule 1 Home 
Office Procedure), brains were removed from the skull and placed in Dulbecco's 
Phosphate Buffered Saline (DPBS) supplemented with 10% glucose and 5% HEPES 
Figure 2.4 Schematic representation of genomic alleles of transgenic mice used. (A) 
Wild Type Fgf10 locus shows approximate positions of three exons and two introns. 
(B) In the Fgf10+/CreERT2 line, the Cre-ERT2-IRES-YFP construct was inserted at the 
end of Exon1, disrupting beginning of the Intron1 sequence as well. (C) In the 
Fgf10nLacZ/+ reporter, the nuclear LacZ (nLacZ) sequence was incorporated under the 
Fgf10 promoter, but upstream of the Exon1. (D) The ROSA26-tomato line has a 
STOP cassette, flanked by two loxP sites, incorporated upstream of the Tomato 
sequence but downstream of the ROSA26 promoter.  
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solution. The subventricular zone (SVZ) and hypothalamus regions were finely 
dissected out and then dissociated in a pre-warmed (37˚C) PPD digestion solution 
(comprised of 0.1mg/ml Papain; 1mg/ml Dispase II; 12.4 mM MgSO4 7H2O in HBSS) 
and incubated further at 37˚C for 2-5min. The tissue was gently triturated using a 
P1000 pipette tip until it was fully dissociated and clumps of cells were no longer 
visible. Dissociated cells were then centrifuged at 1000rpm, excess PPD solution was 
separated from the pellet and the cells were washed twice in a culture medium, by 
gentle dissociation and centrifugation. After the last wash, the pellet was resuspended 
in 2ml of a culture media and passed through 40µm nylon cell strainer to obtain a 
solution of single cells. 
 
 
Part 2.5 Primary cell cultures 
 
2.5.1 Establishment and growth of neurospheres  
 
Single cell suspension of hypothalamic cells was seeded in a T25 flask in a NB-
B27 medium (Neurobasal A medium (Gibco 10888-022) supplemented with 2% B27, 
2µg/ml heparin, 1% Pen&Strep and 1% Glutamax solution). EGF and FGF2 growth 
factors were added fresh into the culture at a 20ng/µl concentration each. Cells were 
then incubated in 5% CO2 at 37⁰C in a humidified chamber. Cultures were fed twice a 
week, supplying fresh amount of growth factors at each feed. Growth of the culture was 
monitored every 2-3 days and when spheres reached 300-400µm in a diameter, they 
were passaged.  
To passage neurospheres, cells were dissociated by gentle trituration of 
spheres with P1000 pipette tip. Dissociated cells were then passed through a 40µm cell 
strainer to remove any cell aggregations and the resulting filtrate, containing single 




2.5.2 Measuring growth rate of neurospheres  
 
To determine the growth rate of neurospheres, single cells were seeded at 
clonal levels and the diameter of neurospheres was measured every 3-4 days. At each 
time point, 10 random neurospheres were measured. Since neurospheres do not grow 
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uniformly and small as well as big neurospheres are normally present in the same 
culture, to avoid cell death of an overgrown culture, the bigger spheres were measured.  
Diameter measurements were taken until the spheres reached the passaging 
stage and care was taken to avoid measuring spheres that have clearly merged 
together (see Chapter 6). In a culture of neurospheres derived from the Fgf10+/CreERT2 
::ROSA26Rtomato-DsRed mouse, the expression of tomato was visualised using a 
fluorescent microscope. The growth rate was calculated using the following equation: 
 
Where “d0” is initial diameter, “dn” is diameter after “n” days in culture and 
growth rate is expressed as percentage.  
 
When the neurospheres reached the passaging stage (ranging from 12-35 days 
depending on a passage number), the whole process was repeated. Cultures were 
passaged up to 6 times, until the passaged cells become quiescent and stopped 
forming neurospheres. 
 
2.5.3 Induction of neurosphere differentiation into neurons and glial cells 
 
Neurospheres were dissociated into single cell suspension by gently triturating 
with a P1000 pipette tip, and subsequently seeded at a 50x103 cells/well concentration 
on glass coverslips (placed in a 24 well plate and previously coated with 20µg/ml poly-
D-lysine). To further stimulate differentiation, the NB-B27 growth medium was 
supplemented with 10% FBS and replaced every 3-4 days for 2 weeks. Differentiated 
cells were then fixed for 15min in 4% paraformaldehyde (PFA), immunolabelled with 
cell-type specific marker antibodies (see below) and mounted onto microscope slides.  
 
2.5.4 Fluorescence-activated cell sorting (FACS) of primary hypothalamic cells 
 
Several attempts were made to separate and isolate population of tomato 
fluorescence expressing cells from the remainder from the hypothalamic cell 
suspension. Cells were freshly dissected and dissociated from hypothalamic extract of 
the minimum number of two Fgf-tomato reporter and corresponding number of wild 
type control mice at the age of P8, pulsed in vivo with tamoxifen at the age of P4-P5.  
Cells were dissociated in a pre-warmed (37˚C) PPD digestion solution (comprised of 
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0.1mg/ml Papain; 1mg/ml Dispase II; 12.4 mM MgSO4 7H2O in HBSS) and incubated 
further at 37˚C for 2-5min. The tissue was gently triturated using a P1000 pipette tip 
until it was fully dissociated and clumps of cells were no longer visible. Subsequently 
cells were washed with HBSS supplemented with 0.01%BSA and 2mM EDTA, which 
was used to prevent cell aggregation, importing during the process of cell sorting. Cells 
were then passed through 40µm nylon cell strainer, to remove debris and ensure single 
cell suspension, which was then subjected to the FACS sorting machine operated by a 
qualified technician at Institute of Food Research, Norwich. Sorted cells were collected 
in 2ml of 100% FBS.  
 
2.5.5 Establishment and growth of hypothalamic monolayer cell cultures 
 
Mouse hypothalamus was freshly isolated from brains of 2-6 weeks old wild 
type (WT) or Fgf10-lacZ or tomato reporter mice. Hypothalamic cells were then 
dissociated and grown as a monolayer in DMEM/F12 HAMs media (Gibco 21331) 
supplemented with 5% FBS; 1% penicillin/streptomycin; 1% GlutaMAX; 1% B27 
Supplement (Gibco); 35 µg/ml bovine pituitary extract (Invitrogen) and 20 ng/µl each of 
EGF and FGF2 (Peprotech). 
The cells were seeded in a T25 flask or a six/ twelve-well plates at clonal 
densities (approximately 5x104cell/ml), unless stated otherwise. The culture medium 
was replaced every 3-4 days and cells were maintained for either 6-10 days, or for the 
long term studies for >30 days. For the immunolabelling purposes cells were also 
seeded and cultured on PDL-coated glass coverslips. 
 
2.5.6 Passaging of hypothalamic monolayer cell cultures 
 
Sub-confluent cultures (~80% confluency) were passaged by treating cells with 
Trypsin-EDTA (0.05%) (Gibco). After removal of the growth media, cells were washed 
with Cell Harvest Buffer (0.02%EDTA Na2
+, 0.9%NaCl, HEPES (free acid) 2.38g/L, 
125µl/L Phenol Red, pH7.2) and then incubated with Trypsin at 37⁰C for 2-5min. 
Removal of the cells from the bottom of the culture dish was aided by tapping on the 
side of the dish untill all cells had dislodged. Trypsin was inactivated by addition of the 
culture medium and cells were re-seeded (1 in 10 dilution) in a fresh container at clonal 
densities.  
In order to determine the proportion of LacZ expressing cells, cultured from 
Fgf10-LacZ reporter, cells were obtained from eight mice at the age of P35, pulled 
together and cultured across 2 individual T25 dishes at semi-clonal densities. During 
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passaging, one of the dishes was stained with X-gal solution to determine the 
proportion of cells expressing β-gal, while the other was passaged according to the 
protocol, again providing at least 2 individual culture dishes.  
 
2.5.7 X-gal staining of monolayer cell culture 
 
Cells were rinsed with PBS and fixed with 0.5% glutaraldehyde (prepared in 
PBS) for 15min at RT. Then cells were rinsed three times with PBS and once with 
ddH20 for 5min, and incubated for 30 min at 37⁰C in (pre warmed) staining solution 
containing 2mM MgCl2, 5mM K4Fe(CN)6, 5mM K3Fe(CN)6) and 0.5µg/ml X-gal (X-gal 
stock solution was prepared at 20mg/mL in 8% N,N Dimethylformamide and stored in 
aliquots at -20⁰C). Once blue colour was evident, cells were rinsed several times in 
PBS and fixed for 10min with 4% PFA solution.  
 
2.5.8 Measuring growth rate of LacZ positive patches 
 
Cells derived from Fgf10-LacZ reporter mice (at the age of P8, P30 and P40) 
were cultured at semi-clonal densities, which gave rise to clonal patches of cells. 
Treatment with X-gal solution allowed to identify the LacZ expressing cell patches, 
within each number of cells was counted. From each culture 3 biggest patches were 
selected as an indication of the maximum propagation potential of the given culture. 
Therefore at P8, ‘n’ number of mice was equal to 3 and number of colonies analysed 
was 9. At P30, cells were derived from 10 mice and 30 colonies were analysed, 
whereas at P40, 9 mice were used and 27 colonies selected. It was assumed that the 
cells were undergoing symmetrical division and therefore the cell patches were growing 
exponentially. Therefore the growth rate of each patch was calculated according to the 





Where: P(t) = number of cells at time t   
P0 = initial amount of cells at time t = 0 (time of seeding) – because it was 
assumed each cell patch was a clonal cluster (due to seeding at semi-clonal density), it 
was presumed that each cell patch  was derived from an individual proliferating cell, 
therefore P0 = 1  
r = the growth rate   
t = time (number of days in culture) before fixing   
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2.5.9 Tamoxifen treatment of hypothalamic cell monolayers in vitro 
 
Small patches of ~5 days old monolayer cultures of cells, derived from the 
Fgf10-tomato reporter mouse, were treated with 3µg/ml tamoxifen drug (kept in stock of 
20mg/ml in DMSO), previously replacing the cell media 12-24h prior to drug treatment. 
To administer the drug, the culture media was briefly removed from the culture dish 
(leaving a small amount to prevent cells from drying) and placed in a Falcon tube, 
where tamoxifen was added to and mixed with. The drug containing media was re-
applied to cells for 24h, then replaced with the fresh one and cultured for further 7-10 
days or until confluent. The expression of the tomato protein in live cells was checked 
under the fluorescent inverted microscope. To account for possible cell death, the 
control cells were treated with corresponding amount of DMSO. 
 
2.5.10 Differentiation of hypothalamic cell monolayers 
  
Single cell suspensions derived from Fgf10-tomato reporter mouse 
hypothalamus were seeded on PDL-coated glass coverslips at a very high density 
(approximately 5x105 cell/ml) and cultured for 10-30 day, until a top layer of 
differentiated neurons had emerged (see Fig. 6.16A) (Louis et al., 2013). Cultures were 
then fixed with 4% PFA 15min and immunolabelled with fluorescent antibodies. 
 
2.5.11 Profiling of FGFs and FGFRs expression of cultured hypothalamic cell by 
RT-PCR 
 
RNA was extracted from sub-confluent (~80%) culture of wild type (WT) 
hypothalamic cell monolayer grown in 10cm Petri dishes. Cultured cells were rinsed 
once with PBS and covered with 1ml of Trizol reagent, before being scraped off and, 
transferred to microcentrifuge tube.  After 5 min incubation in Trizol at RT, 200µl 
chloroform was added to the tube, shaken vigorously for 15sec, incubated for a further 
3min at RT and centrifuged at 12000rpm 15min 4⁰C. Samples had separated into 
several layers and the top aqueous (clear) layer containing RNA was removed, RNA 
was precipitated by addition of 500µl Isopropanol for 10min at RT and sample was 
centrifuged at 12000rpm for 15min 4⁰C, as a result of which a pellet formed on the side 
of the tube. After careful removal of the supernatant the pellet was washed with 1ml of 
75% EtOH, vortexed for 5min 4⁰C and centrifuged further 9000rpm 12min 4⁰C. The 
supernatant was removed, and the pellet was briefly air-dried and re-suspended in 30µl 
of RNAse free ddH20. To fully dissolve the RNA, the sample was incubated 10min at 
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55⁰C. The Concentration and purity of RNA in the sample was determined using a 
Nanodrop spectrophotometer.  
RT-PCR reaction was performed using the Illustra Ready-To-Go™ RT-PCR 
Beads (GE Healthcare) in accordance with the manufacturer’s instructions. Briefly, 
lyophilized beads (containing M-MuLV Reverse Transcriptase, RNase Inhibitor, buffer, 
nucleotides, and Taq DNA Polymerase) were rehydrated with RNAse free water and 
kept on ice until the beads had fully dissolved. 1µg of sample RNA and 1µl of poly-
d(T)12-18 primers (Invitrogen 18418012) were added to each reaction tube and mixed 
gently. Samples were then subjected to the first stage of reverse transcription PCR 
cycle (see table). After the reaction was completed pairs of FGF and FGFR-specific 
primers (Hajihosseini and Dickson, 1999, Hajihosseini and Heath, 2002) was added 
each tube, which were then subjected to second phase of PCR cycle (Table 2.6). 
Detection of β-actin transcript was used as a general control for the PCR conditions. 
Following the completed two stage RT-PCR, the samples were resolved on a 1% 
agarose-TBE gel through electrophoresis and visualised with ethidium bromide under 
UV illumination.  
 
 





2.5.12 Establishment of primary astrocyte cultures 
 
Brains were removed from 3-4 day old wild type (WT) mouse pups and placed 
in the Dulbecco's Phosphate Buffered Saline (DPBS) supplemented with 10% glucose, 
0.02M HEPES solution. Cortices were removed from 5 brains, freed of meninges, 
transferred to 5ml (1ml/ 2 cortices) of DPBS containing 0.025% Trypsin-EDTA (pre-
Table 2.6 RT-PCR cycles used for profiling of Fgf ligands and Fgf Receptors.  
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warmed), minced by trituration with 1.6mm needle and incubated 10 min at 37⁰C. 
Trypsin was then inactivated by addition of 10%FBS/DMEM. Cell clumps were further 
dissociated by subsequent trituration in a syringe fitted first with a 0.8mm and then 
0.6mm sterile needle. Finally, cell suspension was passed through 40µm nylon 
membrane cell strainer, centrifuged for 5min at 1000rpm and the resulting cell pellet 
was re-suspended in 10%FBS/DMEM (supplemented with 1% penicillin/streptomycin, 
1% GlutaMAX). Dissociated suspension of single cells were cultured in three T75 
flasks and kept at 5% CO2 at 37⁰C, in a humidified incubator. Cultures were fed with 
fresh 10%FBS/DMEM 24h after plating and then every 2-3 days, until confluent.  
 
Part 2.6 Culture of cell lines 
 
2.6.1 ARPE-19 cells 
 
ARPE-19 a monolayer of uniform population of highly proliferative, polarised 
epithelial human retinal pigment epithelial (RPE) cells (Dunn et al., 1996). These cells 
were maintained in DMEM/F12 HAMs media (Gibco 31330) supplemented with 
10%FBS, 0.001% Gentamicin (Sigma Aldrich G1397). Cells were fed every 2-3 days 
and passaged twice a week, by 1 in 4 dilution of a 70-80% confluent culture grown in 
T75 flasks. For experiments (immunolabelling, transfection etc.) cells were seeded at 
5x104 cells/well concentration, in 24-well plate, on PDL-coated glass coverslips. 
 
2.6.2 ATDC5 cells 
 
ATDC5 cells, originally cloned from the AT805 mouse embryonic 
teratocarcinoma cell line is a chondrogenic cell line that can go through a process 
analogous to chondrocyte differentiation (Yao and Wang, 2013). This cell line was 
obtained as a kind gift of Dr. Jelena Gavrilović (University of East Anglia).  
In their undifferentiated state, ATDC5 cells are normally grown in ‘maintenance 
medium’ - DMEM/F12 HAMs media (Gibco 21331) containing 5% (v/v) FBS, 1% (v/v) 
L-glutamine and 1% (v/v) penicillin/streptomycin (Invitrogen) supplemented with 10 
μg/ml Human Transferrin (Sigma Aldrich T8158) and 30nM Sodium Selenite (Sigma 
Aldrich). Cells within a culture normally divide once daily and the cultures were 
passaged twice a week at 1:8 or 1:16 of 70-80% confluent flask.  
 For experiments, undifferentiated ATDC5 cells were seeded on PDL-coated 
glass coverslips, placed in a 24 well plates, at the density of 15x103 cells/well. These 
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cultures were then either used as undifferentiated cells in particular experiments (e.g. 
DNA transfection) or induced to differentiate. 
 In order to induce differentiation of ATDC5 cells, undifferentiated cells were 
grown for 1-2 days to sub-confluency in maintenance media and then stimulated with  
insulin (Atsumi et al., 1990, Temu et al., 2010). Briefly, the maintenance media was 
replaced with the ‘differentiation media’ - DMEM/F12 HAMs media (Gibco 21331) 
containing 5% (v/v) FBS, 1% (v/v) L-glutamine and 1% (v/v) penicillin/streptomycin 
(Invitrogen), supplemented with insulin, transferrin and sodium selenite (ITS) premix 
(Invitrogen 41400) and 50 µg/ml ascorbic acid sodium salt (Sigma Aldrich A4034). This 
was referred to as Day 0 of differentiation, and then cells were fed with fresh 
differentiation media every 2-3 days for up to 14 days. As a control, undifferentiated 
ATDC5 cells were grown for in parallel in maintenance media. The differentiating cells 
form 3D structures, referred here to ‘differentiation nodules’, that begin to be visible at 
Day 7 of differentiation and are clearly established at Day 14 (see Chapter 5). 
 
2.6.3 293T-HEK cells 
 
Human Embryonic Kidney 293T cells were maintained in DMEM/F12 HAMs 
media (Gibco 31330) supplemented with 10%FBS and 1% penicillin/streptomycin. 
Cells were fed every 2-3 days and the cultures were passaged three times a week at 
1:10 of 70-80% confluent flask. 
For experiments, (e.g. transfection) cells were seeded at 5x103 cells/well 
concentration, on PDL/fibronectin-coated glass coverslips, placed in a 24 well plates, 
unless stated otherwise. 
 
 
Part 2.7 Cell culture associated experimental methods 
 
All cells (primary and cell lines) were maintained in a humidified incubator at 
37°C with 5% CO2. Cells were maintained and handled under sterile conditions and 
regularly screened for bacteria and mycoplasma infection. 
 
2.7.1 Cell passaging and seeding 
 
To maintain their proliferative state, cell were passaged at required confluency 
(typically at 70-80%) through treatment with 0.25% Trypsin-EDTA (Gibco 25200056). 
Briefly, after removal of the growth media, cells were washed with PBS or Cell Harvest 




+, 0.9%NaCl, HEPES (free acid) 2.38g/L, 125µl/L Phenol Red, 
pH7.2) and then incubated with Trypsin (3ml/T75 culture flask) at 37⁰C for 1-2 min. 
Dislodging of trypsinized cells was aided by gentle tapping on the side of the dish. 
Trypsin was inactivated by addition of the culture medium containing serum (FBS) and 
cells were re-seeded in a fresh container at required densities. Prior to plating, cell 
density in the suspension was measured using a haemocytometer.  
 
2.7.2 Coating of glass coverslips with matrix molecules 
 
When required, glass coverslips or plastic surfaces of the culture dishes were 
coated either with a poly-D-lysine hydrobromide (PDL) or fibronectin.  
Poly-D-lysine is a positively charged amino acid polymer that improves the 
attachment of cultured cells, particularly neurons, glial cells and transfected cells to 
plastic or glass surfaces. To coat, PDL (Sigma Aldrich P6407) used at a final 
concentration of 20µg/ml solution, was applied to submerge glass coverslips or the 
required dish surface and incubated at 37⁰C overnight. After removal of the PDL 
solution coverslips or dishes were washed with water and left in sterile environment to 
air-dry before applying cells to the coated surfaces. PDL coated dishes and coverslips, 
if not used immediately, were stored (sterilely packaged) at 4⁰C for maximum of 3 
weeks.  
Fibronectin is a glycoprotein of the extracellular matrix (ECM), known to bind to 
integrins (membrane-spanning receptor proteins) thereby providing a potent 
physiological substrate for cell attachment. Fibronectin (Sigma Aldrich F1141) at 
1mg/ml stock solution, was dissolved in PBS to 0.8 μg/mL, applied to a glass coverslip 
or dish surface and incubated 1h 37⁰C. Fibronectin solution was then removed, the 
coated surface rinsed with PBS and used immediately for the cell culture.  
 
2.7.3 Transfection of cultured cells 
 
A variety of different transfection reagents, including JetPrime Reagent, 
Lipofectamine, Viromer, Fugene 6 and Calcium Phosphate method, were tested for 
optimal transfection of primary cells or cell lines with DNA plasmids. It was established 
that JetPrime Reagent and Calcium Phosphate provide the most efficient mode of DNA 
construct delivery, under the experimental procedures needed for this work. 
The Jet Prime Reagent (Polyplus Transfections) transfection method was 
optimised for the best results using manufacturer’s suggestions. Unless stated 
otherwise, for the routine transfections cells were cultured in a 24 well plate (on a 
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coated glass coverslips) till 70-80% confluency. In a microcentifuge tube, 100µl/well of 
the JetPrime Buffer and 0.8-1µg of plasmid DNA was mixed well and complemented 
with addition of The JetPrime Reagent (2µl/well) at 1:2 of DNA to JP Reagent ratio. 
Sample was mixed well and incubated 15min RT before applying to the cell media in 
the culture wells. Following 4h incubation, cells were washed and fed with fresh media. 
Typically transfected cells were fixed and immunolabelled 24h post transfection, unless 
stated otherwise. The same proportion of reagents was retained for different size 
culture dishes.  
For the Calcium Phosphate (CaPO4) precipitate transfection, cells were cultured 
to approximately 50-60% confluence in a T75 flask. To a microcentrifuge tube 62µl 2M 
CaCl2.2H2O and 24 µg DNA (at concentration ≥ 1 µg/µl) were added sequentially and 
made up to 600 µl with ddH2O. This mix was applied in drop-wise fashion, shaking 
vigorously, to 600 µl of 2xHEPES Buffered Saline (HBS) pH 7.02-7.12 (diluted from 
stock of 10xHBS - 8.18% NaCl (w/v (3.3g)); 5.94% HEPES (w/v (2.4g)); 0.2% Na2HPO4 
(w/v (0.08g)) in 40ml ddH2O; filter sterilised (0.2µm) and stored at 4°C) and allowed to 
stand at RT for 5 min. The formed precipitate was added drop-wise to the cells in 
normal growth media and incubated for 6-12h at 37⁰C. Transfected cells were washed 
then cultured in UltraCHO (Lonza:12-724Q) for 24h, then used for further studies (e.g. 
fixed or lysed for protein extraction). The same proportion of reagents was retained for 
different size culture dishes (volumes were scaled depending on surface area of culture 
dish (cm2)).  
 
2.7.4 Glycerol shock mediated cell transfection 
 
 Glycerol shock is a technique used to increase the rate of cell transfection, by 
stimulating cells to uptake the plasmid DNA. Cells were cultured and transfected as per 
usual, using JetPrime Reagent. Four hours post incubation with the reagent, cells were 
washed with fresh cell culture media. Subsequently cells were submerged in 15% 
Glycerol (in PBS) and incubated for 2min at 37⁰C, with was followed by immediate and 
thorough but gentle wash with media. Cells were then cultured as per usual.  
 
2.7.5 Immunocytochemistry (ICC) 
 
In preparation for immunolabelling, cultured cells (whether cell lines or primary 
cells) were rinsed in PBS to remove traces of culturing medium and fixed in 4% PFA 
solution for 15 min RT. Alternatively, cells were fixed using ice-cold 100% Methanol, 
incubated 5min -20⁰C. Cells were then washed in PBS and treated with 1% NP-40 
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detergent to permeabilize the cell membranes, allowing antibody penetration. 
Subsequently cells were blocked in 10% normal goat serum (NGS) solution for 1h RT, 
to prevent non-specific binding of antibodies. Cells were then incubated with primary 
antibodies diluted in 0.2% NGS at 4⁰C overnight, rinsed several times in 0.2% NGS 
solution and incubated for 1 hour at RT with the relevant species-specific secondary 
antibodies conjugated to Alexa 488 or 568 and diluted in 0.2% NGS, and in some 
cases also with phalloidin488 dye [1:1000] (Life Technologies A12379) to visualise 
cytoskeleton (as it binds to filamentous actin molecules). Full list of antibodies used 
and their concentration is shown in Table 2.7 and Table 2.8. Finally cells were rinsed in 
PBS and counterstained with nuclear dye Hoechst 33342 Trihydrochloride, Trihydrate 
(Hoechst) [1:10000] (Thermo Fisher Scientific H13399) for 10min at RT and rinsed with 
PBS and ddH2O. Glass coverslips were mounted onto microscope slides using 
Vectrashield (Vector Laboratories) solution and sealed with clear nail varnish enamel to 







Table 2.7 Primary antibodies used for either Immunocytochemistry (ICC) or Western 
Blotting (WB). Host species abbreviation: Chk – chicken; Ms – mouse; Rb – Rabbit; Rt 
– Rat.  








2.7.6 Analysis of cell transfection rate and intra-cellular protein distribution 
 
For cell transfection experiments, a typical experiment (per construct) consisted 
of transfecting two coverslips, and taking measurements from five random fields of 
view (under 10x objective) on each coverslip (total of 10 measurements per sample). 
Within each photographed area, total number of cells as well as total number of 
transfected cells was quantified. The pattern of HA localization in each cell (‘exclusively 
nuclear’; ‘predominantly nuclear’, ‘predominantly cytoplasmic’, ‘exclusively 
cytoplasmic’; and ‘equal distribution’, where HA signal was as strong in the cytoplasm 
as it was in the nucleus) was expressed as a percentage of the number of transfected 








Table 2.8 Secondary antibodies used for either Immunocytochemistry (ICC) or 
Western Blotting (WB). Host species abbreviation: Chk – chicken; Ms – mouse; Rb – 
Rabbit; Rt – Rat.  
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2.7.7 Measurements of co-localisation of fluorescent markers  
 
 Co-localisation of two fluorescently labelled markers could signify protein-
protein interaction. To determine whether given protein undergoes secretion from the 
cell, markers of secretory pathway were assessed for interaction with the HA-tagged 
protein, by determination of the level of co-localisation of two fluorescent channels – 
red and green.  
From fluorescent images 10 random cells were analysed using Volocity 6.3 
software (Fig. 2.5). Region of interest (ROI) corresponding to the area of the cell was 
selected and the co-localisation of markers was quantified by the software, selecting 
the appropriate channels: red (Alexa 568) as HA tag and green (Alexa 488) as the 
secretory pathway marker (either ERp60, βCOP or TGN46). Appropriate thresholds 
were set by the software, which calculations are based on the simultaneous 
estimations of the maximum threshold of intensity for each colour below which pixels 
do not show any statistical correlation (Costes et al., 2004). From performed 
calculations a scatter plot has been generated by the software of which each axis 
represents the ascending marker levels present within the two analysed channels, 
where two perfectly co-localized channels, generate a scatter plot where the points fall 
in a line at 45 degrees to either axis (Fig. 2.5A). On the contrary the horizontal line of 
scatter points signifies no correlation between the markers, therefore no co-localisation 
(Fig. 2.5B). 
Furthermore from intensity values within thresholds the software generates 
calculations of the Pearson’s Correlation coefficient (Rr) (Barlow et al., 2010), which 
describes the correlation of the intensity distribution between channels. Values range 
from -1.0 to 1.0, where values from 0 to 0.5 indicate no significant correlation between 
the given markers and values close to -1.0 indicate complete negative correlation. 
Importantly values that indicate co-localisation range from 0.5 to 1.0.  
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2.7.8 BrdU pulsing of cultured cells  
 
To pulse cells with BrdU, cell media was removed from the culture and 
supplemented with BrdU (3µg/ml final concentration), mixed and promptly placed back 
onto cultured cells. Cells were incubated with BrdU for 4h and fixed immediately with 
4%PFA for 15min at RT. Fixed cells were washed well with PBS and treated with 1M 
HCl (in ddH2O) 30min 47°C to denature nuclear DNA thereby promoting anti-BrdU 
antibody access to DNA. Cells were subsequently washed once in ddH2O for 5min, 
then three times in PBS for 5min, after which the immunohistochemistry was performed 
as usual.  
 
Figure 2.5 Representative images and graphs of quantification of co-localisation of 
two fluorescent markers using Velocity 6.3 software, where an area of the cell has 
been selected for analysis. (A) Image of G145E fluorescence and ERp60 marker, 
which serves as an example of positive correlation. (B) Image of G145E fluorescence 
and TGN46 marker, showing an example of no or very little correlation. Red channel 
(Alexa 568) corresponded to HA tagged protein expression and the green (Alexa 488) 
represented the secretory pathway markers. Black arrows point to the set thresholds 
generated by the software.  
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2.7.9 Induced growth arrest and cell cycle inhibition of cell culture 
 
In order to inhibit cell growth at specific cell cycle two methods were applied: 
drug treatment and serum starvation.  
The drug Nocodazole (Sigma Aldrich M1404) which interferes with the 
polymerization of microtubules and formation of mitotic spindle, was used at a final 
concentration within a range of 0.2µg/ml (allowing the optimal inhibition but preventing 
cell stress) to arrest cells at G2/M phase of cell cycle. The drug was applied to cultures, 
4h post application of DNA transfection reagents, and incubated for 12h followed by an 
immediate fixation with 4% PFA.  
Serum-deprivation prevents cell growth and arrests cells at the G1/G0 phase of 
the cell cycle. Normal growth media was removed from sub-confluent cell culture 
(70%), cells were rinsed several times with culture media lacking serum and incubated 
with the same for 24-48h prior to transfection, then also throughout the whole DNA 
transfection procedure. Subsequently, cells were fixed and immunolabelled. 
   
2.7.10 Alcian Blue and Alizarin Red staining of differentiated mesenchymal cells 
 
Alcian Blue and Alizarin red are chemical dyes that mark chondrogenic 
differentiation. The Alcian Blue is a type of polyvalent dye, used to stain acidic 
polysaccharides such as glycosaminoglycans found in cartilage. The Alizarin Red is an 
organic compound of a red colour that stains the presence of calcific deposition present 
within cells of an osteogenic lineage. During each stage of this procedure a great care 
was taken and each solution was applied very gently as the cultures peel off easily of 
the bottom of the dish.  
For Alcian Blue staining, differentiated ATDC5 cells which appear as ‘nodules’ 
were fixed with ice-cold 100% Methanol (5min -20°C) and incubated 30min RT with 
Alcian Blue dye (0.5%w/v, 0.1M HCl in ddH2O). Alternatively, for Alizarin Red staining, 
the dye (2% solution prepared in ddH2O pH 4.1-4.3) was applied for 10min at RT. 




Part 2.8 Microscopy, imaging and image analysis 
 
Fluorescently-labelled samples were visualised using a selection of 
microscopes (depending on the sample) including: Zeiss Axioimager M2 with an 
Apotome attachment, Zeiss Axioplan2 imaging and Zeiss LSM510 META confocal. 
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Live cell cultures as well as X-gal and Alcian Blue stained cells were imaged with Zeiss 
Axiovert40CFL microscope using phase contrast or fluorescent expression.  
Images were acquired using Axiovision 4.8 software and then further processed 
using ImageJ and Adobe Photoshop CS4.  
 
 
Part 2.9 Protein analysis  
 
2.9.1 Protein extraction from cell lysate 
 
For extraction of the protein from whole cell lysate, cells were cultured in a 
100mm Petri dishes and transfected using the JetPrime Reagent. 24h post transfection 
cultures were placed on ice and washed several times with ice-cold PBS to remove 
traces of media. To each dish, 300µl of Modified RIPA cell lysis buffer (50mM Tris 
pH7.4, 150mM NaCl, 2.5mM MgCl2, 1%(v/v) NP-40, 0.05%(v/v) Triton X-100, 
0.5%(w/v) Na-deoxycholate ) containing Halt Protease Inhibitors (1:100 dilution) 
(ThermoScientific 78430) was added, and cells were scraped off three times every 
10min using a cell scraper.  
To separate cell debris from the protein mixture, the scraped solution was 
transferred into a pre-chilled microcentrifuge Eppendorf tube and centrifuged at 
12000rpm for 15min at 4°C. The resulting supernatant, containing protein, was then 
placed in a fresh, pre-chilled tube and used straight away or stored at -20°C for later 
use. Protein concentration in the sample was determined using Pierce™ BCA Protein 
Assay Kit (ThermoScientific 23225).  
 
2.9.2 Trichloroacetic acid (TCA)-mediated protein precipitation 
 
Cultures of cells grown in three 100mm diameter Petri dishes were transfected 
with plasmid DNA and after 4h incubation cells were rinsed twice with PBS to remove 
traces of serum, and cultured in 5ml of serum-free culture media. 24h-48h post 
transfection, the media was collected and centrifuged (1500rpm 10min) to remove cell 
debris. To maximise extracted protein yield, cultures cells were occasionally incubated 
with fresh serum-free media and supernatants were collected and pooled with 
previously collected samples. 
Trichloroacetic acid (5% of final concentration) was added to the collected 
media and incubated overnight at 4°C. To pellet the precipitated protein, the samples 
were centrifuged at 12000rpm for 15min at 4°C, the supernatant was removed and the 
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protein pellet washed twice in ice-cold 150µl acetone at 4°C, finally transferring the 
sample into the microcentrifuge Eppendorf tube. Samples were centrifuged at 
12000rpm for 15min at 4°C. The final pellet was re-suspended in 5X Sample Buffer and 
stored at -20°C.  
 
2.9.3 SDS-PAGE and protein transfer 
 
Proteins run through the polyacrylamide gel electrophoresis (PAGE) were first 
denaturated and reduced by the Sodium dodecyl sulphate (SDS). Binding of SDS 
disrupts non-covalent protein bonds through electrostatic repulsion, causing protein 
denaturation (loss of native molecular conformation) that results in proteins unfolding 
into a rod-like shape; thereby eliminates differences in protein shape as a factor for 
separation on the gel.  
Typically 30µg of total protein from cell lysate was prepared for western blotting 
by mixing with 5X Sample Buffer (625mM TRIS-Base pH 6.8, 2%(w/v) SDS, 10%(v/v) 
glycerol, bromophenol blue and 5% β-mercaptoethanol) and ddH20, bringing the total 
sample volume to 25µl Protein samples were further denaturated by boiling for 2min at 
95˚C. Samples were loaded and run on a homemade gel – 10% resolving gel 
(40%(v/v) acrylamide, 375 mM Tris, 0.1% (v/v) Ammonium Persulphate, 0.25%(v/v) 
TEMED) and 5% stacking gel (40%(v/v) acrylamide, 125 mM Tris, 0.15%(v/v) 
Ammonium Persulphate, 0.4%(v/v) TEMED). Samples were run along with a protein 
ladder (PageRulerTM Plus ThermoScientific 26619) at 200V per gel in running buffer 
(25 mM Glycine, 250 mM Tris, 1% (w/v) SDS) for 35 min. The resolving gel, transfer 
membrane and thick filter paper were soaked in a Transfer Buffer (39mM Glycine, 
48mM Tri-HCl, 0.0375%SDS, pH8.3 and 20% methanol) for approximately 10 min. 
Protein was transferred using the semi-dry method, at 15V for 35min. 
 
2.9.4 Western Blotting of protein samples 
 
Following protein transfer, membranes were blocked in 10% (w/v) non-fat milk 
powder or in 3-5%(w/v) BSA in PBST (PBS and 0.5% Tween-20) at RT for 1-3h. 
Following blocking, the membranes were incubated in antibody solution (diluted in 
0.5% milk/3%BSA in PBST) overnight at 4⁰C and then washed excessively in 0.5% 
milk PBST over a period of 1h at RT. Membranes were then incubated with secondary 
antibody diluted in 0.5% milk/3%BSA in PBST for 1h RT, after which all membranes 
were washed multiple times in PBST for 30 min. Full list of antibodies used and their 
concentration is shown in Table 2.7 and Table 2.8. 
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For the antibody detection, membranes were incubated in ECL solution 
(100mM Tris pH8, 1.25mM Luminol, 0.2mM Coumaric Acid and 0.01% H2O2) for 5min 
and exposed to hyperfilm (GE Healthcare). Exposure times varied according to the 
sample from 15s -15min. 
If required, membranes were stripped with Stripping Buffer (0.2M Glycine, 0.5M 
NaCl, pH 2.8) 2x 5min then washed 1x ddH2O and 2x PBST, before they were re-
blocked and reblotted according to the same protocol. 
 
2.9.5 Protein deglycosylation 
 
 Protein glycosylation is a form of post-translational modification and can either 
occur on N-linked-glycosylation sites or O-linked-glycosylation sites, which is controlled 
by different enzymes and generated by different types of chemical bonds. In order to 
determine which protein sites are glycosylated the removal of protein glycosylation was 
obtained by two means: (1) treatment with Protein Deglycosylation Mix (New England 
BioLabs P6039S), which is a cocktail of enzymes designed to remove all types of 
glycosylation; and (2) treatment with PNGase F (New England BioLabs P0704S), an 
enzyme known to remove almost all N-linked oligosaccharides from proteins.  
 First ARPE cells were transfected with specific constructs and protein was 
obtained from the whole cell lysate. 25µg of protein was combined with 2µl of 10X 
Glycoprotein Denaturing Buffer and water, providing total reaction volume of 20µl. 
Protein samples were primarily denatured by heating for 10min at 100°C. For the 
removal of N-linked oligosaccharides to the samples 4µl of 10X G7 Reaction Buffer, 4µl 
of 10%NP40 and 2µl of PNGaseF enzyme was added, generating the reaction volume 
to 40µl in total by addition of ddH2O. However for removal of all oligosaccharides, to 
the samples 5µl of 10X G7 Reaction Buffer, 5µl of 10%NP40 and 5µl of 
Deglycosylation Enzyme Coctail was added, generating the reaction volume to 50µl in 
total by addition of 15µl of ddH2O. 
 
2.9.6 Subcellular Fractionation 
 
Cell fractionation (cytoplasmic versus nuclear) was carried out according to the 
protocol of Dimauro et al. (Dimauro et al., 2012). Briefly, 24 hours post transfection, 
HEK 293T cells were washed twice with cold PBS, and pelleted down at 4°C 500xg for 
5min. The cytoplasmic fraction was then separated from the rest of the cell content by 
treating cells with STM buffer (250 mM sucrose; 50 mM Tris–HCl pH 7.4; 5 mM MgCl2) 
in the presence of 1% Halt protease inhibitor cocktail (Thermo Fisher Scientific) 
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incubating on ice for 45min. The samples were centrifuged at 4°C 800xg for 15min and 
as a result of which the supernatant contained the cytosolic fraction whilst the 
remaining pellet contained the nuclear fraction.  
To purify protein from cell debris, the cytoplasmic fraction was washed in STM 
buffer and protein content was precipitated in pre-cooled Acetone (4x sample volume) 
for 1h at -20°C. To remove the acetone, the sample was centrifuged at 4°C 12000xg 
for 5min and the obtained pellet was briefly air-dried for about 10min. Finally the 
cytosolic fraction was re-suspended in STM buffer (containing the protease inhibitors).  
To remove any remaining cytoplasmic proteins, the nuclear fraction pellet was 
washed twice by subsequent re-suspension in the STM buffer 4°C 500xg, then for 
15min. The washed pellet was treated with NET buffer (20 mM HEPES pH 7.9; 1.5 mM 
MgCl2; 0.5 M NaCl; 0.2 mM EDTA; 20% glycerol; and 1% TritonX-100) in the presence 
of 1% Halt cocktail, incubated on ice for 45 min. The debris was removed by pelleting it 
down through centrifugation at 9000xg and the obtained supernatant generated the 
nuclear fraction.  
 
 
Part 2.10 Statistics 
 
 
All statistical tests were performed using IMB SPSS Statistics 22. For normally 
distributed data with equal variances either independent sample Student t-test (if 
comparing two samples of equal variance) or ANOVA with post hoc Tukey (when 
comparing more than two samples of equal variance) were performed. For samples 
with varying variances Mann-Whitney U (comparing two-groups) or Krusal-Wallis (more 
than two samples) were used.    
Within the figure legends, for each significance level ‘stars’ were used that refer 
to specific probability level ‘P’ precisely:  
‘no stars’ corresponds to P>0.05 – no statistical significance 
*  denotes P≤0.05 
**  denotes P≤0.01 
***  denotes P≤0.001 








 In silico analysis of the Fgf10 gene and protein structure 
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Part 3.1 Overview of bioinformatics 
 
Secretory FGF10 molecule, upon release from the cell, binds with strong affinity 
to FGFR2IIIb (Fig. 1.4B) (see Chapter 1). However, recombinant rat FGF10 has been 
found in the nuclei of cultured cells (lacking endogenous expression of this protein) 
(Bagai et al., 2002), suggesting an alternative functioning pathway for the protein. 
Furthermore, FGF10 contains a putative nuclear localisation sequence (NLS)–like 
motif, that is based on a sequence homology to NLS found in FGF1 (Kosman et al., 
2007, Zhan et al., 1992). However it is a ‘weak’ motif, that only partially influences 
FGF10’s nuclear translocation (Kosman et al., 2007), suggesting the presence of other 
factors regulating localisation and function of FGF10. Moreover, Fgf10 is expressed in 
the mouse hypothalamus, which is not complemented by an expression of its cognate 
receptor FGFR2IIIb (Hajihosseini et al., 2008), suggesting alternative mechanisms of 
action of FGF10.  
Bioinformatics (i.e. the in silico research method) is the application of 
computational techniques to understand and organise information associated with 
biological macromolecules and their mutual interactions. Advantages of the system 
include prediction with high probability of molecular models and hypotheses, as well as 
storage of vast amount of data and its quick and efficient processing. In the field of 
genetics freely available programs, including Basic Local Alignment Search Tool 
(BLAST) (Altschul et al., 1990) that allow comparison of nucleotide sequences, are 
essential tools in genome sequencing and annotating occurring mutations, such as in 
Genome Wide Association Studies (GWAS) (Londin et al., 2013). Bioinformatics is 
widely used in genomics and proteomics analysis, for example specific programs are 
designed to provide separation of the signal from noise in high-throughput gene 
expression studies, such as microarrays and mass spectrometry. Furthermore, 
computer algorithms and mathematical models are an indispensable part of systems 
biology, unravelling protein-protein interactions and their complicated networks (e.g. 
the metabolic pathway).  
 Importantly, bioinformatics is an essential and central part of structural biology, 
generating three dimensional visual models of nucleic acids and protein molecules.  
Those models are applied to simulate the intramolecular interactions, reducing time 
and costs of experimental procedures and are vital for drug targets identification and 
design. For example, crystal structure analysis of human recombinase Rad51 binding 
to BRC repeats of BRCA2, revealed specific binding residues potentially useful as 
targets of drugs that through disrupting the interaction could lead to cancer treatment 
(Blundell et al., 2006). Interestingly, bioinformatics has also been used to address 
biological activity of various molecules, including FGFs. Analysis of molecular model of 
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FGF1, FGFR2IIIc and heparan sulphate proteoglycan (HSPG) complex revealed the 
critical role of heparin in receptor activation. The receptor dimerization was shown to 
take place due to heparin-induced conformational change in the receptor itself 
(Pellegrini et al., 2000), which is likely to occur in other FGFRs. The progression from 
protein structure visualisation led to ‘molecular dynamic simulation’ (MDS), that is 
based on Newton's laws of motion and provides information about movement of atoms 
around rotatable bonds. Such programs are expanded further into computational 
algorithms termed ‘docking algorithms’, allowing in silico prediction of two molecules 
reacting together.  
Advances in biology and computer sciences increase the resourcefulness of 
bioinformatics. Innovation in computer storage capabilities and improvements in 
mathematical models lead to more reliable results and allow valid predictions about the 
molecules that have not been experimentally addressed yet. Bioinformatics at the 
moment allows for the gathering of assumptions and predictions, providing a starting 
point to studies otherwise difficult to undertake. 
FGF ligands, including FGF10, are the subject of intensive studies, providing a 
wide and in-depth knowledge, allowing a comprehensive base for further in silico 




Although much is already known about Fgf10’s genomic sequence and protein 
structure (see Chapter 1), recent advances in technology and bioinformatics tools 
provide novel approaches to further studies.  
 The aim of this part of the thesis is to examine FGF10’s DNA and protein 
sequence, using in silico tools to analyse: (1) existence, positioning within the protein 
structure and functionality of potential NLS; (2) existence of putative post-translational 
modifications (PTM), i.e. SUMOylation and Glycosylation, that could affect nuclear 
import of FGF10; (3) and existence of putative regulatory sites within a promoter region 
of Fgf10 driving the expression of the protein. These will provide preliminary predictions 
of the protein’s structure and function, as well as aid in determining the putative mode 
of FGF10’s nuclear incorporation, which can be followed up with experimental 
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Part 3.2 Discovery and analysis of putative NLS within FGF10 
 
3.2.1 Identification of a novel NLS within FGF10 
 
FGF10 is found in the cell nucleus. However, the underlying mechanisms of its 
nuclear translocation remain unclear (Bagai et al., 2002, Kosman et al., 2007). The 
sequence proposed to act as NLS, within rat FGF10 corresponding to 
142NKKGKLY148 (here on referred to NLS1) (Fig. 3.1B,C,E), was shown to be 
insufficient to act as a fully functioning nuclear import motif (Kosman et al., 2007). 
Therefore, FGF10 molecule was analysed in the context of additional non-classical 
NLS or NLS-like motifs necessary for the protein’s nuclear transport.   
Searches based on PSORT tools (WoLF PSORT and PSORT II), which use 
mathematical models to find consensus motifs within a sequence, predicted no 
classical NLS present within the rat FGF10 sequence and these results are in 
agreement with earlier literature (Kosman et al., 2007). However, both programs 
predicted stretches of basic residues within the rat FGF10, with overall content of 
12.4% of the whole sequence, suggesting the possibility of existence of non-classical 
NLS. FGF molecules share up to 74% sequence similarity (Ornitz and Itoh, 2001) and 
FGF10 is well conserved between different species (Fig. 3.2A). However, providing that 
even slight structural differences, such as variation of a single residue, can determine 
the function of the protein (Makarenkova et al., 2009), the searches were also 
performed for primary human and mouse FGF10 sequences. Similarly, no classical 
NLS was found in human and mice. All of the following searches were then performed 
on human, mouse and rat sequences however, each time the three species displayed 
similar outcomes (data not shown). Therefore, the following results correspond to rat 
FGF10 sequence, particularly since recombinant rat protein was used in experimental 
work (see Chapters 4&5) and data shown here, unless stated otherwise, is a 
representative of all three species.  
Examination of the non-classical NLS was performed using NLStradamus, a 
tool that analyses the composition of residues within the protein sequence and 
searches for specific clusters of basic residues rather than consensus motifs (Nguyen 
Ba et al., 2009). This approach allowed identification of a novel putative NLS-like motif, 
corresponding to rat 192APRRGQKTRRK202 sequence (Fig. 3.1A) (Appendix 1), 
residing close to the C-terminus of the protein (Fig. 3.2A). This prediction was then 
further confirmed by a NucPred, a genetic programming (GP) software (see Chapter 2). 
This is a machine-learning technique that automatically develops computer programs in 
an artificial evolutionary process, to analyse the protein sequence, compare to existing 
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nuclear proteins and classify parts of the protein sequence as “nuclear” or “not nuclear” 














The NucPred’s analysis showed that within FGF10’s sequence, a stretch of 
amino acids spanning residues 194RRGQKTRRK202 displayed the highest positive 
Figure 3.1 Identification of non-classical NLS2 within FGF10 sequence. (A) The 
NLStradamus predicts existence of a single NLS motif beyond its set probability 
threshold (red) based on clusters of basic residues. (B) NucPred results determine the 
NLS2 region as “likely/positive” to drive nuclear import of FGF10, as shown by the 
yellow-green colouring. 
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score for influencing the molecule’s nuclear targeting (Fig. 3.1B). Therefore, the two 
NLS-prediction tools suggested the existence of a non-classical NLS within FGF10, 
which was then named NLS2. This sequence is located on the protein surface and 
resides outside of the receptor interacting interface (Fig. 3.2B). 50% of this NLS2 
sequence is composed of basic amino acid residues (Arginine/R and Lysine/L) and the 
side chains are protruding out from the centre of the molecule, providing availability for 














Interestingly, in the protein’s 3D structure, the NLS2 is positioned in a close 
proximity to the NLS1 (Fig. 3.2B). Moreover it was noted that a residue from NLS1, the 
Figure 3.2 Conservation and position of NLS2 within primary and tertiary structure of 
FGF10. (A) NLS1 (green) and NLS2 (red) are well conserved between vertebrate 
species and reside about 44 residues apart within primary sequence of FGF10. (B) Both 
surface exposed NLS motifs come into close contact within the tertiary structure of the 
protein and positioned away from the FGF10 (light brown) and FGFR2IIIb (blue) 
interface; figures viewed from two angles. (C) NLSs directly interact through an H-bond 
between G145 residue (purple) and G196 in NLS2; figures drawn using 1NUN PDB file 
and Chimera 1.9 software. 
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Glycine 145 forms an H-bond with a residue located in the NLS2, Glycine 196 (Fig. 
3.2C). The tools predicted the NLS2 sequence as a “weak” NLS-like motif that might be 
similar to NLS1, which was experimentally shown to act as a “weak” NLS by Kosman et 
al.  (Kosman et al., 2007). This raised the intriguing possibility that the two weak NLS 
motifs are advantageous to typical paracrine protein as they may act together to 
provide a stronger signal targeting FGF10 into the cell nucleus, allowing control over 
the levels of protein’s nuclear import.  
Sequence alignments showed that NLS1 and NLS2 are well conserved within 
the primary sequence of FGF10 between various vertebrate species, ranging from fish 
to humans (Fig. 3.2A).  A high level of species conservation could suggest that NLS1 
and NLS2 regions were maintained by evolution, despite speciation, and therefore may 
be key aspects to the FGF10’s function. Furthermore, the sequence of FGF10 was 
aligned to sequences of known FGFs that translocate into the cell nucleus: FGF1 







FGF10  MWKWILTHCASAFPHLPGCCCCFLLLFLVSSVPVTCQALGQDMVSPEATNSSSSSSSSSS 60 
FGF3   --------------------MGLIWLLLLS------------LLEPGWPATGPGTRLRR- 27 
FGF2   ------------------------------------------MAAGSITSLPALPEDGGG 18 
FGF1   ------------------------------------------MAEGEITTFAALTERFN- 17 
                                                 :     .   . .      
  
FGF10  SSSFSSPSSAGRHVRSYNHLQGDVRWRKLFSFT-KYFLKIEKNGKVSGTKKENCPYSILE 119 
FGF3   --------DAGGRGGVYEHLGGAPRRRKLYCAT-KYHLQLHPSGRVNGS-LENSAYSILE 77 
FGF2   ----------------AFPPGHFKDPKRLYCKNGGFFLRIHPDGRVDGVREKSDPHVKLQ 62 
FGF1   -----------------LPLGNYKKPKLLYCSNGGHFLRILPDGTVDGTRDRSDQHIQLQ 60 
                                 : *:. .  ..*::  .* *.*   ..  :  *: 
  
FGF10  ITSVEIGVVAVKAINSNYYLAMNKKGKLYGSKEFNNDCKLKERIEENGYNTYAS--FNWQ 177 
FGF3   ITAVEVGVVAIKGLFSGRYLAMNKRGRLYASEHYNAECEFVERIHELGYNTYASRLYRTG 137 
FGF2   LQAEERGVVSIKGVCANRYLAMKEDGRLLASKCVTEECFFFERLESNNYNTYRS--RKYS 120 
FGF1   LSAESAGEVYIKGTETGQYLAMDTEGLLYGSQTPNEECLFLERLEENHYNTYTS--KKHA 118 
       : : . * * :*.  :. ****.  * * .*:  . :* : **:..  **** *   .   
  
FGF10  HNG----------RQMYVALNGKGAPRRGQKTRRKNTSAHFLPMVVHS------------ 215 
FGF3   PSGPGARRQPGAQRPWYVSVNGKGRPRRGFKTRRTQKSSLFLPRVLGHKDHEMVRLLQSG 197 
FGF2   S--------------WYVALKRTGQYKLGSKTGPGQKAILFLPMSAKS------------ 154 
FGF1   EKN------------WFVGLKKNGSCKRGPRTHYGQKAILFLPLPVSSD----------- 155 
                       :*.:: .*  : * :*   :.:  ***                  
  
FGF10  ------------------------------------------------ 
FGF3   QPQAPGEGSQPRQRRQKKQSPGDHGKMEHLPTKATTSAQLDTGGLAMA 245 
FGF2   ------------------------------------------------ 
FGF1   ------------------------------------------------ 
Figure 3.3 NLSs of different FGF proteins appear conserved within a N-terminal protein 
region.  NLS2 (red) of FGF10 corresponds to one of the NLS-motifs of FGF3 (yellow) 
and resides in close proximity to NLS of FGF2 (brown) and FGF1 (blue); NLS1 of 
FGF10 shown in green. Figures drawn using Clustal 2.1 software. 
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The NLS2 motif of FGF10 corresponds to one of the NLS-motifs found within FGF3. 
Moreover, in close proximity to this region resides NLS of FGF2 and a bipartite NLS of 
FGF1 (Fig. 3.2). Similarly, conservation of the same region within proteins from 
different subfamilies could suggest that this particular region of FGF molecules is also 
important for their nuclear import. 
FGF10 and FGF3 both belong to the FGF7 subfamily and share similar nuclear 
localisation motifs. It is likely therefore that these are also present in the remaining 
members of the subfamily. To determine if the NLS1 and NLS2 are conserved within 
FGF7 subfamily members, the sequences were aligned and assessed for presence of 
basic residues. Within all molecules the regions corresponding to NLS1 and NLS2 of 
FGF10 are well conserved, with a very high content of basic residues (Fig. 3.4). 
Moreover, besides FGF3, the NLS2 region of FGF10 shows high conservation within 
FGF22. Members of the same subfamily share structural and functional properties (see 
Chapter 1). High level of conservation of NLS motifs within all members could be linked 
to their structural or functional importance. Moreover, this raises an exciting possibility 
that all members of this subfamily may potentially be found in the cell nucleus. 
However testing this hypothesis is beyond the scope of this project and will not be 








Proteins that are imported into the nucleus are also often exported out, and 
transport in either direction requires chaperone proteins. To facilitate protein’s nuclear 
export these chaperones (known as karyopherins) often recognise and bind to specific 
Figure 3.4 Sequence alignments of FGF7 subfamily members (rat). The NLS1 
(green) and NLS2 (red) of FGF10 show full conservation (blue) and high number of 
basic (purple) residues within corresponding regions of FGF3, FGF7 and FGF22. 
Figures drawn using Clustal 2.1 software 
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consensus motifs on the cargo proteins’ surface, called nuclear export sequences 
(NES) (see Chapter 1). To predict existence of NES within FGF10 couple of 
bioinformatics tools was used such as LocNES, which is designed to search for 
consensus NESs, or ValidNESs, a program that determines presence of NES based on 
specific amino acid frequencies (see Chapter 2). However these could not detect 
existence of any NESs and most likely FGF10 is not transported out of the nucleus 
through classical pathway, or alternatively it is not transported out of the nucleus at all.  
 
3.2.2 Potential interactions between FGF10’s NLS2 and importins 
 
 
Importins are nuclear transport chaperones that bind to NLS present on a 
protein’s surface and guide the cargo protein through the molecular pores into cell’s 
nucleus. Importins are distinguished as Importin α and Importin β subunits, each 
referring to a large family of molecules. The α and β subunits form a complex allowing 
transport of a cargo protein through the nuclear pore. Typically Importin-α binds the 
cargo protein and Importin-β interacts with the nuclear channel proteins (Fig. 1.10), 
although Importin-β is also found to bind non-classical NLS and transport proteins 
without the aid of Importin-α (see Chapter 1). It was therefore hypothesised that 
FGF10’s NLS2 motif binds to an isoform of Importin in order to translocate into cell 
nucleus. To provide a basis for experimental approach, identification of putative 
FGF10(NLS2)-to-importin interactions was performed using a bioinformatics ‘molecular 
docking’ tool (see Chapter 2).  
In collaboration with Mr Georgios Iakovou, who designed and generated 
molecular docking software based on haptic system (Iakovou et al., 2015), interactions 
between FGF10’s NLS2 and Importin α or Importin β subunits were tested. The binding 
interactions of the two proteins were based on the repulsion forces generated between 
the two molecules, meaning that the closer the calculated repulsion force value to zero, 
the more likely the interaction to occur in nature (see Chapter 2). The in sillico results 
suggest that FGF10 utilising its NLS2 binds more strongly to an Importin-α isoform, 
with the repulsion force of -289.18 kcal/mol, than to an Importin-β, where a repulsion 
force ranges between -500 to -800 kcal/mol (Fig. 3.5A). Nonetheless the software 
predicts also a strong, non-chemical attraction towards Importin-β that attributes mainly 
to electrostatics forces. Four different attempts were made to determine the most likely 
binding of FGF10 to Importin-β, with the best (strongest) force prediction of -584.98 
kcal/mol (Fig. 3.5B), the weakest of -717.97 kcal/mol (Fig. 3.5C) and two of middle 
range corresponding to -612.69 kcal/mol (Fig. 3.5D) and -649.88 kcal/mol (Fig. 3.5E).  
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Unfortunately, the system cannot adapt to conformational changes that the 
protein molecules might display during binding. Often, protein-protein interaction results 
in slight conformational changes to at least one of the protein’s structure, providing 
flexibility that allows binding to occur. These however, cannot be predicted/designed 
and interpreted by the software without prior experimentally achieved knowledge of 
complex’s crystal structure. Whilst the molecular docking system remains an aid to 
experimental studies, it cannot replace them.  






Figure 3.5 Molecular modelling of FGF10 binding predictions to Importins-α and -β. (A) 
The most likely prediction of naturally occurring interaction between FGF10 (light brown)-
NLS2 (red) to Importin-α (blue), viewed from two angles. (B-E) Different variations of 
putative binding of Importin-β (green) to FGF10, all displaying higher repulsion forces 
than binding to Importin-α, hence less likely to occur.  
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Part 3.3 Analysis of putative post-translational modifications of FGF10 
 
3.3.1 The influence of a putative SUMOylation site on nuclear import of FGF10 
 
The family of Small Ubiquitin-like Modifier (SUMO) proteins modify function of 
other proteins by covalently attaching to or being removed from them, in a process of 
SUMOylation (Hay, 2005). The SUMOylation is a form of post-translational modification 
involved in multiple cellular processes. It can aid protein stability as in the case of Ago2 
protein (Sahin et al., 2014, Lee and Kim, 2015) as well as affect gene expression and 
integrity of a genome as it regulates the PML/p53 tumour suppressor network (Muller et 
al., 2004). Moreover SUMOylation can affect progression through the cell cycle (Eifler 
and Vertegaal, 2015), for example the E2-conjugating enzyme Ubc9 was shown to be 
required for progression through mitosis by degrading M-phase cyclins (Seufert et al., 
1995). Therefore, SUMOylation of FGF10 could impact the intra-cellular function of an 
otherwise secreted protein. Importantly SUMOylation is also involved in nuclear-
cytosolic transport (Grunwald and Bono, 2011, Chen et al., 2013, Sedek and Strous, 
2013) and enzymes  involved  in  SUMO  conjugation  (Ubc9 and the E3-ligase 
RanBP2) are found at the nuclear pores in vertebrates (Melchior et al., 2003). Hence, 
putative SUMOylation of FGF10 could have a profound effect on its nuclear import. 
SUMO proteins, in a process of SUMOylation generate covalent interactions in an 
ATP-dependent reaction, forming an isopeptide bond with the amino group of a Lysine 
residue in the acceptor protein. Moreover the Lysine residue is positioned within a 
tetrapeptide consensus motif Ψ-K-x-D/E where Ψ is a hydrophobic residue; K is the 
lysine conjugated to SUMO; x is any amino acid; and D or E are an acidic residues 
(Melchior et al., 2003). 
The primary sequence of FGF10 was tested for any putative SUMOylation 
sites. Application of two independent bioinformatics tools, GPS-SUMO and PCI-SUMO 
(see Chapter 2), predicted the existence of only one SUMOylation site within rat FGF10 
corresponding to Lysine/K at position 98 (Fig. 3.6A&B). This site was also predicted in 
the human sequence at position K91 (Fig. 3.6D) (Appendix 2). The K98 resides on the 
protein surface and is positioned away from the NLS1 and NLS2 (Fig. 3.6C) as well as 
receptor binding site. Interestingly, within mouse FGF10 sequence Threonine (T92) 
replaces Lysine (Fig. 3.6D) resulting in the abrogation of SUMOylation (Appendix 2). 
Sequence alignment showed that SUMOylation may be also present in chicken, but is 
likely to be absent within frog and fish FGF10 sequences (Fig. 3.6D). Lack of 
conservation of this domain suggests that the putative SUMOylation site may not be a 
crucial element affecting function of FGF10 but it is possible that it generates slight, 
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species specific differences in the protein function. However to establish its true 
function (or lack thereof) it requires experimental testing.  
  
Figure 3.6 Predictions of FGF10’s SUMOylation site. (A) GPS-SUMO prediction with 
medium stringency settings results in identification of K98 residue (B) Similarly the 
PCI-SUMO predicts K98 as putative SUMOylation site. (C) The K98 (in orange) 
resides on the protein’s surface and away from the NLS1 and NLS2. (D) The 
SUMOylation site (orange) is present in rat, human and chicken sequences and is 
absent in other species (in purple corresponding residues).  
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3.3.2 Identification of putative glycosylation sites in FGF10 protein sequence 
 
Upon translation, secreted proteins advance through the secretory pathway, 
towards the cell membrane from where they are secreted out. Most of these newly 
synthesised proteins contain a ‘Signal Peptide’ (SP) located at the N-terminus of the 
molecule, targeting the protein to the ER and towards the rest of the pathway. Upon 
protein maturation the signal peptide is removed and the protein becomes fully folded 
with the aid of chaperone proteins (see Chapter 1).  As a typical secretory protein 
FGF10 was shown (using SignalP4.1 software) to contain a SP at its N-terminus (Fig. 
3.7), that corresponds to the first 36-39 residues depending on the species, which is in 





  Figure 3.7 Predicted Signal Peptide (SP) of rat FGF10 according to SignalP4.1 – note 
the cleavage site located between residues 36 and 37. C-score - raw cleavage site 
score (output from networks trained to distinguish signal peptide cleavage sites); S-
score - signal peptide score (output from networks trained to distinguish positions 
within SPs from positions in the mature part of the proteins and from proteins without 
signal peptides); Y-score - combined cleavage site score (combination of the C-score 
and the slope of the S-score).  
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 Secretory proteins passing through the rough ER often undergo glycosylation - 
an enzymatic process during which glycans (sugars) are attached to specific sites on a 
protein structure. In the N-linked type of glycosylation, glycans are attached to a 
nitrogen atom found on the side-chains of Asparagine/N or Arginine/R residues. N-
linked glycosylation is important for protein folding and stability (Tannous et al., 2015), 
and can affect protein function. For example, ablation of the glycosylation cassette in 
FGF4 results in the generation of two truncated protein isoforms, both showing higher 
biological activity than the full length FGF4 (Bellosta et al., 1993). The O-linked glycans 
are attached to the hydroxyl oxygen of Serine/S, Threonine/T, Tyrosine/Y, hydroxyl-
Lysine, or hydroxyl-Proline. O-linked glycosylation also plays a role in protein folding, 
stability as well as degradation which translates onto protein function. For example, 
impairment of FGF23 O-glycosylation generates an inactive form of the protein that 
leads to Hyperostosis-hyperphosphatemia syndrome in humans (Frishberg et al., 
2007). Importantly, there is evidence showing that glycosylation also influences protein 
nuclear import, even being sufficient to drive protein into the nucleus (Rondanino et al., 
2003, Monsigny et al., 2004). However, certain types of glycosylation, especially those 
located in close proximity to a NLS, can prevent nuclear import (Schlummer et al., 
2006). Since FGF10 is a secreted protein it is important to determine its putative sites 
of glycosylation.  
A range of different bioinformatics tools predicting the glycosylation sites on a 
protein molecule are available online (see Chapter 2). Using different tools, there was a 
major similarity in the results searching for the N- and O-linked glycosylation within 
FGF10 rat sequence (Fig. 3.8A&B). Overall, taking into account small differences 
between the search tools, it was assumed that the rat FGF10 carries at least 2 putative 
N-linked and about 24 O-linked glycosylation sites (Fig. 3.8C).  Interestingly two of 
those were located in close proximity to NLS2 sequence – the N-linked site 203 
Asparagine/N and on O-linked site 204 Threonine/T. The significance of this is 
unknown but these sites could directly affect the functioning of NLS2, e.g. attract or 
prevent binding to Importin molecules. No glycosylation sites were found in close 
proximity of NLS1 site. Further searches showed that there was very little variation in 
predicted FGF10 glycosylation sites between different mammalian species (data not 
shown). 
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Figure 3.8 Identification of putative rFGF10’s glycosylation sites. Examples of 
identification of N-glycosylation by (A) NetNGlyc 1.0 Server and (B) GlycoEP 
software. (C) Collective predictions of bioinformatics tools – rFGF10 potentially 
carries 2 N-linked (purple) and 26 O-linked (blue) glycosylation sites; positions of 
NLS1 (green) and NLS2 (red) are also marked.   
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Part 3.4 Transcription of Fgf10 may be controlled by multiple promoters 
 
The knowledge of mechanisms leading to a spatio-temporal transcription of 
Fgf10 could aid in resolving the function it serves. Genetically modified Fgf10-reporter 
mice, referred to as the Fgf10-LacZ mice, have a LacZ reporter placed within the Fgf10 
promoter region and are used frequently to track the expression of the FGF10 protein 
(see Chapter 1, 2 and 6) (Kelly et al., 2001). These modifications to the promoter 
partially impair Fgf10 transcription (Mailleux et al., 2005). Therefore, using 
bioinformatics, possible promoter-positioning sites were proposed, that could be useful 
in future studies.  
The Eukaryotic Promoter Database (EPD) tool was used to analyse a region 
spanning  from  1000bp upstream of human Fgf10 translational start site to 100bp into 
the sequence of the first codon (-1000 to +100). The searches predicted five different 
sites for potential TATA-box positions (Fig. 3.9A), two sites for potential position of GC-
box (Fig. 3.9B) and no sites for CAATT-box. Interestingly, none of these sites 
correspond to a promoter site predicted by a different bioinformatics tool, the Neural 
Network Promoter Prediction software, that predicted only one promoter site located at 
-243 to -293bp upstream of the Fgf10 translational start site.  
Previous studies using Fgf10 LacZ-reporter mouse showed that the promoter 
(or some regulatory cis-elements) lay further upstream than 114kb from the Fgf10 ATG 
region (Kelly et al., 2001) (Chapter 2). Therefore an attempt was made to analyse the 
UTR region of Fgf10 genomic sequence further upstream than 114kb. The analysis of 
7618 nucleotides of mouse genomic sequence located -900 to -77087bp on 
chromosome 13 upstream of the Fgf10 translational start site, using the Promoter 2.0 
Prediction tool, resulted in identification of 17 putative promoter regions (Fig. 3.9C). 
However, the functionality of these putative promoter regions requires 
experimental validation.  
 







Figure 3.9 Putative promoter regions of Fgf10 gene. (A) there are 5 putative TATA 
box regions and (B) 2 putative GC-rich regions as determined by EPD software. (C) 
Further upstream of the Fgf10 translational start site there are several other 
putative promoter regions of high (red) and moderate (blue) plausibility as predicted 
by Promoter 2.0 software. 
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Part 3.5 Conclusion and Discussion 
 
There is evidence that besides its secretory functions FGF10 can also 
translocate into a cell nucleus (Kosman et al., 2007, Bagai et al., 2002)(also shown 
later on in this thesis Chapter 4) through yet undescribed mechanisms (Kosman et al., 
2007). In this study a range of bioinformatics tools was used to analyse FGF10 protein 
in context of nuclear translocation and establish possible basis for further studies.  
It was found that FGF10 may contain two putative motifs, NLS1 and NLS2 that 
in the protein 3D structure reside in close proximity to each other (Fig. 3.1). Mutation of 
NLS1 does not prevent the protein from entering the nucleus. However, it causes a 
shift in the ratio of the nuclear-to-cytoplasmic protein presence, towards cytoplasmic 
(Kosman et al., 2007). Therefore, speculation has arisen that the two weak NLS motifs 
act together to generate a stronger signal driving protein’s nuclear import. Presumably, 
at least one of the motifs is recognised by and interacts with an Importin chaperone, 
and this interaction is then further facilitated by the second NLS motif, promoting 
efficient nuclear transport. This arrangement of signals could provide the dual fate of 
the FGF10 – finely balanced opposing signals allow competition between the two 
intracellular trafficking pathways, either targeting the protein towards the secretory 
pathway or translocating it into cell nucleus. Similarly, multiple NLS-like motifs within 
FGF3 allow for the efficient protein import, competing with the signal peptide directing 
FGF3 to the secretory pathway. Moreover, alteration of the distance between the signal 
peptide cleavage site and one of the NLS motifs through introduction of a variable 
length spacer of random structure, negatively affected the nuclear import of the protein 
(Kiefer et al., 1994b). Therefore, the position of the motifs within the protein structure is 
crucial to the protein intracellular distribution, which perhaps also pertains to FGF10.  
Furthermore, FGF3 belongs to the same subfamily as FGF10. Sequence 
alignments revealed a conservation between FGF10’s putative NLS2 and one of the 
nuclear import motifs found within FGF3 (Fig. 3.2). Moreover, FGF7 and FGF22, both 
showed high content of basic residues within the NLS2 sequence region (Fig. 3.3). 
FGF22 was detected in the nucleus of human breast adenocarcinoma cells (MCF-7) 
however, the mechanisms leading to its nuclear import are not described (Beyer et al., 
2003). Both NLS1 and NLS2 motifs have their paralogues in other FGF7 subfamily 
members and orthologues in other vertebrate species. These motifs therefore have 
been maintained throughout evolution, suggesting they might be of a structural or 
functional value to the protein. Sequence conservation was shown to determine its 
functional importance within a protein, and has been used to detect residues involved 
in ligand binding (Liang et al., 2006) and protein-protein interactions (Mintseris and 
Weng, 2005, Capra and Singh, 2007). Since three of the four members of the 
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subfamily have been detected in the cell nucleus, an interesting possibility could be 
raised that they all might serve an important nuclear role, which requires further 
investigation, beyond the scope of this project.   
Interestingly, FGF10 was predicted to contain no Nuclear Export Sequences 
(NES). NES is a short stretch of 4 hydrophobic residues, usually Leucines/L, that bind 
to Exportins and targets the protein out from the nucleus into the cytoplasm. It is 
possible that FGF10 contains an atypical NES that cannot be detected by the limited 
capabilities of current software tools. It is also possible that FGF10 is exported out from 
the nucleus in an atypical fashion. For example, some isoforms of Importin proteins 
show bi-directional properties (Mingot et al., 2001). Another possibility is that FGF10 is 
not exported and possibly undergoes proteolytic degradation in the nucleus itself, for 
example by the nuclear ubiquitin-proteasome system (von Mikecz et al., 2008). 
Importins belong to a large family of transport proteins, known as karyopherins. 
Both isoforms, α and β are able to transport their cargo proteins into cell nucleus. 
Specific interaction between FGF10 and a karyopherin requires experimental 
determination. For example, in a process of immunoprecipitation FGF10 in a complex 
with putative isoforms of importin could be isolated from a cell lysate FGF10. The 
specific Importin isoform could be further analysed through mass spectrometry. 
Bioinformatics predictions provide prior knowledge about certain protein interactions, 
which is advantageous to experimental procedures. Typically, Importin-α would bind to 
a classical NLS that promotes its interaction with Importin-β, and stimulates further 
incorporation of the whole complex into cell nucleus (see Chapter 1). Importin-β is also 
known to directly transport into cell nucleus proteins with an atypical NLS motif (Marfori 
et al., 2011). It was therefore predicted that FGF10, containing two non-consensus 
NLS-motifs, would implement only Importin-β as a nuclear import chaperone. 
Surprisingly, the results of the bioinformatics analysis show that, despite its atypical 
NLS motifs, FGF10 is more likely to interact with Importin-α, than Importin-β. The 
interaction site of FGF10-Importin α is predicted to occur within a minor site of the 
Importin-α. Typically interactions between Importin-α and its cargo happens within its 
major groove, and examples include human androgen receptor (Cutress et al., 2008), 
phospholipid scramblase 1 (PLSCR1) (Chen et al., 2005), c-Myc, SV40 and 
nucleoplasmin (Npl) (Marfori et al., 2011, Fontes et al., 2000). However, several 
proteins, for example nucleoporin Nup50 (Matsuura and Stewart, 2005), are known to 
bind within the minor groove (Kosugi et al., 2009). The selection of FGF10 NLS2-
Importin-β predictions showed that these interactions were mainly generated by 
electrostatic forces (Fig. 3.4.). Large networks of electrostatic forces have already been 
shown essential and sufficient for other proteins (e.g. Parathyroid hormone-related 
protein (PTHrP) and Snurportin-1), providing their transport into cell nucleus by 
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Importin-β (Marfori et al., 2011). Although these are only predictions, they provide good 
basis to presume that FGF10 is able to interact with karyopherins.  
In summary, bioinformatics tools suggested sites of FGF10, where putative 
post-translational modifications (PTM), such as SUMOylation and glycosylation could 
occur, which provided further implications to FGF10’s nuclear transport mechanism. 
Both of these PTMs have been known to assist and even drive protein nuclear import 
and accumulation (Freiman and Tjian, 2003, Rondanino et al., 2003). Therefore, 
potentially they act to strengthen the weak NLS signal, facilitating the nuclear import. 
On the contrary, it is also possible that in specific cases the PTMs prevent the protein 
from entering the nucleus, for example through glycosylation of sites close to NLS2. 
However, the two protein PTMs showed species-specific differences (Fig. 3.5), and are 
therefore unlikely to be global regulators of the FGF10’s intra-cellular distribution.  
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Chapter 4  
Intra-cellular distribution of FGF10 reveals a putative novel endogenous 
function 
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 This chapter is divided into several sections, where it will be investigated 
whether endogenously expressed Fgf10 can translocate into cell nucleus. Moreover, it 
will be studied, whether earlier identified NLS1 and NLS2 are involved in FGF10 
nuclear trafficking. Additionally, mutation within FGF10 causing in humans LADD 
syndrome, which falls within NLS1, will be analysed in a context of nuclear trafficking of 
the protein. Lastly, the functional purpose of nuclear FGF10 will be addressed.  
 
Part 4.1 Generation of recombinant FGF10 as a tool to study its endogenous 
function 
 
Previous studies of externally applied FGF10’s trafficking by Kosman and 
colleagues (Kosman et al., 2007) and bioinformatics analyses (see Chapter 3) 
collectively suggest that FGF10 may be transported into cell nucleus via two NLS-
motifs. Endogenous detection of the protein is essential for its visual identification and 
determination of intra-cellular distribution. Several methods are already available, 
including FGF10-specific antibodies and transgenic reporter mice (see Chapter 2&6). 
Currently several companies offer antibodies against FGF10, including Abcam, 
Abnova, R&D Systems and Santa Cruz. These antibodies have been used, for 
example, to show expression of FGF10 in mammary tumours, where it is meant to act 
as an oncogene (Theodorou et al., 2004); or within pancreatic cancer, where it induces 
cell migration and invasion (Nomura et al., 2008);  and within an in vitro system, where 
excess of FGF10  was shown to stimulate maturation of bovine oocyte (Zhang et al., 
2010a). However, these studies applied the antibody in the presence of high levels of 
FGF10, achieved either in overexpressed cancerous tissue or detecting accumulated 
recombinant protein. When tested on multiple occasions and under different settings, in 
order to detect endogenous FGF10 protein within cell culture and tissue sections, these 
antibodies yielded no signal or unreliable results (Hajihosseini’s laboratory data not 
shown).  
An alternative way to detect protein expression is through use of transgenic 
mice expressing reporter proteins driven by the Fgf10 promoter (Chapters 2&6). This 
allows visualising in vivo sites of Fgf10’s expression, for example within ocular glands 
or mouse brain (Makarenkova et al., 2000, Hajihosseini et al., 2008), which allows 
study of the function it performs there. For example, FGF10 was shown to be an 
essential component of lacrimal gland development (see Chapter 1). Unfortunately the 
regulation of Fgf10 transcription and the exact positioning of Fgf10 promoter regions 
remain unclear (Chapters 1&3). Therefore, modification of the Fgf10 allele causes 
reduction of transcript levels, resulting in reporter mice being mildly hypomorphic for 
Fgf10 (Mailleux et al., 2005, El Agha et al., 2012). Moreover reporter proteins do not 
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provide information about intra-cellular localisation of the FGF10, as these are not 
FGF10-reporter fusions.  
To overcome the above obstacles, a protein-to-tag fusion construct can be 
generated, expressed and then easily and reliably detected in a mammalian culture 
system. There are a variety of affinity tags available, including peptide tags such as 
His-tag, which corresponds to 5 to10 histidine amino acids bound by a nickel or cobalt 
chelate; and protein tags, such as Maltose binding protein-tag (MBP-tag), which is a 
protein that binds to amylose agarose. However, one of the commonly chosen tags is 
attachment of a fluorescent protein (Crivat and Taraska, 2012, Stadler et al., 2013), 
such as GFP and mCherry. Attachment of each tag presents its advantages and 
disadvantages. Fusion of FGF10 to a fluorescent protein can provide the possibility of 
detecting protein’s localisation in live cell cultures and monitoring its dynamics over 
time. Importantly differences are noticed between different fluorescent proteins, for 
example, high photo-stability of mCherry protein makes it more desirable tag than GFP 
tag. Moreover, mCherry acts as a monomeric molecule as opposed to other 
fluorophores, such as GFP that often dimerise spontaneously (Shaner et al., 2004), 
which could result in changes to the protein function and localisation which does not 
correspond to processes happening in vivo.  
On the contrary, linking another protein molecule to a small FGF10 (~20kDa) 
might obscure folding, stability and intra-cellular localisation of FGF10 within a cell 
(Lisenbee et al., 2003, Marks and Nolan, 2006), which constitutes a major drawback of 
the Fgf10-mCherry system. Therefore, FGF10 was fused to a very small Hemagglutinin 
A (HA) tag, which can be reliably detected by anti-HA antibodies. The small affinity 
tags, like the HA tag, have been shown to have a minimal effect on tertiary structure 
and biological activity of the protein they are fused to (Terpe, 2003). This system can 
therefore provide robust information about the FGF10 intra-cellular localisation.  
 
Aims 
This part of the study concentrates on visualising and tracking the intracellular 
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4.1.1 Generation and validation of rFgf10-HA fusion construct  
 
A rat Fgf10 cDNA sequence was amplified through a PCR reaction from the 
pGEM-T vector. Simultaneously, the sequence coding for HA tag was incorporated to 
the Fgf10’s 3’ end, through use of specific primers, generating a 707bp long cDNA 
strand (Fig. 4.1A). The amplified product was cloned into a mammalian expression 
vector, denoted pN1-rFgf10HA (see Chapter 2) (Fig. 4.1A).  
To validate the successful incorporation of the Fgf10HA into the vector, the 
construct was digested with ScaI enzyme as Fgf10 carries a unique ScaI site, not 
found in the cloning vector backbone. Therefore, digestion of pN1-rFgf10HA with ScaI 
enzyme generated a linearized product of a 4633bp size (Fig. 4.1B). The original 
rFgf10-pGEM-T contains ScaI site within the vector backbone, additional to one found 
within Fgf10, which upon ScaI digestion generated two 2160bp and 1435bp DNA 
pieces (Fig. 4.1B).  
Correct cloning of the Fgf10HA insert was also validated by PCR reaction using 
primers binding within the vector but flanking the rFgf10-HA sequence (Fig. 4.1A). The 
reactions generated a 941bp product showing successful incorporation of rFgf10-HA 
and a 369bp DNA fragment of the empty vector control (Fig. 4.1C).   
Sanger sequencing of the of the PCR products revealed no mutations within the 





















Figure 4.1 Generation of the pN1-rFgf10-HA construct. (A) Schematic representation 
of the pN1-rFgf10-HA, showing positions of forward and reverse primers used for 
PCR validation reactions. (B) ScaI restriction enzyme digest of the pN1-rFgf10-HA, 
and digested ‘D’ and undigested ‘UD’ controls; black arrowhead point to digested 
products. (C) Construct validation by PCR with yellow arrowheads pointing to two 
DNA pieces generated due to the presence/absence of the insert. (D) A fragment of 
Sanger sequence trace revealing no mutations within either the Fgf10 or HA coding 
sequence 
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4.1.2 Transient cell transfections reveal intra-cellular FGF10HA localisation 
 
To determine the intracellular distribution of FGF10, the pN1-rFgf10HA 
construct was transiently transfected into human retinal pigment epithelial cells ARPE 
cell line. The cell line was chosen as a tool to study protein localisation due to their 
typical ease of accepting transfected DNA. Transfection was performed using JetPrime 
(Polypus), which is a polymer-based reagent that minimizes adverse cytotoxic effects 
triggered by transfection (see Chapter 2). The expression of the protein was visualised 
24h post-transfection, by fluorescently immunolabelling with anti-HA antibody and 
scrutinised under high power confocal microscopy, which has shown the protein 
localising to specific nuclear loci (Fig. 4.2A). Moreover, co-labelling of HA with a 
nucleolar protein called Fibrillarin, has further demonstrated that FGF10HA was 
targeted to the nucleolus (Fig. 4.2B).  
It was observed that from all of the transfected cells in a given culture only a 
subset demonstrated the nuclear HA label. Furthermore a variety of cellular 
distributions of FGF10HA were observed and these were categorised into five groups: 
(i) ‘exclusively nuclear’; (ii) ‘predominantly nuclear’, (iii) ‘predominantly cytoplasmic’, (iv) 
‘exclusively cytoplasmic’; and (v) ‘equal distribution’ of the HA signal in both cytoplasm 







Figure 4.2 Detection and analysis of HA staining, indicative of FGF10 presence revealed 
nuclear protein localisation. (A) Staining was scrutinised under high power confocal 
microscopy; scale bar 20µm. (B) Co-localisation of HA staining with Fibrillarin marker 
(yellow arrowhead)  revealed nucleolar localisation of FGF10HA within the cell nucleus; 
scale bar 20µm. 
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To analyse the intra-cellular distribution of the rFGF10-HA, ARPE cells, which 
were cultured on a 13mm diameter microscope glass coverslips and fixed 24h post 
transient transfection, subsequently immunofluorescently labelled and scrutinised by 
microscopy. Ten random fields of view were chosen across two different coverslips (5 
from each coverslip), and the total number of cells present, as well as the total number 
of transfected cells and the cellular distribution of HA within each cell were determined. 
Cell transfection was performed on four separate occasions allowing reliable statistical 
analysis (see Chapter 2).   
Importantly, in at least 15% of transfected cells rFGF10HA was found 
exclusively in the cell nucleus. Statistically, there is no significant difference between 
the different HA localisations (ANOVA p=0.223, F=1.611, n=4) and therefore it could be 
presumed that FGF10 is as likely to be found in cell nucleus as it is in the cytoplasm 
(Fig. 4.3B). To control for the transfection efficiency and HA visualisation, the ARPE 
cells were transfected simultaneously with a pmCherry-N1 vector - the backbone vector 
that was used to generate the pN1-rFgf10HA construct (see Chapter 2). Unlike 
rFGF10HA, the mCherry fluorescent protein was found ubiquitously present around the 
cell, and did not show predominant localisation within nucleus or cytoplasm (Fig. 4.3A). 
Moreover, it was noted that whereas nuclear FGF10HA was found within the nucleoli 
(Fig. 4.2&4.3), mCherry showed more diffused, non-specific pattern of expression, 
suggesting that it is not targeted to any particular site/loci within the nucleus or 
cytoplasm (Fig. 4.3A). 
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Figure 4.3 Intra-cellular distribution of rFGF10-HA in ARPE cell culture. (A) Detection 
of the HA (red) depending on the intensity of the staining was categorised into 5 
categories, while mCherry is ubiquitously expressed around the cell; Scale bar 20µm. 
(B) Quantification of the percentage of cells expressing HA in any of the specific 
patterns shows that there is no statistically significant difference of FGF10’s intra-
cellular localisations (ANOVA p=0.223, F=1.611, n=4). 
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Detection of rFGF10HA in the nucleus was not specific to ARPE epithelial cells 
as transfection of the rFGF10HA construct into a variety of different cell types showed 
similar results. Hence, rFGF10HA was also found in the nucleus of mesenchymal 
(ATDC5), human embryonic kidney (HEK 293T), as well as primary astrocytes and 
hypothalamic neural cells (see Chapter 6) (Fig. 4.4). These results suggested that 
nuclear translocation of FGF10 may be a global phenomenon, putatively taking place in 











Figure 4.4 Different cell types show similar patterns of FGF10HA intracellular 
distribution. Micrographs showing examples of transiently transfected FGF10HA 
localised within the nucleus of epithelial (ARPE), mesenchymal (ATDC5), and human 
embryonic kidney (HEK 293T) cells as well as primary astrocytes and hypothalamic 
neural cells; Scale bar 50µm.   
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On average, regardless of the cell type analysed only about 10-30% of total 
transfected cells displayed rFGF10HA expression and 50-60% the control mCherry 
protein. Therefore, the achieved transfection rate - calculated as a percentage of total 
number of transfected cells from total number of cells present (see Chapter2), was 
reasonably low. A higher rate of transfection is desirable for overexpression studies, 
immunoprecipitation of a protein from the culture and any other required experiments. 
Several different transfection methods were tested, such as Calcium Phosphate 
precipitation; Lipofectamine® 3000 Reagent (Thermo Fisher Scientific); TurboFect 
Transfection Reagent (Thermo Fisher Scientific); and FuGENE®6 (Promega). However, 
none improve the transfection rate of <30% obtained with JetPrime Reagent. During 
transfection optimisation, factors such as cell density, amount of DNA and transfection 
reagent, incubation time and toxicity of the reagent, type of cells, time post transfection 
were taken into account and meticulously adjusted for each reagent every time. 
Furthermore, to enhance the transfection efficiency the method of ‘glycerol shocking’ 
was tested on several occasions, but with no significant improvement. The highest 
transfection rate of rFGF10HA was achieved in HEK 293T cells, ranging from 30-40%, 
while the mCherry’s transfection ranged between 60-80% depending on the assay. 
This is not surprising, because HEK 293T cells are widely used for DNA transfection 
and mammalian protein expression, and with high transfection success rate, as 
demonstrated in a study analysing functional nuclear export signal (NES) in the green 
fluorescent protein asFP499 (Mustafa et al., 2006) or whilst determining the role of 
semaphorin-3F (s3f) on inhibition of FGF2 signalling during tumour angiogenesis 
(Kessler et al., 2004).  
 
4.1.3 Conclusion  
 
A recombinant rat FGF10 protein fused to small HA tag was detected in cells’ 
nucleus where it localised to a subset of nucleoli. This appears to be a universal 
phenomenon, found across multiple cell types in vitro. Although a mouse recombinant 
Fgf10HA construct has been generated before, its intracellular distribution was not 
described (Beer et al., 1997). Therefore here for the first time it was shown that 
rFGF10HA is found in the nucleus of multiple types of cells.  
In the absence of reliable FGF10-specific antibodies, the rFgf10-HA hence 
provides a good tool for further studies of FGF10 intracellular function.  
Subsequently, it was investigated whether NLS1 and NLS2 drive the nuclear 
translocation of FGF10HA, either separately or in cooperation, analysing each motif 
individually.   
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Part 4.2 Mutation of NLS1-motif perturbs intracellular distribution of FGF10 
 
The NLS1-motif of FGF10 (rat 142NKKGKLY148) has been proposed by 
Kosman and colleagues (Kosman et al., 2007) and analysed in the context of binding 
to importins through basic residues. The results showed that mutations of Lysines/K 
into neutral Threonine/T residues did not prevent FGF10 from entering the cell nucleus. 
However, it resulted in a higher than normal abundance of the cytoplasmic protein 
(Kosman et al., 2007). These experiments were based on exogenous application of the 
wild type and mutant protein to the cell culture, showing that the protein translocating 
into the nucleus was previously endocytosed.  
Interestingly, analysis of human anomalies caused by Fgf10 mutations show 
that a single residue substitution within NLS1 – the G138E (rat G145E) causes LADD 
syndrome (Entesarian et al., 2007), which was omitted in the previous studies of the 
NLS1 (Kosman et al., 2007). The intriguing positioning of the G145E mutation within 
the NLS1 could suggest a role in the nuclear import of FGF10. In this part of the 
chapter, the effects of the mutation within NLS1 will be analysed in a context of 
endogenously produced protein, rather than exogenous treatment of a cell culture 
performed by Kosman et al. (Kosman et al., 2007).  
 
4.2.1 Overview of human syndromes related to FGF10 function.  
 
Aplasia of lacrimal and salivary glands (ALSG; OMIM 180920) and lacrimo-
auriculo-dento-digital (LADD; OMIM 149730) syndromes are rare autosomal dominant 
disorders which, with various severities, result in defective development of lacrimal and 
salivary tract, often accompanied by abnormalities of the face, ears, eyes, mouth, 
teeth, digits and genitourinary system. These syndromes are caused by heterozygous 
missense mutations within FGF10 and FGFR2 genes (Milunsky et al., 2006, Rohmann 
et al., 2006, Entesarian et al., 2007, Scheckenbach et al., 2008) (Fig. 4.5). Similar 
phenotypes were also described in Fgf10 or FgfR2 heterozygous mice (Min et al., 
1998, Entesarian et al., 2005). Defects caused by the described mutations are 
attributed to an impaired FGF10-FGFR2 binding or reduced stability and folding of the 
mutant protein (Shams et al., 2007). However, the molecular mechanism/s by which 
the Glycine (G) 138 to Glutamic Acid (E) substitution in NLS1 causes LADD syndrome 
is thus far unknown (Fig. 4.5).  
 
Aims  
The fact that mutation of hG138 (rG145) residue resulted in malfunction of the 
FGF10, signifies potentially it is one of the key residues within the protein sequence. 
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The peculiar position of this residue within NLS1 was analysed in the context of nuclear 
transport of the mutant FGF10 protein. 
 
    
Figure 4.5 Human heterozygous mutations of Fgf10 or FgfR2 result in ALSG or 
LADD syndromes, through characterised or predicted molecular mechanisms. 
However, a de novo arising G138E mutation generated phenotype characteristics 
between of those of ALSG and LADD syndromes through so far undescribed 
means. Star (*) indicates FGF10 mutations positioned outside its receptor binding 
site.  
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4.2.2 Glycine residing within FGF10-NLS1 is a well conserved residue 
 
Through analysis of the FGF10 primary sequence it was revealed that the 
Glycine residue (mutation of which resulted in LADD) was well conserved among all 
vertebrate species (Fig. 4.6A). Moreover, this Glycine residue was present within all 
members of the subfamily to which FGF10 belongs (Fig. 4.6B) and it was found to be 
conserved in representative FGFs from other FGF subfamilies (Fig. 4.6C). Such 
extreme conservation suggests that human G138 (rat G145) residue may play an 











Figure 4.6 Extreme conservation of rFGF10’s Glycine 145 (G145) residue across 
vertebrate species (A) as well as all other FGF molecules (B&C) signifies its functional 
importance within the protein.  
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4.2.3 Glycine 145 to Glutamic Acid residue substitution impairs intracellular 
distribution of FGF10 protein   
 
To investigate the molecular importance of the Glycine 145 residue, an LADD-
like mutation to Glutamic Acid/E was introduced into the rFGF10HA construct through 
site-directed mutagenesis (see Chapter 2). Correct incorporation of the mutation was 
determined by Sanger sequencing (Fig. 4.7A) and confirmed by alignment of DNA 
sequences with the WT rFgf10-HA (Fig. 4.7B).  
Intra-cellular localisation of transiently transfected G145E-HA (here on called 
G145E) into ARPE cells was scrutinised by high resolution confocal microscopy. 
Interestingly, unlike non-mutated FGF10, the G145E mutant was completely absent 
from the cell nucleus, and concentrated in a high abundance within the cell cytoplasm 
(Fig. 4.7C). Therefore, the G145E residue substitution seemed to perturb the nuclear 







Figure 4.7 Successful generation of G145E mutation by single base substitution.  (A) 
Incorporation of the mutation was confirmed by Sanger Sequencing. (B) Sequence 
alignment of rFGF10HA (lowercase) and G145E (uppercase) shows the single base 
change resulting in G to E substitution. (C) Confocal microscopy image reveal G145E 
nuclear exclusion within the ARPE cell culture; Scale bar 20µm. 
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Moreover, similar results were obtained regardless of the type of the transfected 
cells, as G145E was absent from the nucleus in epithelial (ARPE), mesenchymal 
(ATDC5) (Fig. 4.8) and neural (primary neural culture derived from hypothalamus) cells 
(see Chapter 6). Irrespective of cell type, rFGF10HA was found in the cell nucleus of at 
least 25% of total transfected cells, whereas G145E was invariably seen only in the 














Figure 4.8 Analysis of the G145E mutant. (A) Nuclear exclusion was not specific to a 
particular cell type and similar results are obtained by detecting the florescent HA 
staining in ARPE and ATDC5 cell culture; Scale bar 40µm. (B) Quantification of the 
intracellular distribution of G145E in regards to non-mutated FGF10HA shows similar 
results in epithelial (ARPE) and mesenchymal (ATDC5) cell lines (Student T-test 
p≤0.001, n=3, error bar = SE). 
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4.2.4 A Glycine residue per se at position 145 is essential for the nuclear import 
of FGF10  
 
It is conceivable that the LADD causing substitution of small neutral Glycine 
residue into a big and acidic Glutamate could result in disruption to FGF10 interaction 
with Importins (Fig. 4.9A). This hypothesis was tested through mutation of Glycine to a 
smaller and neutral residue, which theoretically should restore the protein’s interaction 
with nuclear transport chaperones and yield similar intracellular distribution pattern as 
the non-mutated FGF10. Surprisingly, mutations of Glycine 145 to Valine/V (G145V) or 
Alanine/A (G145A) also resulted in complete nuclear exclusion of the protein (Fig. 4.9). 
Valine, in comparison to Glutamate is a small and non-polar residue, although its short 
side-chain is branched (Fig. 4.9), potentially causing steric repulsion that could explain 
still existing interruption to FGF10-Importin binding site. Alanine, by contrast, is the 
second (after Glycine) smallest residue, with a non-reactive methyl group on its short 
side-chain (Fig. 4.9), which should not prevent the whole region from binding to another 
molecule. Therefore it seems that the Glycine 145 per se is important for the 
intracellular distribution of FGF10 and any mutation of this particular residue leads to 
nuclear exclusion of the protein.  
Bioinformatics analysis of the 3D structure of the FGF10 molecule revealed that 
the G145 residue within NLS1 generates a direct H-bond with a Glycine 196 within 
NLS2 sequence (Fig. 4.9 and Chapter 3). It was therefore investigated if this bond 
between the two NLS sites is crucial for the nuclear import of the protein, and becomes 
disrupted during the G145E residue substitution. However, mutation of the Glycine 196 
to Glutamic Acid does not cause nuclear exclusion of the protein and the intra-cellular 
localisation of G196E is similar to the non-mutated FGF10 (Fig. 4.9).  
These results show that the Glycine 145 per se is somehow important for the 
nuclear translocation of the FGF10 protein.  
 
 




Figure 4.9 Structural analysis of Glycine at position 145. (A&B) In comparison to 
Glycine/G, the Glutamate/E residue contains big and acidic side chain that could affect 
binding to nuclear chaperone protein. (C) Substitution to smaller Valine (G145V-HA) 
and (D) Alanine (G145A-HA) was nuclearly excluded resembling G145E. (D) Glycine/G 
196 (G196) residue forms a direct H-bond (blue line) with G145 but G196E mutant is not 
nuclearly excluded (yellow arrowhead); Scale bar 40µm. 
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 4.2.5 Conclusion   
 
Although the basic residues within NLS1 do not appear to have a major role in 
the intracellular distribution of the FGF10 (Kosman et al., 2007), the G145 residue 
within the sequence was shown to be crucial for the nuclear import of the protein. The 
G145E most likely indirectly impaired the FGF10-importin binding and the effect of 
mutation could not be rescued by substitution with other small residues, such as Valine 
and Alanine. Moreover, the H-bond generated between the NLS1 and NLS2 through 
the G145 is unlikely to be affected by the mutation to Glutamic Acid as mirroring of the 
G145E mutation by the G196E within the NLS2, did not perturb the nuclear import of 
the protein.  
 The subsequent investigations asked whether Glycine at position 145 is the 
only residue implicated in the nuclear translocation, or whether NLS2 also plays a role 
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Part 4.3 Perturbation of NLS2 impairs nuclear import of FGF10 protein. 
 
 The basic amino acids within a NLS can attract and bind to Importins (see 
Chapter 3). Therefore mutations of these residues would disrupt this protein-protein 
interaction, preventing FGF10 from entering the cell nucleus. It was proposed that, due 
to their positioning within the protein tertiary structure, NLS1 and NLS2 act collectively 
to generate a stronger signal targeting FGF10 to the nucleus.  
 
Aims 
The aim of this section was to determine whether abrogation of NLS2 motif 
alone affects localisation of the FGF10 within a cell.   
 
 
4.3.1 Impact of NLS2 mutations on the intracellular distribution of FGF10 
 
 
The side chains of Arginine and Lysine residues have long positively-charged 
side chains that fit into the acidic grooves on Importin proteins. The NLS2 sequence, 
194 RRGQKTRRK 202, harbours six basic residues. To investigate the contribution of 
each residue, each was substituted to much smaller and electrically neutral 
Threonines, which are unlikely to generate strong interactions with the Importin sites 
(Fig. 4.10A). The rFGF10HA vector was used as a template for all of the mutagenesis 
constructs, so that all proteins could be detected with the HA antibody. All generated 
mutation-bearing constructs were screened and validated by Sanger sequencing, as 
for G145E (Appendix 3).  
All six basic residues within NLS2 were sequentially mutated using site-directed 
mutagenesis (see Chapter 2) (Fig 4.10B) in order to identify a potential key residue 
mediating the nuclear or nucleolar import of FGF10. For example, mutation of specific 
residues within NLS of FGF2 had a significant impact on protein nuclear and nucleolar 
localisation (Sheng, 2004). All FGF10 mutant variants were assessed in a similar 
fashion to the earlier described rFGF10HA for their intra-cellular localisation (see 
section 4.1.2). HA staining found exclusively or predominantly in the nucleus was 
classified as ‘nuclear’ and similarly, HA staining found exclusively or predominantly in 
the cytoplasm was classified as ‘cytoplasmic’. Statistically there was no significant 
difference between the nuclear or cytoplasmic protein localisation of FGF10HA protein 
in these assays (ANOVA p>0.05, F=15.482 & F=41.366), suggesting that individually 
none of the basic residues within NLS2 mediate nuclear import of FGF10 (Fig. 
4.10C&D). Moreover, none of the single mutants affected the localisation of the protein 
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within cell nucleolus. Therefore, single mutations appeared not to perturb intra-cellular 
distribution of the FGF10 protein (Fig. 4.10E).  
However, when double mutations at the N-terminal and C-terminal sections of 
the sequence were generated, i.e. the R194T/R195T, R200T/R201T and R200T/K202T 
(Fig. 4.10B), in comparison to the non-mutated FGF10 a higher proportion of cells 
displayed HA localising within the cytoplasm (ANOVA p<0.0001, F=15.482) (Fig. 
4.10C&D). Moreover, perturbation of the N-terminal section of the NLS2, the 
R194T&R195T double mutant was significantly less likely to enter the nucleus than  
FGF10HA (ANOVA p<0.0001, F=15.366) (Fig. 4.10C&D). None of the double mutants 
seemed to affect the nucleolar entry of the protein. By contrast, mutation of four 
residues within the NLS2, the R194T/R195T/R200T/K202T (here called 4T-NLS2) 
caused 98% of the protein to be found in the cytoplasm, significantly limiting the 
nuclear import of FGF10 (ANOVA p<0.0001, F=15.482) (Fig. 4.10C&D).   
 Mutation of NLS2 caused impairment in the nuclear transport of the FGF10 
protein, meaning that NLS2 is essential for nuclear entry of FGF10.  
 
 
4.3.2 Conclusion  
 
Single mutations with the NLS2 sequence appeared not to perturb the 
intracellular distribution of FGF10, unlike a single G145E mutation within the NLS1. 
However, combination of mutations of the basic residues resulted in significant 
impairment of the nuclear import, suggesting therefore that NLS2 potentially attracts 
and binds to importins.  
Non-mutated FGF10 localised to the nucleolus. The nucleolar targeting signals 
can overlap with their nuclear localization signals. For example Lysine128 residing 
within NLS of FGF2, alone controls its nucleolar (but not nuclear) localization of the 
protein (Sheng, 2004). None of the mutants within C-terminal NLS of FGF2 appeared 
to interfere with nucleolar localisation of the protein, even after translocation into the 
nucleus. Therefore nuclear and nucleolar targeting of the FGF10 is likely to occur via 
different motifs and mechanisms.  
Both, the G145E (within NLS1) and the 4T-NLS2 mutants resulted in the 
nuclear exclusion of FGF10. However, the observed cytoplasmic retention of the 
mutants is thought to be generated through different means. Therefore, the putative 
molecular mechanisms driving the nuclear exclusion caused by these mutants will be 
explored further and addressed in a context of FGF10’s nuclear function.  
 
 






Figure 4.10 Analysis of NLS2 (A) Schematic representation of putative replacement 
of basic (K&L) residues with neutral (T) within NLS impairs binding to importin protein 
and abrogates nuclear import of the protein. (B) Table of mutations made within 
NLS2. (C&D) Quantification of the percent of protein found in cell nucleus or in the 
cytoplasm, 24h post transient transfection into the ARPE cell line (ANOVA, n=4). (E) 
Fluorescent images of the representative protein distribution within a cell; Scale bar 
20µm.  
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Part 4.4 Mutations within NLS1 and NLS2 trigger different nuclear exclusion 
mechanisms  
 
The NLS1 and NLS2 motifs are positioned in close proximity to each other 
within the FGF10 tertiary structure (see Chapter 3). It was proposed that they may act 
in combination to generate a strong signal driving protein to the cell nucleus. However 
the G145E mutation alone seemed to result in a nuclear exclusion of FGF10 that is 
thought independent of the binding to importin.  
 
Aims 
The aim of this part of the chapter is to analyse the putative molecular 
mechanisms driving the nuclear exclusion of G145E and 4T-NLS2 mutants. Moreover, 
through analysis of the mutants investigate whether the NLS1 and NLS2 possibly 
cooperate or work independently of each other to generate nuclear import of FGF10.   
 
 
4.4.1 Intra-cellular distribution of FGF10 and its mutants over time period 
 
Multiple proteins are known to undergo nucleocytoplasmic shuttling, examples 
including ERK (Michailovici et al., 2014), galectin3 (Arnoys et al., 2015), Rac1 
(Navarro-Lerida et al., 2015) and mammalian target of rapamycin (mTOR) (Rosner and 
Hengstschlager, 2012) as well as signal transducers and activators of transcription 
(STATs) (Xu and Massague, 2004). Therefore, proteins that enter the nucleus are often 
also transported out depending on the stage of cell cycle, function that they serve and 
interactions with other molecules, as protein binding could cause either nuclear or 
cytoplasmic sequestration. The transient transfection of FGF10 could potentially result 
in an initial and temporary accumulation of the protein within a cell nucleus, 
subsequently leading to its nuclear export at the later stages of cell cycle. Similarly, the 
nuclear exclusion of the G145E mutation may also be a temporary result.  
To determine whether the wild type (WT) and mutant FGF10 proteins undergo 
nucleocytoplasmic shuttling and display differential intracellular distribution patterns 
over time, they were transiently transfected into a culture of epithelial ARPE cells (see 
Chapter 2) and analysed after 24, 48 and 72h post transfection, detecting HA epitope 
through fluorescent immunohistochemistry. Two single mutations within NLS2 (R194T 
and K198T) were also chosen as additional controls.  After 24h, the mutants did not 
differ significantly from FGF10HA in terms of their nuclear and cytoplasmic distribution 
(see Chapter 4, page17-19 (above)). However, the single residue changes showed that 
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the nuclear exclusion is peculiar to G145E and not any other potential single mutation 
within the FGF10 sequence.  
At each investigated time point, 24, 48 or 72h post transfection, at least 20% of 
the transfected cells with FGF10HA showed presence of the protein in the nucleus 
(Fig. 4.11), demonstrating that the nuclear import of FGF10 was not a temporary effect. 
Moreover, comparable proportion of transfected cells displayed protein present in the 
cell nucleus at 72h as 24h post transfection, suggesting that HA tagged FGF10 was not 
accumulating in the nucleus over time and therefore it was unlikely to undergo nuclear 
retention or nucleolar sequestration. The data rather suggest that FGF10HA shuttles 
freely in and out of the nucleus. The controls corresponding to single mutants within 
NLS2 showed similar intra-cellular distribution to the non-mutated FGF10, as expected 
(Fig. 4.11).   
At the same time, at least 90% the G145E is detected only in the cytoplasm, 
with the remaining 10% corresponded to the “unclassified” category (obscured protein 
distribution), which suggests that the G145E mutant did not enter cell nucleus, even 
after a longer (72h) period of time and that the mutation fully abolished the 
nucleocytoplasmic shuttling of the protein.  





Figure 4.11 Intra-cellular distribution of FGF10HA and its mutants show  little variation 
at (A) 24h, (B) 48h and (C) 72h post transfection (ANOVA, n=3).  
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4.4.2 Mutant proteins display different molecular properties than FGF10HA 
 
To assure that the results of fluorescent immunohistochemistry are a genuine 
reflection of FGF10HA’s intracellular distribution, FGF10HA and its mutants were 
further investigated by Western Blot analysis, specifically within cell’s nuclear and 
cytoplasmic fractions. For this, HEK 293T cells were used because these cells were 
previously shown to express a proportion of a FGF10-HA protein in the cell nucleus 
(Fig. 4.4); are easily cultured and transfected with DNA, but additionally undergo 
subcellular fractionation more easily than ARPE cell type. Therefore, HEK 293Ts were 
chosen for this analysis and used interchangeably with the ARPE cells in further 
experiments. Thus cultures of HEK 293T cells were transfected with the FGF10HA, 
G145E and 4T-NLS2 mutants or mCherry positive control that was shown to be 
ubiquitously expressed within the cell (Fritz et al., 2008). Cells were harvested 24h post 
transfection, and their cytoplasmic and nuclear fractions separated using protocols 
described by Dimauro and colleagues (Dimauro et al., 2012). Firstly the cytoplasmic 
protein fraction was separated and purified through centrifugation in a sugar based 
buffer, subsequently followed by isolation and purification of nuclear fraction in salt 
based buffer (see Chapter 2). The fractions were then analysed on a SDS-
polyacrylamide gel in a semi-quantitative fashion (see Chapter 2).  
All HA tagged proteins and the control mCherry were found in the cytoplasm. 
Interestingly, the FGF10HA, G145E and 4T-NLS2 displayed different molecular weight 
protein isoforms within the cytoplasmic fraction (Fig. 4.12). The molecular weight of 
non-mature (full length) and mature (lacking signal peptide) rat FGF10HA 
corresponded respectively to 25kDa and 21kDa. Whilst, within the cytoplasmic fraction 
mature and non-mature FGF10HA protein was detected, the smaller (secreted) protein 
was more abundant than the non-mature FGF10. This may suggest that either, the 
newly generated protein was rapidly processed to maturation or, that the transient 
transfection generates limited transcript levels and restricts the protein production. 
Interestingly, high abundance of the mature protein was present within the nuclear 
fraction whereas the non-mature protein could not be detected in the nuclear fraction 
(Fig. 4.12).  
 








The cytoplasmic fraction also contained both of the mutant proteins, the G145E 
and 4T-NLS2. The 4T-NLS2, similarly to the non-mutated FGF10HA, was present in 
the non-mature and mature version of the protein (25 and 21kDa), but the mutant 
protein of 21kDa was not as abundant as the wild type FGF10. Interestingly, the 
G145E mutant could only be detected as the non-mature protein (25kDa). Surprisingly, 
another isoform of mutated proteins was detected within the cytoplasmic fraction, which 
corresponded to about 30kDa. This protein isoform was not detected within the 
cytoplasmic fraction of the non-mutated FGF10HA (Fig. 4.12). Importantly, in 
concordance with the fluorescent immunohistochemistry, the G145E and 4T-NLS2 
mutants were virtually absent from the nuclear fraction (Fig. 4.12).  
One possibility was that an introduction of any mutation within FGF10 would 
cause the appearance of the different protein isoform of about 30kDa. Further analysis 
of a whole cell lysate revealed that the higher molecular weight band of 30kDa was not 
detected in protein samples of single mutation within the NLS2 – the K198T and the 
R194T (Fig. 4.13). However, the cell lysate samples of mutants that impair nuclear 
translocation, the G145E, G145V, R200T&K202T and 4T-NLS2, all contained the 
additional protein isoforms of 30kDa, which will be further investigated in a section 
4.3.3.  
Importantly, only samples containing mutants of the G145 residue did not 
contain the 21kDa secreted version of the mature FGF10 (Fig. 4.13), suggesting that 
these proteins did not undergo maturation.  
Figure 4.12 FGF10HA was found in both, cytoplasmic and nuclear fractions of the HEK 
293T cells, whereas the mutant proteins G145E and 4T-NLS2 were detected only in the 
cytoplasmic fraction of the cell. Representative of n=3.   












4.4.3 Nuclear-excluded FGF10 mutants undergo hyper-glycosylation 
 
Interestingly, cell lysate samples of FGF10HA mutants showing nuclear 
exclusion contained the additional 30kDa protein isoform, which was absent in non-
mutated FGF10HA. Based on its size and the reduced conditions of SDS page, the 
30kDa product was an unlikely product of intracellular FGF10 homo-dimerization (>50 
kDa) or FGF10-FGFR2IIIb complex formation (>110 kDa). Therefore, likely it 
represented a form of a post-translational modification, putatively affecting the 
nucleocytoplasmic shuttling of the protein.  
As a secreted protein, FGF10 undergoes glycosylation and was predicted to 
carry at least 26 glycosylation sites (see Chapter 3). Therefore, the possibility that 
30kDa protein represents a hyper-glycosylated form of FGF10 was investigated. Cell 
lysates containing FGF10HA, G145E, 4T-NLS2 and a selection of single and double 
mutants were deglycosylated with PNGase F (‘N’ deglycosylation) or a cocktail of ‘O 
and N’ deglycosylating enzymes (using Protein Deglycosylation Mix) (see Chapter 2).  
Interestingly, within all samples N-deglycosylation alone was sufficient to 
reduce 30kDa protein product to a single 25kDa (Fig. 4.14). Surprisingly, the 21kDa 
secretory product was also abolished in these assays, which could be due to low 
Figure 4.13 Analysis of the whole ARPE cell lysate revealed that mutants impairing 
the nuclear import of FGF10 (lanes 2,3,7,8) existed in 30kDa isoform of the protein 
that was absent in the non-mutated FGF10. Moreover, mutation of G145 residue 
(lanes 2,3) results in lack of the detection of the mature 21kDa protein. SMAD2-HA 
(kind gift of Dr A. Chantry) and lysate of non-transfected cells serve as positive and 
negative control respectively, controlling for antibody specificity towards HA. 
Representative of n=10. 
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stability of a mature version of a protein and susceptibility to degradation (Buchtova et 
al., 2015), not being able to withstand the enzymatic treatments. Nonetheless, the 
reduction of the 30kDa protein size to 25kDa suggests that the higher isoform of the 














4.4.4 LADD-like mutation disrupts secretion of the protein  
 
A proportion of the mutant FGF10 produced is hyper-glycosylated with the N-
linked type of glycosylation (Fig. 4.14). Biosynthesis of all N-linked oligosaccharides 
(glycans) is a multi-step process that begins in the rough ER, followed by entry into the 
Golgi complex with protein bearing one or more oligosaccharide chains. However, 
abnormal glycosylation patterns can obscure the folding of the protein and its 
progression through the secretory pathway. Therefore, in order to determine whether 
the secretion of the mutant proteins was potentially affected by the hyper-glycosylation 
status and differed from that of non-mutated FGF10HA, the wild type and mutant 
proteins secretion was investigated.  
To compare the extent of secretion of the non-mutated FGF10HA to the mutant 
G145E and 4T-NLS2 culture media was collected 24 and 48h post transfection of the 
epithelial ARPE cells with the HA tagged constructs. Subsequently a total protein 
precipitation from the media was performed and the samples were analysed on a SDS-
Figure 4.14 Treatment of HA tagged proteins with deglycosylation enzymes revealed that 
high molecular weight isoform (approximately 30kDa) of the mutant proteins was caused 
by N-linked hyper-glycosylation. ARPE whole cell lysate samples were treated with two 
types of De-glycosylation enzymes: commercial Protein Deglycosylation Mix (+O,N) 
removing all types of glycosylation and PNGase F (+N) removing N- linked glycosylation 
alone; (-) signifies sample not treated with enzymes. Representative of n=3. 
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polyacrylamide gel (see Chapter 2). Unfortunately, low transfection levels did not 
permit isolation of sufficient amount of secreted protein to achieve detectable levels of 
either WT or mutant proteins, preventing comparison of the secretory potential of WT 
and mutant FGF10. Moreover, addition of heparin to the media, used normally to 
stabilise any secreted FGF protein and allow its release into cell media from the cell 
surface, did not provide any detectable levels of the HA tagged protein. Similar 
problems with isolation of a secreted mouse FGF10 protein from cell media have been 
reported previously in literature (Beer et al., 1997). Therefore, to determine whether 
hyper-glycosylated proteins that are absent from the cell nucleus retain their secretory 
properties, the progression of FGF10HA, the G145E and the 4T-NLS2 along the 
secretory pathway was compared using markers that delineate the intermediate steps 
of the secretory pathway (Fig. 4.15).  For this, transfected cells were co-
immunolabelled with antibodies against –HA in combination with anti-ERp60 (an early 
secretory pathway marker within ER), anti-βCOP (a marker of transport between ER 
and Golgi) and anti-TGN46 (demarcating Golgi and vehicle transport stages) (Fig. 
4.15A). Ten random cells was selected and co-localisation of the markers measured 
with specific computer software tool, basing on their fluorescent exposure (see Chapter 
2). Whilst FGF10HA and 4T-NLS2 co-localised with all three markers (Fig. 
4.15B,C,E,F,H,I,K), expression of G145E was restricted to the ERp60-positive 
compartment (Fig. 4.15B,D,G,J).  
The results showed that the 4T-NLS2 mutant, although hyper-glycosylated, 
progressed through the secretory pathway in similar fashion to FGF10. However, the 
G145E mutant protein failed to progress through this pathway. Moreover high level of 
co-localisation with the ERp60 protein (Fig. 4.15B,D) suggests that instead, it has 














Figure 4.15 Tracking of proteins’ progression through the secretory pathway. (A) 
Schematic of secretory pathway and its stage-specific markers:  ERp60 (early ER 
stage); βCOP and TGN46 (late ER stages). (B) Quantification of fluorescence co-
localisation between secretory pathway markers and HA-tagged proteins; FGF10HA 
and 4T-NLS2 show values above 0.5 Pearson’s Correlation coefficient, indicative of co-
localisation with all markers, whereas G145E co-localises only with the ERp60. (C-K) 
ARPE cells transfected with (C,F,I) FGF10-HA, (D,G,J) G145E and (E,H,K) 4T-NLS2 
and probed with the secretion pathway markers, showing that unlike the WT and 4T-
NLS2 proteins, (which were processed through the pathway), the mutant G145E was 
sequestered at the ER stage. Scale bars: 20 µm in all panels. 
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4.4.5 Conclusion  
 
The aim of this part of the chapter was to determine whether the nuclear 
exclusion caused by mutations within NLS1 and NLS2 is driven by similar molecular 
mechanisms. It was found that both the G145E and 4T-NLS2 mutants were detected 
only within the cell cytoplasm, as shown by compartmentalisation of HEK cells and 
immunofluorescence labelling of HA tagged proteins (Fig. 4.12). Furthermore, both 
mutants were shown to undergo hyper-N-glycosylation, although only the 4T-NLS2 
mutant progressed through the classical protein secretory pathway (Fig. 4.15). 
In regards to the cell fractionation, it may appear that more FGF10 protein 
concentrated within cell nucleus than in the cytoplasm. However, the protein 
concentration between cytoplasmic and nuclear fractions cannot be directly compared, 
despite the fact they were derived from the same pool of cells. The concentration of 
protein was aimed to maintain constant across cytoplasmic and nuclear fractions, as 
shown by the Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Fibrillarin 
controls (Fig. 4.12). However, the total content of cytoplasmic proteins was different to 
total content of nuclear protein. HA tagged constructs would require purification (e.g. 
through protein immunoprecipitation) from the fractions prior to WB analysis in order to 
allow for reliable direct protein concentration comparison.  
Importantly, hyper-N-glycosylation was also observed by Beer and colleagues 
in the mouse HA tagged FGF10. Prevention of this hyper-glycosylation was achieved 
through treatment of the HEK cells with glycosylation inhibitor, Tunicamycin (Beer et 
al., 1997). Tunicamycin is a mixture of homologous nucleoside antibiotics that block 
enzymes catalysing the N-linked glycosylation and therefore causes cell cycle arrest in 
G1 phase.  Moreover, inhibition of glycosylation resulted in increased levels of 25kDa 
form of the protein (Beer et al., 1997), similarly to results presented here (Fig. 4.14). 
Each protein possesses its individual glycosylation pattern and correct glycosylation is 
crucial to protein biosynthesis and function. Whilst the O-linked sugars are added one 
at a time, the N-linked glycosylation begins with an addition of a large oligosaccharide, 
containing 14 sugar residues. Normally, certain sugar residues are subsequently 
removed, whilst others are added until correct arrangement is achieved for each 
protein. Failure of this system prevents the protein to progress further from the ER into 
other stages of the pathway, that most likely takes place in case of the hyper-
glycosylated proteins (Nicolaou et al., 2012, Dersh et al., 2014, Tannous et al., 2015).  
Further investigations could include blocking of the glycosylation in situ within 
the cell culture with the Tunicamycin in similar fashion to previous studies, which could 
reveal whether the mutant G145E can progress through the entire secretory pathway.  
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Part 4.5 Analysis of potential biological role of nuclear FGF10 
 
Secreted FGF10 acts in a dose dependent manner by binding to FGFR2IIIb and 
any deviations result in developmental malformations, as demonstrated during teeth 
formation, where insufficient FGF10 signalling during molar development resulted in 
undeveloped tooth crown, whilst overexpression causes expansion of the crown 
epithelium of the tooth (Yokohama-Tamaki et al., 2006) (see Chapter 1). Therefore, a 
nuclear retention and immobilisation of the FGF10 protein could provide another level 
of post translational control of the amount of protein undergoing secretion. On the 
contrary, FGF10HA did not appear to over-accumulate within the nucleus over period 
of 72h, meaning that nuclear protein observed did not appear more abundant than 24h 
post transfection. This suggests FGF10 is more likely to undergo nucleocytoplasmic 
shuttling, rather than nuclear sequestration (Fig. 4.11). Nuclear entry of the protein at 
specific stage of the cell cycle could suggest protein’s role in a control of cell 
proliferation and/or cell growth. In order to assess the stage of cell cycle when FGF10 
enters the cell nucleus, transiently transfected with FGF10HA culture of ARPE cells 
was paused at G1 and G2 growth phases, through chemical treatment and by serum 
starvation (see Chapter 2). 
To inhibit the cell cycle, the growth of ARPE cells was constrained by serum 
removal from the cell culture. Serum starvation causes cell growth restriction at G0/G1 
phase, induces quiescence and prevents cell proliferation. Interestingly, FGF10 was 
found to translocate into cell nucleus even in quiescent ARPE cells, concluding from 
which that the nuclear import of FGF10 was independent of cell division (Fig. 4.16A).  
During the cell division (mitosis), the nuclear envelope breaks down removing a 
physical barrier between the nuclear and cytoplasmic proteins. Since the FGF10HA 
was transiently transfected into already quiescent culture of cells, the results 
demonstrate that the breakdown of nuclear envelope is not necessary for the protein’s 
nuclear translocation. Furthermore, mitosis is preceded by G2 phase of rapid cell 
growth and protein synthesis. Importantly, nuclear import of proteins (e.g. complex of 
cyclin B1/CDK1 (Porter and Donoghue, 2003) at this stage of cell cycle is strictly 
regulated for two reasons: firstly G2 serves as a DNA damage checkpoint, and 
secondly it exhibits control of the mitotic entry (Fig. 4.16B). Transiently transfected 
FGF10HA was detected in a nucleus of ARPEs treated with the nocodazole drug. 
Nocodazole is a known inhibitor of G2/M phase transition as it interferes with the 
polymerization of microtubules, and prevents formation of metaphase spindles. The 
results therefore demonstrate that FGF10 translocated into the nucleus before and 
after the proliferative stage of DNA replication and synthesis (S phase). 
  














During the S phase proteins involved in DNA replication, as well as detecting 
DNA damage and repair, such as ataxia telangiectasia and Rad3-related protein (ATR) 
(Marechal and Zou, 2013) are transported into the nucleus. The serum starvation data 
shows that FGF10 was present in a nucleus at a G1 phase just preceding DNA 
replication (Fig. 4.16A), and therefore it is essential to determine whether it affects cell 
proliferation itself. To test whether FGF10 is present in a nucleus of replicating cells, 
sister cultures of mesenchymal ATDC5 cells were transfected with the HA-tagged 
constructs encoding FGF10, as well as G145E or 4T-NLS2-bearing mutations, which 
were shown not to enter the cell nucleus, or mCherry as control. The ATDC5 cultures 
were chosen to analyse the cell proliferation effect, because in vivo FGF10 usually is 
generated within the mesenchyme, therefore may be likely to translocate endogenously 
into the nucleus within mesenchymal cells. The transfected cultures were pulsed for 4 
hours with BrdU, which typically becomes incorporated into the cell nucleus during the 
S phase of a cell cycle. Co-expression of BrdU with HA or mCherry indicated actively 
proliferating cells (Fig. 4.17A). Interestingly, in comparison to mCherry-transfected 
cells, all FGF10-bearing constructs showed a significant reduction in cell proliferation 
Figure 4.16 Cell cycle stage specific nuclear import of FGF10. (A) FGF10HA was 
transported into the cell nucleus in a quiescent (serum starved) culture of ARPE cells. 
(B) FGF10HA was found in the cell nucleus in ARPE culture arrested at G2/M phase 
through treatment with nocodazole drug. (C) Schematic diagram of the cell cycle, 
showing that nuclear FGF10 is found at growth phase 1 (G1), growth phase 2 (G2), 
that follows synthesis (S) phase and precedes mitosis (M). Scale bar 20µm.   
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(ANOVA, post-hoc Tukey p=0.004, n=5). Only a small proportion of cells expressing 
FGF10 (~10%) showed incorporation of BrdU marker (Fig. 4.17B). Intriguingly, none of 
those cells that incorporated BrdU also showed nuclear presence of HA (Fig. 4.17A). 
Therefore FGF10HA was either not translocated into the nucleus in actively 
proliferating cells, or FGF10 functioned in the cell nucleus to abrogate cell replication. 
Interestingly, in comparison to the mCherry control, the G145E and 4T-NLS2 
transfections also resulted in the reduction of the cell proliferation (ANOVA, post-hoc 
Tukey p=0.015 and 0.026 respectively, n=5), in similar fashion to the non-mutated 
FGF10HA (ANOVA, post-hoc Tukey p>0.05, n=5) (Fig. 4.17B). Importantly these 
proliferating cells co-expressing HA and BrdU markers, did incorporate the HA-tagged 
protein into cell nucleus. There is a possibility that this reduction of cell proliferation 
observed in the mutation-bearing constructs could be a process independent of the one 
observed in FGF10HA. To determine whether intrinsic factors can interfere with 
conclusive results of this study, the culture of ATDC5 cells was assessed for 
expression (in a semi-quantitative manner) of FGF7-subfamily ligands and all FGF 
Receptors’ isoforms (see Chapter 5). The RT-PCR profiling for ligands and receptors 
revealed that ATDC5 cells express transcripts for FGF10 itself and at lower levels its 
receptor, the FGFR2IIIb (Fig. 5.3). Consequently, it is possible that endogenously 
generated FGF10 was able to compensate for the effects of the mutant constructs, 
perhaps through cell autonomous mechanisms. However, this study would require 
further investigation to fully determine the mechanisms driving the observed reduction 
of cell proliferation.  
 
  





  Figure 4.17 Transient expression of FGF10HA and its mutants affects the 
proliferation potential of ATDC5 cells. (A) Representative immunofluorescent images 
of co-localisation of BrdU marker of cell proliferation and HA staining; note lack of 
nuclear FGF10HA expression; scale bar 20µm. (B) Quantification of proliferating cells 
expressing the HA-tagged constructs or mCherry protein (ANOVA, F=6.77, p<0.01, 
n=5).  
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Part 4.6 Discussion 
 
FGF10 is a secreted protein that upon release from the mesenchymal cells 
binds to receptor FGFR2IIIb on adjacent epithelium, stimulating downstream molecular 
pathways to drive cell proliferation and differentiation. However, transiently transfected 
FGF10, fused to a small HA tag, was detected in the nucleus of multiple cell types even 
72h post transfection. Furthermore, the nuclear import of FGF10 depended on the 
G145 residue (within NLS1) and NLS2 sequence, which is presumed to interact with 
Importin chaperones. Nuclear FGF10 localised to the nucleolus where it may be 
involved in regulation of the cell proliferation. Moreover, nuclear exclusion of FGF10 
through mutation within NLS1 (G145E) and NLS2 (4T-NLS2) appeared to occur 
independently, through two different mechanisms.  
Analysis of the tertiary structure of the FGF10 revealed close positioning of 
NLS1 and NLS2 as well as a capacity for direct interaction through an H-bond (see 
Chapter 3). Therefore, it was investigated whether the two weak motifs provide one 
stronger signal driving FGF10 into the cell nucleus. The results showed that a single 
mutation in NLS1, G145E, which causes LADD syndrome in humans (G138E), 
prevented the nuclear import of FGF10 in similar manner to a combination of 4 
mutations within NLS2 (4T-NLS2). The ablation of the nuclear import of FGF10 
molecule could be an underlying cause for the symptoms of the LADD syndrome 
caused by the human G138E mutation, which has not been described before.  
Further investigation revealed however that the G145E was also unlikely to be 
secreted out of the cells thereby indirectly impairing FGF-receptor signalling pathway. 
Several lines of evidence suggested that the G145E most likely encountered folding 
problems and therefore did not undergo further normal processing. The mutant 
accumulated at high levels at the ER, where it was associated with the ERp60 protein 
(Fig. 4.15). The ERp60 is known to play a role in folding of the newly synthesised 
protein and shows association with other molecular chaperones specific for the N-
glycosylation of proteins (Koivunen et al., 1996). Since the mutant showed hyper-N-
glycosylation (Fig. 4.14), it is therefore possible that the G145E was misfolded causing 
its greater association with the ERp60 and the glycosylation chaperones. This 
interaction potentially prevented the protein’s further functional roles. The HA-tagged 
construct was detected within the cell cytoplasm even after 72h, suggesting that 
regardless of misfolding, the protein did not undergo degradation, although further 
studies are required to confirm this hypothesis. Misfolded proteins are likely to become 
substrates of the ER-associated protein degradation (ERAD), a multi-step ‘quality 
control’ mechanism involving an assortment of enzymes acting to prevent accumulation 
of misfolded proteins in the lumen and membrane of the ER (Ruggiano et al., 2014). 
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Therefore, to fully determine whether G145E mutation caused ER stress or was 
degraded, the mutant could be, for example, analysed in the context of ERAD pathway.  
Moreover, the substitution of the Glycine (G) to other small residues, like Valine 
or even Alanine (the second smallest amino acid) also resulted in nuclear exclusion of 
the protein (Fig. 4.9). Biochemical studies have shown that Glycine at key positions 
within a protein molecule allows high flexibility of torsion angles in the polypeptide 
chain that otherwise are prevented by other residues (Zhao et al., 2012, Chen et al., 
2011). Therefore, disruption of this particular residue can lead into protein misfolding 
and structural issues, rather than interfering with binding to Importins. Moreover the 
G145 residue is located on a protein structure within one of the loops (Fig. 4.9). Loops 
often serve functional roles, also in protein folding, and mutations can negatively affect 
the protein’s structure. In conclusion, the mutation of the G145E residue, may lead to 
protein structural defects, causing its ER retention and consequently loss of FGF10-
function. 
On the other hand, the 4T-NLS2 mutant showed nuclear exclusion by 
potentially impairing the site of binding to Importin chaperone. The introduced 
mutations could cause a pool of generated protein molecules to encounter folding 
defects, and therefore, similarly to G145E undergo hyper-N-glycosylation at the ER. 
Nonetheless, the protein was able to follow the normal secretory pathway, similarly to 
the non-mutated FGF10HA (Fig. 4.15), showing therefore that a proportion of the 
protein folded and functioned normally. Moreover, even a minor perturbation of the 
NLS2 motif, such as mutation of couple of basic residues, limited the nuclear import of 
FGF10 molecule (Fig. 4.10). Major disruptions to the NLS2 resulted in nuclear 
exclusion of the protein altogether implying that this sequence was absolutely crucial 
for the nuclear import of the FGF10. To conclusively determine whether NLS2 alone is 
sufficient to target a protein to the nucleus, it would be possible to integrate the motif 
into a fluorescent protein of similar size to FGF10, and measure accumulation of the 
resulting complex in the cell nucleus.  
Proteins found within cell nucleus serve several functions, for example multiple 
nuclear proteins are required to regulate transcription machinery, and transcription 
factors binding to DNA further modulate gene expression. Moreover some proteins are 
involved in DNA packaging into chromosomes and others determine DNA protection 
against mutation and degradation.  In addition, a range of proteins play differential roles 
within the cell nucleolus, an organelle known as a site for assembly of ribosomal 
subunits. Transiently transfected nuclear FGF10 localised within the nucleolus (Fig. 
4.2) where it could possibly interact with ribosomes. However, recent studies show that 
many non-ribosomal proteins accumulate in the nucleolus, for yet undetermined 
reasons (Lin et al., 2008, Catez et al., 2002). Moreover, there is evidence that the 
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nucleolus also plays a role in sequestering regulatory molecules, in response to 
specific environmental cues. Capturing and immobilization of proteins, also known as 
nuclear detention is believed to be a part of post translational regulatory mechanisms, 
to prevent proteins at certain conditions to interact with their binding partners. 
Examples of those include DNMT1, Hsp70, POLD1, and VHL, which bind to the 
nucleolar detention sequence (NoDS), characterised by arginine-rich repeats (Audas et 
al., 2012). It is therefore possible that nucleolar accumulation of FGF10 allows for 
nuclear detention and regulation of the amount of protein available for the secretory 
pathway and hence receptor stimulation. Since FGF10’s receptor stimulation generates 
downstream signals in a FGF10-dose dependent manner (see Chapter1), the process 
of nucleolar detention could provide further regulation of the FGF10-FGFR2IIIb 
signalling.  
However, analysis of protein intracellular distribution over period of a 72h 
showed that accumulation of FGF10 in the nucleus did not change significantly over a 
period of time (Fig.  4.11), suggesting that FGF10 most likely did not undergo nucleolar 
sequestration. Presumably FGF10 shuttles in and out of the nucleus, which requires 
future experimental investigation, for example through ‘molecular tracking’ - by 
observing and measuring the distribution of fluorescently tagged FGF10 in live cultures 
over a set period of time. Bioinformatics analysis did not show any classical nuclear 
export signals (NES) within FGF10 sequence and therefore, if FGF10 is transported 
out of the nucleus, it would most likely take place in a non-conventional manner (see 
Chapter 3). Although FGF10 having molecular weight of 21-25kDa is a small enough 
molecule to freely diffuse in and out of the nuclear pores, experiments performed in 
literature show that practically all proteins are actively chaperoned into the nucleus 
(Christie et al., 2015) (see Chapter 1).  
Some proteins within nucleolus are responsible for modifying small RNAs, 
assembling ribonucleoprotein and contributing indirectly to regulating aging processes 
(Oh et al., 2007, Olson et al., 2000, Pederson, 2011). Interestingly, FGF2 and FGF3 
have also been found within the nucleolus. Nucleolar FGF2 directly regulates synthesis 
of ribosomal RNA and stimulates Polymerase I transcription through binding to UBF 
transcription factor (Sheng, 2004, Sheng et al., 2005). Nucleolar FGF3 has been 
postulated to play a role in control of cell cycle and inhibition of cell proliferation through 
binding to NoBP protein (Reimers et al., 2001). Future studies will show if nucleolar 
FGF10 is able to interact with other nuclear proteins in a similar fashion to FGF2 and 
FGF3.  
Secretory FGF10 is known to be involved in proliferation of pancreatic epithelial 
cells (Hart et al., 2003), epithelium of glandular stomach (Shin et al., 2006), and white 
adipose tissue (Konishi et al., 2006). In the absence of FGF10 signalling, pancreatic 
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and heptoblasts progenitor cells fail to proliferate (Norgaard et al., 2003, Berg et al., 
2007). However, the nuclear form of FGF10 within ARPE and ATDC5 cells (Fig. 4.16 
and 4.17) as well as in urothelial cells (Kosman et al., 2007) was associated with cells 
in a quiescent phase, and nuclear FGF10 may potentially be involved in negatively 
regulating cell proliferation. The putative nucleolar retention of FGF10 may possibly 
prevent the protein from entering its secretory pathway and therefore limiting indirectly 
the FGF10’s proliferative effect, in either a paracrine or autocrine manner achieved 
through receptor stimulation. This suggests that nuclear FGF10, either through 
endogenous or restriction of exogenous pathway, counteracts the function of the 
secreted protein. Both FGF2 and FGF3 proteins are also known to display similar 
properties. 
Nuclear FGF3 inhibits DNA synthesis and reduces cell growth (Kiefer and 
Dickson, 1995a) acting in an opposite way to its receptor-signalling role, where it 
functions as an oncogene (Muller et al., 1990). In vitro FGF3 and FGF10 have been 
shown to be mutually redundant, and can compensate for the lack of the other protein 
during induction and formation of the otic placode and inner ear (Wright and Mansour, 
2003, Alvarez et al., 2003). Therefore, it is likely that FGF10 exhibits similar functional 
properties to the FGF3 molecule. 
FGF2 exists as different isoforms with varying protein size, i.e. four high 
molecular weight (HMW) FGF2s have been described, which mostly confine to the cell 
nucleus (Quarto et al., 1991) and one low molecular weight (LMW) which is released 
from the cell and acts through the receptor signalling pathway. Furthermore, the LMW 
FGF2 has also been found within the cell nucleus, often in a complex with its cognate 
receptor (Clarke et al., 2001, Bossard et al., 2003). Although both HMW and LMW 
FGF2 are found in a cell nucleus, they localise to different loci which is reflected in the 
function they serve. LMW FGF2 was found to localise in nucleoli and Cajal bodies 
whereas HMW FGF2 shows a punctate pattern in the nucleoplasm and periphery of 
nucleoli (Claus et al., 2003, Dini et al., 2002). Both LMW and HMW can stimulate cell 
proliferation, but only LMW FGF2 increases cell migration and promotes tumour 
invasion, where HMW has an inhibitory effect (Dini et al., 2002). Moreover the HMW, 
but not LMW, FGF2 variant is necessary for promoting estradiol dependent endothelial 
cell migration and proliferation linked to angiogenesis (Garmy-Susini et al., 2004) 
meaning that the effect of the protein is tissue specific. Interestingly, FGF10 was noted 
to exist in a LMW isoform as it possesses a second translational site at Met position 42 
(of the rat sequence) generating a protein of 19.2kDa (Lu, 1999) (Hajihosseini’s 
unpublished data), but the potential function of this isoform has not been described yet. 
This LMW isoform was not detected in this study, although it is possible that translation 
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from additional Met sites occurs in a spatio-temporal manner, controlled by specific 
activators and therefore require future studies.  
Regardless of its molecular weight, it is possible that a typically known as a 
paracrine molecule FGF10 serves an intra-cellular role, stimulating different pathways 
to the ones achieved via a recipient cell, through receptor activation. This intracellular 
function of FGF10 is most likely controlled in a cell and tissue specific manner. 
Therefore role of FGF10 in organogenesis and within adult tissue might require re-
evaluation in all of the currently known systems.  
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Chapter 5  
Putative functions of intracellular FGF10 during differentiation of 
mesenchymal progenitor cells (ATDC5s) 
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Part 5.1 FGF10 signalling is implicated during chondrogenesis and cartilage 
formation 
 
FGF10 is typically produced and secreted by mesenchymal cells, acting on 
FGFR2-IIIb receptor present on adjacent epithelium to drive cell proliferation and 
differentiation. During development mesenchyme is derived from the mesoderm and is 
defined as embryonic connective tissue, however mesenchymal stem cells (MSCs) can 
also be found in the adult organism (Ullah et al., 2015). MSCs were first identified and 
isolated from bone marrow (Friedenstein et al., 1970). They are multipotent stromal 
cells that lack polarity and are able to differentiate, in vivo and in vitro, into osteoblasts 
(bone cells), myocytes (muscle cells), adipocytes (fat cells) and chondrocytes (cartilage 
cells), overall forming a connective tissue (Huang et al., 2015). Chondrocytes form 
cartilage tissue in the process of chondrogenesis, which is regulated by a series of 
cytokine and transcription factor interactions, including TGFβ, FGFs, and insulin-like 
growth factor1 (IGF1) (Lin et al., 2006). The process of chondrogenesis in vitro is 
induced in the presence of dexamethasone, β-glycerol phosphate as well as ascorbic 
acid, and differentiated cells express alkaline phosphatase. At the moment, there are 
several different models utilised in vitro, studying the processes of chondrogenesis, 
with the most prominent involving a so called ‘micromass culture’ derived from 
embryonic limb mesenchymal cells. During embryonic development, MSCs losing their 
pluripotency typically proliferate rapidly, crowding together and forming dense 
aggregates of chondrogenic cells, which often display properties of cartilage. The 
‘micromass culture’ involves differentiation of MSCs into such cartilage aggregates, 
termed ‘nodules’, thus mimicking the processes taking place in vivo (DeLise et al., 
2000). Moreover, chondrocytes show osteogenic properties through accumulation of 
calcium during differentiation, which eventually forms a mineralized extracellular matrix 
(ECM). Subsequently, in vivo, the differentiated cells begin secreting type II collagen, 
aggrecan, and anionic proteoglycans, found for example in articular cartilage, which 
covers the ends of the bones (Williams and Hare, 2011).  
The process of chondrogenesis is an indispensable part of skeleton patterning 
in vertebrates. During limb formation, following condensation of mesenchymal cells, the 
proliferating chondrocytes form cellular columns. These are oriented along the 
longitudinal axis of the developing bone, midway along which these mitotically active 
cells differentiate into non-proliferative prehypertrophic chondrocytes. Chondrocyte 
hypertrophy is a tightly regulated process with key players being Sox9, Runt-related 
transcription factor2 (Runx2) and Runx3, Indian Hedgehog (IHH), BMP, Wnt and FGFs, 
that leads eventually to bone elongation. Hypertrophic chondrocytes can also begin to 
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mineralize their extracellular matrix and have the capacity to differentiate into 
osteoblasts (reviewed by (Ornitz and Marie, 2015)).  
Fibroblast growth factors (including FGF10), together with other signalling 
factors (e.g. Wnts) (Danopoulos et al., 2013), are known to play a role in bone and 
cartilage formation, an example of which includes maintenance of the limb bud 
outgrowth. FGF10 generates a primary signal to coelomic epithelium that causes 
induction of an epithelial-to-mesenchymal cell transition, forming eventually a 
mesenchymal bulge. Further FGF10 signals emerging from the mesenchyme induce 
the formation of ectopic ectodermal ridge (AER), which subsequently secretes primarily 
FGF8 and then also FGF4, FGF9 and FGF17 (Sun et al., 2000). These FGFs generate 
reciprocal signals back to the mesenchymal cells, further maintaining the expression of 
Fgf10 resulting finally in proper growth and patterning of the limb bud along three axes 
– dorsoventral, proximodistal and anterio-posterior (Sekine et al., 1999). These FGF 
reciprocal signals ensure the viability of chondrogenic precursors that eventually form 
the cartilage templates of the limb (ten Berge et al., 2008).  
Although the main known players of cartilage formation within the FGF family 
are FGF2, FGF8, FGF9 and FGF18 (Ellman et al., 2013, Ornitz and Marie, 2015), 
FGF10 was also shown to be involved during chondrogenesis. For example, FGF10 is 
responsible for the formation of a uniform cartilaginous sleeve during the development 
of a trachea. In humans suffering from the Apert Syndrome, FGF10’s cognate receptor 
FGFR2IIIb, is ectopically expressed in the mesenchyme and this leads to increased 
proliferation of mesenchymal cells stimulated by atypical autocrine FGF10 signalling 
and results in tracheal stenosis, i.e. formation of a uniform tracheal cartilaginous sleeve 
(Tiozzo et al., 2009). On the other hand, overexpression of Fgf10 results in totally 
disorganized cartilage rings because of reduced cartilage formation. Furthermore, 
inactivation of FGF10 production results in shortened trachea with severe defects in 
patterning of the cartilage rings. FGF10 therefore is not required for the induction of 
cartilage differentiation, but it is involved in the proper patterning of trachea during 
mesenchymal differentiation (Sala et al., 2011).  
FGF10 is also indirectly implicated in cartilage differentiation during lacrimal 
gland development. During chondrogenesis, the expression of collagens II and IX 
contributes to the formation and elongation of the lacrimal bud, and is controlled by 
Sox9 transcription factor. FGF10 regulates Sox9 function in the lacrimal buds, which 
leads to generation of a feed-forward signalling loop, where genes activated by Sox9 
act to maintain FGF10 signalling (Chen et al., 2014, Makarenkova et al., 2000). A 
similar Sox9-FGF10 signalling loop maintains the mesenchymal tissue, regulating 
pancreatic progenitor cells (Seymour et al., 2012). 
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Terao and colleagues show that the role of FGF10 signalling extends beyond 
the epithelial stimulation and FGF10 regulates the size and shape of Meckel's cartilage 
during mandibular morphogenesis (Terao et al., 2011). Endogenous overexpression of 
Fgf10 induces the elongation of Meckel's cartilage by influencing chondrocyte 
differentiation, but not increased cell proliferation. Moreover overexpression of Fgf10 in 
mandibular mesenchyme leads to expression of chondrogenic marker genes.  
FGF10 is also involved in craniosynostosis and other pathologies associated 
with bone and cartilage formation that have been generated through abnormal or 
elevated levels of the FGFR2. Knocking down levels of FGF10 in mice harbouring an 
Apert syndrome-type gain-of-FGFR2 mutation, can restore normal skeletal 
development (Hajihosseini et al., 2009).  
Collectively, these studies show that paracrine FGF10 signalling is an integral 
part of mesenchymal cells maintenance, differentiation and patterning, particularly that 




Paracrine FGF10 signalling affects mesenchymal differentiation and 
chondrogenesis. However, FGF10 can also translocate into the nucleus of 
mesenchymal cells (Chapter 4, Fig. 4.4). The aim of this study was therefore to 
investigate whether nuclear FGF10 affects the proliferation or differentiation of cultured 
chondrocyte progenitors.  
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Part 5.2 Mesenchymal ATDC5 cells as a model to study chondrogenesis 
 
ATDC5 cells were first described by Atsumi and colleagues in 1990, who 
isolated mouse teratocarcinoma fibroblastic cells and noticed their chondrogenic 
potential, by comparing it to other established cell lines, including C3H10T1/2 and 
RJC3.1 (Atsumi et al., 1990). Successive studies have shown that ATDC5 cells 
undergo a process of cellular condensation leading to sequential progressions 
analogous to chondrogenic differentiation. Culture of differentiated ATDC5s forms  
nodules with chondrocytic characteristics, i.e. elevated type X collagen expression, 
secretion of type II collagen, aggrecan and other extracellular matrix (ECM) molecules 
and matrix mineralization (Shukunami et al., 1996, Shukunami et al., 1997, Shukunami 
et al., 1998). Other advantages of using the ATDC5 culture system to study 
chondrogenesis, is that cells proliferate easily and can be maintained in their 
undifferentiated state. Therefore ATDC5 cells are widely used to investigate the 
intermediate steps of the mesenchymal differentiation as well as endochondral bone 
formation (Yao and Wang, 2013). 
At a sub-confluent stage, undifferentiated ATDC5 cells were described as 
culture of cells with elongated and fibroblast-like morphology, able to proliferate until 
cells formed a confluent monolayer (Shukunami et al., 1996). Differentiation of ATDC5s 
is a multistep process, similar to those taking place in vivo, and initiated in vitro by 
supplementation of cultures with insulin and ascorbic acid (Temu et al., 2010).  
In this work, the morphology and stage of confluency of ATDC5 culture was 
monitored daily under phase-contrast light microscope. Undifferentiated cells were 
seeded on glass coverslips in 24-well plate, cultured for 2 days to reach full confluency 
(Fig. 5.1A) and then induced to differentiate, alongside non-induced control sister 
cultures. During the early differentiation stages, which takes about 7 days (Fig. 5.1A), 
cells of a spindle-like morphology condensed and became polarised. Later, the cells 
grouped together into circular assemblies, discarded their monolayer behaviour, and 
slowly formed 3D structures. Once the nodules had started to form, the cells displayed 
a round morphology and began to express chondrogenic markers, such as 
glycosaminoglycans and deposition of calcific compounds similarly to that observed by 
other researchers (Shukunami et al., 1996, Atsumi et al., 1990). After 14 days of 
culture, treatment of ATDC5s cells with Alcian Blue (indicating cartilage formation) or 
Alizarin Red (a marker for matrix synthesis) revealed blue or red stained nodules, 
characteristic markers of chondrogenic and bone differentiation, respectively (Fig. 
5.1B). 
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After initial experiments determining the timescale of normal differentiation, 


















Figure 5.1 Differentiation of ATDC5s into chondrocytic nodules is a multistep process. 
(A) Schematic representation of a time scale of ATDC5 cells’ differentiation shows 
that after 7 days of induction cells begin to form nodules, that are fully differentiated 
and shaped after 14 days. (B) After 14 days, the well-established nodules show 
cartilage formation (stained with Alcian Blue) and calcific deposition (stained with 
Alizarin Red), characteristic of mesenchymal differentiation; scale bar 200µm.  
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Part 5.3 Exogenous FGF10 treatment enhances differentiation of ATDC5 cells 
 
FGF10 was shown to stimulate the mesenchymal differentiation through 
activation of its cognate receptor, during mandibular morphogenesis (Terao et al., 
2011). However, at the moment little is known about the effect of FGF10 signalling 
specifically within the ATDC5 chondrogenic progenitors. To determine whether FGF10 
applied exogenously can affect the proliferation or differentiation of the cell culture, 
ATDC5s were seeded in 24-well plate and either stimulated to differentiate or were 
maintained in their undifferentiated state. Confluent cultures were treated with 
recombinant human FGF10 at 1ng, 10ng or 100ng/ml and compared to untreated 
controls (Fig. 5.2A).  
A series of images taken on a days 3, 5 and 7 of FGF10-treated cultures (Fig. 
5.2A) allowed a monitoring of the effects of FGF10 on cell growth and differentiation. In 
the absence of insulin and ascorbic acid, exogenous FGF10 treatment alone could not 
elicit ATDC5 differentiation, whether used at low or high concentrations. Over time the 
differentiating cells became denser and changed shape from elongated to more 
compact, with a smaller cell body. However, the same changes were observed in the 
non-treated control as in the samples stimulated with FGF10. Moreover, when the cells 
formed a uniform monolayer of densely packed cells, they responded to contact 
inhibition and stopped proliferating, i.e. there was no observable difference between 
cultures at day 5 and day 7 of the FGF10 treatment, as well as the non-treated control. 
These results suggested that externally applied FGF10 did not trigger differentiation in 
a culture of undifferentiated ATDC5 cells; but neither did it inhibit cell proliferation to 
delay confluency (Fig. 5.2B).  
 On the contrary, FGF10 accentuated the differentiation of ATDC5s once they 
were induced with insulin and ascorbic acid. On the third day of differentiation the cells 
within all FGF10 treatment assays and including non-treated control, displayed a 
compact and polarised morphology. After 5 days, a great amount of cell death was 
evident and observed as floating cell debris, typical for this stage of differentiation as 
established by earlier pilot experiments. At day 7 of differentiation, the non-treated 
controls began to display small structures of densely packed cells which started to 
overlay each other forming 3D nodule-like structures. Treatment of the cultures with 
1ng/ml of FGF10 showed comparable levels of differentiation to the control, as judged 
by the size and number of nodule-like progenitors formed within both cultures. 
Importantly, cultures treated with 10ng/ml of FGF10 had already displayed several, fully 
formed nodules, characteristic of fully differentiated cells (Fig. 5.2B). Subsequently, 
these nodules grew very rapidly over the period of next two days and resulted in 
massively overgrown culture (data not shown). Treatment of cultures with 100ng/ml of 
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FGF10 led to increased cell death and failure of cells to differentiate even if maintained 









Figure 5.2 Exogenous FGF10 promotes differentiation of ATDC5. (A) Schematic 
representation of the experimental time scale, where FGF10 was applied on days: 0, 
2 and 4 of differentiation, and the cultures were imaged on days: 3. 5 and 7; culture 
was fixed before completing full 14 days of differentiation. (B) A series of 
representative images showing that the treatment of FGF10 did not affect 
undifferentiated cells however, at a concentration of 10ng/ml enhanced the potential 
of already differentiating culture.  
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Mesenchymal cells typically express Fgf10 and further studies of the ATDC5 
culture revealed endogenous expression of Fgf10 in undifferentiated state of the 
culture, which is maintained during cell differentiation (Fig. 5.3). Semi-quantitative RT-
PCR profiling for the ligands that belong to the same subfamily as FGF10 showed that 
Fgf7 is also expressed by the culture of undifferentiated and differentiated ATDC5s, 
although not as prominently as Fgf10 (Fig. 5.3). As expected the receptor FGFR2IIIIc 
was detected, and at a lesser lever the IIIb isoform as well. This intriguing expression 
of both receptor isoforms can be an effect of culture heterogeneity. Alternatively, as a 
transformed cell line, the strict splicing of receptor IIIc and IIIb isoforms may have 
become disrupted but nonetheless, provides a model to test exogenous effects of 
FGF10.  Interestingly MSCs have been found to exist as heterogeneous population of 
cells in vivo and in vitro. They often express diverse surface markers, and even vary in 
morphology and differentiation capabilities (Williams and Hare, 2011). Therefore 
ATDC5s, as one of the types of MSCs, may also exist as a heterogeneous cell 
population. Heterogeneous culture could mean that cells potentially vary in their 
differentiation properties and Fgf10 might not be expressed uniformly across all cells in 
the culture. Use of a uniform culture would be important through implementing clonal 
selection in order to re-establish pure ATDC5 cells, which is beyond the scope of this 
project.  Nonetheless, the ATDC5 culture remains a valuable system showing effects of 
external application of FGF10 on differentiation of chondrocytes.  
 
  









Part 5.4 Endogenous overexpression of FGF10 inhibits differentiation of ATDC5 
cell culture 
 
Since exogenously applied FGF10 enhanced differentiation of ATDC5 cell, it 
was important to determine whether overexpression of the protein endogenously in the 
culture will have similar effect. As before, cultures of ATDC5s were set up and induced 
to differentiate with insulin and ascorbic acid. Sister cultures were then transiently 
transfected with either FGF10HA or G145E and 4T-NLS2 mutation-bearing constructs 
(see Chapter 4) primarily on the day of differentiation induction and then on two other 
occasions, therefore three times in total in order to maximize the overexpression of 
FGF10 within the differentiating culture (Fig. 5.4A). Cultures serving as negative 
controls were treated with transfection reagents alone and positive controls were 
transfected with mCherry fluorescent protein DNA, to demonstrate that transfection 
procedure itself does not disrupt the culture differentiation potential. At the end of the 
differentiation stage, the cultures were stained with Alcian Blue to determine the levels 
of cartilage formation.  
Figure 5.3 Semi-quantitative RT-PCR profiling for FGF7-subfamily ligands and FGF 
Receptors’ isoforms in a culture of undifferentiated and induced to differentiate 
ATDC5 cell culture; note the heterogeneity of the culture, expressing both isoforms of 
the FGFR2 receptor.  
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Interestingly, overexpression of FGF10HA within the culture of ATDC5s caused 
reduction in cell differentiation, even after treatment with insulin and ascorbic acid. After 
7-10 days of differentiation the control cells were dense, compact and small, began to 
overlay each other and form small nodules, with characteristic darker brown colour 
(Fig. 5.4B). Cells transfected with FGF10HA or with mutant-bearing constructs (G145E 
and 4T-NLS2) formed a uniform monolayer of cells that displayed elongated, spindle-
like morphology, characteristic of undifferentiated cells, even on the 12th day of 
differentiation (Fig. 5.4B). Moreover extensive cell death was noted, in the samples 
transfected with G145E mutant when compared to the other assays. However, overall 
cell number did not seem to be affected. This observation requires further investigation, 
using specific markers of cell death and counts of cell numbers to fully assess the 
significance of this observation.  
After 14 days of stimulation, the control assays, here termed as ‘negative’ 
meaning not-transfected as well as ‘positive’, meaning transfected with mCherry, both 
have showed full (i.e. normal) differentiation of the culture with multiple nodules that 
stained readily with Alcian Blue (Fig. 5.4B,C). By contrast, cultures transfected with 
FGF10HA showed only a few and very small ‘patches’ or ‘micro-nodules’ that were 
generated by a small group of condensed cells and have stained with Alcian Blue but 
failed to display a proper 3D nodule-like structure  (Fig. 5.4B). The number of these 
micro-nodules was also significantly reduced in comparison to mCherry and not-
transfected controls (Student T-test p≤0.01, n=5). Interestingly, transfection of mutant 
proteins also inhibited ATDC5 cell differentiation, comparable to FGF10HA (Fig. 5.4B).  









Figure 5.4 Overexpression of FGF10 limits the differentiation potential of the ATDC5 
culture. (A) Schematic representation of the experimental set up; (B) Representative 
images of cultures imaged during later stages of differentiation and stained with Alcian 
Blue. (C) Nodules and micro-nodules (blue regions visible in the culture) were counted 
and compared to controls of not-transfected (NT) cells and cells expressing 
fluorescent mCherry protein (Student T-test p≤0.01, n=5).  
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Part 5.5 Discussion 
 
 Through these primary experiments it was shown that at specific concentrations 
an excess of exogenously applied FGF10 enhances the differentiation of ATDC5 
culture (Fig. 5.2) whilst overexpression of endogenous Fgf10 causes significant cell 
perturbation to the differentiation (Fig. 5.4). 
 Although experiments performed here are primary, requiring further and more 
detailed studies, it was established that FGF10 alone was unable to trigger 
differentiation of ATDC5 chondrogenic progenitors, regardless whether supplied 
exogenously or overexpressed endogenously (Fig. 5.2 and data not shown). The same 
results have been observed in vivo where Fgf10-null mice display normal differentiation 
of mesenchymal cells during development of trachea (Sala et al., 2011). However, 
Fgf10-null mice display a significant decrease in proliferation of mesenchymal cells, 
resulting in abnormal cartilage patterning of trachea (Sala et al., 2011).  
 Externally applied FGF10 at 10-8M, which is a concentration that is more than 
twice as high as concentration of 100ng/ml used in this study, was shown not to affect 
proliferation of either osteoblastic culture of mouse MC3T3-E1 cells, primary 
osteoblasts and ATDC5s (Shimoaka et al., 2002). Similarly, no increase in cell 
proliferation was observed during in vitro treatment of monolayered mandibular cells 
(Terao et al., 2011). In accordance with those results, no significant reduction in cell 
numbers was observed during the treatment with FGF10, either of undifferentiated or 
differentiated cultures of ATDC5s, at any of the FGF10 concentrations tested. 
Although, at the end of the experiment application of high concentrations of FGF10 
(100ng/ml) lead to high levels of cell death, which may have been triggered by an 
altered differentiation processes resulting eventually in apoptosis, as undifferentiated 
culture remains unaffected (Fig. 5.2). To fully establish the effect of FGF10 on cell 
proliferation and cell death in this culture system more detailed studies succeeding the 
gross examination are required with a use of specific markers of cell death, proliferation 
and differentiation, which would provide detailed counts and nodule measurements and 
allow concrete conclusions to be drawn. 
 Unlike FGF18 and FGF2, but in accordance with the results shown here (Fig. 
5.2), 10-8M of FGF10 did not block the differentiation of osteoblastic MC3T3-E1 cell 
culture (Shimoaka et al., 2002). However results shown here indicate that, at a lower 
concentration, FGF10 can actually promote differentiation (Fig. 5.2). Supporting this 
observation, recombinant FGF10 added to a culture of explants (at 5ng/ml) was able to 
promote the formation of cartilage from the lateral mandibular cells (Terao et al., 2011). 
Therefore the effect of FGF10 on chondrocytic differentiation seems to be strictly dose 
dependent.  
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On the other hand, overexpression of FGF10 resulted in a significant abrogation 
of cell differentiation. The result is an unlikely effect of excessive protein accumulation 
as overexpression of mCherry construct did not limit the differentiation potential of 
ATDC5 cells (Fig. 5.4). Moreover, by its nature, transient transfection normally results 
in temporary protein production, which was unlikely to accumulate inside the cell over 
longer period of time. Moreover, FGFs were shown to be unstable and quickly 
degradable proteins in general (Buchtova et al., 2015), therefore further showing that 
protein over-accumulation is an unlikely event. However, the combinatory effect of 
transient transfections was sufficient to affect significantly the early differentiation of the 
culture, impacting subsequently the later stages. Interestingly, enhanced levels of 
endogenous FGF10 seem to have an opposite effect to the external treatment. Similar 
effect has been noticed regarding FGF3, a member of the same subfamily as FGF10. 
Nuclear FGF3 inhibits DNA synthesis and reduces cell growth (Kiefer and Dickson, 
1995a) acting in an opposite fashion to its receptor-signalling role, where it functions as 
an oncogene, promoting cell proliferation (Muller et al., 1990).  
During corticogenesis, FGF10 was shown to control differentiation of the 
stem/progenitor cells, and loss of FGF10 delayed but did not fully block neural cell 
differentiation. Moreover, FGF10 had no effect on cell proliferation (Sahara and 
O'Leary, 2009). Similarly, in ATDC5 culture FGF10 controlled differentiation, but with 
no discernible effects on cell proliferation or initiation of differentiation (Fig. 5.2).  
These experiments provide interesting preliminary results of FGF10 function 
and leave room for further investigations. There are several caveats associated with 
this study that need to be addressed in the future. First of all, the experimental design 
did not control for the secretion of FGF10 and it is unknown therefore how much of the 
overexpression effect seen was caused by the activation of the FGFR2IIIb. However, 
previous experiments have shown that secreted from of FGF10 is undetectable in the 
overexpressed culture system (see Chapter 4), therefore it is unlikely that the protein 
was secreted at equally high levels as 5-10ng/ml and therefore its external signalling 
(promoting differentiation) might have not been as prominent as the internal signals 
(inhibiting differentiation).  
Nonetheless, it would be required to silence the endogenous Fgf10 expression 
in the culture prior to future experiments, potentially through use of genetic 
manipulation tools. That would facilitate determination of whether endogenous FGF10 
is essential for the cell differentiation in first place. Then stimulating the cells with 
external FGF10 would allow comparison with already obtained results. Moreover, 
overexpression of FGF10 protein lacking signal peptide, that currently directs it to the 
secretory pathway, would allow monitoring of the endogenous effect of FGF10 on the 
chondrocytic differentiation.  
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The G145E and 4T-NLS2 mutants proteins, that were shown to be excluded 
from the cell nucleus (Fig. 4.8 & 4.10), appeared to inhibit the cell differentiation in a 
similar manner to non-mutated FGF10 (Fig. 5.4). It is therefore possible that FGF10 
affected the differentiation of ATDC5 cells via a cytoplasmic mechanism. Moreover, 
results presented here could be compromised by the endogenous production of the 
protein. Therefore a more controlled experimental set up would allow drawing clearer 
and more concrete conclusion.  
The remaining matter is that ATDC5s, as one of the types of MSCs, may exist 
as a heterogeneous cell population, displaying two different isoforms of receptor 
FGFR2 (Fig. 5.3). Therefore, as part of the future projects a full characterisation of the 
culture would be required and ideally the cells expressing different types of receptor 
should be separated from each other, rendering pure cell populations. Interestingly, 
population of ATDC5 expressing different receptor isoforms may respond differently to 
FGF10 treatments. Furthermore, it would be crucial to determine whether the effect of 
FGF10 varies from data presented here, in different types of mesenchymal cells, e.g. 
through external treatments with recombinant protein or endogenous overexpression of 
the FGF10HA constructs within the lung mesenchyme or precursors of ocular glands. 
Currently, the commercially available mesenchymal cell lines are mostly limited to 
human and rodent MSC isolated from the bone marrow and adipose tissue, such as 
GIBCO® Mouse (C57BL/6) Mesenchymal Stem Cells, Human Marrow-Derived 
Mesenchymal Stem Cells (ATCC® PCS-500-012™) and STEMPRO® Human Adipose-
Derived Stem Cell, which would provide a system very similar to presented here 
ATDC5 culture. Therefore, future studies might consider generating a primary culture of 
for example, lung mesenchyme, mimicking the in vivo processes where FGF10 seems 
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Chapter 6  
Establishment and characterisation of primary hypothalamic cultures as 
an in vitro tool to determine FGF10 function in tanycytes 
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Part 6.1 Introduction to FGF10 in a culture of hypothalamic stem cells 
 
Fgf10 is expressed in multiple but discrete regions of the postnatal and adult 
brain in a manner that is suggestive of a role in neurogenesis (Hajihosseini et al., 
2008, Haan and Hajihosseini, 2009). Importantly, expression of the FGFR2IIIb 
receptor is virtually absent (Hajihosseini et al., 2008) suggesting an alternative mode 
of function of FGF10. In previous chapters (see Chapter 4 & 5) it was shown that 
FGF10 can translocate into cell nucleus. In hypothalamus, expression of Fgf10 is 
limited to a cell population called tanycytes, which have now been shown to act as 
neural stem/progenitors (see Chapter 1), but the function of FGF10 in these cells is 
currently unclear. Therefore, this system may be used as a great tool to study non-
paracrine function of FGF10. Investigations in vivo are often difficult and require 
prolonged and costly studies (Rodriguez et al., 2005, Bolborea and Dale, 2013, 
Rojczyk-Golebiewska et al., 2014, Goodman and Hajihosseini, 2015).  This can be 
aided by cell culture assays but currently protocols for studies of neurogenic tanycytes 
in vitro are lacking. An in vitro system allows for easier genetic and chemical 
manipulation of cells. Currently, culture of ‘neurospheres’ is the most commonly used 
tool to study properties of neural stem cells in vitro.  
 
6.1.1 Overview of neurosphere forming assay  
 
Stem cells display two cardinal properties, which are the ability to undergo self-
renewal and the ability to differentiate into multiple tissue specific cell types. Therefore, 
adult stem cells serve crucial roles in maintaining tissue homeostasis and repair post 
injury. The discovery of adult neurogenesis, which is generation of new neurons in a 
postnatal brain (see Chapter 1), was shortly followed by in vitro studies of adult neural 
stem cells. The two well established niches of adult neurogenesis are sub-ventricular 
zone (SVZ) and sub-granular zone (SGZ). These are known to harbour stem cells 
shown to retain the capacity to self-renew over an extended period of time, proliferate 
and differentiate into three primary neural cell types, which are neurons, astrocytes, 
and oligodendrocytes (see Chapter 1). These neural stem cells (NSCs) were first 
cultured from an adult SVZ as cell suspension in non-adherent conditions, developed 
into a free-floating spheres, hence called ‘neurospheres’ (Reynolds and Weiss, 1992).  
Since these early studies the ‘neurosphere assay’ has evolved and became more 
refined and the culture was shown to possess all of the properties of neural stem cells, 
such as proliferation potential and ability to undergo multiple passages as well as 
multipotency defined by differentiation into the three neural cell types (Bez et al., 2003). 
Furthermore, neurospheres were shown to express Nestin, Musashi and Sox2 which 
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are markers of neural stem cells (Reynolds and Weiss, 1992, Singec et al., 2006, 
Sousa-Ferreira et al., 2011).  
 
6.1.2 Properties of neurospheres 
 
A neurosphere is presumed to arise from a single cell, which is derived from 
enzymatically dissociated embryonic or adult mammalian CNS tissue. Dissected and 
dissociated single cell suspension is seeded in a non-adherent container, in serum-
free medium and supplemented with EGF and FGF2 growth factors, maintaining their 
stem cell-like properties and facilitate proliferation (Chaichana et al., 2006). These 
single cells then are presumed to proliferate and give rise to clonal spherically shaped 
clusters of cells. As the cells continue to proliferate the sphere becomes larger and 
with greater diameter, that can be used to measure the growth rate of the culture 
(Ladiwala et al., 2012, Mori et al., 2006). However, the spheres do not form any 
nutrient transport network and as the sphere increases with diameter beyond 300-
400µm the cells within the centre loose contact with the nutrients available from the 
media and die (Xiong et al., 2011). This can be observed under light microscope as 
dark brown colour at the centre of the sphere is typically an indication of necrotic cells, 
whilst healthy cells display more translucent (Bez et al., 2003). Before they reach their 
overgrown stage, the neurospheres can be dissociated into single cell suspension and 
reseeded, which is referred to as a passage. Dissociated single cells will proliferate to 
form secondary neurospheres, and the number of times this event can be performed 
(i.e. the number of subsequent passages) is a reflection of propagation potential of the 
neurosphere culture (Xiong et al., 2011).  
Interestingly, it is typical that neurospheres derived from cells plated at the same 
time and under the same culture conditions differ in size and morphology, some 
showing regular and some irregular shapes. Moreover, cells present on the external 
layers of a neurosphere may occasionally display cytoplasmic processes resembling 
cilia or pseudopodia (Bez et al., 2003), which are used by the sphere to propel 
spontaneous locomotion and movement. Neurospheres have a tendency to aggregate 
together in a culture dish and adhere with each other in filopodia-mediated fashion 
(Ladiwala et al., 2012, Wang et al., 2006), showing that the culture is truly dynamic.   
The neurosphere culture system was shown sensitive to the culturing method 
used. The main variable presents cell density which affects culture proliferation, 
differentiation as well as sphere clonality properties. High density cultures due to 
secretion into the culture media intrinsic factors were shown to promote cell survival 
and maintaining proliferation. However, higher culture density results in higher levels 
of sphere aggregation and was shown to reduce sphere clonality (Wang et al., 2006, 
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Coles-Takabe et al., 2008). On the contrary, low cell density levels although promote 
clonality of the culture, reduces the cell survival rate. Variations in cell density were 
shown to alter the microenvironment of the culture, affecting the cell proliferation 
capacity and differentiation potential (Jensen and Parmar, 2006), therefore it is 
essential to culture the neurosphere assay at a constant density.  
 
  
Figure 6.1 Culture of neurospheres (A) Schematic to show the subsequent stages of 
the neurosphere assay derived from tissue dissected from central nervous system, 
such as adult mouse hypothalamus (B) Representative images of culture of 
neurospheres at the stage of single cell suspension and mature spheres of diameter 
~300µm; Scale bar 100µm.  
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6.1.3 Alternative systems of neural stem cell culture 
 
 The neurosphere culture was the first to in vitro system to culture stem cells 
derived from CNS. However, subsequent studies have generated alternative methods, 
which include simple adherent monolayers as well as three-dimensional Matrigel 
cultures. All hold their advantages and disadvantages, for example that monolayer 
culture allows ease of morphological and molecular characterization as well as 
analysis of lineage dynamics of individual cells, difficult to perform using the 
neurosphere assay (Babu et al., 2011, de Seranno et al., 2010). The Matrigel system, 
although expensive, is thought to provide powerful tool generating a proper 
microenvironment, mimicking the in vivo extracellular matrix structure (Pastrana et al., 
2011).  Yet, the neurosphere assay still remains the most commonly used tool to 
unequivocally demonstrate the presence of stem cells in the adult brain, allowing 





Although neurogenesis is now known to take place in the hypothalamus 
(Gould, 2007), and NSC derived from the hypothalamus have been successfully grown 
in vitro as neurospheres, little is known of the exact location of these stems cells within 
hypothalamus (Xu et al., 2005). There seem to be three opposing theories of the origin 
and positioning of the hypothalamic stem cells: one is that the NCS are located in a 
parenchyma; second theory relates the α-tanycytes as the putative stem cells, which 
then give rise to population of cells migrating to the median eminence (Robins et al., 
2013); thirdly, it is thought that the β-tanycytes are the true neural progenitors, which 
express Fgf10 and give rise to precursors that migrate up to the other parts of the 
hypothalamus (Hajihosseini et al., 2008, Haan et al., 2013).  
The purpose of this study is to attempt to decrypt the function of FGF10 in the 
hypothalamic cells and the neurogenic niche through in vitro systems:  
 Use of the well-established neurosphere assay system, to determine whether 
the Fgf10 expressing cells (and therefore β-tanycytes) show characteristics of 
stem cells 
 Compare the characteristics of Fgf10-expressing to the Fgf10-not expressing 
cells, indicating the function of FGF10 
 Establish and characterise a monolayer assay of hypothalamic primary cells as 
an additional tool to study the biology of Fgf10 expressing cells 
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Part 6.2 Neurospheres as a system to study Fgf10-expressing neural cells 
 
Neurospheres assay is an in vitro system, commonly used to study existence 
of NSC in particular areas of developing or adult mammalian central nervous system 
(CNS) (Ladiwala et al., 2012, Gil-Perotin et al., 2013). Neurospheres are generated 
from mitotically active cells, which form spheroid clusters when cultured as a 
suspension in a serum-free medium on a non-adhesive substrate and in the presence 
of EGF and FGF2. 
 
6.2.1 Fgf10-expressing hypothalamic cells can form neurospheres in vitro 
 
Neurosphere assays were cultured with a purpose to determine the stem cell-
like properties of hypothalamic tanycytes expressing Fgf10, in an in vitro cell culture 
system. The hypothalamus was micro-dissected from four wild type (WT) control and 
four Fgf10 reporter, the Fgf10+/CreERT2 ROSAtomato transgenic mice (herein referred to as 
Fgf10-tomato) at postnatal day 10 (see Chapter 2). Prior to dissection, the tomato-
reporter system was conditionally activated by treatment of mice at postnatal day 4 
and 5 (P4-5) with tamoxifen (txn). Thus tomato would become constitutively activated 
in Fgf10-expressing and their descendants (see Chapter 2 and Fig. 6.11A,B). After 
dissection, cells were dissociated and cultured in non-adhesive conditions, with the 
supplementation of growth factors. Cells were also isolated from the SVZ region, a 
well-established neurogenic niche but lacking Fgf10 expression (Gil-Perotin et al., 
2013, Hajihosseini et al., 2008), was used as a control for culture conditions enabling 
neurosphere growth.  
Under the culturing conditions (see Chapter 2) cells derived from the two 
dissected brain regions (the SVZ and the hypothalamus) formed neurospheres, 
regardless of the mouse genotype, either WT or Fgf10-tomato reporter (Fig. 6.2A,B). 
The presence of the tomato reporter was monitored regularly in the live cultures under 
a fluorescent microscope, where the red fluorescence was absent from the control 
groups corresponding to any cells derived from WT mice or Fgf10-tomato SVZ region. 
However, red fluorescence was seen in neurospheres originating from hypothalamus 
of Fgf10-tomato mice (Fig. 6.2A,B).  
Detection of the tomato reporter signifies the expression from the Fgf10 locus, 
meaning that fluorescently labelled hypothalamic neurospheres arose from the Fgf10 
lineage of the β-tanycytes (Haan et al., 2013, Hajihosseini et al., 2008), as post-mitotic 
neurons do not proliferate, therefore do not generate neurospheres. Absence of the 
fluorescence in the SVZ cultures showed that the expression of Fgf10 or its reporter 
was unlikely to occur spontaneously in vitro, after the dissection.  
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The neurosphere cultures were monitored daily through microscopic 
observations for their physical properties. Within a culture of neurospheres, colour of 
the sphere is an indicator of cell survival/ cell death, as a dark brown colour of the 
spheres signifies the cell death, whilst more translucent colour represents healthy cells 
(Bez et al., 2003). Morphologically no difference was observed between the Fgf10-
tomato hypothalamic neurospheres and the control neurospheres. Specifically, no 
difference was noticed in the shape of the spheres or their colour, and cultured 
neurospheres in all assays appeared mostly round, with clearly defined edges with 
light brown/translucent colour, turning darker in the middle as the spheres grew (Fig. 
6.2). Moreover, a minor proportion of neurospheres, occurring within each assays at 
comparable levels, underwent spontaneous differentiation through attaching to the 
bottom of the culture dish. Therefore, regardless of their origin, the neurospheres were 
maintaining at similar levels their stem cell-like characteristics in the in vitro culture. 
Interestingly, the Fgf10-tomato neurospheres on average were smaller in size, than 
neurospheres in the other assays (Fig. 6.2A), which was explored further in section 
6.2.2. 
Neurospheres, showed expression of neural stem cell markers, and importantly 
the Fgf10-tomato positive neurospheres expressed the Sox2 and Nestin markers (Fig. 
6.2C), providing further evidence that the Fgf10-expressing cells in vitro displayed the 
stem/progenitor cells characteristics.  
Interestingly, only approximately 20-30% of all neurospheres cultured from a 
Fgf10-tomato mouse hypothalamus were displaying tomato reporter, which was 
absent in the other spheres present within the same culture dish. This could be 
interpreted in two ways: (1) hypothalamus contains a mixed population of stem cells; 
or (2) a subset of cells turn off the expression of Fgf10/tomato in vitro. This issue was 
addressed further in the section 6.3.  
 
 



















Figure 6.2 Neurosphere assay shows hypothalamic Fgf10-reporter expressing cells 
show neurogenic potential. (A) Primary hypothalamic neurospheres derived from 
Fgf10-tomato mouse showed expression of the tomato fluorescence in contrast to 
tomato negative control spheres derived from wild type (WT) mouse; note that 
regardless equal time in culture the WT and SVZ neurospheres are larger in size than 
the hypothalamic Fgf10-tomato neurospheres; Scale bar 100µm. (B) The control 
spheres derived from SVZ did not express tomato fluorescence, regardless whether 
derived from WT or Fgf10-tomato mouse. (C) The tomato expressing neurospheres 
express also Sox2 – a marker of stem cells; Scale bar 100µm.  
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6.2.2 Analysis of growth rate discrepancies of the hypothalamic neurospheres 
derived from the Fgf10-tomato and WT mice 
 
A defining characteristic of neural stem cells is their ability to self-propagate. 
Accordingly, neurospheres can be passaged with cells still retaining their molecular 
characteristics and multipotency after each passage. Hypothalamic neurospheres 
have been previously shown to retain all of the properties of the stem cells, including 
their propagation potential, in a similar fashion to the neurospheres derived from SVZ 
(Sousa-Ferreira et al., 2011, Cortes-Campos et al., 2015, Haan and Hajihosseini, 
2009). However, the stem cell properties of neurospheres are known to decline with 
the number of passages, and their propagation potential is limited (Jensen and 
Parmar, 2006, Xiong et al., 2011). Propagation potential of neurospheres was shown 
to be directly proportional to the seeding cell density and higher seeding densities 
provide better propagation sustainability. On the contrary, lower seeding densities 
prevent spheres from merging (see Fig. 6.6 and section 6.2.4) allowing “clonal cluster” 
studies (Jensen and Parmar, 2006, Bez et al., 2003).  
To determine whether Fgf10-expressing neurospheres have different passage 
potential from non-Fgf10-expressing neurospheres, the Fgf10-tomato positive 
neurospheres as well as the control assays, were taken through several passages. 
Moreover, the spheres’ growth rate was measured and compared. Briefly, once the 
spheroid cultures reached their maximum size of ~300µm in diameter, they were 
dissociated into single cells, that gave rise to new neurospheres. Seeding these single 
cells at a low density (of 5x102  cells/ml), in new culture dish was defined as a passage 
(see Chapter 2). 
Neurospheres, derived from WT and Fgf10-tomato mice, from SVZ and 
hypothalamus, were passaged a maximum of 3 – 5 times before their propagation 
potential was exhausted and cells stopped proliferating (Fig. 6.3). The passaged 
neurospheres did not vary in their morphology, regardless of their origin and number of 
passages. On average, the spheres were darker in colour in the centre and the outer 
portion was bright and translucent with light, with easy to distinguish round healthy 
cells.  
To determine whether hypothalamic Fgf10-tomato expressing neurospheres 
differ in their propagation potential from the controls, the neurosphere growth rate was 
measured during each passage and calculated as percent of the sphere growth per 
day. The growth rate was calculated by measuring per day an increase in sphere 
diameter and therefore overall sphere size, generated from increase of cell number 
(see Chapter 2). The primary (i.e. post seeding) WT hypothalamic neurospheres had a 
very fast growth rate of 58% increase in size/day, which was approximately three 
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times faster than neurospheres derived from hypothalamus Fgf10-tomato mice, which 
showed only 21% increase/day; and twice as fast as the neurospheres derived from 
SVZ region with 31% increase/day (Fig. 6.3). Nonetheless, this difference in growth 
rate was not observed after subsequent passages and further investigation would be 
required to determine the significance of this observation. In general, there was little 
variation in the percent of growth rate of the control neurospheres: derived from WT 
hypothalamus, WT SVZ as well as Fgf10-tomato SVZ (Fig. 6.3). However, the 
neurospheres obtained from the hypothalamus of the Fgf10-tomato mice on average, 
after each passage, showed slower growth rate in comparison to control neurospheres 
(Fig. 6.3), suggesting that hypothalamic Fgf10-tomato positive cell did not proliferate at 
the same rate as cells derived from control assays. Moreover neurospheres derived 
from the Fgf10-tomato mice could not be passaged to the same extent (number of 
passages) as the neurospheres obtained from WT mice (Fig. 6.3 and observation from 
pilot experiments).  
As a knock-in creERT2 allele, the Fgf10-tomato reporter mouse is technically 
heterozygous for Fgf10, which generates reduced levels of FGF10 comparing to WT 
(see Chapter 2) (El Agha et al., 2012). This could have caused developmental 
problems with associated knock-off effects present later in the adult, and therefore 
could have resulted in the observed reduction of neurosphere proliferation potential. 
This experiment would require several repetition and statistical validation, although it 
has clearly demonstrated that primary hypothalamic neurospheres derived from Fgf10-
expressing cells can be passaged successfully, displaying self-propagation potential.    
  











6.2.3 Analysis of the multipotency of the Fgf10-expressing hypothalamic 
neurospheres 
 
Adult NSC, in vivo and in vitro are able to give rise to differentiated cells of all 
three neural cell types (neurons, astrocytes and oligodendrocytes), which is defined as 
multipotency (Cortés-Campos et al., 2015). However, it is unclear whether expression 
of Fgf10 affects the differentiation potential of hypothalamic neurospheres in vitro, 
therefore tomato-expressing neurospheres, alongside with the controls, were induced 
to differentiate. Neurospheres derived from WT and Fgf10-tomato mice, from SVZ and 
hypothalamus, were dissociated and seeded on PDL coated glass coverslips, which 
provided an adhesive substrate promoting differentiation. Differentiating cultures were 
further stimulated by a withdrawal of growth factors and addition of serum to the 
culture media, as described in literature (Sousa-Ferreira et al., 2011) (see Chapter 2). 
Under these culture conditions, the control SVZ and the hypothalamic 
neurospheres differentiated into all three neural cell types, regardless of their genotype 
of origin - WT or Fgf10-tomato. Cell type composition of differentiated neurospheres 
was revealed using a combination of neural cell-type-specific antibodies. The 
differentiated cells showed expression of the neuronal class III β-tubulin (Tuj1) protein, 





































Figure 6.3 Propagation potential of neurosphere assays, determined by the number 
of passages each assay was able to sustain and growth rate of the neurospheres 
measured between the passages, shows that hypothalamic neurospheres expressing 
tomato reporter had a lower propagation potential than the control spheres. Error bars 
– SE.  
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marker of astrocytes, and the oligodendrocyte transcription factor (Olig2) protein, 
marker of oligodendrocytes (Fig. 6.4A,B). Furthermore, the neurospheres still retained 
their potential to differentiate after 3 to 4 passages, which corresponds to the findings 
presented in literature (Sousa-Ferreira et al., 2011, Cortes-Campos et al., 2015). 
Importantly, the cells derived specifically from Fgf10-tomato hypothalamus 
(and expressing the tomato reporter) differentiated into neurons, astrocytes and 
oligodendrocytes, co-labelling with the lineage specific markers Tuj1, GFAP and Olig2 
respectively (Fig. 6.4C). Therefore, these results show that hypothalamus derived cells 
marked by Fgf10 expression were multipotent neural stem cells, displaying similar 









Figure 6.4 Neurosphere assays demonstrate multipotency by differentiating into 
neurons (Tuj1), astrocytes (GFAP) and oligodendrocytes (Olig2). (A) Differentiated 
neurospheres derived from hypothalamus of WT and Fgf10-tomato mice. (B) All three 
neural cell types differentiate from SVZ of WT and Fgf10-tomato mice. (C) The Fgf10-
tomato hypothalamic cells expressing tomato differentiate into all three types of neural 
stem cells. Scale bar 50µm, (C) bottom panels 20µm; representative images of cells 
differentiated after passage 1 and 2. 
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6.2.4 General caveats and limitations of the neurosphere assays 
 
The neurosphere assay is commonly used as a litmus test for existence of 
neural stem cells in the tissue/brain region from which the cells were derived (Bez et 
al., 2003, Jensen and Parmar, 2006, Chaichana et al., 2006, Desai et al., 2011). 
However, this assay has several limitations that make it unsuitable for progressive 
characterisation and studies of the role of FGF10 in hypothalamic stem cells. 
A culture of hypothalamic neurospheres derived from Fgf10-tomato reporter 
mice results in a heterogeneous population of tomato expressing and tomato negative 
spheres. The cell clusters can migrate around in the cell suspension and when 
encounter another neurosphere they show tendency to merge together (Fig. 6.6A) – a 
phenomenon that is already described in literature (Coles-Takabe et al., 2008, 
Ladiwala et al., 2012, Singec et al., 2006). Merging of the neurospheres is directly 
proportional to the cell culture density, and the higher the cell density the higher 
number of merging events takes place. On the contrary, the low cell density is linked to 
low cell survival rate (Reynolds and Weiss, 1996b, Coles-Takabe et al., 2008, 
Pastrana et al., 2011), resulting in a trade-off between maintaining cell survival and 
reducing merging events. Although, assays presented here were cultured under low/ 
semi-clonal cell density, merging of the spheres was unavoidable (Fig. 6.6A). Merging 
of tomato positive neurospheres with the tomato negative as well as decreasing the 
cell survival rate at low cell density, was thought to prevent reliable in vitro studies of 
FGF10 function in hypothalamic stem cells.  
To circumvent the problem of heterogeneity in hypothalamic reporter negative 
and positive neurospheres, attempts were made to isolate tomato expressing from the 
tomato negative cells, through fluorescence-activated cell sorting (FACS). However, 
for several reasons, this proved unsuccessful: (i) very low number of cells expressed 
the tomato reporter (1.49% of total) vs the non-fluorescent cells (remaining 98.51%) 
(Fig. 6.5B), resulting in a very high noise-to-signal ratio (Donnenberg and Donnenberg, 
2007); and (ii) poor survival rate of sorted cells, due to low final density of the tomato 
positive cells. The FACS has been attempted on 3 separate occasions (performed with 
consultations of experienced scientists) each time providing the same results. Non-
pure population of Fgf10-tomato expressing culture, merging together made the 











Figure 6.5 Representative data of identification and separation by FACS tomato 
fluorescence expressing hypothalamic cells. (A) Control hypothalamic cells not 
expressing tomato contained healthy cells of appropriate size (‘A’ and ‘B’ channels) but 
showed no detection (‘C’ channel ) of ‘tomato’ sorted cells, as determined by the 
Forward (FSC) and Back (BSC) scatters and channel selecting for red Phycoerythrin 
(PE) fluorescence. (B) Tomato expressing cells were successfully detected and sorted 
from the Fgf10-tomato hypothalamic extract, but the sorted number of cells was too low 
for them to survive subsequent culturing.  
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Neurospheres in general, are also prone to attaching to the bottom of the 
culture dish, which leads to their spontaneous differentiation and cell-migration, even 
when cultured in non-adhesive containers in stem-cell promoting conditions. This 
spontaneous differentiation is thought to be directly related to cell culture density and 
therefore, the higher the cell density the greater the levels of spontaneous 
differentiation observed (Viktorov et al., 2007, Pastrana et al., 2011). In the studies 
performed here, through daily observations of the culture container under a light 
microscope, the differentiation was noticed in a similar proportion in all of the tested 
assays – regardless of the mouse genotype (transgenic or WT) or origin of derived 
cells (hypothalamus or SVZ) (Fig. 6.6A). Nonetheless, spontaneous differentiation of 
tomato positive cells, that in their natural in vivo conditions would retain their stem-cell 
potential, might affect the readout of the in vitro obtained results (Fig. 6.6B).  
Although neurospheres are commonly used to study the NSC in vitro, the 
numerous limitations of this cell culture collectively have made it unsuitable for the 
studies of FGF10 function within hypothalamic stem cells. Nonetheless, data shown 
here confirms that hypothalamic tomato positive cells can be cultured as neurospheres 










  Figure 6.6 Examples of come neurosphere culture limitations. (A) Cultured 
neurospheres can spontaneously merge together and differentiate by attaching to 
the bottom of a culture dish. (B) Tomato expressing cells have been found 
attached to the culture dish, which could either undergo differentiation or be lost 
during passaging of the culture, not representing ideal experimental conditions. 
Scale bar 100µm. 
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Part 6.3 In vitro characterisation of the hypothalamic Fgf10 expressing cells 
cultured as a monolayer 
 
The neurosphere assay was the first in vitro system to culture the NSC and is 
still commonly used to study processes taking place during neurogenesis, for example 
to study the effects of Zika virus infection on brain development (Garcez et al., 2016), 
or analysis of effects of magnesium on NSC proliferation (Jia et al., 2016).  
Due to the unsuitability of neurospheres for clonal analysis, studies switched to 
the establishment of a monolayer cultures system, which has the advantage of fully 
exposing cells to a controlled extracellular environment as well as clear assessment of 
the morphology of individual cells, used for example, to study functionality of mouse 
dentate gyrus granule cell-like newly generated neurons (Babu et al., 2007). 
Therefore, in order to study function of FGF10 in tanycytes, a monolayer culture of 
tanycytes has been generated. Moreover, attempts have been made to characterise 
the stem-cell properties of the Fgf10 expressing cells.   
 
6.3.1 Fgf10-LacZ positive primary hypothalamic cells proliferate and propagate 
as a monolayer culture in vitro 
 
The cultures of primary hypothalamic neurospheres (section 6.2) derived from 
Fgf10-tomato mice, displayed a mixed population of tomato expressing and tomato 
negative spheres. To determine whether the cells were derived from a heterogeneous 
population of stem cells within the hypothalamus, they were isolated from an adult 30-
day old (P30) Fgf10nLacZ/+ transgenic mice (herein called Fgf10-LacZ) and cultured as a 
monolayer. The Fgf10-LacZ reporter marks cells expressing Fgf10, due to 
incorporated LacZ gene 114kb upstream of Fgf10 translational start site, generating a 
nuclearly targeted  β-galactosidase (β-gal) product (see Chapter 2). 
Hypothalamic cells from Fgf10-LacZ reporter mice were obtained using similar 
protocols for establishment of neurospheres. Briefly, hypothalamic median eminence 
was micro-dissected, dissociated into single cells and seeded at semi-clonal density of 
approximately 5x102 cells/ml on PDL coated dishes (providing the cells with an 
adhesive substrate). Proliferating cells were observed 2-3 days post seeding, which 
began forming ‘clonal patches’, i.e. groups of various numbers of cells propagating in a 
close proximity, as tight clusters (Fig. 6.7A). After 7 days cells were observed within 
patches ranging in size from two to hundreds of cells; individual cells were rarely 
observed.  
Fgf10-LacZ reporter-positive colonies were revealed by incubation in X-gal 
solution, which generated a blue nuclear staining in cells expressing the LacZ gene 
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(see Chapter 2) (Fig. 6.7A). The β-gal shows high stability in mammalian cells and is 
not degraded easily (Lee et al., 2006) therefore, the presence of β-gal was not treated 
as a direct readout of the expression on Fgf10 in a culture.  
Importantly, β-gal most likely marked any cells that have had either in vitro or in 
vivo expressed Fgf10, regardless whether the gene expression was turned off at later 
stages of the cell life (Fig. 6.11). Therefore, the observed LacZ+ cells represent Fgf10-
expressing hypothalamic tanycytes and/or their descendants. As with neurosphere 
Fgf10-tomato cultures, the clonal patches of monolayer culture derived from Fgf10-
LacZ reporter hypothalamus showed heterogeneity with respect to lacZ-staining (β-gal 
expression) (Fig. 6.7A). Absence of β-gal signifies that these cells have not expressed 
Fgf10 either in vivo or in vitro.  
Importantly, looking at the number of cells derived from young adult mouse 
hypothalamus, on average the LacZ+ number contributed to 36% of total cultured 
cells, which was nearly half as many as LacZ negative numbers (61.3%) (ANOVA 
p=0.000; post hoc Tukey HSD p=0.000) (Fig. 6.7B). This observed difference in the 
number of LacZ+ and LacZ- cells, as well as the difference in the total number of 
patches, suggests that within the hypothalamus there potentially was a heterogeneous 
population of mitotically active cells – one expressing Fgf10 and one that did not 
express Fgf10. Within the monolayer cultures a very small proportion (2.7%) of total 
cell patches contained a mixture of β-gal positive and negative cells (Fig. 6.7B). 
Possibly, this arose from random seeding of two or more progenitor cells in close 
proximity of each other during the plating process.  
From microscopic inspection of the cell shape and size it was concluded that 
morphologically there was no observable difference between the cells expressing the 
LacZ reporter or not. Interestingly, a close inspection under a microscope of the X-gal 
stained culture revealed that pairs of LacZ positive (LacZ+) as well as negative (LacZ-) 
cells were often observed indicating recent cell division (Fig. 6.7A), and demonstrating 
that the culture was mitotically active. Moreover, some cells appeared migratory, which 


















The monolayer cultures yielded significantly less LacZ+ than LacZ- cell 
patches, which could possibly result from a lower number of LacZ+ cells present at 
seeding, meaning that in vivo there are less LacZ+ than LacZ- cells with a potential to 
proliferate. Alternatively expression of Fgf10 (as marked by the presence of the 
reporter) could have decreased the plating efficiency of the cells and/or reduced their 
survival rate. Another plausible explanation is that Fgf10 expression affects cell 
division and proliferation, detaining the cell cycle, or that Fgf10-expressing population 
Figure 6.7 Hypothalamic cells were successfully cultured as proliferative monolayer 
of Fgf10-LacZ expressing and Fgf10-LacZ non-expressing cells. (A) Examples of 
pairs of LacZ-positive cells indicative of cell division generating cell clusters; note the 
presence of Fgf10-LacZ negative cells in the middle panel; scale bar 100µm. (B) 
Percent quantification of LacZ negative and LacZ positive number of patches of the 
total present within a culture suggests existence of a a heterogeneous population of 
proliferative cells (ANOVA p=0.000, n=22). (C) Number of cultured patches changes 
according to the age of a mouse, where the cells are originally derived from (T-test 
p≤0.01; Kruskal-Wallis, Chi-Square p<0.05). Error bars – SE. 
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survival is reduced under these particular culture conditions. This observed difference 
between numbers of LacZ+ and LacZ- cell patches may possibly be linked to the 
function of FGF10 in the hypothalamic neurogenesis, which was explored further in 
subsequent sections.  
 
6.3.2 Differential proliferation of hypothalamic cells in cultures of postnatal vs 
young adult mice 
 
The process of neurogenesis continues postnatally in SVZ and hippocampus, 
but slowly declines with age (Kuhn et al., 1996, Urban and Guillemot, 2014, Abrous et 
al., 2005). Similarly, in the adult hypothalamus the number of proliferating and 
importantly, the number of Fgf10-expressing cells decreases with the age of a mouse 
(Haan et al., 2013). Therefore, it was investigated, whether primary hypothalamic cells 
derived from mice at early postnatal age (P8) have a different propagation potential 
(cultured in vitro) to cells derived from young adult mice (P30 and P40) and whether 
increasing age influences the number of Fgf10-expressing cells cultured in vitro.  
For this, the median eminence from hypothalamus was micro-dissected from 
mice at age P8 (n=3), P30 (n=10) and P40 (n=9), dissociated, seeded and cultured on 
an adhesive substrate in the same fashion as previously described (also see Chapter 
2). Number of assay repeats corresponded to number of mice and hypothalamic 
extracts dissected. Then cells obtained from a single hypothalamus were seeded 
across 3 wells of 24-well plate, cultured for 7 days, fixed and stained with X-gal as 
described above. Cells cultured from the P8 mouse gave rise to significantly greater 
total number of patches (both LacZ+ and LacZ-) than cells cultured from the young 
adult mice (either P30 or P40) (Fig. 6.7C). The number of LacZ negative patches was 
about three times greater at age P8 (91) comparing to P30 (23) or P40 (27) (Kruskal-
Wallis, Chi-Square p=0.039, post hoc Mann-Whitney Test p=0.018; p=0.033). 
Moreover, the total number of LacZ positive patches at age P8 (29) was significantly 
higher comparing to age P30 (11) and P40 (11) (Kruskal-Wallis, Chi-Square p=0.023, 
post hoc Mann-Whitney p=0.011; p=0.012). However, there was no significant 
difference in the number of observed patches between the P30 and P40 (Fig. 6.7C). 
Therefore, the results suggest that in vitro, the proliferation potential of both Fgf10-
expressing and Fgf10-non expressing cells, is greater at early postnatal stages (P8) 
than at the later mouse ages (P30 and P40), which corresponds to the observations 
made in vivo (Haan et al., 2013).  
Interestingly, at P8 (but not at the later ages) there were significantly fewer 
patches of LacZ+ cells than LacZ- (Ttest p=0.0133) (Fig. 6.7C). This could suggest 
that at P8, LacZ- cells have either higher proliferation or survival potential than LacZ+ 
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(Fgf10-expressing) cells, which is lost over time. This intriguing observation was 
further scrutinised in subsequent section.  
 
6.3.3 Analysis of the age-related decline of Fgf10-expressing and not-expressing 
cells  
 
Patches of hypothalamic cells, cultured from mice at age P8, P30 and P40 
varied in size and hence were classified in three categories according to the number of 
cells present within the patch: small patch (1-5 cells), medium patch (6-50 cells) and 
large patch (51 and above) (Fig. 6.8). The cells were seeded at a semi-clonal density 
therefore, it was assumed that the individual patches resulted from clonal propagation 
of individual stem cells and were indication of stem cell proliferation rate, i.e. the larger 
the patch, the greater the proliferation potential of the cells within.  
To determine differences between LacZ+ and LacZ- cell proliferation potential, 









In P8-derived cultures there was significantly greater number of small LacZ+ 
than LacZ- patches (T-test p=0.004) and there was no significant variation in the 
middle sized patches (T-test p=0.09), whereas there were excessively more large 
Figure 6.8 Representative images of small, medium and large patches formed by 
the clonal expansion of primary hypothalamic cells. Patches were either Fgf10-LacZ 
positive or Fgf10-LacZ negative. 
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LacZ- than LacZ+ patches (T-test p=0.007) (Fig. 6.9A). This suggests that the LacZ- 
cells proliferated very quickly and gave rise to a very high number of cells and very 
large patches. By contrast, the LacZ+ cells proliferated at much slower rate and did not 
give rise to the patches to the same extent as the LacZ- cells. Therefore, potentially 
P8-derived LacZ- cells proliferate more rapidly with greater propagation potential than 
LacZ+ cells. Alternatively the survival of the LacZ+ cells was compromised, perhaps 
due to expression and function of Fgf10.  
The variation in number of small, medium and large patches was less prominent in 
cultures derived from mice age P30 and P40 (Fig. 6.9A). There was no significant 
difference in the number of small patches of the LacZ- and the LacZ+ cells (T-test 
p=0.55; 0.62). There was also little variation in the number of LacZ- and LacZ+ 
medium sized patches at the age of P30 (T-test p=0.01) but not at the age of P40 (T-
test p=0.19). At both ages there were few large patches but there was no significant 
difference between the number of LacZ- and LacZ+ cells (T-test p=0.08; 0.13). It 
therefore appears that at the later mouse ages (P30 and P40) there was little 
difference between the proliferation potential of the LacZ negative and LacZ positive 
cells (Fig. 6.9A). 
To determine whether the number of small, medium and large patches of the 
LacZ- and LacZ+ cells changes with the age of a mouse they were derived from, the 
data was compared across the three age groups – P8, P30 and P40. A small variation 
in the number of small LacZ negative patches was observed (Kruskal-Wallis, Chi-
Square p=0.034, post hoc Mann-Whitney Test p=0.084; p=0.019), but no significant 
variation in the LacZ positive small patches was noted (Kruskal-Wallis, Chi-Square 
p=0.26) (Fig. 6.9B). Moreover, the number of medium sized patches found (both 
LacZ+ and LacZ-) decreased with the age of the mouse. 
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Figure 6.9A Primary hypothalamic cells show a different proliferative potential, 
depending on the age of a mouse that they are derived from – comparison of the 
patch sizes within each age group (T-test p≤0.05; Kruskal-Wallis, Chi-Square 
p≤0.05; P8 n=3, P30 n=10, P40 n=9). Error bars – SE. 
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Figure 6.9B Primary hypothalamic cells show a different proliferative potential, 
depending on the age of a mouse that they are derived from, data reformatted to 
show comparison of patch sizes between different mouse ages (T-test p≤0.05; 
Kruskal-Wallis, Chi-Square p≤0.05; P8 n=3, P30 n=10, P40 n=9). Error bars – SE. 
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Interestingly, the most significant difference was seen regarding the large 
patches, showing a high reduction in the number of large LacZ- patches at the P8 
comparing to P30 and P40 (Kruskal-Wallis, Chi-Square p=0.024, post hoc Mann-
Whitney Test p=0.010; p=0.015). On the contrary, the number of large LacZ+ patches 
did not statistically vary between the different age groups (Kruskal-Wallis, Chi-Square 
p=0.284), however there were consistently fewer in number than the LacZ- (Fig. 6.9B). 
Together these results suggest that the proliferation potential of the LacZ- cells was 
significantly affected by the age of the mouse from which they were derived from, 
whereas, in comparison, the proliferation potential of the LacZ+ cells was not severely 
affected by the age of the mouse, although they did not at any point, proliferate at the 
same high rate as the LacZ- cells. 
 
6.3.4 Analysis of cell division rate of hypothalamic monolayers 
  
 Generation of clonal cell patches is a likely result of a combination of rate and 
mode of cell division in relation to the survival of the precursor cells, as well as 
differentiation and survival of the progeny. Two possibilities of cell division can 
potentially take place: (i) cells divide symmetrically and are constantly adding two 
mitotic cells to the pool of precursors, if both daughters remain proliferative, or 
generate a pair of differentiated cells, such as neurons; or (ii) alternatively cells 
undergo asymmetric division and produce at each division one mitotically active 
precursor and one post-mitotic progeny, such as neuron. A combination of both can 
also occur within a culture. In a culture of primary hypothalamic monolayer there was a 
range of patch sizes, from small to large, indicative of not equal rate of cell division 
across the patches. The average mammalian cell cycle was estimated to last 
approximately 24h (Li et al., 2012b). However, some types of cells, such as crypt cells 
in the intestinal epithelium can proliferate as fast as every 9-10h (Al-Dewachi et al., 
1979) and embryonic cells are known to divide in less than 2h, skipping the growth 
phases (Ciemerych et al., 1999).  
 Small patches observed that comprised of 1 to 5 cells, whether expressing 
Fgf10 or not, could have arisen through the death and subsequent loss of the siblings. 
Alternatively, slow dividing precursors, with putative cell cycle greater than 24h, 
undergoing an asymmetric division, over the period of 7 days would generate the 
maximum of seven cells. Another possibility is that the cells have divided 
symmetrically but gave rise to two differentiated and post mitotic daughter cells, which 
rarely were visible in the culture. Most likely, a combination of all of these events could 
have taken place to give rise to very small patches. Numbers of these small patches 
were comparable at all ages, regardless of the expression of Fgf10 (Fig. 6.9A,B), 
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therefore it might be assumed that typically 10% or less of the cultured cells displayed 
such a behaviour.  
 While not able to fully confirm asymmetric division of the small clones, it was 
assumed that clones larger than 50 cells were an evidence for symmetrical division. 
The propagation potential of the LacZ negative cells was greater than the LacZ 
positive, regardless of the mouse age (Fig. 6.9C). The numbers of cells within the 
large LacZ negative patches often considerably exceeded 51 cells and were frequently 
greater than several hundred, even at the age of P40. Potentially these cells have a 
very fast division rate of several hours, or alternatively have arisen from several 
patches proliferating in a close proximity generating one patch. Therefore the earlier 
described comparison of number of patches (see section 6.3.2 and 6.3.3), rather than 
number of cells within a patch was a good indicator of the proliferation potential of 
these cells. 
On the contrary, large patches of the LacZ positive cells did not exceed 
400cells/patch. Therefore in order to determine, whether the propagation potential of 
LacZ positive cells decreased with the age of a mouse, the growth rate of the LacZ 
positive cells derived from the three mouse ages – P8, P30 and P40 was estimated 
and compared. Due to seeding at semi-clonal densities it was assumed that each 
patch was a clonal expansion of a single cells, dividing symmetrically (as NSC) in an 
exponential fashion. Therefore, from each assay (post fixing and staining with X-gal) 
three biggest patches of LacZ positive cells per culture were selected, number of cells 
within was counted and averaged, in order to determine the maximum possible 
proliferation potential of the given culture measuring the exponential growth rate (%) 
(see Chapter 2). At the P8 (n=3, where ‘n’ is the number of mice used), the growth rate 
of 72% was the greatest (Kruskal-Wallis, Chi-Square p=0.021, post hoc Mann-Whitney 
Test p=0.018; p=0.079) whereas, at the age of P30 (n=10) and P40 (n=9) the growth 
rates of 41% and 53% respectively, were closely comparable to each other and 
statistically not significantly different (post hoc Mann-Whitney Test p=0.079) (Fig. 
6.10). Therefore, the growth rate potential, which signifies the proliferation potential of 
the LacZ+ cells derived from young adult mouse (P30/40) is closely comparable to the 
early postnatal mouse (P8), suggesting that the age of the propagation potential of 
LacZ+ (Fgf10 expressing) cells correlates with the age of a mouse.  
 
 









6.3.5 Examination of the Fgf10 expression of the hypothalamic cells cultured in 
vitro  
 
Cultures of cells in vitro are used to reflect and study processes occurring in vivo, 
Cultures of cells in vitro are used to reflect and study processes occurring in vivo, but 
the primary cells may change in culture their molecular content and differentially 
regulate their gene expression (Ming and Song, 2005). The β-gal product of the Fgf10-
LacZ reporter showed high stability in a culture of mammalian cells (Lee et al., 2006). 
Therefore, LacZ reporter marked indiscriminately cells that have either expressed Fg10 
(in vivo or in vitro) or were derived from cells expressing Fgf10, but did not express it 
themselves (Fig. 6.11B).  
In order to determine whether the cultured Fgf10-reporter expressing cells 
were in fact derived from the adult hypothalamic Fgf10 expressing β-tanycytes 
(Hajihosseini et al., 2008), Fgf10CreERT2/ROSAtomato (Fgf10-tomato) (see section 6.2) 
reporter mice were induced with tamoxifen in vivo and cells were harvested from their 
hypothalamus a week later. This conditional reporter system allows time specific 
induction of the tomato reporter protein and therefore marked cells that expressed 
Fgf10 in the adult mouse hypothalamus (see Chapter 2) (Fig. 6.11A,B). Cells derived 
from Fgf10-tomato mice (age approximately P20-P30) were cultured in similar fashion 
to the earlier described Fgf10-LacZ cells (Fig. 6.11B). The tomato fluorescence 
expressing the reporter was detected in live cells under a fluorescent microscope and 
Figure 6.10 Growth rate of the LacZ-positive patches is closely comparable across 
young and older mouse ages. Note that there is no statistical difference between 
growth rate (proliferation potential) of LacZ-positive cell patches at age P8 and P40 
(Kruskal-Wallis, Chi-Square p≤0.05; P8 n=3, P30 n=10, P40 n=9). Error bars – SE. 
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the cultured cells were allowed to proliferate to confluency. Tomato-expressing cells 
were observed, proliferating in small patches, similarly to results obtained with Fgf10-
LacZ reporter (Fig. 6.11C). Unfortunately these cultures presented survival problems 
and could not be seeded under semi-clonal densities, therefore the numbers of 
tomato-positive cells could not be directly compared to the Fgf10-LacZ data. The 
Fgf10-tomato reporter mouse is Fgf10 heterozygote (see Chapter 2) with reduced 
levels of Fgf10, that could affect the development of the hypothalamus and result in a 
poor survival rate of Fgf10-tomato cells in vitro. Nonetheless the results show that the 
cultured cells are derived from adult hypothalamic Fgf10-expressing cells.  
Interestingly, the micrograph images revealed that only few cells within a patch 
were expressing tomato fluorescence (Fig. 6.11C). This suggests that the remaining 
cells within the patch were derived from the Fgf10-non expressing lineage, due to high 
seeding density. It is likely that a proportion of Fgf10-tomato expressing cells had 
lower survival rate than the Fgf10-tomato negative cells, due to either reduced level of 
Fgf10 expression or other (unknown) endogenous function of Fgf10. This could be 
measured in the future, by potential daily monitoring the cell death of cultured colonies.  
The remaining issue was to determine whether Fgf10 continues to be expressed 
in vitro in culture derived from the hypothalamus or whether cells spontaneously turn 
off the gene expression post dissection (Fig. 6.11A,B). The hypothalamus was 
dissected out from tamoxifen non-induced Fgf10-tomato reporter mice (age P44), and 
its cells were seeded, allowed to adhere and proliferate for approximately 3 to 4 days. 
When medium sized patches had developed (~6 to 50 cells/patch), the cultures were 
pulsed with tamoxifen in vitro (see Chapter 2), to trigger the tomato expression and 
test for expression the Fgf10 reporter (Fig. 6.11A), generating a novel in vitro-inducible 
Fgf10-tomato reporter system. Subsequently, the cultures were allowed to proliferate 
to confluency and tomato fluorescence was detected in live cells under fluorescent 
microscope. Several small cell groups were observed to express the tomato reporter. 
This culture also presented cell survival issues and had to be cultured under high cell 
density conditions therefore the number of cells could not be directly compared to 
Fgf10-LacZ reporter data. Importantly, this in vitro inducible system provided an 
unique tool to study Fgf10 expressing cells and showed that a proportion of cells was 
maintaining the expression the Fgf10 under the given culture conditions.  
Collectively the results show that cultured hypothalamic cells were derived from 
adult Fgf10-expressing β-tanycytes and that cultured cells were capable of maintaining 









Figure 6.11 Fgf10-reporters show Fgf10 in vitro and in vivo. (A) Schematic diagram 
of the inducible Fgf10-tomato system, where Cre-ERT2 produced in Fgf10 
expressing cells is retained in cell cytoplasm until treatment with tamoxifen, that 
allows the nuclear incorporation of the complex, which binds to the loxP sites 
removing the STOP cassette and permits the tomato transcription. (B) Schematic of 
the time points at which specific Fgf10-reporters mark the Fgf10-expressing cells; 
note that Fgf10-tomato can be induced both in vivo and in vitro. (C) Primary 
hypothalamic cells expressing tomato fluorescence were cultured as monolayer in 
vitro; note that Fgf10-tomato system was induced in vitro demonstrating that cells do 
not turn off Fgf10-expression in the culture and are derived from hypothalamic β-
tanycytes; Scale bar 100µm.  
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6.3.6 Characterisation of expression of cell markers in monolayer cultures of 
hypothalamus 
 
Primary hypothalamic cells cultured as monolayers propagate in vitro, 
regardless whether they express Fgf10 or not. Although self-propagation is one of the 
properties displayed by the stem cells, it is also a feature of trans-amplifying cell 
progenitors (see Chapter 1) (Fig. 1.12 & 1.13). In order to further define the 
characteristics of cultured hypothalamic cells, the semi-clonal patches derived from 
Fgf10-reporter adult mice, were assessed for expression of markers of stem cells 
Sox2 and Nestin, as well as marker of cell progenitors, NG2, and marker of radial glial 
cells, BLBP. Simultaneously, it was investigated whether the Fgf10-expressing and 
non-expressing cells differ in their expression of these markers. 
The SRY (sex determining region Y)-box 2 (Sox2) is a transcription factor 
found in the cell nucleus. During embryonic neurogenesis, Sox2 is expressed 
throughout development of the neural tube and in proliferating CNS progenitors. It is 
essential for maintaining self-renewal and pluripotency of stem cells and it is 
downregulated during the process of cell differentiation (Graham et al., 2003b). 
Therefore, Sox2 is regarded as one of the markers of undifferentiated stem cells. A 
majority of cells within each of the Fgf10 reporter positive and negative patches 
expressed the Sox2 marker (Fig. 6.12A), regardless of the age of a mouse from which 
the cells originated (range from P8-P40).  
Another well-known marker of NSC is the intermediate filament protein called 
Nestin (Fig. 1.12 & 1.13). It is present in dividing and undifferentiated neural cells and 
becomes downregulated during the process of differentiation (Michalczyk and Ziman, 
2005). Nestin is known to mark mitotic neural cells and it is also involved in dynamic 
and highly proliferating cells. A subpopulation of Fgf10 reporter positive and negative 
cells showed expression of Nestin (Fig. 6.12B).  
The Fgf10 expressing and non-expressing populations of hypothalamic cells 
cultured in vitro differed with respect to the brain lipid binding protein (BLBP). BLBP is 
considered a marker of radial glial cells (von Bohlen und Halbach, 2011), involved in 
the process of cell migration of immature neurons in developing central nervous 
system as well as signaling pathway that lead to differentiation of neurons (Schmid et 
al., 2006), neural precursors (Anthony et al., 2004) and immature neurons (Feng et al., 
1994, Retrosi et al., 2011). Numerous Fgf10-tomato negative cells expressed BLBP, 
which was not detected in the tomato positive cells (Fig. 6.12E). This may indicate that 
a high proportion of the Fgf10 negative cells were cell-progenitors already dedicated to 
the differentiation pathway.  
 













Furthermore, a subset of Fgf10-tomato positive and negative cells expressed 
the neural/glial antigen 2 (NG2). NG2 is a marker of proliferative glial cells (during 
development and in an adult) and neural cell progenitors, which in a majority give rise 
to oligodendrocytes (Levine et al., 2001), but can also differentiate into astrocytes and 
neurons (Trotter et al., 2010). Importantly, expression of NG2 protein is down-
regulated upon maturation and differentiation of the cells (Nishiyama et al., 2009). 
Interestingly, in a culture of hypothalamic monolayers NG2 expression was observed 
within semi-confluent cultures at the periphery of the patches, where the cells from one 
patch came into contact with another patch (Fig. 6.13A,B). NG2 is a large 
transmembrane protein, shown to play a role in cell adhesion, cell-cell communication, 
as well as determination of cell polarity and migration (Biname, 2014). Potentially 
Figure 6.12 Characterisation of hypothalamic monolayer culture by detection of stem 
cell/progenitor markers. Expression of (A) Sox2 and (B) Nestin markers of NSC, was 
observed in Fgf10-tomato (DsRed) positive and Fgf-tomato negative cells; white 
arrowheads point to examples of tomato positive cells co-localising with specific 
marker. (C) Expression of BLBP marker of radial glial cells was observed only in cells 
not expressing the Fgf10-tomato reporter; Scale bar 100µm. 
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contact with a different type of cell, from another patch stimulates cell-cell signaling 
resulting in molecular changes and expression of NG2 (Fig. 6.13C).  
On the contrary, the peculiar expression of NG2 at the periphery of the patches 
could suggest that expression of NG2 is prevented in cells densely packed at the 
center of the patch. Potentially, the cells began to express NG2 and possibly endured 
other molecular changes, when they did not undergo contact-inhibition by other 
surrounding cells (Fig. 6.13D). This suggests that release from contact-inhibition could 
promote differentiation of the cultured cells.  
Alternatively, cells at the center produced a currently unknown morphogen that 
at lower concentration promotes molecular changes resulting in expression of NG2. 
However, this would mean that the patches did not consist of clonal cell clusters but 
each cell within the patch possessed a different identity. The remaining possibility is 
that these NG2 expressing cells are derived from the pool of migratory cell progenitors 
residing within the hypothalamus, rather than true stem cells, and have migrated to 
different locations during period of culture.  
Nonetheless, presence of these NG2 positive progenitor cells suggests that the 
culture has a potential to give rise to differentiated cells in vitro, which was 
subsequently explored further in section 6.3.8. 
 
  





Figure 6.13 NG2 was found expressed in a culture of hypothalamic monolayer.  (A) 
Fgf10-tomato (DsRed) positive cells showed expression of the NG2 marker; white 
arrowheads show examples of co-localising markers. (B) Stitched micrograph images 
showing cells, both tomato positive or negative, expressing NG2 at the periphery of 
the patches; scale bar 100µm. (C) Schematic representation of the theory that 
expression of NG2 within cells at the periphery of the patch, results from mutual 
interaction of cells from neighbouring patches. (D) A schematic to show that cells do 
not express NG2 when residing in close proximity to each other, however they do 
express NG2 when are no longer undergoing contact-inhibition. 









                                                                                                                                            
218 
 
6.3.7 Sub-passaging capacity of cells in hypothalamic monolayer cultures 
 
Stem cells are characterised by their ability to maintain self-propagation, 
therefore it is required, that when cultured in vitro, they are able to undergo passaging. 
It was observed previously that the hypothalamic monolayers self-propagate by 
forming specific clonal patches of Fgf10 expressing and Fgf10 non-expressing cells. 
However, as true NSC they should be able to sustain sub-passaging.  
Therefore, in order to determine whether the hypothalamic monolayer cultures 
were able to withstand passaging, culture of cells derived from WT mice were taken 
through three to four passages. For this, cells were detached from semi-confluent 
(80%) culture dish and re-seeded onto fresh dishes at a 1 in 10 dilution, allowing 
further semi-clonal culture expansion. However, cells plated at (clonal) re-seeding 
density of 5x102 cells/ml stopped proliferating. After passaging, cells formed a uniform 
monolayer without distinctive “cell patches” observed earlier at primary seeding. This 
could have arisen due to higher seeding density as well as more uniform dispersal 
across the culture dish due to low amount of debris comparing to the primary seeding.  
Having established that the culture can be successfully passaged, it was 
important to determine and compare the sub-passaging capacity of Fgf10-ve versus 
Fgf10+ve cells. Passaged cultures derived from the Fgf10-LacZ reporter mouse (age 
P35) were stained with X-gal solution to determine the proportion of β-gal Fgf10-
reporter expressing cells (see Chapter 2 and section 6.3.1). Within the primary culture 
at the point of passaging 71% of cells did not express LacZ reporter and 29% were 
LacZ positive (Fig. 6.14). After passaging, cells have formed a uniform monolayer of 
mixed LacZ+ and LacZ- cells, 80% of which consisted of the LacZ- and only 20% of 
the LacZ+ cells (Fig. 6.14). The proportions of LacZ+ and LacZ- cells appeared to be 
comparable before and after passaging, although further repeats would allow 
statistical comparison to validate conclusion drawn here.  
As this is a novel system, further work would be essential to fully determine the 
character of the passaged cells. It is possible that re-seeding of a primary cell culture 
influences the molecular properties of the cells, affecting therefore their behaviour and 
mutual cell-cell interactions. Furthermore, the culture would require further 
investigations to determine the cell type composition (using stem cell markers) and 
differentiation potential after each subsequent passage, as well as expression of 
Fgf10-reporter. Therefore, to fully establish the effects of sub-passaging on a culture of 
hypothalamic monolayer this experiment requires subsequent repetition and further 
investigation, which was not undertaken in this study due to time limitation also linked 
to the number of mice available. Importantly, the results demonstrate the self-
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propagation potential of the primary hypothalamic monolayer cells, including the cells 








6.3.8 The hypothalamic primary monolayers display multipotency 
 
The ability to differentiate and give rise to all three neural cell lineages - 
neurons, astrocytes and oligodendrocytes, known as multipotency is a key property of 
NSC. To determine their multipotent capability, the primary hypothalamic monolayer 
cultures derived from Fgf10-tomato mice (age P30 and induced in vivo) were 
stimulated to differentiate by seeding at high density and/or culturing for a prolonged 
period of time (see Chapter 2), until round or slightly elongated cells (some also with 
processes) began to emerge on the top of the monolayer (Fig. 6.15A), signifying 
differentiation. Cell type composition of the cultures was then subsequently revealed 
using combination of cell-type-specific immunofluorescent markers of differentiated 
cells. 
The neuronal class III β-tubulin (Tuj1) protein is associated with microtubule 
stability and expressed almost exclusively by neurons and neuronal progenitors (von 
Bohlen und Halbach, 2011). Within the hypothalamic monolayer cultured for at least 30 
days, several Fgf10-tomato positive cells was found to express the Tuj1 marker (Fig. 
6.15B,C), showing their ability to differentiate into neurons. Differentiated neurons 
derived from the hypothalamus were selected against during seeding and therefore 





































Figure 6.14 The primary hypothalamic cultures of Fgf10-LacZ positive and Fgf10-LacZ 
negative cells, were shown to be successfully passaged, demonstrating their 
propagation potential.  
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as deducted from the lack of presence of the Tuj1 marker at the earlier culture stages 
(data not shown). Therefore, presence of neurons is an effect of cells differentiating in 
the culture and not direct seeding of already differentiated cells. Furthermore, majority 
of the tomato negative cells expressed the Tuj1 marker in the culture (Fig. 6.15B,C), 
suggesting that in a long term culture majority of Fgf10 reporter negative cells was 
unable to maintain the stem cell properties and committed to neuronal differentiation.  
To detect astrocytes, the cultures were assessed for expression of glial 
fibrillary acidic protein (GFAP) (Fig. 6.15D). This intermediate filament (IF) protein is a 
commonly used as a marker of astrocytes in vitro and in vivo (Yang et al., 1994, von 
Bohlen und Halbach, 2011). In the cultures of the primary hypothalamic cells, GFAP 
protein was detected in numerous Fgf10-tomato negative cells as well as within 
several tomato positive cells (Fig. 6.15D). Similarly to neurons, the expression of 
GFAP was not detected in the early cultures, showing the capability of the Fgf10 
tomato positive and negative cells to differentiate in vitro into astrocytic lineage. 
The short term culture (7days) was earlier shown to express NG2 marker of 
cell progenitors that in majority give rise to oligodendrocytes (see section 6.3.6). To 
determine whether high density long term culture (>30days) provided cell 
differentiation into oligodendrocytes the culture was assessed for the presence of the 
oligodendrocyte transcription factor 2 (Olig2) protein. Olig2 specifically marks the cells 
dedicated to the oligodendrocytic and moto-neuron lineages (Takebayashi et al., 2000, 
Takebayashi et al., 2002) and it was detected within both Fgf10-tomato positive and 
negative cells (Fig. 6.15E). Again, the presence of the marker is only detectable in the 
high density long-term monolayers and therefore the presence of Olig2 was a result of 
differentiation of cultured cells rather than effect of seeding already differentiated cells.  
Overall, it was found that Fgf10 expressing and some Fgf10 negative cells, 
originating from adult mouse hypothalamus, can give rise to all three types of 
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Figure 6.15 Differentiation potential of the primary hypothalamic Fgf10-tomato 
culture. (A) A schematic representation (left hand side) of phase contrast micrographs 
showing a differentiating hypothalamic culture, where cells at the top layer mostly 
correspond to neurons and oligodendrocytes and are sitting on a layer of astrocytes 
and remaining undifferentiated cells, which were further immunolabelled with 
fluorescent markers to confirm their identity; scale bar 100µm. (B&C) The tomato 
fluorescent cells express also the Tuj1 – a marker of differentiated neurons. (D) The 
tomato positive cells do not show expression of the GFAP marker of astrocytic 
lineage. (E) The tomato fluorescent cells express the Olig2 marker of 
oligodendrocytes; scale bar 100µm.   
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Part 6.4 Expression profile of Fgf ligands and Fgf Receptors in primary 
hypothalamic monolayers  
 
 
Successful induction of the Fgf10-tomato reporter in vitro signifies that Fgf10 
was expressed post dissection, in a culture of hypothalamic monolayers derived from 
adult Fgf10-tomato reporter mouse (Fig. 6.11). FGF10 is a signalling protein that 
through binding to FGFR2IIIb triggers multistage-downstream pathways leading to 
changes in cell proliferation, migration and gene expression. Moreover, on several 
occasions it was shown to work in a cooperative (and sometimes redundant) manner 
with other members of its subfamily, i.e. FGF7, FGF3 and FGF22 (see Chapter1). To 
determine whether the function of FGF10 in the monolayer of primary hypothalamic 
cells may be intertwined with other members of the FGF family it was therefore 
important to establish expression profiles of these proteins in the culture. Furthermore, 
the in vitro culture was generated with the purpose to reflect and study molecular 
processes occurring in vivo. However, cultured primary cells can potentially modify 
their molecular characteristics post dissection, changing their gene expression. 
Therefore it was important to determine any differences in protein profiles, between 
those expressed in vivo (Hajihosseini and Dickson, 1999, Hajihosseini and Heath, 
2002) to those occurring in vitro.  
The use of RT-PCR analysis of sub-confluent cultures, derived from WT mice 
of the age P30, allowed for the semi-quantitative comparison of the expressed mRNA 
levels of each protein. The results showed that Fgf10 was expressed at high levels in 
the in vitro culture (Fig. 6.16A), which agreed with the results of Fgf10-reporter culture 
studies where at least 20% of total number of cultured cells was found to express 
Fgf10 (see section 6.3 and Fig. 6.7). Moreover, strong expression of Fgf1, Fgf13 and 
Fgf21 was also noted. From Fgf10 subfamily members, only a weak expression of 
Fgf7 was detected and no expression of Fgf3 and Fgf22 was observed. Other ligands 
detected within the cultures were: Fgf2, Fgf9, Fgf12, Fgf16 and Fgf18. Some weak 
expression of Fgf5 and Fgf11 was seen as well (Fig. 6.16A).  
There was some discrepancy between the in vivo and in vitro Fgf expression 
profiles. Fgf5 expression was found in the cell culture but not in the hypothalamic 
extract, and the Fgf14, 17 and 20 were found in vivo but not in the monolayers (Fig. 
6.16B). However, expression of these ligands was found at very low levels in each 
case. Another notable difference was that Fgf13 was found expressed at high levels in 
vitro but at low levels in vivo (Fig. 6.16B). Other small differences in expression levels 
might be a result of sample variation or experimental issues.    
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Additionally to the ligands, the FGFR1IIIc and FGFR3IIIc receptors were 
expressed at high levels, the FGFR1IIIb expression was also faintly detected, whereas 
the FGFR3IIIb was not detected at all (Fig. 6.16A). The in vivo studies showed the 
absence of FgfR2IIIb expression from hypothalamus (Hajihosseini et al., 2008). 
Conversely, the RT-PCR profiling of the in vitro monolayer showed that the FgfR2IIIb 
was expressed at low level in the cell culture which was considered negligible when 
compared to the high levels of the FgfR2IIIc isoform expression (Fig. 6.16A). 
Alternative splicing mechanism commits cells to express either one or the other form 
of the receptor, but not both (Holzmann et al., 2012). Therefore, detection of both 
receptor isoforms suggests a mixed population of cells or residual contaminating cells, 
such as meningeal or blood vessels’ cells.   
.   
  







Figure 6.16 Characterisation of expression of Fgfs and FgfRs in a culture of 
hypothalamic monolayer. (A) Semi-quantitative RT-PCR profiling of Fgf ligands and 
receptors in the primary hypothalamic monolayer. (B) Table comparing the Fgf 
expression patterns in vitro to the ones found in vivo; note that the in vivo data was 
generated and provided by members of Dr Hajihosseini laboratory.  
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Part 6.5 Testing the transfection efficiency of cultured primary hypothalamic 
cells 
 
The suspension culture of neurospheres is often difficult to transfect with 
plasmid DNA. Therefore establishment of the primary hypothalamic monolayers aimed 
to provide an alternative tool to study the biology of the Fgf10 expressing hypothalamic 
cells and investigate a role of FGF10 within tanycytes.  
To investigate whether the monolayer of primary hypothalamic cells can 
undergo successful DNA transfection, cultures established from adult WT mice (age 
P28) were transiently transfected with mammalian vectors used in previous studies 
(see Chapter 4), i.e. FGF10 tagged to HA (rFGF10-HA) and its mutant version G145E 
(G145E-HA), as well as a control mCherry. Similarly to the previous studies, the 
mCherry protein was ubiquitously distributed around the cell (Fig. 6.17A), whereas 
FGF10HA was present in both, cell nucleus and cell cytoplasm to various degrees, 
depending on a cell (Fig. 6.17B). As with other cell types, the G145E mutant showed 
nuclear exclusion (Fig. 6.17C) (see Chapter 4).  
Overall, these results showed that the primary hypothalamic monolayers can 
undergo successful cell transfection and could therefore be used in the future, in 
further molecular manipulation. Moreover, it was found that FGF10HA (but not its 
mutant version, G145E) was transported into the cell nucleus of this specific type of 










Figure 6.17 Successful transient transfection of the primary hypothalamic culture 
with DNA plasmids. (A) Transiently transfected mCherry is found ubiquitously 
present around the cell, detected by DsRed immunolabelling. (B) The HA 
immunofluorescence showed that FGF10 was found present in a cell nucleus of the 
hypothalamic cells. (C) Transiently transfected G145E is excluded from the nucleus 
and retained in a cell cytoplasm, determined by the HA immunofluorescence in the 
culture.  
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Part 6.6 Discussion  
 
With the use of the Fgf10-LacZ (Hajihosseini et al., 2008) and the Fgf10-tomato 
(El Agha et al., 2012, Haan et al., 2013) transgenic mice, it has been established that 
Fgf10 is expressed by hypothalamic cells called tanycytes, which display the 
characteristics of stem/progenitor cells.  
Studies of the gene function in vivo, through conditional gene deletion, knock-
out or overexpression are often very laborious, costly and require long time scale for 
analysis. Therefore in vitro systems mimicking the in vivo conditions, provide greater 
experimental flexibility, and generate strong predictions that can be subsequently 
related to the in vivo work. In this study, primary hypothalamic cells were cultured by 
two means – the commonly used NSC assay, known as ‘the neurospheres’, or as an 
adherent monolayer system. These cultures were derived from Fgf10-LacZ and Fgf10-
tomato transgenic (reporter mice, previously used to study Fgf10 in vivo) and used to 
analyse whether Fgf10 expressing cells cultured in vitro show NSC characteristics, in 
similar fashion to the in vivo cells.  
Since the 1990’s, when the culture conditions for the stem cells derived from 
mammalian central nervous system (CNS) were first described (Reynolds and Weiss, 
1992), the neurosphere assay has become a frequently adopted method to isolate, 
enrich and expand NSC in vitro (Gil-Perotin et al., 2013). Furthermore, neurospheres 
derived from adult mouse hypothalamus have been described in literature, where they 
were shown to retain all of the properties of the stem cells, i.e. multipotency, 
expression of stem cell markers, self-propagation and differentiation into functional 
neurons. However, the exact origin of these cells within hypothalamus itself was not 
defined (Cortes-Campos et al., 2015, Sousa-Ferreira et al., 2011). Here, it was 
demonstrated that neurospheres can be successfully cultured and expanded from 
hypothalamic (and SVZ) cells derived from adult Fgf10-tomato transgenic mouse. 
Importantly, the Fgf10-tomato expressing cells formed neurospheres, which 
possessed stem cell-like characteristics, including expression of stem cell markers 
Sox2 and Nestin, multipotency and self-renewal properties with the ability to undergo 
passaging. Therefore, these Fgf10-expressing neurospheres were most likely derived 
from Fgf10-expressing cell lineage within hypothalamus, i.e. the proliferative β 
tanycytes residing within median eminence, which were shown to possess similar 
properties in vivo  (Haan et al., 2013).     
Cultures of primary cells, unlike cell lines, have a restricted and predetermined 
number of cell divisions before entering senescence, therefore the number of times a 
primary cell culture can be passaged is limited (Jensen and Parmar, 2006). Analysis of 
neurosphere passaging revealed that cultures derived from the control WT SVZ, WT 
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hypothalamus and Fgf10-tomato SVZ showed very similar growth rate during 
subsequent passages. Conversely, cultures derived from the Fgf10-tomato positive 
hypothalamus showed delayed growth rate in comparison to the other assays and 
could not be passaged to the same extent as the control cultures derived from the WT 
hypothalamus. The knock-in allele of the Fgf10-creERT2 results in the reduction of the 
Fgf10 mRNA levels even up to 50% (El Agha et al., 2012). Hypomorphic Fgf10 mice 
and humans display defects within multiple organs and tissues (e.g. malformations of 
ocular glands, ears, teeth, kidney, respiratory system and genitalia) (see Chapter4, 
part 4.2) suggesting developmental problems. It is therefore possible that lower levels 
of FGF10 during embryogenesis had further implications on the normal development 
of the brain, affecting also the adult tissue. Therefore knock-down of FGF10 within 
neurosphere cultures, derived from Fgf10-tomato mouse, could putatively affect their 
stem cell properties of self-propagation. Alternatively, expression of Fgf10 could have 
decreased the survival rate of the seeded cells resulting in lower proliferation potential 
rather than affect the cell division. To investigate further the effect of FGF10 and 
validate results observed here, it would be necessary to generate a conditional 
FGF10-knock out neurospheres and investigate their propagation capacity, comparing 
to the WT.  
Due to several limitations, the neurosphere assay is not an ideal system to 
study the role of FGF10 in the hypothalamic cells. Some of the spheres may not be 
clonal structures, but instead are chimeric in nature and composed of small number of 
stem cells and greater number of stem progenitors and differentiated cells (Bez et al., 
2003), similarly to the neurogenic niches observed in vivo. The precursors, or “trans-
amplifying” cells also can give rise to neurospheres in the culture, generating 
difficulties in depicting the true stem cells from the neurosphere population (Pastrana 
et al., 2011). Moreover, neurospheres (and NCS in general) are highly motile, dynamic 
structures and demonstrate a spontaneous locomotion, partly induced by beating 
cellular surface processes. Studies performed have observed the movement of 
neurospheres within cell suspension even when a culture was left untouched in an 
incubator, removing the factor of “induced motility” generated by movement of the 
culture dishes. Moreover, time-lapse imaging studies have shown that neurospheres 
migrate around, interact and generate aggregates even at low cell densities (Ladiwala 
et al., 2012). Neurospheres therefore frequently ‘fuse’ or ‘merge’ together (Fig. 6.6) 
producing an inherent error in the experimental assay in terms of clonality, size and 
growth rate (Mori et al., 2006, Coles-Takabe et al., 2008). To overcome these issues it 
would be important to purify the hypothalamic Fgf10 expressing cells from the 
remaining in the culture. However, attempts to use FACS sorting have proven 
unsuccessful, because conditionally induced reporter expression through in vivo 
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tamoxifen pulsing resulted in small number of Fgf10-tomato expressing hypothalamic 
cells in proportion to the reporter negative cells, generating very high noise-to-signal 
ratio (Fig. 6.5). Moreover any sorted cells struggled to survive due to very low cell 
plating density.  
The encountered limitations of the neurosphere assay have led to generation 
of an adherent monolayer culture. Compared with neurospheres, the monolayer of 
cells may represent more homogenous population of undifferentiated cells, because of 
their uniform exposure to the growth factors and nutrients within the culture medium 
(Bez et al., 2003). Neurospheres display a population of the NCS at the periphery of 
the sphere (Bez et al., 2003, Babu et al., 2007), with differentiated cells present within 
the centre, which have limited contact with the growth factors and other nutrients, 
allowing differentiation to occur. Therefore, monolayer cultures are more likely to 
undergo symmetrical cell division and are less likely to undergo spontaneous 
differentiation (Conti et al., 2005).  
Importantly, the monolayer culture is more accessible to any drug treatments 
and DNA transfections therefore serve as a great tool to study role of FGF10 in 
hypothalamic tanycytes. Although monolayer cultures of NSC have already been 
described, derived from denate gyrus (Babu et al., 2011), SVZ and olfactory bulb 
(Theus et al., 2012). However, the culture of hypothalamic tanycytes, cultured as stem 
cells, is unique to this study.  
An age-related decline in neurogenesis has been confirmed in vivo in mice and 
rats (Bizon and Gallagher, 2003, McDonald and Wojtowicz, 2005, Jin et al., 2003), and 
therefore the neurogenic potential of the adult brain is the greatest in young animal 
and decreases with the age. However, the exact mechanisms that to lead to such a 
decline are yet unclear - perhaps the reduction in proliferative activity is a 
consequence of a lengthening of the cell cycle time or an inherent dwindling of the 
proliferative cell population (Abrous et al., 2005). Moreover, the decline in proliferative 
cells has been noted in vivo specifically in the murine hypothalamus (Haan et al., 
2013).  
The results presented here complement the in vivo studies and primary 
hypothalamic monolayer cell cultures established from the young mice of postnatal 
age of day 8 (P8) generated more and large colonies than cultures obtained from 
young adult mice of age around P30 and P40 (Fig. 6.7). Furthermore, in agreement 
with the neurosphere assays, the monolayer culture shows that there is a 
heterogeneous population of stem/progenitor cells in the postnatal hypothalamus, 
because two different populations of cells, expressing and not-expressing Fgf10, are 
able to self-propagate, are multipotent and express stem cell markers. Similar 
observations have been made in vivo and there is a dispute over where the exact 
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niche of stem cells resides within hypothalamus (Hajihosseini et al., 2008, Haan et al., 
2013, Robins et al., 2013, Li et al., 2012a). It appears likely that the Fgf10-non 
expressing cells cultured in vitro originate from the population of proliferative 
parenchymal cells (Li et al., 2012a) or cells that are located more dorsally around the 
ventricle, called α tanycytes (Robins et al., 2013), as both of these cell niches do not 
express Fgf10, but have been shown to proliferate in vivo.   
In order to assess the propagation potential of the cultured putative 
stem/progenitor cells, size of the generated Fgf10-expressing and non-expressing 
patches was compared. Cultures of Fgf10 reporter negative and positive cells were 
derived from the same mice, grown under identical conditions and were seeded 
simultaneously, therefore the cell growth rate can be compared directly. The size of 
the patch obtained is a balance between rate of the cell division, mode of the division 
(either symmetric or asymmetric), cell survival and differentiation of the progeny. 
Although small patches of either Fgf10-expressing or Fgf10-non expressing cells 
observed were speculated to have arisen through several means, such as asymmetric 
cell division, cell differentiation or cell death, the middle sized (6-50 cells) and bigger 
patches (51+) of cells were assumed an evidence of symmetrical division of cell 
progenitors. Number and size of these patches were putatively an indication of cell 
proliferation potential. The difference in this cell proliferation potential between the 
Fgf10-expressing and Fgf10 negative cells was most prominent at the cultures derived 
from the very young mice (P8) (Fig. 6.9). At this stage, the Fgf10-negative cells were 
very abundant and divided rapidly, whereas only small proportion of Fgf10-expressing 
cells was able to proliferate at similar rate and gave rise to big patches. The 
proliferative potential difference, between the two populations, was somehow lesser at 
the later ages of a mouse (P30-P40), where the propagation of the Fgf10-negative and 
Fgf10-positive cells is closely comparable (Fig. 6.9). This suggests that Fgf10-negative 
cells might not be able to sustain their proliferative potential with the age.  
In general, the number of LacZ-positive cell patches was lower than the LacZ-
negative regardless of the age of the mouse (Fig. 6.7B,C). It is possible that more 
LacZ-negative than LacZ-positive cells were present at seeding, suggesting that there 
might be more LacZ-negative mitotically active cells present in the hypothalamus in 
vivo. Alternatively, expression of Fgf10 marked by the LacZ reporter, could have 
decreased the plating efficiency of the cells by affecting their survival rate, even 
potentially inducing cell death. The remaining possibility is that expression of Fgf10 
affects the cell cycle and controls the rate of cell division, therefore resulting in lower 
number and smaller patches. 
Despite the fact that Fgf10-expressing cells do not give rise to big patches to 
the same extent that Fgf10 non-expressing cells do, there is little variation between 
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different ages of mice. Therefore, regardless of the age of the mouse, in comparison to 
Fgf10-negative cells the Fgf10-expressing cells proliferate at a slow but constant rate 
(Fig. 6.9). On the contrary, the Fgf10-non expressing cells proliferate very rapidly at 
early age of a mouse, but lose their proliferative potential as the mouse ages (Fig. 
6.9). To further explore the proliferative capabilities of the two populations, an 
experiment could be performed culturing cells derived from mice older than P40 
(ranging from young adults, mature, old to very old mice). The prediction would be that 
the differences in the proliferation potential of each culture would reduce with the age 
of the mouse. Moreover, assuming that Fgf10-non expressing cells decline in their 
propagation potential at a greater rate than the Fgf10-expressing cells (that remain 
relatively constant), potentially, at older mouse ages, the Fgf10-expressing cells could 
show greater proliferative potential than Fgf10-negative cells.  
Adult stem cells in vivo are slow dividing, with a very long cell cycle and are 
sometimes considered even quiescent. However, when stimulated (chemically or 
through injury) they become rapidly activated and generate rapidly proliferating neural 
cell precursors (Seri et al., 2001, Kuo et al., 2006). Strict regulation of the cell cycle of 
stem cells prevents build-up of neurons, potentially resulting in tumours and cancer 
(Williams et al., 2015). Besides stem or progenitor cells, each neurogenic niche of an 
adult brain contains a population of fast amplifying precursors, displaying all the 
characteristics of stem cells, i.e. markers of stem-cellness, multipotency and self-
renewal through cell division, however they also have limited life span and are more 
committed than stem cells (Abrous et al., 2005). The population of these trans-
amplifying cell precursors is maintained by the stem/progenitor cells. Due to their slow 
(however constant) dividing character in vitro, the Fgf10-expressing cells potentially 
could be a population of the stem/progenitor cells, whereas the fast dividing Fgf10-non 
expressing cells could arise from the population of precursor cells - rapidly dividing at 
young age of the mouse but losing their proliferation potential with the age of the 
mouse. Furthermore, both cell populations within the culture were shown to undergo 
successful passaging (Fig. 6.14), which further demonstrates their proliferative 
potential. However, it would be important to determine whether the cultures derived 
from different ages display the same passaging potential. Additionally, the number of 
passages, that each of the populations (Fgf10 expressing and non-expressing) is able 
to sustain would also provide the information about self-renewal properties of the cells 
cultured, and could provide a more comprehensive view on the differences between 
populations.  
To further determine the identity of cultured hypothalamic monolayers, the cells 
were assessed for expression of neural stem/progenitor cell markers. Both of the two 
populations, the Fgf10-positive and Fgf10-negative, showed expression of Sox2 and 
                                                                                                                                            
232 
 
Nestin (Fig. 6.12), which are common markers of stem cells (Feng et al., 1994) and 
corresponds to the in vivo studies of hypothalamic tanycytes (Haan et al., 2013). 
However, numerous Fgf10-negative cells expressed BLBP (Fig. 6.12), which is not 
detected in the Fgf10-positive cells. BLBP is a marker of radial glia cells, in vivo it is 
known to participate in a signaling pathway that is critical for differentiating neurons 
(Retrosi et al., 2011). Therefore, it is likely to be detected within the trans-amplifying 
cell precursors, further supporting the theory that the Fgf10-negative cell population 
constitutes a population of cell precursors. 
Important aspect defying stem cells is multipotency and differentiation 
potential. In the provided culture conditions small proportion of the Fgf10-reporter 
positive and negative cells is able to differentiate into all three neural cell lineages: 
neurons, astrocytes and oligodendrocytes (Fig. 6.15). However, a difference was 
noted in the numbers of differentiated cells, where the majority of Fgf10-negative cells 
displayed the differentiation markers and Fgf10-positive cells showed minor levels of 
differentiation. In the given culture conditions, the Fgf10-expressing cells potentially 
are maintaining their stem-cell identity, while the Fgf10 negative cells as “progenitor 
cells” struggle to sustain their stem-cellness and therefore readily differentiate. 
Furthermore, the culture conditions and media composition have a significant impact 
not only on current state of the cell, but can also affect the differentiation potential of 
the culture (Reynolds and Weiss, 1996a). For example, culture media containing 
Brain-derived neurotrophic factor (BDNF) and Sonic Hedgehog (Shh) stimulate NSC to 
differentiate into neurons (Babu et al., 2007) and Platelet-derived growth factor 
(PDGF) promotes survival of oligodendrocytes and therefore stimulates their 
differentiation in the culture (Gogate et al., 1994). Furthermore it was shown that 
treatment of cortical precursors with FGF8b isoform stimulated the differentiation of 
astrocytic lineage of cells (Hajihosseini and Dickson, 1999). At the moment, the 
characterisation of the two different hypothalamic populations of cells (Fgf10-
expressing and not expressing) is preliminary. Therefore, it is possible that these cells 
respond differently to culture composition and may show a varied differentiation 
potential if treated at a wide range of specific conditions, which would require further 
detailed investigation, beyond the scope of this project. 
The hypothalamic monolayer culture system was set up to be used as a tool 
aiding in vivo studies decrypting the function of FGF10 in the hypothalamus. To gain a 
comprehensive view on the in vitro system and its resemblance to the in vivo 
processes, the culture was assessed for expression of all Fgf factors and their 
receptors in a sub-quantified manner using RT-PCR and related to the data obtained 
from acutely extracted hypothalamic tissue (Hajihosseini’s lab, unpublished data). 
Although the in vitro cultures are not the exact replica of the processes taking place in 
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vivo, and existing differences should not be disregarded, nonetheless the profiling 
results showed that expression of Fgf ligands and their receptors majorly corresponds 
in vitro and in vivo. Importantly, the members of the FGF10 subfamily, the FGF3 and 
FGF22 were fully absent in vitro and in vivo, and FGF7 was expressed at very low, 
barely detectable levels. Therefore, unlike in some other systems, e.g. ear (Wright and 
Mansour, 2003), teeth (Harada et al., 1999) and developing salivary and lacrimal buds 
(Govindarajan et al., 2000), FGF10’s role in hypothalamus is not complemented by the 
members of its subfamily, highlighting its importance in this brain region. Interestingly, 
the expression of Fgf10 in vitro is the strongest of all of the FGFs, with similar pattern 
seen in vivo, that further highlights its importance in this brain region. However, this 
assay detects the transcript levels and does not provide information about amount of 
the protein actually generated. Ideally, the levels of each FGF protein would be 
measured, detecting the ligands with protein specific antibodies, which currently are 
majorly unavailable. Furthermore, it is possible that FGF10 acts in cooperation with 
other FGFs to maintain the neurogenic niche, for example FGF2 was shown to 
promote neural cell proliferation in vivo and in vitro (Woodbury and Ikezu, 2014).  The 
exact roles of other FGFs and their receptors in the hypothalamic neurogenic niche 
are still yet to be discovered.  
The exact function of FGF10 in hypothalamus, in vivo or in vitro is still not fully 
determined and unclear. From the transfection studies, with the FGF10HA construct, 
and basing on the evidence from the previous studies in different cell types (see 
Chapters 3, 4 & 5), it is possible that FGF10 serves an intracrine role, acting within the 
cell nucleus. Earlier, it was proposed that the nuclear FGF10 negatively regulated the 
cell cycle, maintained slow cell growth and lowered the cell proliferation rate within the 
epithelial and differentiating mesenchymal cells. This data potentially coincides with 
the results of the Fgf10-expressing population of hypothalamic cells, which show slow 
proliferation rate in respect to the Fgf10-non expressing cells.  
Here it is shown that the monolayer culture can be transiently transfected, 
which provides a great potential for further experiments. It might be used to generate a 
FGF10 overexpression system to analyse the result of its function in the cultured cells. 
Moreover, if the FGF10 nuclear function involves binding to other molecules, the 
tagged FGF10 protein could be used  in immunoprecipitation experiments to pull down 
FGF10’s binding partners. This would provide a very useful indicative of its functioning 
pathway in vivo.  
The transiently transfected FGF10HA was found to translocate into the cell 
nucleus within the hypothalamic culture, providing basis for assumption that a pool of 
endogenously made FGF10 is also able to enter cell nucleus of this specific cell type. 
Therefore, it is possible that the observed differences between the Fgf10-expressing 
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and Fgf10-non expressing populations of cell cultures result from the nuclear function 
of FGF10. Low levels of expression of the FgfR2IIIb in vitro, which could have resulted 
from residue contamination of epithelial meningeal cells, as well as negligible 
expression of the receptor in vivo (Hajihosseini et al., 2008) further could suggest an 
intracrine/nuclear function of FGF10 within this cell population. Alternatively, secreted 
FGF10 acts, through so far undescribed mechanisms, on the population of the Fgf10-
non expressing cells promoting their proliferation or regulating differentiation. Possibly, 
these cells express the FgfR2IIIb (although at a very low levels), allowing the typical 
FGF10-FGFR2IIIb signalling pathway. Secreted FGF10 is known to stimulate 
proliferation of cardiomyocytes (Rochais et al., 2014), cochlear epithelium (Urness et 
al., 2015) as well as some endothelial and tumour cells (Sugimoto et al., 2014). 
However, the FGF10 signalling occurs in a dose dependent manner of receptor ligand 
levels, therefore judging by the negligible receptor transcript levels it is unlikely to 
generate a prominent effect through this pathway. Nonetheless, although implausible, 
until proven so, this theory cannot be discarded. To clarify the receptor presence, the 
two populations would require separation and individual profiling for the ligands and 
receptors, ideally with the determination of protein levels as well.  
Furthermore, it is possible that FGF10 is generated by the tanycytes but 
functions away from the hypothalamus. Potentially, the β-tanycytes secrete FGF10 
either: to the 3V cavity, where it is uptaken by other cells; and/or into the blood 
capillaries lying beneath hypothalamus, where FGF10 serves its function, for example 
in the pituitary gland, lying underneath hypothalamus. On the contrary mature and 
secreted FGF10 as a typical paracrine protein it is relatively unstable (Buchtova et al., 
2015), therefore unlikely to sustain long-distance signalling. However, until tested it 
should not be discarded as an option.  
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Chapter 7  
General Discussion 
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FGF10 deficient mice die shortly after birth demonstrating that this protein plays 
an essential part during normal mammalian development. It is essential for 
development and maintenance of multiple organs, including limbs, lungs, heart, liver, 
kidney, ocular and salivary glands, thymus, white adipose tissue, liver, inner ear, brain, 
teeth and the trachea (Itoh and Ohta, 2014). Furthermore, FGF10 is also expressed 
postnatally in vital adult tissues, such as brain (Hajihosseini et al., 2008), and is an 
important factor involved in the oncogenicity of pancreatic and breast cancer cells 
(Nomura et al., 2008, Theodorou et al., 2004) as well as in ameloblastoma and tumour 
formation (Nakao et al., 2013, Sugimoto et al., 2014). Importantly, mice phenotypes 
caused by the FGF10 knockout closely resemble those observed in FGFR2IIIb 
knockout mice, implying that FGF10-FGFR2IIIb signalling underlies much of Fgf10’s 
effects during the normal mouse multi-organ development. A few discrepancies in the 
FGF10 and FGFR2IIIb knockout phenotypes have been noted, but this may be 
explained by ligand or receptor redundancy (Ornitz and Itoh, 2015).  
In addition to their paracrine role, several FGFs are thought to function cell-
autonomously through intracellular interactions with other molecules. For example, 
FGF1 binds to acidic FGF intracellular binding protein (FIBP) (Kolpakova et al., 1998) 
and mortalin (Mizukoshi et al., 1999) in the cytoplasm. Furthermore, FGFR1 and FGF2 
have been found within cell nucleus where they function to promote pancreatic cancer 
cell invasion (Coleman et al., 2014). Therefore, it is possible that FGF10 also 
possesses cell-autonomous intracellular function/s.  
This study investigated whether FGF10 translocates into the cell nucleus, and if 
so, what are the mechanisms that promote its nuclear transport. Furthermore, as a 
follow on question, it was explored whether nuclear FGF10 serves a functional role 
affecting cell proliferation or cell survival.  
 
 
Part 7.1 Nuclear transport of FGF10 
 
  
 A previous study showed that, when applied exogeneously, recombinant-
FGF10 can be taken up by urothelial cells and translocate into the cell nucleus (Bagai 
et al., 2002, Kosman et al., 2007). By contrast, the studies presented here mimicked 
the in vivo situation to show that FGF10 can enter the nucleus of cells in which it has 
been over-expressed. Often FGFs behave in a cell-specific manner but here it was 
shown that nuclear entry of FGF10 can occur in multiple cell types, including human 
epithelial (ARPEs), mesenchymal chondroprogenitors (ATDC5s), human embryonic 
kidney (HEK 293Ts) as well as primary astrocytes and tanycytes (Fig. 4.4). Therefore, 
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at the molecular level, nuclear translocation of FGF10 appears to be a universal 
process. 
 The most commonly observed nuclear import pathway involves the newly 
translated and fully folded protein being directly translocated into the nucleus (Fig. 
7.1A), an example of which includes proteins involved in DNA damage response, such 
as Rif1 (Xu and Blackburn, 2004), or transcription factors, for instance GATA (Hunter et 
al., 2014). Moreover, both HMW and LMW isoforms of FGF2 translocate endogenously 
into the cell nucleus (Quarto et al., 1991, Dell'Era et al., 1991). Typically, secreted 
proteins possess an N-terminal signal peptide (SP) that targets the newly synthesised 
protein towards the secretory pathway. For this instance, a secretory FGF3 besides its 
SP also possess multiple weak NLS-like motifs, some of which are driving the nuclear 
translocation and others only facilitate the process in subsequent stages, therefore 
allow the competition between protein secretion and nuclear import (Kiefer and 
Dickson, 1995a). FGF3 and FGF10, as close relatives, share a lot of structural, 
biochemical and functional properties (see Chapter 1). Interestingly, one of the FGF10 
NLSs characterised in this study (the NLS2) is homologous to one of the NLS-like 
motifs present in FGF3 (Fig. 3.3). It is therefore tempting to speculate that FGF10, in 
similar fashion to FGF3, is endogenously transported into the cell nucleus, distributing 
the pool of protein molecules between the nuclear and secretory pathway.  
 Alternatively, the protein becomes secreted from the cell and subsequently 
binds to the receptor present on the cell surface, which then causes its internalisation 
(endocytosis) back into cytoplasm, leading to nuclear import, which can take place with 
(Fig. 7.1C), or without the receptor (Fig. 7.1B). For example, the endocytosis of the 
FGF1 protein is stimulated only by binding to FGFR1 or FGFR4, and the protein-
receptor internalisation is independent of the receptor’s tyrosine kinase domain activity 
(Sorensen et al., 2006). Furthermore, FGF2 was shown to co-localise in the nucleus of 
pancreatic cancer cells together with FGFR1. The complex was specifically located at 
sites of RNA polymerase II mediated transcription, suggesting its role in regulation of 
gene transcription involved in cell proliferation (Coleman et al., 2014). Simultaneously, 
non-receptor bound FGF2 was found in the cell nucleolus, and it was speculated that 
FGF2, present within distinct regions of cell nuclei, potentially triggers distinct biological 
effects either with or without its receptor (Coleman et al., 2014), which adds another 
complexity to the system. Interestingly, externally applied to urothelial cells FGF10 was 
thought to co-localise in the nucleus with its cognate FGFR2IIIb receptor (Kosman et 
al., 2007), which does not discredit the fact the protein might also localise in the 
nucleus in a receptor-independent manner.  
  





Figure 7.1 Models of potential pathways of nuclear transport regarding secreted 
proteins. (A) Paracrine and endocrine signalling signifies secretion of a ligand by one 
cell that then binds to a receptor present on a surface of a different cell, triggering 
downstream signalling events. (B) Autocrine signalling is generated by cells that bind 
through the receptors their own secreted ligands. The ligand then might undergo 
endocytosis and be transported to the cell nucleus (C) Upon binding of the ligand, the 
receptor might also undergo internalisation and be transported to the nucleus, 
potentially in a complex with the ligand. (D) Alternatively, a secreted protein can bind 
to adjacent cell, where it becomes endocytosed and potentially translocated into cell 
nucleus.  
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Additionally, secreted protein, binding to the receptor present on the adjacent 
cell, subsequently becomes endocytosed (with or without the receptor) and 
translocated into the nucleus (Fig. 7.1D). If this would be true for FGF10, it would result 
in FGF10’s double effect on the epithelial cells – the classical activation of receptor TK 
phosphorylation at cell surface and then the intracellular, from the cell nucleus. 
Although this scenario is probable, and should be taken into consideration, it is 
tempting to speculate that nuclear FGF10 is more likely to act in a cell-autonomous 
manner (see Chapter 4).  
 
7.1.1 Is the nuclear transport of FGF10 mediated by NLS1 and/or NLS2? 
 
 The classical nuclear import of proteins occurs via interactions with adapter 
proteins, known as karyopherins (or importins) (see Chapter 1) (Fig. 1.10). FGF1, 
FGF2 and FGF3 were all shown to possess more than one NLS (Wesche et al., 2005b, 
Sheng, 2004, Kiefer and Dickson, 1995a). FGF10 was proposed to contain a NLS 
(here named NLS1), which resembles, but is not homologous to NLS found in FGF1 
(Kosman et al., 2007). In this study, through bioinformatics analysis, a second NLS was 
identified within FGF10’s sequence (here named NLS2), positioned within its carboxyl 
terminus (Fig. 3.2). The two NLSs were found positioned in a close proximity in the 
protein’s three dimensional structure, and directly interacting via an H-bond. H-bond 
represents one of the strongest molecular interactions shown crucial for protein folding 
and protein structure. Moreover, H-bonds have also been found to play a role in 
molecular recognition and interactions with other proteins (Nick Pace et al., 2014, 
Huang et al., 2014). On this premise, it was hypothesized whether FGF10’s NLS1 and 
NLS2 cooperated to facilitate its interactions with importin molecules and consequently 
its nuclear import. 
 Kosman and colleagues found that mutation of basic residues within NLS1, 
which typically promote binding to importins, diminishes, but does not abrogate 
FGF10’s nuclear localization (Kosman et al., 2007). By contrast, here it was recognised 
that human G138E mutation was positioned within the NLS1 (Fig. 4.5). This mutation is 
known to cause LADD syndrome in humans, but the molecular mechanisms 
responsible for this phenotype have been so far undescribed (Entesarian et al., 2007).  
Analysis of this mutation, modelled within the equivalent rat protein (G145E) in vitro, 
revealed that the mutation results in protein’s nuclear exclusion. Although, the 
possibility that G145E encodes an unstable protein targeted for rapid degradation 
cannot be excluded, the results suggest that the mutation attenuates the process of 
FGF10 secretion and causes protein’s retention at ER, which is subsequently coupled 
to abrogation of its novel nuclear trafficking role (see Chapter 4). On the contrary, each 
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ligand is known to interact with the D2 domain of a second receptor through a 
secondary receptor binding site (Ibrahimi et al., 2005). G145E may potentially fall within 
this site, reducing the receptor dimerization and signalling without affecting ligand–
receptor binding. However, the results suggest rather that the mutation leads to 
FGF10’s structural and folding complications, resulting in hyperglycosylation and 
cytoplasmic retention. Therefore, it is possible that the observed LADD phenotypes 
caused by G138E are a result of abrogation of two separate FGF10 functioning 
pathways, i.e. indirect attenuation of paracrine signalling in epithelial cells due to 
reduced FGF10 secretion and/or abolition of receptor dimerization, as well as 
diminished endogenous FGF10 function/s.  
 By comparison with NLS1, mutation of residues within the NLS2, especially the 
4T-NLS2, also seem to abrogate the FGF10 nuclear localization, but most likely 
through disruption to the nuclear transport pathway mediated by importin/s (see 
Chapter 3 & 4). Mutation of two basic residues within this sequence already 
significantly diminishes the protein’s nuclear import and further mutation results in 
complete nuclear exclusion. Regardless that NLS2 was predicted as a non-classical 
and weak NLS (see Chapter 3), the experimental results suggest this sequence acts 
via binding to the importins, but the direct protein interaction remains to be 
demonstrated. Similarly to mutation of NLS1, a possibility that the 4T-NLS2 affects 
protein structure and folding and therefore targets it for early degradation, cannot be 
disregarded. In similarity to G145E mutation, the 4T-NLS2 may also undergo 
hyperglycosylation (Fig. 4.14). However, the results also show that, unlike G145E, the 
4T-NLS2 does follow the secretory pathway, therefore most likely retains its paracrine 
function (Fig. 4.15). Furthermore, it cannot be yet discarded that FGF10 might interact 
via NLS2 with a different nuclear-import chaperone, in an importin independent fashion. 
For example, a ribosomal protein called Rpl5 was found to translocate into the nucleus 
via an adaptor protein named symportin-1 (Syo1) and calmodulin was shown to act as 
a nuclear import chaperone, for several transcription factors, such as Non-histone 
chromosomal protein 6A (Nhp6Ap) (Hanover et al., 2007) and Sox9 (Argentaro et al., 
2003). Nonetheless, mutations within the NLS2 demonstrate that integrity of this 
sequence is essential for the nuclear import of FGF10. 
Although both G145E and 4T-NLS2 mutations result in nuclear protein 
exclusion, the results suggest it occurs via different molecular mechanisms. Moreover, 
it appears that NLS2 is essential to target the protein into the nucleus, but it is possible 
that the NLS1 facilitates and aids the process further (Fig. 7.2). 
 
 













7.1.2 Are there other factors potentially affecting nuclear transport of FGF10? 
 
 In addition to the NLS-karyopherins nuclear import pathway, there are other 
known factors that could influence protein intracellular distribution. A range of post-
translational modifications (PTM) have been shown to either promote or prevent 
nuclear import of various proteins. These are known to fine tune the biochemical 
reactions taking place between protein cargo and its chaperone/s by up- or 
downregulating already occurring basal levels of nuclear transport. For example, 
methylation of specific arginine residues is essential for the nuclear accumulation of the 
HMW, but not the LMW isoform of FGF2. Inhibition of methylation resulted in reduction 
of HMW FGF2 nuclear accumulation (Pintucci et al., 1996).  
 Glycosylation is an important form of PTM, that was shown to influence 
protein’s nuclear import in a process employing molecules called lectins (Monsigny et 
al., 2004). Modification of glycosylation status of bovine serum albumin (BSA) have 
shown that glycosylation alone can drive protein’s nuclear import in a cell cycle specific 
manner (Rondanino et al., 2003). Moreover, certain glycosylation patterns, especially 
those located in close proximity to a NLS, can potentially diminish the nuclear 
transport, as demonstrated by glycosylation of Serine residue residing in a close 
Figure 7.2 Representation of the effects caused by FGF10 mutations. FGF10 
(represented as red dots) follows the secretory pathway and is released from the cell 
and it was found translocated into cell nucleus. The LADD-mimicking G145E mutant 
falling into the NLS1 sequence abolished the nuclear transport pathway and, 
moreover, was not found to progress through the secretory pathway, making the 
protein cytoplasmically retained and fully abolishing its secretory and nuclear role. On 
the contrary, the 4T-NLS2 mutation prevented the protein from entering the nucleus 
but did not disrupt its secretion, potentially allowing its receptor-mediated signalling.  
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proximity to NLS of Jun protein (Schlummer et al., 2006). Bioinformatics presented in 
Chapter 3 predicted about 26 putative glycosylation sites within FGF10 (Fig. 3.8), but 
only experimental investigation can pinpoint the key sites which could affect FGF10’s 
intracellular distribution. Interestingly, it has been found that mutated FGF10 showing 
nuclear exclusion (G145E or 4T-NLS2) undergoes hyperglycosylation (Fig. 4.14). 
Possibly the hyperglycosylation prevents the protein from entering the cell nucleus, or 
alternatively the ER retention results in the protein’s hyperglycosylation. Although, the 
hyperglycosylation is associated with protein’s nuclear exclusion, as demonstrated by 
G145E mutant, it is possible that glycosylation of specific non-mutated sites actually 
aids in nuclear transport of FGF10.  
Bioinformatics analysis identified a putative SUMOylation site present within rat 
and human FGF10 sequences but absent from mouse protein (Fig. 3.6). SUMOylation 
is known to play key roles in directing the nuclear import and localisation of 
transcription factors, for example sumoylated version of promyelocytic leukemia (PML) 
protein was detected in either sub-nuclear oncogenic domains or nuclear bodies 
(Freiman and Tjian, 2003). Similarly, LEF1 protein, which is a downstream effector of 
the Wnt signalling pathway, undergoes sequestration into nuclear bodies, regulated by 
SUMOylation (Sachdev et al., 2001). Therefore, SUMOylation appears to regulate the 
activity and function of transcription factors, through targeting them to specific 
transcription sites (Freiman and Tjian, 2003). The fact that FGF10’s SUMOylation site 
most likely is not conserved among species (Fig. 3.6) (although some non-classical 
SUMOylation cannot be excluded), suggests that even if it aids the FGF10’s nuclear 
transport, it may not be the main driving factor. However, this could account for species 
specific differences, and nuclear FGF10 potentially serves more predominant roles in 
rats and humans than in mice.  
 There are also other forms of PTMs that could potentially impact FGF10’s 
nuclear import, for example phosphorylation, that is commonly known to either promote 
or inactivate biological pathways. This seems to be a protein specific event as, for 
example, phosphorylation within the NLS site can either promote or reduce strength of 
importin binding, in a residue dependent manner, which was shown in Epstein-Barr 
virus (EBV) nuclear antigen 1 (EBNA-1) protein (Kitamura et al., 2006). Moreover, in 
specific cases, phosphorylation was shown to enhance docking of cargos to the NPC, 
positioned upstream of an NLS may enhance its recognition by importins, as well as 
mask NLS recognition and cause protein’s cellular retention (Nardozzi et al., 2010). It 
might be likely, that specific phosphorylation patterns further control the FGF10’s 
intracellular localisation.  
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Part 7.2 Putative nuclear function of FGF10 
 
 Regardless of the dynamics and molecular mechanisms driving FGF10’s 
nuclear import, transiently transfected rFGF10HA was found to translocate into the 
nucleus of a variety of cell types (Fig. 4.4). Paracrine FGF10 serves diverse roles 
during development and postnatally, but these could be accompanied by so far 
overlooked intracellular/nuclear role of the protein. It is possible that, targeting of 
FGF10 to the nucleus could play a critical stoichiometric role in regulating the normal 
level of paracrine FGF10 signalling, meaning that the amount of secreted FGF10, 
available for paracrine signalling in epithelial cells, could be titrated down by nuclear-
targeted protein retention. FGF10 is known to act in a dose dependent manner (see 
Chapter 1), and for example genetic knockdown of Fgf10 in a mouse model of Apert 
syndrome rescues much defects caused by hyperactive receptor mutation 
(Hajihosseini et al., 2009). However, Fgf10 is expressed in brain regions, such as 
hypothalamus, which lacks expression of its cognate receptor, the FGFR2IIIb 
(Hajihosseini et al., 2008), suggesting non-paracrine FGF10 function in these tissues. 
 Nuclearly transported proteins play a variety of functions, which are often 
interlinked with protein’s nuclear distribution. Although it cannot be excluded that 
nuclear transported FGF10 subsequently undergoes degradation, it is considered an 
unlikely event, since protein degradation pathways are also present within the cell 
cytoplasm, therefore making the nuclear-import pathway redundant. Moreover, nuclear 
FGF10HA was found to localise to specific loci, and co-localise with Fibrillarin (Fig. 
4.2), which is a protein located in the dense fibrillar component (DFC) of the nucleolus, 
suggesting FGF10 might play a nucleolar function.  
 
7.2.1 Putative nucleolar function of FGF10 
 
Within eukaryotic cells, the nucleolus is considered the largest structure in the 
nucleus and it is commonly known as the site of ribosome synthesis and their 
assembly. The nucleolus is a non-membranous organelle, that is mainly composed of 
proteins and RNA molecules. Nucleolar accumulation of FGF10 (Fig. 4.2) could take 
place by interaction with another nucleolar protein causing indirectly its nucleolar 
retention. Alternatively FGF10 serves a particular nucleolar function. Since, the 
nucleolus is considered as the “ribosome factory”, it is possible, that FGF10 serves a 
function affecting ribosomal biogenesis. Moreover, due to nucleolar sequestration 
processes of regulatory molecules, in response to specific environmental cues, many 
non-ribosomal proteins are captured and immobilized. Nuclear detention prevents 
proteins from interacting with their binding partners, potentially presenting a further post 
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translational regulatory mechanism (Lam and Trinkle-Mulcahy, 2015). Potentially 
FGF10 is also subject to this regulation.  Additionally, recent studies showed that 
nucleolus plays also significant part in modifications of small RNA, RNA editing, 
telomerase  maturation and well as sensing stress and control of cell  cycle  (Lo et al., 
2006).   
Interestingly, other nuclear FGFs, such as FGF2 and FGF3, have been found 
localising within the cell nucleolus. Nucleolar FGF2 directly regulates synthesis of 
ribosomal RNA and stimulates Polymerase I transcription through binding to UBF 
transcription factor (Sheng, 2004, Sheng et al., 2005), and was speculated to drive cell 
proliferation. Moreover, nucleolar function of FGF2 may be associated with pancreatic 
cancer (Coleman et al., 2014). Nucleolar FGF3 has been postulated to play a role in 
control of cell cycle and inhibition of cell proliferation through binding to NoBP protein 
(Reimers et al., 2001). It is therefore tempting to speculate that the nucleolar role of 
FGF10 is also associated with cell proliferation and control of cell cycle, however 
further investigations are necessary before any conclusion can be drawn.  
 
7.2.2 Potential regulation of cell cycle and cell proliferation by FGF10 
 
Several lines of evidence suggest that nuclear accumulation and function of 
FGF10 might be linked to cell cycle and/or cell proliferation control. First, it was 
demonstrated that FGF10 undergoes nuclear translocation in cultured quiescent cells 
(Fig. 4.16). Moreover, nuclear FGF10 was absent in actively proliferating cells as 
judged by segregation of BrdU label and nuclear FGF10-HA in transfected cells (Fig. 
4.17). Therefore, a conclusion can be drawn that either, FGF10 is not translocated into 
the nucleus in actively proliferating cells or nuclear FGF10 obstructs the cell 
proliferation. Nuclear accumulation of over-expressed protein could potentially affect 
the normal cell division rate, which is not directly related to FGF10’s function. However, 
nuclear accumulation of the control mCherry protein did not cause such cell 
proliferation inhibitory effect. Therefore, it is unlikely to take place with regards to 
accumulation of FGF10.  
Interestingly, in a culture of mesenchymal progenitors (ATDC5 cells), transiently 
transfected FGF10HA negatively affected the rate of cell proliferation, which 
subsequently caused knock-on effects on cell differentiation potential (Fig. 5.3). A small 
proportion of cells demonstrated differentiation properties, displaying a small number of 
‘micro-nodules’ indicative of cartilage formation (Fig. 5.3). Nonetheless, the culture has 
retained small degree of differentiation potential, therefore over-expression of FGF10-
HA most likely did not disturb the differentiation processes per se. However, the normal 
processes of initial proliferation of differentiating culture of ATDC5s were disturbed in 
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case of FGF10-HA over-expression (Fig. 5.3). Intriguingly, exogenously applied FGF10 
seemed to promote cell differentiation, suggesting the at least in ATDC5s, paracrine 
and intracrine FGF10 might function in opposite fashion (see Chapter 5). FGF3 was 
earlier shown to present similar properties (Kiefer and Dickson, 1995a).  
Concluding therefore from the results, a model can be proposed where FGF10 
shows dual function: (1) the paracrine stimulation of the receptor present on the 
epithelial cells to stimulate their proliferation and (2) nuclear and inhibitory role of 
proliferation of the mesenchymal cells (Fig. 7.3). There might be a possibility that 
intracrine FGF10 triggers cell death, functioning to induce apoptosis. Observations of 
the FGF10-HA transfected cultures did not suggest greater cell death than the controls 
(see Chapter 4 & 5), but exact measurements are needed to exclude this possibility.  
 
 








 Investigation into Fgf10 expression in a culture of hypothalamic tanycytes (see 
Chapter 6) seems to further support the proposed model of nuclear function restricting 
cell proliferation. In vivo it has been demonstrated that Fgf10 expression demarcates a 
Figure 7.3 Putative model of FGF10’s function. FGF10 (represented as red dots) has 
a well-established receptor-mediated function of resulting in induction of epithelial cell 
proliferation. However, results presented here suggest that FGF10 translocated into 
nucleus of mesenchymal cells might act to restrict cell proliferation.  
                                                                                                                                            
246 
 
niche of proliferative stem cells of the hypothalamus (Hajihosseini et al., 2008, Haan et 
al., 2013), in a tissue that lacks expression of FGFR2IIIb. An in vitro culture of 
hypothalamic cells shows that Fgf10 expressing cells have a potential to proliferate and 
sustain their self-propagation properties over long period of time, yet their division rate 
is slower than Fgf10 non-expressing culture counterpart cells. The results suggest that 
Fgf10 expressing cells correspond to the population of slow dividing true 
stem/progenitor cells in contrast to Fgf10-non expressing fast dividing trans-amplifying 
cell progenitors (see Chapter 6). Again, the possibility that Fgf10 expression triggers 
cell death or limits cell survival cannot be excluded. However, the results rather 
indicate that FGF10 might function intracellularly, in the culture of hypothalamic 
tanycytes to control the division rate of true stem cells.  
FGF10 might not be the main player determining the cell progression thought 
the cell cycle, however it might affect other factors controlling cell division checkpoints. 
Furthermore, it seems that the receptor-mediated paracrine function of FGF10 
generates stronger signals that can override the intracellular/nuclear function of the 
protein. For example, in cardiomyocytes FGF10-FGFR2IIIb cell-autonomous signalling 
results in promotion of cell proliferation (Rochais et al., 2014) therefore, the putative 
endogenous FGF10 inhibitory signals would have been superseded by the inducible 
signals from the conventional receptor phosphorylation pathway. In a more likely 
scenario, nuclear FGF10 acts as additional restriction/control system, potentially 
through binding to key factors of cell transcription machinery, or other cell cycle check-
points determinants, to affect their function. These processes could be tissue, time and 
species specific.  
Control of cell division might be important from several aspects. For example, 
during development FGF10 is expressed in mesenchymal cells and promotes 
proliferation of epithelium. Therefore, it seems logical that a cell-autonomous 
mechanism should restrict mesenchymal cell proliferation, allowing epithelial cells to 
proliferate. Moreover, adult neural stem cells are characterised by slow cell division to 
prevent accumulation of new neurons in the brain, which could lead to brain tumours 
and other complications. FGF10 has already been implicated in cancer formation. For 
example, externally applied FGF10 stimulated the proliferation and cancer formation of 
ameloblastoma in a dose dependent manner, through stimulation of the MAPK 
pathway (Nakao et al., 2013). Furthermore, FGF10-FGFR2IIIb signalling was shown to 
induce migration and invasion of pancreatic cancer cells, where FGF10 is actually 
expressed in stromal cells surrounding pancreatic cancer cells (Nomura et al., 2008). 
Moreover, high levels of Fgf10 expression were shown to promote sarcoma (non-
epithelial type of tumour) formation, whereas expression of Fgf10 did not stimulate the 
fibrosarcoma (mesenchymal tumour) formation (Sugimoto et al., 2014), although both 
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types of tissue were shown to express the Fgfr2IIIb. This further shows that FGF10 
signalling might be controlled by a variety of factors. Moreover, Fgf10 is highly 
overexpressed in a subset of human breast carcinomas and acts as a potent oncogene 
in mammary epithelial cells (Theodorou et al., 2004). Therefore, generation of FGF10 
functioning only through the nucleus, in a proliferation inhibitory fashion, could provide 
a system limiting cancer formation. However, further studies are required to fully 
determine the nuclear/intracellular function of the protein.  
 
 
Part 7.3 Future work 
 
  
 To further elucidate the intracellular distribution and nuclear role of FGF10, a 
number of investigations could be carried out in the future. Some experiments could be 
carried out, in order to further clarify the dynamics driving FGF10’s nuclear import, 
others to determine the molecular mechanisms of FGF10’s nuclear function. 
 It should be investigated whether FGF10 is found within cell nucleus with or 
without its receptor. As shown by the example of FGF2, ligand-receptor complex 
translocation might have a differential function to the ligand alone (Coleman et al., 
2014), which could be determined by immunolabelling of both proteins and assessing 
their co-localisation in different cell compartments.  
 In order to fully assess whether the NLS sequences function collectively to drive 
FGF10 to the cell nucleus, several basic residues could be mutated within both 
sequences, for example, K143 and K144 of NLS1 and K200 and K201 of NLS2. Other 
combinations also should be explored. Generating more than 4 mutations at the time 
might lead to protein misfolding and structural issues. Furthermore, in order to 
determine whether either of these sequences alone can drive protein’s nuclear 
translocation, NLS1 and NLS2 could be attached to a fluorescent protein and 
transfected into a cell culture. The fluorescent protein-NLS fusion would be expected to 
show a high degree of nuclear accumulation. Moreover, it could be explored whether 
they are able to drive the nuclear import of the fluorescent protein in cooperation. It 
could be investigated whether fusing two NLSs at the same time strengthens the 
signal. In FGF10 primary sequence NLS1 and NLS2 are located at a distance from 
each other, coming in close contact only in protein’s 3D structure and without this 
strategic positioning they might not perform their function in similar fashion to the one 
they might in FGF10. Nonetheless, the possibility could be explored, whether 
individually the sequences would show too “weak” to fully target the protein to the 
nucleus.  
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Protein nuclear targeting might be strengthened by various PTM. Mutations of 
previously predicted bioinformatically sites of SUMOylation, glycosylation or 
phosphorylation, could be carried out and analysed in a context of promoting or 
preventing FGF10’s nuclear transport.  
Another element, to fully support the NLS2 transport of the FGF10 would be to 
determine whether the 4T-NLS2 mutation retains its paracrine function, by binding to 
the receptor. This could be performed via protein purification and assessing direct 
protein-protein (4T-NLS2 to FGFR2IIIb) interaction for example, applying yeast two 
hybrid technique, or through comparison of the epithelial cell stimulation of non-
mutated FGF10 and 4T-NLS2 proteins. It would be expected that the mutant shows 
no/little difference to the wild type FGF10.  
To investigate whether FGF10 plays a specific role within the cell nucleus it 
would be important to determine whether FGF10 interacts with other molecules in the 
nucleus itself or in the cytoplasm. It would be possible to determine whether the FGF10 
possesses any binding partners through performing immunoprecipitation of the protein 
from the different cell compartments (such as nucleus and cytoplasm) with its putative 
complex/s. Furthermore, performing this study in a culture of hypothalamic tanycytes, 
where the intracellular role of FGF10 might be of most significance because of a 
presumed absence of its paracrine function. List of putative FGF10 binding partners 
(excluding housekeeping genes, like protein folding chaperones) could significantly 
help to identify the exact role the protein serves in the nucleus. Moreover, it could 
provide information about the mechanism of FGF10 nuclear import – either through 
binding to specific isoform of importin or other chaperone/s.  
To fully investigate whether FGF10 possesses and intracellular role, one of the 
key aspects would be generation of protein that does not become released from the 
cell. Ablation of the signal peptide (SP) targeting FGF10 to the secretory pathway 
should result in majority of a protein accumulating in the nucleus. Assuming that the 
protein would not display any folding or structural issues, it could be used in parallel 
with the external application of FGF10, testing the paracrine vs intracrine effects of the 
protein of a cell culture.  
Furthermore, it has been hypothesised whether nuclear FGF10 affects cell 
proliferation. To further investigate this hypothesis, one of the possibilities would be to 
knock out expression of Fgf10, for example from the hypothalamic cultures of 
tanycytes, or mesenchymal cell line that typically expresses the protein. Therefore, it 
could be investigated whether the knockout of FGF10 affected the cell proliferation rate 
through observation of cell numbers, assessing the number of cells showing 
expression of cell proliferation markers (e.g. BrdU), and/or assessing the cell death, for 
example by counting number of cells positive for Trypan Blue reagent.  
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FGF10 was shown to perform a variety of functions in a cell type dependent 
manner. Another interesting investigation into the function of FGF10 could be through 
generation of inducible system, where expression of the protein can be turned on and 
off. Especially, if the system was able to express different versions of the protein – one 
paracrine, where the protein would be unable to translocate into cell nucleus, but 
function solely through the cell secretory pathway (e.g. 4T-NLS2), and second, where 
the protein would only act in an intracrine manner, by ablation of the SP.  Application of 
this system in a variety of different cell types, including cancer cells could test the 
specific tissue-dependent FGF10’s function. Importantly, the inducible system, where 
the protein’s expression has the potential to be turned on and off would allow to 
determine whether the expression of Fgf10 causes cell death, which is otherwise 
difficult to measure if cells are expressing the protein at the time of seeding.  
Lastly, application of antibodies reliably detecting the endogenous levels of 
FGF10 would provide information, whether in vivo, FGF10 is translocated into cell 




                                                                                                                                            
250 
 
List of abbreviations 
 
3D    – third dimension  
3V    – third ventricle 
AER    – apical ectodermal ridge 
αIBB    – Impβ1-binding domain 
Alk5    – TGFβ type I receptor  
Alx4    – aristaless-like homeobox protein 
ALSG    – aplasia of lacrimal and salivary glands syndrome 
An1    – anosmin-1  
ARC    – arcuate nucleus of hypothalamus  
Arm    – armadillo  
ARPE-19   – human retinal pigment epithelial cells 
ATP    – adenosine triphosphate 
ATR    – ataxia telangiectasia and Rad3-related protein 
B1/CDK1   – isoform of cyclin B1 in a complex with CDK1 
Barx2    – homeobox protein 
BDNF    – brain-derived neurotrophic factor 
βCOP    – coat protein (coatomer) β 
β-gal    – β-galactosidase 
β-Kap    – β-karyopherin 
BLAST   – Basic Local Alignment Search Tool 
BLBP    – brain lipid binding protein 
BRCA2   – breast cancer type 2 susceptibility protein 
BrdU    – 5’bromo 2’deoxyuridine 
BSA    – bovine serum albumin 
BSC    – back scatter 
C-terminal   – protein’s carboxyl terminal 
C/EBPβ   – CCAAT/enhancer binding protein 
CDK1    – cyclin-dependent kinase 1 
CEP57   – centrosomal protein of 57 kDa 
ChIP    – chromatin immunoprecipitation 
CIP    – calf alkaline phosphatase 
CK2    – casein kinase 2 
c-Myc    – cellular myelocytomatosis protien 
CNS    – central nervous system 
COS    – acronym of CV-1 Origin with the SV40 genetic material 
CRM1    – chromosomal maintenance 1 
                                                                                                                                            
251 
 
CSF    – cerebrospinal fluid 
D1, D2, D3   – immunoglobulin–like domains of FGFRs 
DAG    – diacylglycerol  
DFC    – dense fibrillar component  
DMN    – dorsomedial nucleus of hypothalamus 
DMSO   – dimethyl sulfoxide 
DPBS    – Dulbecco's phosphate buffered saline 
EBNA-1   – Epstein-Barr virus (EBV) nuclear antigen 1 
ECM   – extra-cellular matrix 
EGF    – epidermal growth factor 
EPD    – Eukaryotic Promoter Database 
ER    – endoplasmic reticulum 
ERAD    – ER-associated protein degradation 
ERK    – extracellular signal-regulated kinases 
ERp60   – an isoform of Protein disulphide-isomerase 
ETM    – epithelial-to-mesenchyme signalling  
EtOH    – Ethanol  
FACS    – fluorescence-activated cell sorting 
FAST1   – forkhead activin signal transducer-1 
FASTA  – a DNA and protein sequence alignment software package 
FBS    – foetal bovine serum 
FDM    – form deprivation myopia 
FGF    – fibroblast growth factor 
FGF-BP   – FGF-binding protein 
FGFR    – fibroblast growth factor receptor 
FHFs    – FGF homologous factors  
FIBP    – acidic fibroblast growth factor intracellular-binding protein 
FLRT3   – fibronectin leucine-rich transmembrane protein 3 
FOXO3   – forkhead box O 3 
FSC    – forward scatter  
FTC    – familial tumoral calcinosis 
GAG    – glycosaminoglycans 
GAPDH   – glyceraldehyde 3-phosphate dehydrogenase 
GATA3   – trans-acting T-cell-specific transcription factor GATA3 
GC box   – guanosine-cytosine rich DNA regions 
GDP/GTP   – guanosine diphosphate/ guanosine triphosphate 
GFAP    – glial fibrillary acidic protein 
GLUT1   – glucose transporter 1  
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GRB2    – growth factor receptor-bound protein 2 
GWAS   – Genome Wide Association Studies 
H-bond   – hydrogen bonds 
HA    – Hemagglutinin A 
HBS    – HEPES buffered saline 
HEAT   – huntingtin, elongation factor 3, protein phosphatase 2A and 
TOR1    – serine/threonine-protein kinase 
HEK    – human embryonic kidney cells 
HEPES   – 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HMW    – high molecular weight 
HS    – heparan sulfate 
Hs6st    – 6-O-sulfotransferase protein 
HSGAGs   – heparan sulphate glycosaminoglycans 
Hsp90    – heat shock protein 90 
HSSE    – heparan sulfate-synthesizing enzymes 
ICC    – immunocytochemistry  
IF    – intermediate filament 
Ig    – immunoglobulin  
IGF1    – insulin-like growth factor 1 
IHP    – inositol hexaphosphate 
Imp-α    – importin-α 
Imp-β    – importin-β 
IP3    – inositol triphosphate 
Isl1    – insulin gene enhancer protein 1 
KGF    – keratinocyte growth factors 
L6/TAXREB107  – ribosomal protein  
LADD    – lacrimo-auriculo-dento-digital syndrome 
LEF1    – lymphoid enhancer-binding factor 1 
Lfng    – lunatic fringe 
LHN    – lateral hypothalamic nucleus 
LHX3    – LIM/homeobox protein3 
LMW    – low molecular weight 
LRRC59   – leucine rich repeat containing 59 
MAPK   – mitogen-activated protein kinases 
MCF-7   – human breast adenocarcinoma cells, acronym of Michigan       
Cancer Foundation-7 
MDS    – molecular dynamic simulation 
ME    – median eminence 
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MKP    – MAP kinase phosphatase  
MMPs    – matrix metalloproteinases 
MSC    – mesenchymal stem cells 
MSX    – Msh homeobox 1 transcription factor 
MTE    – mesenchymal-to-epithelial signalling 
mTOR   – mammalian target of rapamycin  
N-terminal   – protein’s amino terminal 
NBM    – nucleolar binding motifs 
NCAM   – neural cell adhesion molecules 
NCBI    – National Center for Biotechnology Information 
NDST1   – bifunctional heparan sulfate N-deacetylase/N-sulfotransferase1 
NES   – nuclear export sequence 
NF-κB    – nuclear factor kappa-light-chain-enhancer of activated B cells 
NGS    – normal goat serum 
NG2    – neural/glial antigen 2 
Nhp6Ap   – Non-histone chromosomal protein 6A 
NLS    – nuclear localisation sequence 
NKX    – homeobox protein 
NoBP    – nucleolar binding protein 
NPC    – nuclear pore complex  
NSC    – neural stem cells 
Nups    – nucleoporins  
Olig2    – oligodendrocyte transcription factor 
P    – postnatal day 
p27kip1    – cyclin-dependent kinase inhibitor 
PAGE    – polyacrylamide gel electrophoresis  
PAX6    – paired box protein 6 
PBS    – phosphate buffered saline 
PBST   – phosphate buffered saline with Tween-20 
PBX1   – pre-B-cell leukaemia transcription factor 1 
PDB    – Protein Data Bank  
PDGF    – platelet-derived growth factor 
PDL    – poly-D-lysine hydrobromide 
PE    – Phycoerythrin 
PEA3    – polyoma enhancer activator 3 
pERK    – phospho -ERK 
PFA    – paraformaldehyde  
PI3K    – phosphatidylinositol-4,5-bisphosphate 3-kinase 
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PIP2    – phosphatidylinositol-4,5-biphosphate 
PKC    – protein kinase C 
PLC    – phospholipase C 
PLC γ1   – is also known as FGFR substrate 1 (FRS1) 
PML    – promyelocytic leukemia 
PNGase F  – Peptide -N-Glycosidase F 
PNS    – peripheral nervous system 
PPARγ   – peroxisome proliferator activated receptor 
PTHrP   – parathyroid hormone-related protein 
PTM    – post-translational modifications 
PVN    – paraventricular nucleus of hypothalamus 
RA    – retinoic acid 
RAF    – acronym for Rapidly Accelerated Fibrosarcoma 
RAF1   – RAF proto-oncogene serine/threonine-protein kinase or c-Raf 
RanGAP   – Ran GTPase-activating protein 
RanGEF   – Ran guanine nucleotide exchange factor 
RMS    – rostral migratory stream  
ROI    – region of interest 
RPS19   – ribosomal protein 
RT    – room temperature 
RT-PCR   – reverse transcription polymerase chain reaction 
SDS    – sodium dodecyl sulfate 
SE    – standard error 
SEF   – similar expression to fgf genes 
Sey    – small eye phenotype 
Shh    – sonic hedgehog  
Shp2    – aka tyrosine-protein phosphatase non-receptor type 11 
SIM    – SUMO-interaction motif 
SMAD   – amalgam of ‘mothers against decapentaplegic’ (MAD) 
(Drosophila) and ‘small body size’ (SMA) (C.elegants) 
SNP1    – snurportin1  
SOS1    – son of sevenless 
Sox2    – sex determining region Y (SRY) - box 2 
Sox9    – Sry-related HMG box 9 
SP    – signal peptide 
Sp1    – specificity protein 1 
SPRY    – sprouty family of proteins 
STATs   – signal transducers and activators of transcription 
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SUMO   – small Ubiquitin-like modifiers  
SGZ    – subgranular zone 
SON    – supraoptic nucleus 
SOS    – sucrose octasulfate 
SVZ   – subventricular zone  
Syo-1    – symportin-1, name derived from “synchronized import” 
TAE    – Tris base, acetic acid and EDTA buffer solution 
TBE    – Tris, Borate, EDTA buffer solution 
TBX5    – T-box transcription factor 5 
TCA    – Trichloroacetic acid 
TGFβ    – transforming growth factor 
TGN46   – trans-Golgi network integral membrane protein 2 
TK    – tyrosine kinase  
Tm    – melting temperature  
Tuj1    – neuronal class III β-tubulin 
Txn    – tamoxifen  
UBF    – Upstream binding factor 
Ugdh    – UDP-glucose dehydrogenase 
VMN    – ventromedial nucleus of hypothalamus 
WB    – western blot 
Wnt    – amalgam of ‘wingless’ (Drosophila) and ‘int1’ (mouse) 
WT    – wild type 
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Appendix 1: Representative data demonstrating similarities of results 






  Appendix 1 Results of NLStradamus showing positioning of NLS2 sequence present 
within mouse (A) and human (B) FGF10 sequences. Note the sequence conservation 
between the species.  
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Appendix 2 A SUMOylation site was predicted within human FGF10 at position K91 
(A), but not within mouse protein (B).  
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Appendix 3: Representative data showing sequencing results of mutated sites 




  Appendix 3 Each residue substitution causing mutation has been validated through 
Sanger sequencing and compared to WT FGF10HA sequence. (A) Representative 
data showing single base substitution causing K198T mutation. (B) Representative 
data showing single base substitution causing R200T mutation. 
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